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RHEUMATOID ARTHRITIS
Rheumatoid arthritis (RA) is a systemic autoimmune disease that is characterised by 
persistent inflammation and destruction of the small joints 1. The disease can result in 
significant morbidity with pain, loss of function and work disability and consequently high 
socio-economic costs 2–4. It is the most common inflammatory arthritis with a worldwide 
prevalence of 0.5-1% and mostly affects middle-aged female (female male ratio 3:1), but it can 
occur at every age 1. Based on data of Dutch general practitioners (NIVEL), the prevalence in 
the Netherlands was in 2013 1.3% 5.
The etiology of RA is largely unknown, but RA is considered to have an autoimmune 
origin because of the presence of autoreactive antibodies. These autoantibodies include 
rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) 1. Especially ACPA 
has a high specificity for RA (ACPA is only present in 1% of the general population 6) and 
can be detected in 50-60% of all early RA patients 7–9. Although several pathophysiological 
mechanisms have been proposed, it is still unclear how RA-related autoantibodies exert 
their effects 10. However, ACPA-positive and ACPA-negative RA are considered different 
disease entities with different underlying pathogeneses and disease courses 11. Recently, novel 
autoantibody systems in RA have been identified, such as anti-carbamylated protein antibodies 
(anti-CarP).12 These autoantibodies were present in both ACPA-positive and ACPA-negative 
patients, suggesting broad autoantibody production within RA and autoimmunity also in 
patients currently considered as seronegative.
In addition, more than 100 genetic risk factors for RA have been identified thus 
far 13. Although the heritability of RA is reported to be up to 50% in both ACPA-positive 
and ACPA-negative RA 14, they have a different genetic background and most genetic risk 
factors are identified within ACPA-positive RA 11,15. The most important genetic risk factor 
for ACPA-positive RA is located in the HLA-DRB1 region. The predisposing alleles share a 
similar amino acid sequence at positions 70-74 in the peptide-binding groove of the HLA-
DRB1 molecule (the shared epitope (SE)). The SE hypothesis postulates that the SE motif 
itself may be directly involved in the pathogenesis of RA by allowing the presentation of an 
arthritogenic peptide to T-cells 16. Recently, a further refinement of the association of HLA 
with RA was proposed by making use of advanced statistical analyses 17. Variations in HLA-
DRB1 position 11 most strongly associated with development of both ACPA-positive 17 and 
ACPA-negative RA 18; within ACPA-positive RA this association was independent of the SE 
status 17.
Furthermore, environmental factors might play a role in RA development. Many 
potential environmental risk factors have been suggested 19, but smoking is the only widely 
replicated environmental risk factor, especially for ACPA-positive RA in patients carrying 
HLA-SE alleles 20.
Therapeutic approaches for RA have changed considerably the last decades from 
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conservative step-up strategies to early and aggressive treat-to-target strategies with disease-
modifying antirheumatic drugs (DMARDs) and biologics 21. The importance of early 
treatment was set by observations that delay of treatment initiation was associated with a 
worse disease outcome, such as more severe joint damage and a lower chance on achieving 
remission 8,22,23. The concept of the ‘window of opportunity’ proposed that there is an early 
phase in the disease in which the disease can be modified more successfully, presumably 
because the underlying disease processes are not yet fully matured 24. The exact duration of 
this period is unknown, though it has been suggested that this period consist of 12 weeks 
and is a confined period 25. Because treatment initiation in this early phase result in more 
beneficial long-term outcomes, the field of RA is moving into identifying RA in very early 
disease stages.
THE PHENOTYPE OF RA
A typical clinical presentation of RA consists of joint pain and swelling, morning stiffness and 
a symmetric polyarthritis of the small hand and foot joints. In addition, systemic symptoms 
such as fatigue and weight loss can be present. However, the presentation of RA may be 
considerably heterogeneous. In clinical practice, the diagnosis is made based on the judgment 
and expertise of the rheumatologist as no diagnostic test or diagnostic criteria for RA exist. 
Classification criteria for RA have been developed to identify homogeneous groups 
of patients for enrolment in clinical studies, particularly trials. The 1987 ACR criteria for RA 
were designed to differentiate patients with established RA from patients with other types 
of rheumatic diseases (Table 1) 26. These criteria included the items radiographic changes 
and rheumatoid nodules which are characteristic for advanced disease and classify mainly 
patients with established RA. With the increasing insights that early treatment initiation in 
RA is beneficial, clinical trials were designed to treat patients in more early disease phases. 
For this purpose, the 1987 criteria were inappropriate because of its poor sensitivity to classify 
patients with early RA. 
The 2010 ACR/EULAR criteria for RA were developed to identify RA patients in 
early disease and focused on features in early arthritis that associated with persistent and/
or erosive disease (Table 1) 27. Radiographic changes were not included as these were not 
characteristic for early disease. However, it was decided that when erosions typically for RA 
were present a patient was classified as RA in order to capture also patients with established 
but inactive disease who did not fulfil the criteria of early disease 27,28. The new criteria indeed 
classified more patients in early disease but also resulted in more heterogeneity in patients 
classified as RA 29. In line with this, the phenotype at RA presentation and during the course 
of RA is different when disease is classified according to the 1987 criteria or 2010 criteria 30,31.
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PRECLINICAL RA
RA has a period of preclinical disease. This became well-recognised because of observations 
that ACPA and RF could be detected several years before the presentation with RA 32,33. This 
was studied in cohorts of blood donors from whom multiple blood samples of RA patients were 
available before their arthritis became clinically detectable. The frequency of autoantibody 
positivity as well as the level and the epitope spreading increased when approaching the 
moment of symptom onset 32–35, indicating maturation of the autoantibody response in the 
preclinical period. Using a similar study approach, markers of systemic inflammation and 
biomarkers of bone metabolism were found to be increased in the preclinical phase 36–38. 
These findings suggested that disease processes within RA can be active years to months 
before a patient presents with RA.
Recently, the EULAR study group for risk factors for RA formulated terminology to be 
used during the different preclinical and early phases of RA that could be used as framework 
for future research 39. Six phases (phases A-F) of RA development were formulated: (A) 
genetic risk factors for RA, (B) environmental risk factors for RA, (C) systemic autoimmunity 
associated with RA, (D) symptoms without clinical arthritis, (E) unclassified arthritis and (F) 
RA (Figure 1) 39. It was emphasised that the phases could be used in a combinatorial manner, 
indicating that a patient can be in two phases concurrently. In addition, patients do not have 
Table 1. Classification criteria for RA
1987 ACR criteria 26 2010 ACR/EULAR criteria 27
Morning stiffness Joint involvement* 
  1 large joint (0)
Arthritis of 3 or more joint areas   2-10 large joints (1)
  1-3 small joints (2)
Arthritis of hand joints   4-10 small joints (3)
  >10 joints (at least 1 small joint) (5)
Rheumatoid nodules Serology
  Negative RF and negative ACPA (0)
Serum RF   Low-positive RF or low-positive ACPA (2)
  High-positive RF or high-positive ACPA (3)
Radiographic changes Acute-phase reactants
  Normal CRP and normal ESR (0)
  Abnormal CRP or abnormal ESR (1)
Duration of symptoms 
  <6 weeks (0)
  ≥6 weeks (1)
1987 ACR criteria: patients fulfilling ≥ 4 out of 7 criteria are classified as RA
2010 EULAR/ACR criteria: patients with a score of ≥6 out of 10 are classified as RA
*Refers to any swollen or tender joint on examination
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to pass through all phases and the phases do not necessarily occur in the same order before 
RA develops. Importantly, the term ‘pre-RA’ should only be used retrospectively as it was 
considered inappropriate to label healthy persons with certain genetic or environmental risk 
factors as having pre-RA as the majority of them will never develop RA 39. This latter, is in 
line with the clinical point of view of development of RA in which a patient is healthy until 
presenting with complaints (Figure 1).
Figure 1. The phases of RA development as defined by the EULAR study group for risk factors for RA (A) and 
according to the clinical point of view (B)
CLINICALLY SUSPECT ARTHRALGIA
One of the defined early phases in RA development was the phase of symptoms without 
clinical arthritis (Figure 1). Although it was widely recognised by the study group that many 
patients with RA have a period of symptoms that is likely to be related to the development of 
RA before they develop clinical arthritis, the symptoms that are specific for this early phase 
were not specified.
Identifying patients in the early symptomatic phase without arthritis is challenging 
as arthralgia is the main symptom of most patients presenting to rheumatologists and the 
majority will never develop RA. In addition, to allow studies on this early symptomatic phase 
it is needed that arthralgia patients with an increased prior chance on RA are identified. This 
can be done by adding the criterion of having RA-related autoantibodies to the arthralgia 
40,41. Another approach is to make distinctions based on the type of arthralgia. Patients with 
Clinically Suspect Arthralgia (CSA) have arthralgia that is because of the character of the 
symptoms considered by their rheumatologist as clinically suspect to progress to RA over 
time. This approach is based on the clinical expertise of the rheumatologist and proposes that 
clinical expertise is a valuable tool to select patients with an increased risk of RA. Selecting 
patients on clinical grounds before ordering additional tests is in line with clinical practice 
(Figure 1) and allows identifying both autoantibody-positive and autoantibody-negative RA 
in an early symptomatic phase.
Clinically Suspect Arthralgia cohort
The CSA cohort is an inception cohort that was set up in Leiden in April 2012 to study the 
early symptomatic RA phase without clinical arthritis. The inclusion criteria are the presence 
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of arthralgia of the small joints for less than one year which, because of the character of 
the symptoms, is considered by the rheumatologist as being suspect to progress to RA over 
time. No further criteria are made with regards to the type of symptoms and thus inclusion 
is essentially based on the expert opinion of the rheumatologist. Importantly, CSA is not 
present if clinical arthritis was observed at physical examination or another explanation for 
the arthralgia was more likely (such as osteoarthritis or fibromyalgia). 
At baseline, questionnaires are completed, physical examination performed, blood 
obtained and X-rays and MRI made.  Magnetic Resonance Imaging (MRI) of the MCP2-5, 
wrist and MTP1-5 joints of the most painful side, or the dominant side in case of equally 
severe symptoms at both sides, is performed within two weeks after clinical assessment. The 
joints are scanned with an 1.5 Tesla extremity MRI-scanner using contrast-enhancement and 
according to the RA MRI scoring system (RAMRIS) protocol 42. 
Patients are prospectively followed with scheduled visits at 4, 12 and 24 months. If 
necessary (for instance when the patient noticed swollen joints) patients are seen in between 
the scheduled visits by their rheumatologist. Follow-up ends earlier when clinical arthritis 
has developed.
MRI in Clinically Suspect Arthralgia
Local subclinical inflammation might be present in the early symptomatic phase of RA 
without clinical arthritis 43–45. MRI is a very sensitive imaging modality and more sensitive 
than physical examination to measure local inflammation 42,46. This makes MRI a suitable 
tool for evaluating the earliest inflammatory changes in the small joints of patients that might 
be in the early phase of RA. MRI depicts inflammation of the synovium of joints (synovitis) 
and tendons (tenosynovitis). In addition, it is the only imaging modality that can depict 
bone marrow edema (BME), which is also called osteitis in RA and is a strong predictor 
for progression of joint damage in RA 42,47. The presence of a validated semi-quantitatively 
scoring methodology (the Outcome Measures in Rheumatology Clinical Trials (OMERACT) 
RA MRI scoring system (RAMRIS)) makes MRI very suitable for research as the extent and 
severity of MRI features can be compared objectively 42,48.
SEVERITY OF RA COURSE
The course of RA is variable between patients; some patients have a disabling, persistent 
course with severe joint destruction while others have a more mild disease course. The 
biologic processes underlying these interindividual differences in joint destruction and 
disease persistence are incompletely understood thus far. In addition, differentiating patients 
who will develop a severe disease course from patients with a mild disease course is not yet 
accurate 49,50, hampering individualised treatment. 
To evaluate the disease course in RA several outcome measures are used. Disease 
activity is commonly assessed by the Disease Activity Score (DAS) which is a composite 
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measure of the swollen and tender joint count, the patient global assessment of the disease 
activity on a visual analog scale (VAS) and the level of acute phase reactants 51. Functional 
disability is mostly measured by the Health Assessment Questionnaire Disability Index 
(HAQ-DI) which consists of 20 questions in eight categories of functioning 52. The traditional 
long-term outcome in RA is the severity of destruction of the small joints, one of the hallmarks 
of RA 53. Another important long-term outcome is arthritis persistence. 
Joint damage as disease outcome
The severity of damage of the hand and feet joints, assessed on radiographs is the key outcome 
measure in RA. This outcome measure has several advantages. First, it is considered to reflect 
the cumulative burden of inflammation and thus represents the disease history 53. In addition, 
joint damage is strongly associated with other outcome measures, such as functional disability 
55. And third, it is very suitable as outcome measure for research purposes because of the 
presence of validated scoring methods that allows evaluating the extent of joint damage on 
radiographs objectively 53. 
The most commonly applied scoring method is the Sharp-van der Heijde scoring 
(SHS) method. This measure quantitatively evaluates the extent of erosions (range 0-280) 
and joint space narrowing (which reflects cartilage damage, range 0-168) in both hands and 
feet 56. Another scoring methodology is the Larsen score 57, which gives a combined score 
for erosions and joint space narrowing per joint. The SHS is more sensitive to detect changes 
over time though also more time-consuming than the Larsen score 53.  
To study joint damage, it is preferred that the study population has serial radiographs 
over time instead of one radiograph at a single time point to capture the progression in 
joint damage over time adequately. In addition, when investigating specific risk factors 
for the severity of joint damage the studied patients are ideally untreated to evaluate the 
risk factor in relation to the natural course of joint damage. The latter may be the case for 
patients diagnosed and treated in eras when early tailored treatment and use of biologics 
were uncommon. However, large well-defined longitudinal cohorts including such patients 
are scarce. To overcome these limitations, results of several (small) cohorts can be combined 
in meta-analyses and adjustments can be made for the applied treatment strategy. 
Risk factors for joint damage progression 
Joint destruction is caused by a disbalance between bone degradation and formation. In 
RA, several inflammatory and immune cell types can be present in the synovial membrane. 
Two cell types can be considered of particular importance in destruction of bone and 
cartilage. Synovial fibroblasts are considered important for cartilage degradation. These 
cells, physiologically involved in the secretion of synovial fluid, can be present abundantly in 
the synovial membrane in RA and can behave aggressively with invasion of the underlying 
cartilage. Dysregulated osteoclast activation is mainly involved in bone degradation 1,58. Why 
these processes occur and how they are initiated is incompletely understand, but several risk 
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factors for joint damage have been identified.
The most important risk factor for severe joint damage progression is the presence 
of autoantibodies, mainly ACPA. Also inflammatory markers are associated with more 
severe joint damage progression. Autoantibodies and inflammatory markers together explain 
approximately 30% of variance in joint destruction after 5 years of disease 59. 
In addition, genetic factors play a major role in the severity of joint damage as 
the heritability of the severity of joint damage has been estimated to be 45-58% 60. Several 
genetic risk factors for joint damage have been identified thus far and have been replicated 
in independent cohorts 61, which is needed in the field of genetics to prevent false-positive 
findings. Most findings were done using candidate gene studies 62–71 that were dedicated to 
genes associated with RA development or genes involved in inflammation, immunity or bone 
homeostasis, though hypothesis-free genome-wide association studies (GWAS) have also 
been used 72. The HLA-DBR1 SE was the first identified genetic risk factor for joint damage 
and similar as for the association of the SE with RA development, SE was not associated with 
joint damage progression as such but predisposed to ACPA-positive RA that is associated 
with more severe joint damage 62. In addition, genetic risk factors were identified in CD40, 
C5orf30, IL15, IL2RA, IL4R, DKK1, GRZB, MMP9, OPG and SPAG16 63–72. However, a large 
part of the total genetic effect is considered to be still unexplained.
Arthritis persistence as disease outcome
Persistent arthritis is the other hallmark of RA and can be studied by evaluating its 
opposite: achieving DMARD-free sustained remission which is defined as the sustained 
absence of clinical arthritis at physical examination without the use of DMARDs (including 
corticosteroids). This outcome can be considered the most favourable outcome in RA as it 
approximates cure of RA 54. 
Only a few risk factors for arthritis persistence (absence of achieving DMARD-
free sustained remission) have been reported and replicated. One of these factors is 
prolonged symptom duration at treatment start 23,54, which points to the so-called ‘window 
of opportunity’ in RA. Another risk factor is the presence of autoantibodies 54,59, but these 
explain only a proportion of the variance in arthritis persistence as the large majority of 
autoantibody negative patients have persistent disease and some patients with autoantibodies 
can achieve remission 73. The HLA-DRB1 SE is the only genetic risk factor that has been 
found associated with arthritis persistence thus far. To get more comprehension into the 
mechanisms promoting the chronic nature of RA further risk factors for arthritis persistence 
need to be identified.
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AIMS AND OUTLINE OF THIS THESIS
In general this thesis has two main aims:
1. to investigate the early phase with Clinically Suspect Arthralgia
2. to identify genetic risk factors for disease severity in rheumatoid arthritis 
The thesis contains three parts.
In Part I, the very early phases of RA without clinically detectable arthritis, mainly the 
phase of Clinically Suspect Arthralgia (CSA), is examined. In Chapter 2, it is systematically 
reviewed what is currently known on the preclinical phases of RA. This was done within the 
framework of the phases for the preclinical and early phases of RA formulated by the EULAR 
study group for risk factors for RA. In Chapter 3, the CSA approach and the CSA cohort are 
introduced. The characteristics of patients with CSA are described and the symptoms, signs 
and serological markers that are related to subclinical inflammation on MRI are studied. 
Chapter 4 evaluates whether subclinical MRI-inflammation is, similar as in ACPA-positive 
arthralgia patients, also present in ACPA-negative arthralgia patients who are considered 
prone to progress to RA. For comparisons, also healthy controls and ACPA-negative RA 
patients are evaluated. Chapter 5 is the first longitudinal study on patients with CSA and 
investigates progression from CSA to clinically detectable arthritis. Associations between 
clinical and serological factors and subclinical MRI-inflammation with the development of 
clinical arthritis are examined. In Chapter 6, the diagnostic accuracy of the clinical expertise 
for CSA is explored. Chapter 7 describes the process in which a EULAR taskforce develops 
an expert-opinion based definition for CSA which may serve as the basis for observational 
studies and trials in this phase.
In Part II, genetic risk factors for a more severe course of RA, in particular joint 
damage progression, are investigated. These studies are mainly performed within the Leiden 
Early Arthritis Clinic (EAC) cohort 59. Since 1993 patients with arthritis of at least one joint 
and symptom duration less than two years have been included in this population-based 
inception cohort and prospectively followed during yearly visits. Chapter 8 evaluates the 
contribution of the known genetic risk factors to the variance in the severity of joint damage 
progression and to the accuracy of predicting this severity. Chapter 9-11 describes candidate 
gene studies for the severity of joint damage. In Chapter 9, a variant in FOXO3A that was 
reported to associate with joint damage in RA is replicated. In Chapter 10, a variant in SPP1 is 
studied that was reported to associate with the development of ACPA-negative RA. Chapter 
11 aims to clarify associations of variants in IL6, IL10, C5-TRAF1 and FCRL3 that have been 
reported to associate with joint damage but for which the results of different studies were 
contradictory. Chapter 12 focuses on position 11 at HLA-DRB1 which was recently reported 
to have a strong association with RA development. In Chapter 13, genetic risk factors for 
joint damage are studied in relation to arthritis persistence, another long-term outcome. In 
Chapter 14, serum level osteoprotegerin is studied in relation to arthritis persistence.
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In Part III, other outcomes are studied. In Chapter 15, it is investigated whether 
the occurrence of DMARD-free sustained remission is promoted by improved treatment 
strategies and the relevance of achieving this outcome from patient perspective. Chapter 
16 focuses on fatigue in RA; its eight year course and associations with inflammation and 
improved treatment strategies are studied. 
Finally, Chapter 17 provides a summary and discussion of the results that are 
described in this thesis.
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Introduction
Rheumatoid arthritis (RA) affects 1% of the population worldwide and is characterised 
by persistent inflammation and joint damage. It has repeatedly been observed that early 
initiation of disease-modifying therapy reduces the severity of the disease course, as measured 
by fewer signs and symptoms and less structural damage. Early treatment is associated with 
less severe joint damage progression and increased chances of achieving disease-modifying 
antirheumatic drug-free sustained remission 1,2. Observations that treatment in the very early 
phase of RA is more effective, conceivably because the load of disease cells is smaller or because 
disease mechanisms are not yet settled, have led to increased interest in the earliest disease 
phases. Ideally, this period is used to modify the disease course and improve the outcome 
of RA. The timeframe of this treatment-susceptible period is, however, unknown. Several 
recent studies have provided data indicating that disease processes are already active in the 
preclinical phase (the period before arthritis becomes clinically detectable). Consequently, 
it is at present unclear when RA actually starts. The concept that the disease starts when 
arthritis has become (clinically) detectable is no longer valid.
Herein we systematically review what is presently known of the preclinical phase of 
RA. With the assistance of a medical librarian, we performed a search for the central terms 
“rheumatoid arthritis,” “preclinical,” “autoantibody-positive arthralgia,” and “developing RA” 
in the medical literature databases Medline (Ovid version), PubMed, EMBase (Ovid version), 
and Web of Science up to December 2012 (Figure 1). Findings from the identified articles, 
combined with additional hand-searched articles from the reference lists of the identified 
articles, are summarized here. This overview will lead to the identification of research items 
that need to be explored in order to identify patients in the preclinical phase who will develop 
RA. This may ultimately allow individualized interventions during the preclinical phase.
Basis of pre-RA
Although interest in the preclinical phase has increased considerably during the last 
few years, the idea that disease processes related to RA occur before arthritis is clinically 
detectable was proposed more than two decades ago. The prevalence of rheumatoid factor 
(RF) in the preclinical phase of RA was first observed in Finnish and Icelandic patients 
with RA 3,4. Increased prevalences of antifilaggrin and antiperinuclear antibodies were also 
reported 5,6. The first large longitudinal population study of pre-RA was performed in the 
high-risk population of Pima Indians, showing that the presence of RF was a risk factor for 
the development of RA, and that this risk increased in parallel with the RF level 7. Similar 
observations were noted in a longitudinal study that evaluated another high-risk population, 
multicase families 8,9. These studies have formed the basis for what is now called pre-RA.
Approximately 15 years later, the pre-RA phase received renewed attention. Rantapää-
Dahlqvist et al 10 and Nielen et al 11 studied serum samples from RA patients collected serially 
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in the preclinical phase and observed that the prevalence of autoantibodies increased over 
time and that this increase can take place even years before RA becomes clinically evident. 
These two studies served as subsequent landmark studies, after which the number of 
publications on systemic and local responses and symptoms in the preclinical phase of RA 
rapidly increased (Figure 1).
Figure 1. Number of original publications on the preclinical phases of RA. In total, 964 references were extracted 
from the medical databases Medline (Ovid version), PubMed, EM-Base (Ovid version), and Web of Science. Animal 
studies, reviews, conference abstracts, case reports, case series, studies including patients 18 years of age, and studies 
in languages other than English were excluded. A total of 66 unique publications on systemic autoimmunity (phase 
C) and other systemic or local responses associated with RA and symptoms without clinical arthritis (phase D) 
published before December 1, 2012 were identified.
Definition of pre-RA
Many different terms are used to describe the phases that occur before clinically manifest 
RA. These include “pre-RA,” “preclinical RA,” and “(very) early RA.” In order to achieve 
homogeneity in terminology, in 2011 the study group for risk factors for RA, established by 
the European League Against Rheumatism (EULAR) Standing Committee on Investigative 
Rheumatology, formulated a recommendation for terminology to be used with regard to 
the preclinical and earliest clinically apparent phases of RA 12. Six phases (phases A-F) of 
RA development were formulated. These are phase A, genetic risk factors for RA; phase B, 
environmental risk factors for RA; phase C, systemic autoimmunity associated with RA; 
phase D, symptoms without clinical arthritis; phase E, unclassified arthritis; and phase F, 
RA (Figure 2A). It was emphasized that patients do not have to pass through all phases and 
that the phases do not necessarily occur in the same order before RA eventually develops. In 
addition, a patient can be in two phases concurrently. Importantly, it was also recommended 
that the term “pre-RA” only be used retrospectively. This recommendation was made since if 
all persons who carry certain genetic risk factors or who are exposed to certain environmental 
risk factors were labeled as having pre-RA, many persons who will never develop RA would 
inappropriately have been classified as being in a predisease stage. The proposed phases are 
relevant since they form a framework for future research. Below we review the data available 
on preclinical arthritis within the framework of these study group formulated phases.
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Genetic risk factors for RA
The first phase at which individuals develop an increased risk of RA is at conception, when 
a subject inherits risk alleles for RA from his or her parents (phase A). More than 40 such 
risk alleles are currently known, and the majority of these variants are commonly present. 
When evaluating the frequencies of these risk alleles in the population, the chance that an 
individual carries none of the RA risk alleles is 7.1x10-13%; in other words, almost everyone 
carries one or several of these risk alleles. This calculation underlines the relevance of using 
the term “pre-RA” only retrospectively. These genetic variants have small effect sizes, and a 
large proportion of the population carrying risk alleles never develops RA.
Figure 2. Overview of the preclinical phases of RA and the designs of the studies of the preclinical phases that have 
been performed. (A) The six phases of preclinical and earliest clinically apparent RA, as defined by the EULAR study 
group for risk factors for RA. (B) Nested case-control study design. A predefined set of subjects (e.g., blood donors) 
is followed up. From this set of subjects, RA cases are identified and for each case, a specified number of matched 
controls who have not developed RA is selected. Biomarkers are compared between preclinically collected samples 
from these cases and the controls. (C) Prospective cohort study design. Autoantibody-positive arthralgia patients are 
identified and followed up prospectively.
Environmental risk factors for RA
The heritability of RA has been estimated at 60% 13, implying that 40% of the variance 
in developing RA might be explained by environmental risk factors (phase B). Many 
environmental risk factors have been studied, and smoking is the best replicated environmental 
risk factor 14,15. Smoking predisposes to RA particularly in patients who carry specific HLA-
DRB1 alleles, e.g., smokers carrying two HLA-DRB1 alleles have a 21-fold increased risk of 
developing anti-citrullinated peptide antibody (ACPA)-positive RA 16. Despite the high odds 
ratio in this subgroup, a large majority of smokers do not develop RA. Weaker interactions 
have also been demonstrated between other genes and smoking 17.
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The genetic and environmental risk factors conceptually constitute the earliest 
preclinical phases of RA. These risk factors have already been known for some time, and an 
extensive discussion of these risk factors is beyond the scope of this review.
The next two preclinical phases, “developing systemic autoimmunity associated with 
RA” (phase C) and “symptoms without clinical arthritis” (phase D), have been studied in 
the last few years. This has been done using mainly two different study designs: nested case-
control studies and prospective cohort studies. As will be discussed, the design of the study 
determined the sort of outcome that was obtained and the conclusions that can be drawn.
From RA back to pre-RA systemic autoimmunity
Studies associating RA with systemic autoimmune responses in the preclinical phase (phase 
C, with or without phase A and B) were mainly performed using a nested case-control study 
design (also called case-control studies in a cohort) (Figure 2B). In this type of study, RA cases 
were identified who were members of a predefined dataset, e.g., a cohort of blood donors 
from whom blood samples were obtained at least once 10,18. For each RA patient, a specified 
number of matched controls who had not developed RA was selected from the same dataset. 
Consequently, blood samples from RA cases that were collected and stored years before the 
onset of arthritis could be compared with blood samples from matched controls.
Compared to full prospective cohort studies, the main advantage of this study design 
is the smaller number of study subjects that is required, which coincides with lower efforts 
and costs. However, this study design also has limitations. The cases and controls are selected, 
which may give rise to sampling error and bias. Second, the time of onset of symptoms 
and arthritis in the cases is not exactly known, leaving the timing of the appearance of 
autoantibodies in relationship to the onset of symptoms unexplored. Furthermore, in 
several studies the healthy controls were not carefully evaluated for rheumatic diseases; this 
might have led to an overestimation of the prevalence of autoantibodies in controls and 
an underestimation of the specificity. Using nested case-control studies, the biomarkers 
described below have been identified to be abnormally regulated in the preclinical phases of 
RA (see also Table 1).
Autoantibodies - In the nested case-control studies by Rantapää-Dahlqvist et al 10 
and Nielen et al 11, 83 Swedish patients with RA (73.1% IgM-RF-positive and 70.1% ACPA-
positive) and 79 Dutch patients with RA (frequencies of autoantibodies at diagnosis not 
reported), respectively, who were donors to a blood bank before symptom onset were studied 
10,11. A total of 98 pre-RA blood samples were available for the patients in the Swedish study, 
and a total of 1,078 pre-RA blood samples were available for the patients in the Dutch study. 
In the Swedish study, the presence of IgM-RF and ACPA was reported in 19.3% and 33.7%, 
respectively, of the RA cases within 10 years before RA diagnosis, compared to 6.0% and 1.8%, 
respectively, of the matched controls 11. Similarly, in the Dutch dataset, 27.8% of the patients 
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were IgM-RF-positive and 40.5% were ACPA-positive within 15 years prior to RA diagnosis, 
compared to 1.1% and 0.6%, respectively, of the matched controls 10. Similar frequencies of 
IgM-RF and ACPA in the pre-RA phase were reported in several cohorts in Norway, Sweden, 
and the US 18–21. Even higher frequencies were reported in the pre-RA phase in a military 
cohort in the US (57% IgM-RF-positive and 61% ACPA-positive) 22. Comparison of these 
frequencies with the prevalence of IgM-RF and ACPA observed in other patients with early 
arthritis (58% and 53%, respectively 2) is potentially scientifically incorrect; nonetheless, this 
comparison suggests that in a large proportion of autoantibody-positive RA patients the 
autoantibodies are already present in the preclinical period.
Based on the proportion of RA cases with autoantibodies in the preclinical phase 
(sensitivity) and the proportion of controls without autoantibodies (specificity) in the studied 
cohorts, the risk of developing arthritis for individuals with autoantibodies in the general 
population was estimated. In these calculations the population-based frequency of RA was 
set as a pretest probability. The risk of developing RA within 5 years 11 and at any time in life 
10 was estimated at 1.5% and 4%, respectively, in subjects who were IgM-RF-positive and 5.3% 
and 16%, respectively, in subjects who were ACPA-positive.
Regarding the time course of autoantibody development, the frequency of 
autoantibody positivity as well as the levels of these autoantibodies increased approaching the 
onset of symptoms 10,11,18,22,23. It is unclear whether IgM-RF or ACPA appears earlier in time. 
Although in the Swedish cohort IgM-RF could be detected earlier than ACPA 10, in the Dutch 
cohort ACPA was detected earlier than IgM-RF (median duration from seroconversion to 
symptom onset 2.0 years for IgM-RF and 4.8 years for ACPA) 11. In a US cohort, IgM-RF and 
ACPA appeared concurrently in the pre-RA phase (6.0 years for IgM-RF and 5.4 years for 
ACPA) 22. With regard to the ACPA response, the number of epitopes to which the response 
is directed increased over time and in parallel with the increase in ACPA level approaching 
the onset of symptoms, revealing that this response matures in the preclinical disease phases 
24–26.
Markers of systemic inflammation - Various acute-phase reactants, cytokines, 
cytokine-related factors, and chemokines were measured in serum samples that were collected 
once (one sample per case) or serially from RA patients prior to symptom onset. In the studies 
in which serum was obtained at a single time point, the period between sample collection and 
RA diagnosis was variable, with a maximum of 20 years; only a small number of samples were 
obtained within one year of symptom onset. These studies with single samples do not allow 
drawing conclusions with regard to the evolution of systemic markers of inflammation over 
time before arthritis onset, and negative findings are difficult to interpret since they might 
potentially be the result of analyzing samples that were obtained too early.
None of the single serum sample-based studies, except for one 27, demonstrated 
increased levels of C-reactive protein (CRP) or other acute-phase reactants (i.e., secretory 
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phospholipase A2) during the pre-RA phase, irrespective of autoantibody status or time 
to diagnosis 20,27–30. However, a study evaluating serially collected serum samples from 
autoantibody-positive RA cases demonstrated increased levels in significantly more cases 
than controls 31. Other investigators measured CRP serially over time in serum samples 
collected from RA patients during the preclinical period and observed a statistically 
significant increase in median CRP levels, although within the normal range, in the periods 
4-5 years, 1-2 years, and 0-1 years prior to diagnosis 32. A gradual increase in CRP level was 
observed both in autoantibody-positive and autoantibody-negative cases, with the highest 
level observed at the time closest to arthritis onset. Furthermore, at all preclinical time 
points studied, the autoantibody-positive patients had slightly higher CRP levels than the 
autoantibody-negative patients 32.
Over 30 different cytokines have been studied using different techniques with different 
sensitivities; the majority of these were measured in the single serum sample-based studies. 
Since the time period between collection of serum sample and RA onset was variable in these 
studies, the results cannot be easily compared to look for replication. Nonetheless, the levels 
of some cytokines (tumor necrosis factor α [TNFα] and/or the soluble TNF receptor type I/II, 
which parallels TNFα levels, and interleukin-6 [IL-6]) were increased during the preclinical 
phase in several studies. Both TNFα and IL-6 levels were significantly increased during 
the pre-RA phase in most 18,19,24,30,31,33 but not all studies 18,29,33. More variable results were 
found for other markers, including different interleukins, granulocyte-macrophage colony-
stimulating factor, monocyte chemotactic protein 1, and interferon-γ. In the presence of 
increased cytokine levels, these results were most often found in both autoantibody-positive 
and autoantibody-negative cases, but autoantibody-positive cases had generally higher levels 
than the autoantibody-negative cases 19,24,29. These levels were also the highest close to the 
diagnosis of RA 19.
It remains unclear whether levels of the inflammatory markers increase before, after, 
or simultaneously with the development of autoantibodies. No time lag was found between 
the increase in CRP level and the presence of autoantibodies in some studies 32,34, whereas 
another study suggested a longer predating period for autoantibodies than for increased 
cytokine levels 18. Consistent with this finding, a recent study showed that the increase in 
ACPA level was followed by an elevation in cytokine levels 24. Interestingly, Deane et al 
studied serum samples from cases that were ACPA-negative but would later in the pre-RA 
period become ACPA-positive and showed higher proportions of positive cytokines in these 
samples than in control samples, suggesting that the increase in autoantibodies occurred later 
in time than the change in the levels of inflammatory markers 31.
Biomarkers of bone metabolism - Two nested case-control studies examined some 
markers of bone metabolism during the preclinical phase, but no definitive conclusions could 
be drawn. One study reported a higher prevalence of increased levels of cartilage oligomeric 
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matrix protein, but this was only present in a subgroup of autoantibody-negative patients 
during the period closest to diagnosis 21. The other study reported an increase in N-terminal 
type I procollagen propeptide and osteoprotegerin; this latter finding is not straightforward 
to explain 35.
Lipid profile and cardiovascular disease - Whether the lipid profile is changed in the 
preclinical phase is also unknown. Although a more atherogenic lipid profile was found in 
preclinical serum samples from RA patients compared to controls in one study 36, in a North 
American study increased levels of proatherogenic factors were less prevalent in pre-RA cases 
compared to controls 37. Large studies were performed on the risk of cardiovascular disease, 
and contradictory results were also observed in those studies. Both increased and similar 
prevalences of myocardial infarction and coronary heart disease in patients in the preclinical 
phase of RA compared to controls were reported 38–40.
From autoimmunity with symptoms to clinical arthritis
In the nested case-control studies described above, the phases F (RA) and C (systemic 
autoimmunity) were studied, without addressing the phase in between (phase D, symptoms 
without clinical arthritis). A combination of phase C (systemic autoimmunity, with or 
without phase A and B) and phase D, however, was the starting point of prospective studies 
that examined progression from autoantibody-positive arthralgia to the onset of arthritis. 
The large majority of the published prospective data originate from the same cohort of 
patients with arthralgia in Amsterdam, the Netherlands. Patients with a combination of 
any kind of nontraumatic arthralgia and IgM-RF or ACPA positivity were recruited and 
followed up 41. After a median duration of 7–12 months, 18–35% of the autoantibody-positive 
arthralgia patients developed clinically detectable arthritis 41–48. Interestingly, as described 
above, in patients without symptoms (phase C) the chance of RA development in those 
who were ACPA-positive was estimated to be 5.3% 11 and 16% 10 and thus was seemingly 
lower than the chance observed in patients with autoantibodies and arthralgia included in 
the Amsterdam study. In this cohort study there were no requirements regarding the type of 
symptoms, which is consistent with the description of phase D by the EULAR study group 
12 where the type of symptoms that predispose to RA were also not explicated. Intriguingly, 
however, in a subanalysis of patients with so-called inflammatory arthralgia (defined as 
symmetric arthralgia of small joints), 6 of 10 patients developed arthritis 41. The risk factors 
for progression to clinical arthritis that were identified are described below (see also Table 
2). For most factors, identification was based on one cohort study and replication in other 
longitudinal studies is still lacking.
Autoantibodies - The presence and level of ACPA 41 and the number of recognized 
epitopes 45 were associated with arthritis development (90% of the arthralgia patients who 
developed arthritis were ACPA-positive, compared to 58% of the patients who did not develop 
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arthritis). In this cohort, the presence of IgM-RF (but not its level) was only associated with 
arthritis development in the concomitant presence of ACPA 41.
Markers of systemic inflammation - Although some markers showed a trend toward 
higher levels in the patients who developed arthritis, no acute-phase reactant or cytokine was 
significantly associated with an increased risk of arthritis 41,47.
Lipid profile and cardiovascular risk - Slight differences were seen in lipid profile 
between the patients whose symptoms did and those whose symptoms did not progress to 
arthritis. After adjustment for ACPA status, a lower apolipoprotein A-I level was associated 
with progression to arthritis 48. Another observational study of the Amsterdam cohort 
examining IgM-RFM- and/or ACPA-positive individuals with arthralgia or individuals with 
a family history of RA showed that smoking and being overweight were associated with 
arthritis development 49.
Imaging of local joint inflammation in the preclinical phase - Thus far, we have 
not yet discussed whether there is local inflammation in the joints in the preclinical phase. 
Practical, and perhaps also ethical, hurdles hamper performing synovial biopsies in patients 
with symptoms without clinical arthritis. Nonetheless, inflammation was demonstrated in 
synovial tissue from clinically uninvolved knees in RA patients who later developed clinically 
detectable arthritis in the biopsied knee, indicating that a phase of asymptomatic arthritis 
precedes clinical arthritis 50.
Recently, three different imaging modalities (ultrasonography, magnetic resonance 
imaging [MRI], and positron emission tomography [PET]) were used in cross-sectional or 
prospective studies of autoantibody-positive patients with arthralgia, assessing the presence 
of local subclinical inflammation. The study that used ultrasonography demonstrated 
abnormalities that were associated with progression to arthritis at the level of the joint but not 
at the level of the patient 44. More studies of ultrasonography are required to evaluate whether 
it is valuable for identifying preclinical inflammation.
Another study from Amsterdam used PET and observed increased uptake on the 
hand or wrist in 4 of the 9 ACPA-positive arthralgia patients who later developed arthritis 
46. A comparable study evaluating MRI of the knees of autoantibody-positive arthralgia 
patients did not find differences between patients who did and those who did not progress to 
clinical arthritis. It was not reported what proportion of the scanned patients had symptoms 
in the scanned knee 43. A recent cross-sectional MRI study was performed on a different 
set of ACPA-positive arthralgia patients than those included in the prospective cohort 
described above and evaluated inflammation using MRI of the hand and foot joints 51. ACPA-
positive patients with arthralgia of small joints had higher MRI inflammation scores than 
healthy controls, but lower scores than ACPA-positive RA patients. Furthermore, the MRI 
inflammation levels were significantly associated with the CRP levels in the ACPA-positive 
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arthralgia patients 51. These data support the notion that there is also local inflammation in 
the preclinical phase of RA. Despite these positive initial findings, the numbers of patients 
included in these studies were small, and further imaging studies are needed to increase 
insight into processes occurring locally in the joint in the preclinical phase.
Summary of what is acknowledged
In summary, multiple studies have evaluated various biomarkers in the preclinical phases 
of RA. There is convincing evidence that autoantibody development and maturation occurs 
before clinically detectable arthritis develops. The time course between autoantibody and 
symptom development is still indefinite, and multiple large prospective studies starting in 
the symptom-free period have not been published. Furthermore, based on the data available, 
there is suggestive evidence that inflammation occurs in the preclinical phase of RA, both 
locally in the joint and measurable in the systemic circulation. Some of the results on this 
subject are contradictory, however, as increased levels of acute-phase reactants and cytokines 
were observed in some of the nested case-control studies, but not in the prospective cohort 
study. The time course between the appearance of autoantibodies and inflammation also 
remains to be elucidated.
There are factors that should be taken into consideration when interpreting the results 
of the studies reviewed here. The number of RA cases in most studies was not large, and 
in the prospective studies depended on the duration of follow-up. In addition, the available 
findings obtained in prospectively followed up autoantibody-positive arthralgia patients 
are largely based on a single Dutch cohort. Hence, these data are not yet replicated and the 
generalizability of the findings has not yet been assessed. Future studies in large and different 
cohorts are required for validation.
What subsequently needs to be assessed?
Although evidence has emerged that autoimmune deregulation starts in the preclinical phase, 
several major issues are yet unexplored. Table 3 provides a research agenda. The biologic basis 
for the development of RA-related autoimmunity is not yet elucidated. It has been suggested 
that RA-related autoantibodies are generated on extraarticular sites and are associated with 
mucosal inflammation 52–54. Associations with periodontitis, antibodies to Porphyromonas 
gingivalis 52,53, and airway abnormalities 54 have been described, but the causality is unclear.
Observations that autoantibodies against citrullinated vimentin can activate 
osteoclasts 55 and that the presence of RF is a significant predictor of cardiovascular events 
and mortality in individuals without RA 56 suggest that the presence of these autoantibodies is 
harmful. Given the prevalence of ACPA in the general population of 1%, a relevant question 
is to consider when the presence of autoantibodies is benign or detrimental.
For individuals with abnormal test results, e.g., the presence of RA-related 
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autoantibodies or abnormalities on imaging, the main question is what the absolute risk is 
for progression to arthritis. These risks may differ in the presence of several other abnormal 
test results and also depend on the presence or absence of certain symptoms. Furthermore, 
in order to explore the preclinical phase at the individual level, the persons who will progress 
to developing arthritis and RA need to be identified with high accuracy (for instance with 
a greater than 80% chance of arthritis/RA development if test results are positive). The 
development of such risk stratification is basic to the design of preventive trials. To date, one 
preventive trial has been performed in a total population of autoantibody-positive arthralgia 
patients; dexamethasone was not effective in the median study period of 26 months 57.
Longitudinal cohort studies
Large and multiple prospective follow-up studies are needed to answer these questions and 
to validate the answers. Fortunately, several initiatives have been formed to establish such 
cohorts, starting with either the general population or high-risk populations (e.g., family 
members of RA patients, arthralgia patients, or ACPA-positive individuals). One of the 
approaches of the Studies of the Etiology of RA (SERA) group in the US and of El-Gabalawy 
et al in studying North American Native populations in Canada is to start with persons who 
are at increased risk because of family history 58. These first-degree relatives of RA patients 
who do not themselves have clinical arthritis are being followed up. The Canadian North 
American Native population forms a unique population to identify individuals who may 
be in the pre-RA period because of the high prevalence of ACPA (4-19%) and RA (±3%) 
59. Cross-sectional baseline results of these studies have already shown higher levels of 
multiple inflammation markers 60 and an association of some inflammation markers with 
autoantibodies in these first-degree relatives without clinical arthritis 61.
The two available cohorts of autoantibody-positive individuals from Amsterdam, 
the Netherlands, are extensively described in this review 41,43. The Leiden approach is to 
longitudinally study patients with “clinically suspect arthralgia.” This indicates arthralgia 
that, because of the character of the symptoms, the rheumatologist suspects will progress 
to arthritis over time; IgM-RF or ACPA-positivity is not required. The presence of local 
inflammation in all of these persons will be studied in detail with dedicated extremity MRI of 
the wrist, hand, and foot joints.
Hopefully, the results of future studies will increase our understanding of the 
processes occurring during the preclinical phase of RA and enable targeted intervention in 
these processes before the clinical picture that is characteristic for RA has evolved.
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Table 3. Research agenda for examining the preclinical phase of RA
1. Where (in what tissue or organ) does inflammation in the light of RA start? 
2. What is the timing between genetic factors, environmental exposures, and the development of autoimmunity 
and arthritis? Similarly, what is the temporal relationship between the onset of inflammation, autoantibodies 
and symptoms in the pre-RA phase?
3. In which persons or circumstances is the presence of RA-related autoantibodies not harmful and not 
associated with progression towards disease and in which persons or circumstances are RA-related 
autoantibodies detrimental, indicating a very early phase of RA?
4. What is the predictive value of the variables mentioned below in the pre-RA stages A, B, C and D for the 
development of RA? 
• Genetic and epigenetic variants
• Environmental factors
• RA-related autoantibodies
• Serologic inflammation markers




5. Does preclinical inflammation occur in ACPA- and/or RF-negative RA?
6. Can we, with the help of prospective studies, adequately identify the individuals who will progress to RA in 
each of the pre-RA phases? (This may be challenging given the low prior chance on RA in the earliest pre-RA 
phases) Such risk stratification is basic to the development of dedicated preventive trials in the pre-RA phases. 
7. Does treatment in the pre-RA phase prevent disease chronicity?
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The phase of arthralgia is the earliest moment to clinically recognize patients who may develop 
Rheumatoid Arthritis (RA). Previous imaging studies in the arthralgia phase have shown 
that inflammation precedes RA development. It is unknown which symptoms/characteristics 
relate to subclinical joint inflammation as measured by MRI. Among all patients with 
arthralgia, those with clinically suspect arthralgia (CSA) are suspected to progress to arthritis 
according to the clinical judgement of their rheumatologists. We determined the symptoms/
characteristics of patients with CSA who had inflammation on MRI. 
Methods 
102 patients with CSA and without clinical arthritis were included. They completed 
questionnaires, underwent joint counts and unilateral 1.5T MRI of MCP joints 2–4, wrist 
and MTP joints 1–5. Synovitis, bone marrow edema (BME) and tenosynovitis were scored 
according to the OMERACT rheumatoid arthritis MRI scoring system. Symptoms and signs 
were related to MRI inflammation (based on MRI scores in symptom-free controls; a sum 
of synovitis, BME and tenosynovitis scores ≥3 was considered positive). Whether certain 
clinical characteristics frequently occurred together with MRI inflammation was studied by 
partial least squares analysis. 
Results 
MRI was performed in 93 patients with CSA, 44% of whom had subclinical MRI 
inflammation. Synovitis was the most prevalent inflammatory feature on MRI (20%). Patients 
with MRI inflammation were older and were more frequently positive for anti-citrullinated 
peptide antibodies than patients without MRI inflammation (p<0.001 and 0.049). In PLS 
analysis, including 16 clinical and serological characteristics as independent variables and 
MRI inflammation as dependent variable, no clear clusters of patients with and without MRI 
inflammation were identified.
Conclusions 
Subclinical inflammation as measured by MRI is present in 44% of patients with CSA. A 
combination of symptoms/characteristics incompletely differentiated patients with and 
without MRI inflammation.
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INTRODUCTION
Rheumatoid arthritis (RA) has a period of preclinical disease. According to a recent EULAR 
study group, this period can be split into several phases namely, genetic and environmental 
risk factors for RA, systemic autoimmunity associated with RA,  symptoms  without  clinical 
arthritis  and unclassified arthritis 1. Although genetic and serological risk factors for RA 
have been extensively studied 2,3, the phase of symptoms without clinical arthritis is relatively 
unexplored. The type of arthralgia and concomitant symptoms that are characteristic 
of a preclinical phase of RA have not yet been studied. Also, regularly used terms such as 
inflammatory arthralgia are not uniformly defined. 
Early treatment of RA and thus early identification of disease is associated with 
improved disease outcome 4,5. Hence, there is a need to characterize the patients with 
arthralgia who are actually at risk of RA in order to identify them from the many patients 
presenting with arthralgia to rheumatology outpatient clinics. 
Previous studies on the preclinical phase of symptoms without clinical arthritis 
evaluated patients with any arthralgia who had an increased risk of RA because of the presence 
of anti-citrullinated peptide antibodies (ACPA) or rheumatoid factor (RF). Of these patients, 
18–35% developed arthritis after a median follow-up of around 12 months 6–8. As only 60% of 
patients with RA are ACPA-positive 9 and ACPA are also prevalent in the population who do 
not progress to RA 10,11, we decided to study the preclinical phase with a different approach. 
We started from a clinical point of view and  evaluated patients presenting with recent-onset 
arthralgia that was, according to the rheumatologist, clinically suspected to progress to RA 
over time; this was called ‘clinically suspect arthralgia’ (CSA). Whether or not a patient had 
CSA was decided by the treating rheumatologist at the first visit before any laboratory results 
were known; having autoantibodies was not a requirement for having CSA. 
It is known that systemic markers of inflammation are increased in the preclinical 
phase of RA 6,12–18. Local inflammation in small joints has also been observed using different 
imaging technologies 19–21. MRI is a sensitive tool and is more sensitive than physical 
examination to measure local inflammation 22. It detects synovitis, bone marrow edema 
(BME), this is also called osteitis and tenosynovitis, and is most suitable for evaluating the 
earliest inflammatory changes in the small joints of patients considered potentially to be in 
the preclinical phase of RA 23,24. 
Our ultimate aim is to identify patients with RA at the stage of having symptoms 
without clinical arthritis. In this study we considered the presence of local subclinical joint 
inflammation on MRI as a proxy for RA-at-risk. We aim to describe the characteristics of 
patients with CSA and to investigate in these patients the symptoms, signs and laboratory 
markers that are related to subclinical local inflammation visualised by MRI. 
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METHODS
Clinically suspect arthralgia (CSA) cohort
The CSA cohort is a population-based inception cohort started in April 2012 at the 
rheumatology outpatient clinic in Leiden, the Netherlands, with the aim of studying the 
preclinical phase of RA. The Leiden University Medical Centre is the only rheumatology 
referral centre in a healthcare region of 400,000 inhabitants. The inclusion criterion was the 
presence of arthralgia of the small joints for <1 year which, because of the character of the 
symptoms, was considered by the rheumatologist as being suspect to progress to arthritis 
over time. Thus, inclusion was essentially based on the ‘gut feeling’ of the rheumatologist. As 
it is not known which symptoms are predictive for arthritis development, no further criteria 
were included with regard to the type of symptoms. Importantly, when clinical arthritis was 
present at physical examination or another explanation for the arthralgia was likely such as 
Heberden’s or Bouchard’s nodes or tender points, the patients were not included.
The set-up of the rheumatology outpatient clinic of the Leiden University Medical 
Center is uniquely suited to identify patients in an early disease phase. For several years 
general practitioners have been encouraged to send any patient with a suspicion of arthritis 
to our outpatient clinic. The focus on early recognition was enhanced by the institution of an 
Early Arthritis Recognition Clinic (EARC) in 2010 25. Although the aim of this EARC was to 
improve early detection of clinically detectable arthritis, it also provided the opportunity to 
identify patients with clinically suspect arthralgia.
At the first visit to the rheumatology outpatient clinic a senior rheumatologist 
or rheumatologist in training supervised by a senior rheumatologist decided, based on 
the findings of anamnesis and physical examination, whether a patient had clinically 
suspect arthralgia. After informed consent and inclusion, the rheumatologist completed 
questionnaires regarding the presenting symptoms (onset, character, localisation), current 
symptoms (inflammatory character, morning stiffness, fatigue) and medical and family 
histories. Patients filled out questionnaires regarding social status, smoking, alcohol use and 
work ability, the Health Assessment Questionnaire (HAQ), the Short-Form health survey-36 
(SF-36) and the perceived stress scale. A 66-swollen joint count and 68-tender joint count 
(66-SJC and 68-TJC) were performed by trained research nurses. Blood samples were taken 
for routine diagnostic laboratory screening (including C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), IgM-RF and ACPA (anti-CCP2, Eurodiagnostica, the Netherlands) 
and stored to determine other serum markers at a later time. An MRI was performed when 
no contraindications for MRI were present. Patients were followed longitudinally for the 
development of arthritis for at least 2 years with scheduled visits at 4, 12 and 24 months. If 
considered necessary (e.g., if patients noticed swollen joints), patients were seen in between 
the scheduled visits by their rheumatologist. At each follow-up visit, questionnaires were 
completed, joint counts were performed and blood samples taken. Follow-up ended earlier 
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when arthralgia had progressed to clinical arthritis. This study evaluated baseline data.
MRI scanning and scoring
MRI of the hand (wrist and metacarpophalangeal (MCP) joints) and forefoot 
(metatarsophalangeal (MTP) joints) was performed within 2 weeks of clinical assessment at 
the most painful or, in the case of equally severe symptoms on both sides, the dominant side. 
Patients were asked not to use any nonsteroidal anti-inflammatory drugs (NSAIDs) during 
the 24 hours before MRI. The joints were scanned with an MSK-extreme 1.5T MRI-scanner 
(GE, Wisconsin, USA). For the MCP joints and wrist the following sequences were acquired: 
coronal T1-weighted fast spin echo (FSE) and T2-weighted FSE with frequency selective fat 
saturation (fatsat) and, following intravenous administration of 0.1 mmol/kg gadolinium 
contrast, coronal and axial T1-weighted FSE fatsat. For the MTP joints, axial T1-weighted 
FSE and T2-weighted FSE fatsat sequences were obtained. Because of time limitations, post-
contrast and coronal sequences were initially not obtained for the MTP joints. After 78 MRIs 
had been performed, post-contrast and coronal sequences were also performed in the feet 
(see online Supplementary File 2 for a detailed scan protocol).
Synovitis and BME were scored according to the Outcome Measures in Rheumatology 
Clinical Trials (OMERACT) rheumatoid arthritis MRI scoring system (RAMRIS) 23. Although 
the RAMRIS was not developed to score MTP joints, others have previously adapted the 
RAMRIS to score MTP joints as well 26. Tenosynovitis in the MCP joints and wrists was 
assessed as described by Haavardsholm et al 24. Scoring was performed by one trained reader 
(HWvS) who was blinded to clinical data; the within-reader intraclass correlation coefficient 
for the total RAMRIS score was 0.94 and for the combined inflammation score was 0.91. 
The combined inflammation score (sum of the synovitis, BME and tenosynovitis scores) 
was the main measure of local subclinical MRI inflammation. The cut-off for the presence of 
MRI inflammation was defined using the MRI scores (scored by HWvS) of 19 symptom-free 
healthy subjects of comparable age and gender (mean age of controls 46 years, 79% women) 
who underwent MRI of the MCP, wrist and MTP joints on the dominant side, as described 
previously 20. A combined inflammation score of ≥2, ≥3 and ≥4 was present in 21%, 10% and 
0% of these healthy subjects, respectively. Based on this, a cut-off of ≥3 was primarily used.
Statistical analyses
MRI scores were studied after dichotomisation. Characteristics were compared using χ2 tests, 
unpaired t tests and Mann-Whitney U tests as appropriate.
To explore whether a combination of certain clinical and serological characteristics 
frequently occurred together in patients with subclinical MRI inflammation, partial least 
squares discriminant analysis (PLS-DA) was used. PLS analysis does not test the statistically 
significance of differences between groups but is a variable reduction technique. It combines 
variables that frequently occur together in the so-called latent factors and presents for each 
factor the variance in the outcome that is explained by this factor. Ideally, one finds a few 
50 |       Chapter 3
3
latent factors that explain most of the observed variance. PLS-DA is the variant of PLS with a 
categorical outcome. Gender, age, presence of family history of RA, symptom characteristics 
(duration, onset, localisation, morning stiffness), 68-TJC, body mass index (BMI), smoking, 
ESR, CRP and the presence of IgM-RF and ACPA were included in the PLS as independent 
variables and the presence of MRI inflammation was included as untransformed dependent 
variable. Identified latent factors were plotted to explore whether there were distinguishable 
groups of patients which may represent patients with and without MRI inflammation.
The best cut-off point for clinically relevant MRI inflammation (associated with RA 
development) is not yet known and will be revealed by longitudinal studies. For this study 
we have used a cut-off score of ≥3 to dichotomise the group for the presence or absence of 
MRI-defined inflammation. In subanalyses a cut-off score of ≥4 for MRI inflammation was 
evaluated.
SPSS V.20.0 was used for analysis; p-values<0.05 were considered significant.
RESULTS
Clinical characteristics of patients with CSA
Between April 2012 and August 2013, 1,558 patients presented to the rheumatology outpatient 
clinic of the Leiden University Medical Centre with arthralgia. Of these, 102 (6.5%) were 
considered as being clinically suspect for progression to arthritis and included in the CSA 
cohort. The main reasons provided by rheumatologists to consider the arthralgia as clinically 
suspect were: joint pain that was worst in the early morning and improved with movement 
during the day; the presence of morning stiffness for ≥60 min; and a positive family history 
for RA. Table 1 presents the baseline characteristics of the included patients and Figure 1 
shows the location of their tender joints.
MRI characteristics of patients with CSA
MRI was performed in 93 patients. For the final analysis a combined inflammation score 
of ≥3 was used, but the components of all the MRI characteristics are shown in Table 2 
and in online Supplementary Table 1. Most individual lesions had a RAMRIS score of 1. 
Particularly for BME, bones with a score of 2 or 3 were rare. When evaluating the total scores 
for synovitis, BME and tenosynovitis separately, 52.7%, 51.6% and 35.5%, respectively, of 
the patients had a score of ≥1. Likewise, 20.4%, 9.7% and 10.8% had a score of ≥3 for the 
respective individual MRI features (Table 2). When summing the scores of all three MRI 
features, 41 patients (44.1%) had a combined inflammation score of ≥3 and were considered 
as ‘MRI inflammation positive’.
Most inflammatory features were observed in the bones and joints of the wrist. 
Synovitis was most prevalent in the intercarpal, radiocarpal, MTP1 and MCP3 joints. BME 
occurred mainly in the capitate, lunate and MTP1. Tenosynovitis was most frequent in MCP3 
(see online Supplementary Table 1 for a complete overview). Figure 2 presents examples of 
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patients with subclinical inflammation on MRI.
Table 1. Patient and symptom characteristics (n=102)
Characteristic
Women, n (%) 74 (72.5)
Age in years, mean (SD) 43.3 (13.3)
Family history of RA, n (%) 50 (32.4)
Symptom duration
  In weeks, median (IQR) 15.1 (8.9–26.4)
  ≤12 weeks, n (%) 36 (36.7)
Symptom onset
  Gradual (>1 week, either continuous or waxing and waning), n (%) 80 (78.4)
  Subacute (<1 week), n (%) 21 (20.8)
Character of initial symptoms*
  Pain, n (%) 95 (93.1)
  Stiffness, n (%) 70 (68.6)
  Functional disability, n (%) 28 (27.5)
Localisation of initial symptoms
  Small joints, n (%) 81 (79.4)
  Small and large joints, n (%) 15 (14.7)
  Large joints, n (%) 6 (5.9)
Localisation of initial symptoms
  Upper extremities, n (%) 68 (66.7)
  Upper and lower extremities, n (%) 24 (23.5)
  Lower extremities, n (%) 9 (8.8)
Localisation of initial symptoms
  Symmetrical, n (%) 73 (71.6)
  Asymmetrical, n (%) 29 (28.4)
Presence of inflammatory character joint pain†, n (%) 78 (76.5)
Presence of morning stiffness ≥60 minutes, n (%) 44 (43.1)
Presence of fatigue, n (%) 27 (26.5)
HAQ median (IQR) 0.56 (0.25–0.88)
Daily use of NSAIDs, n (%) 20 (19.6)
BMI in kg/m2 median (IQR) 25.1 (22.8–29.6)
68-TJC median (IQR) 6 (3–11)
Current smoker, n (%) 21 (20.6)
Current alcohol user§, n (%) 66 (66.7)
Autoantibody status
  ACPA- and/or IgM-RF-positive, n (%) 29 (28.4)
  Only ACPA-positive (>7 U/mL), n (%) 4 (3.9)
  Only IgM-RF-positive (>3.5 IU/mL), n (%) 14 (13.7)
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  ACPA and IgM-RF-positive, n (%) 11 (10.8)
Increased CRP (>10 mg/L), n (%) 14 (13.7)
Increased ESR (reference for age), n (%) 13 (12.7)
Symptoms were noted by rheumatologists as reported by the patients. Data on symptom duration and BMI were 
missing in four patients; symptom onset, intermittent symptoms present and initial localisation (upper, upper and 
lower, lower, symmetrical, asymmetrical) were missing in one patient; 68-TJC was missing in three patients; alcohol 
use was missing in three patients; and HAQ was missing in 24 patients. *A patient can have more than one character 
of the initial symptoms. †Defined as joint pain that is worst in the early morning and improves with movement 
during the day. §Patients not consuming daily alcohol but only one or few beverages a week were considered as 
alcohol users.
Figure 1. Localisation of tender joints in the patients with CSA without clinical arthritis. Data presented are 
percentages of patients; since a patient can have several tender joints, the total exceeds 100%. The median (IQR) 
68-tender joint count was 6 (3–11).
Comparison of patient characteristics and subclinical MRI inflammation
Characteristics were compared between patients with (n=41) and without subclinical MRI 
inflammation using the predefined cut-off score of ≥3 (n=52) (Table 3). Patients with MRI 
inflammation were significantly older (mean 50.4 years vs 37.9 years, p<0.001) and more 
frequently ACPA-positive (22.0% vs 7.7%, p=0.049). Patients with MRI inflammation also 
had a non-significant tendency to more frequently have a subacute symptom onset, symptom 
onset in both small and large joints and in the lower extremities, morning stiffness ≥60 min, 
a higher BMI, a lower 68-TJC and an increased ESR.
Clustering of variables
Subsequently, to identify whether a combination of symptoms, signs and serological markers 
could distinguish the subsets of patients with and without subclinical MRI inflammation, a 
PLS analysis was performed with the presence of MRI inflammation as the outcome. Two 
latent factors were found that together explained 42.0% of the observed variance in MRI 
inflammation. The major important variables in these latent factors are patient groups were 
observed, although a slight tendency to some clustering was noted (Figure 3).
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Table 2. Frequencies of MRI-features in patients with CSA, assessed using the RAMRIS dichotomised at several 
cut-off points
≥1 ≥2 ≥3 ≥4
Synovitis score
  All joints 49 (52.7%) 28 (30.1%) 19 (20.4%) 9 (9.7%)
  MCP joints 20 (21.5%) 7 (7.5%) 5 (5.4%) 4 (4.3%)
  Wrist 35 (37.6%) 20 (21.5%) 5 (5.4%) 2 (2.2%)
  MTP joints 20 (21.5%) 4 (4.3%) 2 (2.2%) 2 (2.2%)
BME score 
  All joints 48 (51.6%) 22 (23.7%) 9 (9.7%) 3 (3.2%)
  MCP joints 5 (5.4%) 1 (1.1%) - -
  Wrist 38 (40.9%) 12 (12.9%) 5 (5.4%) 2 (2.2%)
  MTP joints 17 (18.3%) 4 (4.3%) 1 (1.1%) 1 (1.1%)
Tenosynovitis score*
  All joints 33 (35.5%) 16 (17.2%) 10 (10.8%) 5 (5.4%)
  MCP joints 25 (26.9%) 10 (10.8%) 6 (6.5%) 4 (4.3%)
  Wrist 17 (18.3%) 8 (8.6%) 4 (4.3%) 1 (1.1%)
  MTP joints NA NA NA NA
Combined inflammation score†
  All joints 71 (76.3%) 55 (59.1%) 41 (44.1%) 27 (29.0%)
  MCP joints 33 (35.5%) 19 (20.4%) 9 (9.7%) 9 (9.7%)
  Wrist 56 (60.2%) 39 (41.9%) 26 (28.0%) 13 (14.0%)
  MTP joints 30 (32.3%) 12 (12.9%) 3 (3.2%) 3 (3.2%)
* Not assessed in the feet. †Sum of synovitis, BME and tenosynovitis scores. Median total synovitis, BME, 
tenosynovitis and combined inflammation scores were all low, respectively 1 (IQR 0-2), 1 (IQR 0-1), 0 (IQR 0-1) 
and 2 (IQR 1-4). The potential range for the MRI scores according to RAMRIS are 0-36 for synovitis, 0-54 for 
tenosynovitis, 0-99 for BME and 0-189 for combined inflammation. NA=not assessed.
Subanalyses
MRI inflammation was defined as a combined inflammation score of ≥3. Because this cut-
off is arbitrary, analyses were repeated with a cut-off score of ≥4. Patients with a combined 
inflammation score of ≥4 were significantly older (p<0.001), more often had morning stiffness 
≥60 min (p=0.030), a lower 68-TJC (p=0.047) and more often had increased CRP (p=0.007) 
and ESR levels (p=0.003) than patients with a score of <4 (see online Supplementary Table 3). 
In PLS analysis, two latent factors were found that together explained 34.5% of the variance 
when MRI inflammation was defined as a combined inflammation score of ≥4. The patients’ 
scores of these two factors are shown in online Supplementary Figure 1. No clear clusters 
were observed.
Follow-up of MRI-defined inflammation
To date, 29 patients with MRI inflammation have been followed for at least 4 months. 
Although this follow-up duration is short, 10 of these patients (34.5%) developed arthritis. 
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These patients had a median combined inflammation score of 4 (range 3-20). The patients 
were diagnosed with RA (n=8), unclassified arthritis (n=1) and psoriatic arthritis (n=1).
Figure 2. Subclinical inflammation shown on MRIs of MCP joints (A), wrist (B, C) and MTP) joints (D) of patients 
with CSA without clinically detectable arthritis. These images belong to four different patients. (A) Post-contrast 
axial T1-weighted FSE image with fat saturation of the MCP joints showing enhancement of the sheaths of the flexor 
tendons of MCP3 and MCP4, consistent with tenosynovitis. Synovitis is also present in the MCP2 and MCP3 joints. 
(B) Coronal T2-weighted FSE image with fat saturation of the wrist showing high signal intensity in the intercarpal 
joints (with enhancement on the post-contrast sequence, consistent with synovitis) and BME in the lunate. (C) Post-
contrast axial T1-weighted FSE image with fat saturation of the wrist showing intercarpal synovitis and tenosynovitis 
of the extensor compartments 2, 5 and 6. (D) Axial T2-weighted FSE image with fat saturation of the MTP joints 
with BME in the head of the fifth metatarsal bone. No synovitis is detected. Patient C developed clinically detectable 
arthritis in this wrist during follow-up.
DISCUSSION
In the present study we aimed to describe clinical and MRI characteristics of patients with 
CSA. We observed that subclinical MRI inflammation was present in 44% of all patients 
and that 35% of these patients with CSA had already progressed to clinical arthritis within 
at least 4 months of follow-up. The studied symptoms and characteristics could not clearly 
differentiate between patients with CSA with and without MRI inflammation.
Our approach was to select patients with arthralgia who were, according to the 
rheumatologist, suspected of progressing to arthritis over time. Since the symptomatic phase 
without arthritis in the pre-RA phase is not uniformly explicated and it is not known what 
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Women, n (%) 29 (70.7) 39 (75.0) 0.64
Age in years, mean (SD) 50.4 (13.7) 37.9 (11.1) <0.001
Family history of RA, n (%) 12 (29.3) 18 (34.6) 0.58
Symptom duration
  In weeks, median (IQR) 14.8 (8.4-30.9) 14.6 (8.9-26.4) 0.90
  ≤12 weeks, n (%) 17/40 (42.5) 17/49 (34.7) 0.45
Symptom onset 0.12
  Gradual, n (%) 29 (70.7) 43/51 (84.3)
  Subacute, n (%) 12 (29.3) 8/51 (15.7)
Localisation of initial symptoms 0.12
  Small joints, n (%) 31 (75.6) 45 (86.5)
  Large joints, n (%) 2 (4.9) 4 (7.7)
  Both, n (%) 8 (19.5) 3 (5.8)
Localisation of initial symptoms 0.15
  Upper extremities, n (%) 28 (68.3) 37 (71.2)
  Lower extremities, n (%) 6 (14.6) 2 (3.8%)
  Both, n (%) 7 (17.1) 13 (25.0)
Symmetrical localization of initial 
symptoms, n (%)
28 (68.3) 36/51 (71.4) 0.81
Presence of inflammatory character joint 
pain‡, n (%)
29 (70.7) 41 (78.8) 0.37
Presence of morning stiffness
  In minutes, median (IQR) 60 (15-90) 45 (15-90) 0.34
  ≥60 minutes, n (%) 21 (51.2) 18 (34.6) 0.11
BMI, median (IQR) in kg/m2 25.7 (23.1-30.3) 24.5 (21.8-27.8) 0.089
68-TJC, median (IQR) 4 (2.5-9.0) 6 (3-14.3) 0.10
Current smoker, n (%) 8 (19.5) 11 (21.2) 0.85
Current alcohol user§, n (%) 27/40 (67.5) 33/50 (66.0) 0.88
ACPA-positivity, n (%) 9 (22.0) 4 (7.7) 0.049
IgM-RF-positivity, n (%) 12 (29.3) 10 (19.2) 0.26
Increased CRP (>10 mg/L), n (%) 7 (17.1) 4 (7.7) 0.16
Increased ESR (reference for age), n (%) 7 (17.1) 3 (5.8) 0.081
*Subclinical MRI inflammation is defined as a combined inflammation score (sum of synovitis, BME and 
tenosynovitis scores) ≥3. †Calculated with the χ2, unpaired t or Mann-Whitney U tests as appropriate. ‡Defined as 
joint pain that is worst in the early morning and improves with movement during the day. §Patients not consuming 
daily alcohol but only one or few beverages a week were considered as alcohol users. Data on symptom duration and 
BMI were missing in 4 patients; symptom onset and symmetrical localization in 1 patient; 68-TJC in 2 patients and 
alcohol use in 3 patients.
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Figure 3. Clustering of variables in patients with clinically suspect arthralgia related to inflammation on MRI. In this 
plot each dot indicates a single person. Latent factor scores indicate how strongly each factor is represented in each 
patient. A dot indicates how much the variance in an individual patient is being described by latent factor 1 on the 
x-axis in relation to latent factor 2 on the y-axis. Patients with a combined inflammation score of ≥3 are considered 
as having subclinical MRI inflammation and are represented by a circle, whereas patients with a combined 
inflammation score of <3 who are considered as having no MRI inflammation are represented by a triangle. No 
clearly distinguishable groups were observed, although a tendency to some clustering was observed to discern 
patients with and without MRI inflammation. Patients with MRI inflammation were older and more frequently 
had a subacute symptom onset, initial localisation in the large joints, initial localisation in the lower extremities and 
morning stiffness ≥60 min, a lower 68-TJC, a higher BMI and more often had increased ESR and positivity for ACPA 
and IgM-RF compared with patients without MRI inflammation.
type of arthralgia is specific for the pre-RA phase, we decided to depend on the ‘gut feeling’ 
(clinical expertise) of trained rheumatologists to select patients who were suspected as being 
in a preclinical phase of RA. Whether or not a patient had CSA was determined at the first 
visit before any blood tests had been performed, and thus did not depend on the knowledge 
of the autoantibody status of the patient. This concept is different from that used in studies on 
the preclinical phase that select persons with an increased risk of RA because of the presence 
of autoantibodies 7 or a positive family history 27. The advantage of the current CSA approach 
is that it is in line with clinical practice where patients present with certain symptoms and 
the decision to perform additional investigations is based on the clinical presentation. 
Furthermore, it may allow identification of ACPA-negative RA in the preclinical phase.
The present study is the first large study to use dedicated MRI in patients at risk 
of RA. Our finding that subclinical inflammation as defined by MRI is present in 44% of 
patients with CSA is to some extent in line with the results of previous smaller studies. A 
previous MRI study among 22 patients with ACPA-positive arthralgia showed higher MRI 
inflammation scores in these patients compared with controls 20. Subclinical inflammation 
has also been visualised by positron emission tomography and ultrasonography 19,21.
The joints and bones mostly affected by MRI-defined inflammation in our CSA cohort 
were locations where MRI inflammation is observed in patients with early arthritis patients 
(MCP3 joint, capitate and lunate, radiocarpal and intercarpal joints) 22. This strengthens the 
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indication that the inflammation observed in the patients with CSA in our study might be a 
precursor of clinical arthritis. The patients with CSA also frequently had inflammation in the 
MTP1 joint; this joint showed inflammation most frequently in the symptom-free controls 
(26%) and presumably inflammation here is not specific for RA.
Since MRI is a sensitive imaging technique, a relevant issue is which scores are normal 
and which reflect pathology. Several MRI studies on a small number of healthy volunteers 
showed MRI abnormalities to some extent 20,28,29. Due to different scoring methods and 
different readers used, the data are difficult to compare. An advantage of the present study 
is that it included MRIs of 19 symptom-free controls of comparable age and gender to the 
patients with CSA. Based on our impression that a score of 1 or 2 is rather minimal and that a 
score of ≥3 was observed in only 10% of controls, this cut-off was used to define the presence 
of MRI inflammation. Because we were aware that this cut-off is rather arbitrary and none 
of the controls had a score of ≥4, sensitivity analyses were done with a score of ≥4 as the 
definition of MRI inflammation. This showed similar results, although morning stiffness, TJC 
and the acute phase reactants were then also significantly associated with MRI inflammation. 
Ultimately, longer follow-up is needed to study the conversion to clinical arthritis. This will 
also reveal which cut-off of MRI-defined inflammation is associated with progression to 
clinical arthritis and RA.
This study has limitations. Because of time limitations we initially chose not to 
perform coronal sequences (perpendicular to the axis of the metatarsals) and post-contrast 
images of the MTP joints. Synovitis of the MTP joints was therefore initially assessed without 
contrast enhancement on axial sequences. Although previous studies have reported that 
eliminating contrast affected the reliability of synovitis scoring compared with contrast-
enhanced MRI, the sensitivity was reported to be high (78–90%) and the specificity moderate 
(31–79%) 30,31. After 78 MRIs the scanning protocol was changed and coronal and post-
contrast sequences of the foot were included, so synovitis in the MTP joints could be as 
reliably scored as in the wrist and MCP joints. As a consequence of the moderate specificity 
of non-contrast sequences, the synovitis scores of the MTP joints of the patients scanned by 
the first protocol might have been overestimated. On the other hand, due to lack of coronal 
sequences in the first protocol, the synovitis scores of the MTP joints might have been 
underestimated. However, synovitis of the MTP joints made a relatively small contribution 
to the total MRI inflammation score in the present data. A second limitation is the number 
of patients. Despite the infrastructural investments at our department to identify arthralgia 
patients early, the large majority of patients with arthralgia who presented at our outpatient 
clinic did not have CSA. Larger studies are needed to increase our understanding of the 
processes driving progression of subclinical inflammation in the pre-RA phases.
In the present study subclinical MRI inflammation was considered as proxy for 
RA-at-risk. Whether all patients with MRI inflammation will eventually develop arthritis is 
uncertain and unlikely. This will be studied during subsequent follow-up.
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In conclusion, the preclinical phase of RA ‘symptoms without clinical arthritis’ 
was investigated by studying patients with CSA. Subclinical inflammation on MRI was 
observed in 44% of these patients. A combination of symptoms/characteristics incompletely 
differentiated patients with and without MRI inflammation. Follow-up will show which 
characteristics relate to the development of RA.
SUPPLEMENTARY DATA
Supplementary data are published on the website of the Annals of the Rheumatic Diseases.
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It is known that anti-citrullinated peptide antibody (ACPA)-positive rheumatoid arthritis 
(RA) has a preclinical phase. Whether this phase is also present in ACPA-negative RA is 
unknown. To determine this, we studied ACPA-negative arthralgia patients who were 
considered prone to progress to RA for local subclinical inflammation observed on hand and 
foot magnetic resonance imaging (MRI) scans.
Methods
We studied a total of 64 ACPA-negative patients without clinically detectable arthritis and with 
arthralgia of the small joints within the previous 1 year. Because of the character of the patients’ 
symptoms, the rheumatologists considered these patients to be prone to progress to RA. For 
comparisons, we evaluated 19 healthy, symptom-free controls and 20 ACPA-negative RA 
patients, who were identified according to the 1987 ACR criteria. All participants underwent 
MRI of unilateral wrist, metacarpophalangeal and metatarsophalangeal joints. Synovitis and 
bone marrow edema (BME) were scored according to the OMERACT rheumatoid arthritis 
magnetic resonance imaging scoring system, and the scores were summed to yield the ‘MRI 
inflammation score’. Scores were compared between groups. Among the ACPA-negative 
arthralgia patients, MRI inflammation scores were related to C-reactive protein (CRP) levels 
and the tenderness of scanned joints.
Results
MRI inflammation scores increased progressively among the groups of controls and ACPA-
negative arthralgia and RA patients (median scores 0, 1 and 10, respectively; p< 0.001). The 
MRI inflammation scores of ACPA-negative arthralgia patients were significantly higher than 
those of controls (p=0.018). In particular, the synovitis scores were higher in ACPA-negative 
arthralgia patients (p=0.046). Among the ACPA-negative arthralgia patients, inflammation 
was observed predominantly in the wrist (53%). The synovitis scores were associated with 
CRP levels (p=0.007) and joint tenderness (p=0.026). Despite the limited follow-up duration, 
five patients developed clinically detectable arthritis. These five patients had higher scores for 
MRI inflammation (p=0.001), synovitis (p=0.002) and BME (p=0.003) compared to the other 
patients.
Conclusion
Subclinical synovitis was observed in the small joints of ACPA-negative arthralgia patients, 
and especially in patients whose conditions progressed to clinically detectable arthritis. 
This finding suggests the presence of a preclinical phase in ACPA-negative RA. Further 
longitudinal studies of these lesions and patients are required to confirm this hypothesis.
63MRI in ACPA-negative arthralgia       |
4
INTRODUCTION
Early recognition of rheumatoid arthritis (RA) and early treatment initiation of it have 
been proven to be effective in reducing the disease burden over time 1,2. For the past few 
years, interest in the early disease phase has also covered the preclinical phase of RA 3. It 
has been shown that RA-specific autoantibodies 4,5 and serologic inflammatory markers 
are increased months to years before development of RA 6,7. Also, subclinical inflammation 
locally in the small joints of autoantibody-positive arthralgia patients without clinical 
arthritis was visualised using ultrasonography, positron emission tomography (PET) and 
magnetic resonance imaging (MRI) 8–10. Previous studies that investigated the preclinical 
phase of RA mainly or solely focused on anti-citrullinated peptide antibody (ACPA) positive 
RA. Consequently, it is not known whether ACPA-negative RA also has a preclinical phase. 
Nonetheless, up to half of all patients in early RA cohorts are ACPA-negative 1,11,12.
MRI is a suitable modality for studying early inflammatory changes in the small 
joints of patients in the preclinical phase of RA. It detects synovitis and is the only imaging 
modality that depicts bone marrow edema (BME), an MRI feature that is strongly associated 
with disease progression 13–15. The availability of dedicated MRI scanners has increased the 
accessibility and comfort of MRI scanning. Additionally, the presence of a validated scoring 
methodology (the Outcome Measures in Rheumatology Clinical Trials (OMERACT) 
rheumatoid arthritis magnetic resonance imaging scoring system (RAMRIS)) allows 
comparison of the extent and severity of MRI features for research purposes 15.
In the present study, we used MRI of the hand and foot to evaluate whether ACPA-
negative RA, like ACPA-positive RA, has a preclinical phase with local inflammation in 
small joints. Persons with any type of arthralgia are prevalent in the general population and 
at rheumatologic outpatient clinics. Because the majority of arthralgia patients are ACPA-
negative and will never develop RA, it is challenging to identify the ACPA-negative arthralgia 
patients that might be in a preclinical phase of RA. We studied ACPA-negative patients 
without clinical arthritis and with recent-onset arthralgia of small joints who, because of the 
character of their symptoms, were considered prone to have disease likely to progress to RA 
by the treating rheumatologists. For comparisons, healthy controls and ACPA-negative RA 
patients were also studied.
METHODS
Participants
Three groups of participants were studied. The first group consisted of 64 ACPA-negative 
arthralgia patients recruited at the Leiden University Medical Centre between April 2012 
and June 2013. The rheumatologists were requested to include patients who presented to the 
outpatient clinic without clinical arthritis upon physical examination but with arthralgia of 
the hand or foot joints of less than 1 year’s duration of a type that was considered to have 
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an increased chance to progress to RA. This suspicion was based on symptoms and signs, 
combined with the gut feelings of the rheumatologists. Hence, based on the rheumatologists’ 
clinical impression, these patients were considered to be in a preclinical phase of RA. The 
rheumatologists were encouraged to include patients whom they had otherwise also followed 
and not discharged because they were concerned that these patients had an increased risk 
for RA development. Because no type of arthralgia has yet been defined to be specific for the 
preclinical phase of RA, we could not assign more specific criteria with regard to the type of 
arthralgia patients to be included. Importantly, when another explanation for the patients’ 
arthralgia was more likely, such as fibromyalgia, osteoarthritis or an inflammatory rheumatic 
disease, these patients were not included. In our present study, among all patients with 
arthralgia, the 64 patients who tested negative for ACPA (anti-CCCP2, Euro Diagnostica AB, 
Nijmegen, the Netherlands) were selected. The second group comprised 20 ACPA-negative 
patients who met the 1987 ACR criteria for RA 16. These patients were included in the Leiden 
Early Arthritis Clinic cohort between August 2010 and July 2012. The third group consisted 
of 19 healthy controls without joint symptoms. Written informed consent was obtained from 
all participants. Approval of the study protocol was obtained from the local Medical Ethics 
Committee of the Leiden University Medical Centre.
Magnetic resonance imaging
All participants underwent MRI of the wrist, metacarpophalangeal (MCP) joints and 
metatarsophalangeal (MTP) joints with an ONI MSK Extreme 1.5T MRI scanner (GE 
Healthcare Life Sciences, Madison, WI, USA). In the arthralgia and RA patients, MRI of 
the most painful side was performed within 2 weeks after the first visit. In cases of equally 
severe symptoms on both sides, the dominant side was scanned. Patients were asked not 
to use any nonsteroidal anti-inflammatory drugs (NSAIDs) during the 24 hours before 
undergoing MRI. The healthy symptom-free controls underwent MRI of the dominant side. 
The following sequences were acquired for MCP joints and wrists: a coronal T1-weighted fast 
spin echo (FSE) sequence, a coronal T2-weighted FSE sequence with fat saturation and, after 
intravenous gadolinium contrast enhancement (0.1 mmol/kg), coronal and axial T1-weighted 
FSE sequences with fat saturation. Axial T1-weighted FSE sequences and T2-weighted FSE 
sequences with fat saturation of MTP joints were acquired. Owing to time constraints, post-
contrast-enhanced images were not obtained of the MTP joints. For ethical reasons, contrast 
agents were not administered in controls. Synovitis and BME were scored quantitatively 
according to the OMERACT RAMRIS system 15. The sum of the synovitis and BME scores 
yielded the ‘MRI inflammation score’. Scoring was performed by one trained reader, 47% of 
the scans were read twice and the within-reader intraclass correlation coefficient for the MRI 
inflammation score was 0.91.
Analyses
Comparisons were made using a Mann-Whitney U test, Kruskal-Wallis test or χ2 test as 
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appropriate. In the ACPA-negative arthralgia patients, linear regression analyses were used 
to study whether C-reactive protein (CRP) level was associated with MRI-determined 
inflammation scores. The associations between tenderness and degree of inflammation 
observed on MRI scans were tested by performing generalised estimating equations. This 
model took into account that, in every patient, ten joints were assessed. The unstructured 
correlation matrix was used. SPSS version 20.0 software (SPSS, Chicago, IL, USA) was used 
for calculations. P-values <0.05 were considered significant.
RESULTS
ACPA-negative arthralgia patients prioritised by the rheumatologists
The rheumatologists were requested to state the primary reasons why they assumed that the 
arthralgia patients had an increased risk for RA development. The main reasons provided 
were joint pain that was worst in the early morning and improved with movement during the 
day (thus making it an inflammatory type of arthralgia), the presence of morning stiffness 
of ≥60 minutes and/or a positive family history of RA. The baseline characteristics of the 
ACPA-negative arthralgia patients, as well as those of the ACPA-negative RA patients and 
symptom-free controls, are presented in Table 1. The ACPA-negative arthralgia patients who 
were considered at risk for progression to RA had a mean age of 42 years, and 72% were 
Table 1. Patient characteristics
Characteristics Symptom-free controls ACPA-negative 
arthralgia
ACPA-negative RA
(n = 19) (n = 64) (n = 20)
Mean age, yr (SD) 46.2 (11.8) 41.9 (14.3) 58.7 (14.5)
Females, n (%) 15 (78.9) 46 (71.9) 11 (55.0)
Positive family history of RA, n (%) N/A 25 (39.1) 4 (20.0)
Median symptom duration at time of 
inclusion, wk (IQR)
N/A 13.4 (8.4 to 26.4) 17.6 (11.5 to 25.9)
Gradual symptom onset, n (%) N/A 48 (75.0) 12 (60.0)
Initial symptom localisation, n (%) N/A
   Upper extremities, n (%) 47 (73.4) 10 (50.0)
   Lower extremities, n (%) 2 (3.1) 4 (20.0)
   Upper and lower extremities, n (%) 15 (23.4) 6 (30.0)
Symmetrical localisation, n (%) N/A 46 (71.9) 13 (65.0)
Median morning stiffness, min (IQR) N/A 45 (15 to 90) 120 (30 to 120)
Median tender joint count in 68 joints (IQR) 0 5.5 (3 to 10.8) 12 (4.8 to 17.8)
Median swollen joint count 66 joints (IQR) 0 0 6 (4 to 11)
ACPA positivity (>7.0 IU/ml), n (%) N/A 0 0
IgM RF positivity (>3.5 IU/ml), n (%) N/A 9 (14.1) 3 (15.0)
Increased CRP level (>10 mg/L), n (%) N/A 10 (15.6) 11 (55.0)
N/A=not applicable
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female. The symptoms of most patients had started gradually (75%) and initially involved 
the upper extremities (73%). Tender joints were localised predominantly in the proximal 
interphalangeal (PIP) joints (60%) and the MCP joints (52%). Nine patients (14%) were 
rheumatoid factor (RF)-positive.
MRI findings in the three groups
The median (interquartile range (IQR)) MRI inflammation scores in symptom-free controls, 
ACPA-negative arthralgia patients and ACPA-negative RA patients were 0 (0 to 1), 1 (1 to 3) 
and 10 (10 to 16), respectively (p<0.001) (Figure 1).
MRI findings in ACPA-negative arthralgia patients and symptom-free controls
The ACPA-negative arthralgia patients were compared with the symptom-free controls 
(Figure 1). Eight (42.1%) of the nineteen symptom-free controls and forty-four (68.8%) of 
the sixty-four ACPA-negative arthralgia patients had any sign of inflammation based on MRI 
(inflammation score ≥1) (p=0.035). The median MRI inflammation scores were significantly 
higher in the ACPA-negative arthralgia patients than in controls (p=0.018). Subsequently, 
synovitis and BME scores were evaluated separately. This analysis showed that synovitis scores 
were significantly higher in ACPA-negative arthralgia patients than in controls (p=0.046), 
in contrast to BME patients (p=0.20) (Figure 1). Thus, compared to controls, patients with 
ACPA-negative arthralgia in particular had higher subclinical synovitis scores of small joints.
The proportion of patients with any sign of inflammation (synovitis and/or BME) on 
MRI in the wrist, MCP joints and MTP joints were, respectively, 53.1%, 20.3% and 31.3%. 
Synovitis was observed predominantly in the intercarpal (29.7%), radiocarpal (21.9%), MTP1 
(17.2%) and MCP3 joints (14.1%). BME was most often present in the capitate (20.3%), lunate 
(15.6%) and MTP1 joints (15.6%). Figure 2 shows examples of inflammation visualised on 
MRI scans.
Evaluation of rheumatoid factor in ACPA-negative patients
Subsequently, the ACPA-negative arthralgia patients were assigned to RF-positive (n=9) 
and RF-negative (n=55) groups. No differences in MRI inflammation, synovitis and BME 
scores were observed (p=0.63, 0.62 and 0.90, respectively) (Additional file 1: Figure S1). We 
observed similar differences when the ACPA-negative RA patients were stratified.
Evaluation of traditional measures of inflammation in ACPA-negative arthralgia 
patients
Furthermore, we evaluated whether the degree of inflammation visualised on MRI scans of 
ACPA-negative arthralgia patients was associated with the level of serological inflammation 
as measured by CRP levels. The synovitis score was significantly associated with CRP level 
(β=0.10, p=0.007), indicating that each 1 mg/L increase in CRP level resulted in a 0.10 
increase in synovitis score. The BME score was not associated with CRP level (p=0.88). Also, 
the MRI-based inflammation score was not significantly associated with CRP level (β=0.10, 
67MRI in ACPA-negative arthralgia       |
4
Figure 1. MRI-based inflammation scores shown separately for the three study groups. (A) MRI inflammation 
scores (synovitis plus bone marrow edema (BME)). (B) Synovitis scores. (C) Bone marrow edema scores. The three 
study groups are the symptom-free controls, the ACPA-negative arthralgia patients and the ACPA-negative RA 
patients, based on the 1987 criteria for RA 16. The scores presented are for all participants individually (dots) and 
the median scores per group (horizontal lines). The black dots indicate the ACPA-negative patients who developed 
clinically detectable arthritis during the median follow-up of 9 months. The y-axes are split because RA patients had 
higher scores than the symptom-free controls and ACPA-negative arthralgia patients. The presented p-values were 
obtained by comparing the scores of ACPA-negative arthralgia patients and symptom-free controls. All p<0.001 for 
differences in MRI-based inflammation, synovitis and BME scores between the three groups. BME=bone marrow 
edema.
p=0.066).
Subsequently, we studied whether tender joints had higher MRI-based scores than 
non-tender joints. The presence of joint tenderness was significantly associated with synovitis 
score (p=0.026, OR=1.15), indicating that tender joints had 15% higher odds on one point 
increase in synovitis score compared to non-tender joints. No significant associations were 
observed between joint tenderness and BME scores (p=0.18) or MRI-based inflammation 
scores (p=0.53).
Follow-up of ACPA-negative arthralgia patients
The follow-up duration of the ACPA-negative arthralgia patients was still limited at a median 
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of 9 months (IQR 5 to 11). During this period, five of the ACPA-negative arthralgia patients 
developed clinical arthritis as detected by their rheumatologists during physical examinations 
(7.8%). Median (IQR) scores for MRI-based inflammation, synovitis and BME for these 
patients were, respectively, 5 (4 to 8.5), 3 (1.5 to 7) and 2 (1.5 to 2.5) (Figure 1). These scores 
were significantly higher than those of the ACPA-negative arthralgia patients who did not 
or had not yet developed clinical arthritis (inflammation: p=0.001; synovitis: p=0.002; and 
BME: p=0.003). Of the five patients who developed clinical arthritis, three were diagnosed 
with RA, one with unclassified arthritis and one with psoriatic arthritis. At the time of clinical 
arthritis development, all patients were still ACPA-negative.
DISCUSSION
Early intervention in RA is associated with a more favorable disease course 1,2. The recognition 
that systemic inflammatory markers are increased in the preclinical phase 6,7 and that 
inflammation is also locally present in small joints has increased interest in investigation of 
the preclinical phase of RA 8–10. The ultimate hope is that intervention in the preclinical phase 
Figure 2. Subclinical inflammation visualised by MRI of MCP joints and wrists of two different ACPA-negative 
arthralgia patients without clinically detectable arthritis. The white lines in the top coronal images reflect the 
localisation of the bottom axial images. (A) Post-contrast enhancement coronal (A1) and axial (A2) T1-weighted 
FSE images with fat saturation showing enhancement of the MCP2, MCP3 and MCP5 joints, which is consistent 
with active synovitis. Also, pronounced tenosynovitis in the third flexor tendon is present, although tenosynovitis is 
not included in the OMERACT RAMRIS score and was not evaluated in the present study. This patient developed 
clinically detectable arthritis during follow-up. (B) Post-contrast enhancement coronal (B1) and axial (B2) T1-
weighted FSE images with fat saturation showing bone marrow edema and erosions (confirmed on the pre-contrast 
enhancement T1-weighted FSE sequence) in the lunate. Also, there is active synovitis in the intercarpal joint.
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will prevent the development of the classical picture of RA. The large majority of studies on 
the preclinical phase have focused on patients with ACPA 3. To the best of our knowledge, 
this study is the first to assess whether local subclinical inflammation is also present in 
ACPA-negative pre-RA patients. We observed that ACPA-negative arthralgia patients had 
higher MRI-based inflammation scores than healthy participants and that higher MRI-based 
synovitis scores were associated with higher CRP levels. 
Identifying ACPA-negative arthralgia patients with an increased chance of developing 
RA is more challenging compared to other pre-RA studies were the presence of RA-related 
autoantibodies was measured and considered as a marker of increased risk. In the present 
study, rheumatologists were asked to select patients who, in their view, had an increased 
chance of developing RA. Because no type of arthralgia has yet been defined to be specific 
for pre-RA, we could not assign more specific criteria with regard to the type of arthralgia to 
be included. Retrospectively, the reasons for rheumatologists to consider patients as having 
an increased chance for developing RA were mainly joint pain that was worst in the early 
morning and improved with movement during the day (an inflammatory type of pain), 
the presence of morning stiffness of ≥60 minutes and a positive family history for RA. An 
advantage of the approach used in present study is that it resembles current clinical practice. 
It is of note that the studied arthralgia patients were selected from a total number of 1,335 
arthralgia patients who visited our outpatient clinic between April 2012 and June 2013. The 
observation that 69% of the patients who were considered to have an increased chance of 
developing RA had any signs of subclinical inflammation on MRI scans might indicate that 
the rheumatologists did reasonably well in selecting ACPA-negative arthralgia patients.
The MRI inflammation scores were higher in ACPA-negative arthralgia patients than 
in symptom-free controls. Patients with ACPA-negative RA had much higher MRI-based 
inflammation scores than those in the other two groups, which was expected because these 
patients had clinically detectable joint inflammation. The inflammatory lesions observed in 
ACPA-negative arthralgia patients were small, but were located at locations that are known to 
be affected in RA, such as the intercarpal bones and the MCP3 and MTP1 joints 14.
Interestingly, MRI-based synovitis scores, but not BME scores, were increased 
in ACPA-negative arthralgia patients compared to symptom-free controls. BME is more 
prevalent in ACPA-positive RA patients than in ACPA-negative RA patients, and it is a strong 
predictor of progression of joint destruction 13,14,17. The finding of no increase in BME score 
in the preclinical phase of ACPA-negative patients might suggest that BME is not an early 
phenomenon in ACPA-negative RA or reflects a lower prevalence of BME in ACPA-negative 
RA patients, a subset of RA that is also characterised by less severe radiological progression 
18. Larger and longitudinal studies are required to determine the value of BME in this disease 
subset.
This study has several limitations. The number of symptom-free controls studied is 
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relatively low. Second, for ethical reasons, the controls did not receive intravenous contrast 
fluid. Researchers in previous studies have suggested that eliminating contrast enhancement 
does not affect BME scores, although it may affect the reliability of synovitis scoring 19,20. In 
studies in which MRI scans with contrast enhancement were used as the gold standard, the 
sensitivity for synovitis scoring on the basis of high-field MRI without contrast enhancement 
has been reported to be high (78% to 90%), but the specificity has been reported to be 
moderate (31% to 79%) 19,20. As a consequence of the moderate specificity in this study, 
the scores of the symptom-free controls might have been overestimated. Consequently, 
the differences in synovitis scores between the arthralgia patients and the healthy controls 
might have been underestimated. So, although the absence of contrast enhancement in the 
controls is a clear limitation, the results of previous studies 19,20 indicate that the differences 
might have been larger in cases of contrast administration to controls. Another limitation 
is the short duration of follow-up, which ranged from 1 to 16 months. The present study 
therefore provides mainly cross-sectional data. Longer follow-up is required to determine 
which ACPA-negative arthralgia patients and which inflammatory lesions detected by MRI 
are most predictive of progression to clinically detectable arthritis. Nonetheless, it is notable 
that arthralgia patients who developed clinical arthritis had higher MRI-based inflammation 
scores. A research question that remains unanswered is the long-term course of inflammation 
detected on MRI scans. Serial MRI scans are needed to determine whether MRI-based 
inflammation is relapsing, remitting or stable over time.
CONCLUSION
ACPA-negative arthralgia patients, especially patients whose conditions progress to clinical 
arthritis, have subclinical inflammation visualised on MRI scans of the hand and foot, 
suggesting that also ACPA-negative RA has a preclinical symptomatic phase.
SUPPLEMENTARY DATA
Supplementary data are published on the website of Arthritis, Research & Therapy.
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Patients with clinically suspect arthralgia (CSA) have, according to their rheumatologists, 
an increased risk of rheumatoid arthritis (RA), but their actual outcome is unexplored. This 
longitudinal study investigated (1) progression from CSA to clinically detectable arthritis and 
(2) associations of clinical factors, serological factors (among which are anti-citrullinated 
peptide antibodies (ACPA)) and MRI-detected subclinical inflammation with arthritis 
development.
Methods
150 patients with CSA were followed for ≥6 months. At baseline, clinical and serological 
data were collected and unilateral 1.5 T-MRI of metacarpophalangeal (MCP), wrist and 
metatarsophalangeal (MTP) joints was made. MRI scoring was done according to the RA 
MRI scoring system. Subclinical MRI inflammation was defined based on MRI results of 193 
symptom-free persons.
Results 
During follow-up (median=75 weeks, IQR=41-106 weeks), 30 patients developed clinical 
arthritis; 87% did so <20 weeks after inclusion. In multivariable analyses, age, localisation 
of initial symptoms in small and large joints (compared with small joints only), C-reactive 
protein level, ACPA-positivity and subclinical MRI inflammation significantly associated 
with arthritis development; ACPA and MRI inflammation were most strongly associated (HR 
(95% CI) respectively, 6.43 (2.57 to 16.05) and 5.07 (1.77 to 14.50)). After 1 year follow-up, 
31% of the patients with MRI inflammation and 71% of the ACPA-positive patients with MRI 
inflammation had progressed to arthritis. Forty-three per cent of the patients that developed 
arthritis within 1 year were ACPA-negative; 78% of them had subclinical MRI inflammation 
at baseline. When MRI inflammation was absent arthritis development was infrequent (6% in 
all patients with CSA and 3% in ACPA-negative patients with CSA).
Conclusions 
Subclinical MRI inflammation precedes clinical arthritis with a few months. Subclinical 
MRI inflammation is, independent of other factors such as ACPA, associated with arthritis 
development.
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INTRODUCTION
There is an upcoming need to identify individuals in the very early phase of rheumatoid 
arthritis (RA) in which clinically apparent arthritis is not yet present. Although not proven, 
it is assumed that treatment initiation in this phase enables better disease modification and 
might contribute towards preventing arthritis becoming chronic. The first possible moment 
to clinically recognise patients at risk of RA is the phase of symptoms without clinically 
detectable arthritis 1. The symptoms that are specific for this phase are not yet identified, 
but clinical expertise might be an accurate tool to select patients with arthralgia with an 
increased risk of RA 2. Patients with arthralgia that, based on their symptoms and signs, have 
an increased risk of RA according to their rheumatologists, are indicated to have clinically 
suspect arthralgia (CSA) 3. The approach to select patients on clinical grounds before ordering 
additional tests is in line with clinical care and allows identifying autoantibody-positive and 
autoantibody-negative RA in the phase before clinically detectable arthritis.
Thus far, the long-term outcome of patients with arthralgia that were clinically 
suspect for progression to RA has not been investigated extensively. Moreover, the value of 
risk factors or tests in patients with CSA is unexplored. Two previous studies on patients 
with unspecified arthralgia or aspecific musculoskeletal symptoms who had RA-related 
autoantibodies revealed that morning stiffness, joint tenderness and (high levels of) anti-
citrullinated peptide antibodies (ACPA) were associated with arthritis development 4,5. 
However, the prognostic value for arthritis development of clinical and serological factors in 
patients with CSA is still unknown.
Also the value of advanced imaging in patients with CSA is unexplored. In a previous 
cross-sectional study, we observed that 44% of the patients with CSA had MRI-detected 
subclinical inflammation of hand and foot joints and that these patients with subclinical 
inflammation could not be adequately identified by presence of clinical or serological 
characteristics, suggesting that MRI-detected inflammation may have some diagnostic 
value. Though the predictive value of MRI-detected inflammation has still to be determined 
3, an advantage of MRI is its sensitivity to detect inflammation 6,7. MRI depicts synovitis, 
tenosynovitis and bone marrow oedema (BME), that is also called ‘osteitis’ in RA 8,9. Because 
the specificity of MRI-detected inflammation has been studied scarcely, we recently performed 
MRI of hands and feet in 193 symptom-free persons 10. These data served as reference and 
allowed to define MRI-detected subclinical inflammation for the present study.
In this first longitudinal study on patients with CSA, we aimed to determine (1) 
progression to clinically detectable arthritis, (2) the association of clinical and serological 
factors (among which are ACPA) with progression to clinical arthritis, (3) the association 
of subclinical MRI inflammation with progression to clinical arthritis and (4) whether 
subclinical MRI inflammation has an additive value compared with the other mentioned risk 
factors.




All patients were included in the CSA cohort which is described previously in detail 
elsewhere 3. This inception cohort was set up in 2012 in the Leiden University Medical 
Centre (Netherlands), which is the only referral centre in a healthcare population of >400000 
inhabitants to study the symptomatic phase of RA without clinically detectable arthritis. 
Inclusion criteria were having arthralgia of the small joints for <1 year that was, according 
to the clinical expertise of the rheumatologist, suspected to progress to RA over time. No 
further criteria were made with regards to the type of symptoms and thus inclusion was 
essentially based on the expert opinion of the rheumatologist. Importantly, CSA was not 
present if clinical arthritis was observed at physical examination or another explanation for 
the arthralgia was more likely (eg, osteoarthritis and fibromyalgia).
At baseline, questionnaires (among others on work ability, the Health Assessment 
Questionnaire and Short-Form health survey-36) were completed, physical examination 
performed, blood obtained (among others for determination of ACPA (anti-cyclic 
citrullinated peptide 2 (anti-CCP2), positive if >7 U/mL, Eurodiagnostica, Netherlands) and 
IgM rheumatoid factor (RF) (positive if >3.5 IU/mL) and an MRI performed 3.
Patients were prospectively followed with scheduled visits at 4 months, 12 months 
and 24 months. If necessary (for instance when the patient experienced more symptoms 
or noticed a swollen joint) patients were seen in between the scheduled visits by their 
rheumatologist. Follow-up ended earlier when clinical arthritis had developed.
For the present study, the patients with a follow-up duration of ≥6 months were 
selected; these patients (n=150) were included between April 2012 and July 2014. None of the 
patients with CSA were treated with disease-modifying antirheumatic drugs (DMARDs) or 
(systemic and local) glucocorticoids prior to inclusion and during follow-up.
MRI scanning and scoring
MRI of the metacarpophalangeal (MCP)2–5, wrist and metatarsophalangeal (MTP)1–5 
joints of the most painful side, or the dominant side in case of equally severe symptoms at 
both sides, was performed ≤2 weeks after clinical assessment. Patients were asked not to 
use nonsteroidal anti-inflammatory drugs (NSAIDs) during 24 h before MRI. The joints 
were scanned with a musculoskeletal (MSK)-extremity 1.5T-MRI scanner (GE, Wisconsin, 
USA) using contrast-enhancement and according to the RA MRI scoring system (RAMRIS) 
protocol. See online Supplementary File 1 for a detailed scan protocol.
Synovitis and BME in the MCP, wrist and MTP joints were scored according 
to the Outcome Measures in Rheumatology Clinical Trials (OMERACT) RAMRIS 8, 
the carpometacarpal (CMC)-1 joint (trapezium and base metacarpal-1) was excluded. 
Tenosynovitis in the wrist and MCP joints was assessed as described by Haavardsholm et al 
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9. The sum of the synovitis, BME and tenosynovitis scores was the total MRI inflammation 
score. Scoring was performed by two independent trained readers (HWvS, LM) blinded 
to clinical data. The within-reader intraclass correlation coefficients for the total MRI 
inflammation score were 0.99 and 0.98; the between-reader interclass correlation coefficient 
was 0.96. Mean scores of the two readers were studied.
At the time of analyses, MRIs were also categorised into positive or negative for 
subclinical MRI-detected inflammation. Frequencies of MRI-detected synovitis, tenosynovitis 
and BME that were observed at the same anatomical location in symptom-free persons 
recruited from the general population of the same age category were used as reference (see 
additional file in this chapter) 10. In these symptom-free persons it was observed that MRI-
detected inflammation was prevalent, especially at higher age and at preferential locations. 
Subclinical MRI inflammation was considered present if (1) both readers scored that joint (or 
bone in case of BME) positive for MRI inflammation and (2) the score obtained at a joint/
bone was present in <5% of age-matched symptom-free persons. For example, subclinical 
MRI inflammation was present when both readers scored grade ≥1 for synovitis at MCP3 
in a 30-year old patient. The MRI was considered negative if only one reader scored grade 
1 and the other reader grade 0. If the patient was aged 50 years and both readers scored 
grade 1, the MRI was also negative as ≥5% of symptom-free persons of the same age category 
had also synovitis grade 1 at MCP3 10. The MRI results were not reported to the treating 
rheumatologist.
Outcome
The main outcome was development of arthritis detected at physical examination (66 joints 
were assessed) by the rheumatologist. If arthritis was achieved, follow-up in the CSA cohort 
ended. In sensitivity analyses another outcome, initiation of DMARD therapy (including 
steroids), was studied. Medical files of all patients were studied on these outcomes until 24 
December 2014.
Statistical analyses
Cox proportional hazards regression analyses were used. Time to clinical arthritis was the 
time from inclusion to the date of first detection of clinical arthritis. Patients who did not 
develop arthritis were censored at the date of the 2 years’ follow-up visit or at the date that all 
medical files were studied on arthritis development. Additionally, the diagnostic performance 
of ACPA-positivity and presence of subclinical MRI inflammation were evaluated for arthritis 
development at 1 year follow-up. Details on the statistical methods are presented in online 
Supplementary File 2).




One hundred and fifty patients with CSA were studied. Table 1 presents the baseline 
characteristics. Mean age of the studied patients was 43.2 years (SD 12.9) and 72.7% were 
female. The median symptom duration was 18 weeks (IQR 9-30) and 16.0% were ACPA-
positive (Table 1).
Development of clinical arthritis
During follow-up one patient developed gout. This patient was excluded from further analyses 
as the patient did not belong to the non-arthritis group and the diagnosis was outside the 
spectrum of chronic arthritis/RA. The remaining 149 patients with CSA had a median follow-
up duration of 75 weeks (IQR 41-106). Within this follow-up period 30 patients developed 
clinically detectable arthritis. At arthritis development, 23 patients were diagnosed with RA 
(according to the 2010 ACR/EULAR criteria), 6 with undifferentiated arthritis and 1 with 
psoriatic arthritis.
The median time period between inclusion and arthritis development was 7 weeks. 
Table 1. Baseline clinical and MRI characteristics of all patients and separately for the patients that have and have 










Age in years, mean (SD) 43.2 (12.9) 43.1 (12.8) 43.9 (13.7)
Female, n (%) 109 (72.7) 87 (73.1) 22 (73.3)
Family history positive for RA, n (%) 51 (34.0) 38 (31.9) 12 (40.0)
Symptom duration# in weeks, med (IQR) (n=141) 18 (9-30) 18 (10-31) 17 (8-30)
Gradual symptom onset (>1 week) (n=149) 31 (20.8) 95 (80.5) 22 (73.3)
Localisation of initial symptoms (n=149)
  Small joints, n (%) 127 (85.2) 107 (90.7) 19 (63.3)
  Small and large joints, n (%) 15 (10.1) 6 (5.1) 9 (30.0)
  Large joints, n (%) 7 (4.7) 5 (4.2) 2 (6.7)
Localisation of initial symptoms
  Upper extremities, n (%) 108 (72.0) 88 (73.9) 20 (66.7)
  Upper and lower extremities, n (%) 28 (18.7) 21 (17.6) 7 (23.3)
  Lower extremities, n (%) 14 (9.3) 10 (8.4) 3 (10.0)
Symmetrical localisation of initial symptoms, n (%) (n=149) 110 (73.8) 91 (77.1) 19 (63.3)
Morning stiffness ≥60 min at inclusion, n (%) (n=144) 53 (36.8) 38 (33.6) 15 (50.0)
68-TJC, med (IQR) (n=146) 5 (3-10) 6 (3-10) 5 (3-7.5)
BMI in kg/m2, mean (SD) (n=149) 26.6 (5.2) 26.5 (5.0) 26.7 (6.1)
Present smoker, n (%) 38 (25.3) 29 (24.4) 9 (30.0)
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CRP-level in mg/L, med (IQR) 0 (0-4.6) 0 (0-4) 1.5 (0-14.5)
CRP-level >5 mg/L, n (%) 31 (20.7) 21 (17.6) 10 (33.3)
RF-positive (>3.5 IU/mL), n (%) 33 (22.0) 15 (12.6) 18 (60.0)
ACPA-positive (>7 U/mL), n (%) 24 (16.0) 8 (6.7) 16 (53.3)
MRI characteristics 









Presence of any MRI-detected inflammation, n (%) 66 (45.8) 44 (37.9) 22 (81.5)
    Only synovitis, n (%) 9 (6.3) 9 (7.8) 0 (0)
    Only BME, n (%) 12 (8.3) 10 (8.6) 2 (7.4)
    Only tenosynovitis, n (%) 15 (10.4) 7 (6.0) 8 (29.6)
    Synovitis and BME, n (%) 3 (2.1) 2 (1.7) 1 (3.7)
    Synovitis and tenosynovitis, n (%) 18 (12.5) 12 (10.3) 6 (22.2)
    BME and tenosynovitis, n (%) 2 (1.4) 1 (0.9) 1 (3.7)
    Synovitis, BME and tenosynovitis, n (%) 7 (4.9) 3 (2.6) 4 (14.8)
Presence of MRI-detected synovitis, n (%) 37 (25.7) 26 (22.4) 11 (40.7)
Presence of MRI-detected BME, n (%) 24 (16.7) 16 (13.8) 8 (29.6)
Presence of MRI-detected tenosynovitis, n (%) 42 (29.2) 23 (19.8) 19 (70.4)
38 patients (25.3%) were positive for ACPA and/or RF.
The median total RAMRIS inflammation score was 2 (IQR 1-5); the total RAMRIS scores for synovitis, BME and 
tenosynovitis were 1 (IQR 0-2.5), 0.5 (IQR 0-1.5) and 0 (IQR 0-1.5), respectively. Characteristics were not compared 
between the groups of patients that have and have not developed clinical arthritis during follow-up because the 
patients have different follow-up durations.
* One patient that developed gout during follow-up was excluded from further analyses as the patient did not belong 
to the non-arthritis group and the diagnosis was outside the spectrum of chronic arthritis/RA.
# Duration since the start of symptoms
Of all patients that progressed to arthritis, 87% had done so within 20 weeks after inclusion 
(Figure 1).
Clinical factors and ACPA in relation to arthritis development
In order to investigate whether baseline clinical factors and ACPA were associated with 
progression from CSA to clinical arthritis, univariable Cox regression analyses were 
performed (Table 2). An increased hazard on developing arthritis was observed for patients 
that presented with initial symptoms located in the small and large joints (HR=5.28 compared 
with small joints only (95% CI 2.38 to 11.73, p<0.001), patients with higher C reactive protein 
(CRP) levels (HR=1.06/mg/L, 95% CI 1.03 to 1.09, p<0.001), RF-positive patients (HR=6.94, 
95% CI 3.34 to 14.43, p<0.001) and ACPA-positive patients (HR=10.07, 95% CI 4.87 to 
20.82, p<0.001)). Age, presence of morning stiffness and number of tender joints were not 
significantly associated.
Subclinical MRI inflammation in relation to arthritis development
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Table 2. Results of univariable Cox regression analyses of baseline clinical and serological factors in relation to 
arthritis development
HR (95% CI) p-value
Age, per year 1.004 (0.98 to 1.03) 0.78
Female 1.02 (0.45 to 2.29) 0.96
Family history positive for RA 1.37 (0.66 to 2.85) 0.39
Symptom duration per week 
(n=141)
0.99 (0.98 to 1.01) 0.32
Gradual symptom onset (n=148) 0.68 (0.30 to 1.53) 0.35
Localisation of initial symptoms 
(n=148)
  Small joints only Ref Ref
  Large joints only 1.89 (0.44 to 8.14) 0.39
  Small and large joints 5.28 (2.38 to 11.73) <0.001
Localisation of initial symptoms 
  Upper extremities Ref Ref
  Lower extremities 1.36 (0.40 to 4.58) 0.62
  Upper and lower extremities 1.47 (0.62 to 3.47) 0.38
Symmetrical localisation of initial 
symptoms (n=148)
0.59 (0.28 to 1.23) 0.16
Morning stiffness ≥60 min (n=143) 1.89 (0.92 to 3.87) 0.081
68-TJC (n=145) 0.98 (0.93 to 1.04) 0.47
BMI, per kg/m2 (n=147) 1.01 (0.94 to 1.08) 0.80
Present smoker 1.28 (0.59 to 2.79) 0.54
CRP-level, per mg/L 1.06 (1.03 to 1.09) <0.001
RF-positive 6.94 (3.34 to 14.43) <0.001
ACPA-positive 10.07 (4.87 to 20.82) <0.001
Presented are the HRs of univariable analyses including 149 patients with CSA of which 30 developed clinical 
arthritis. When data on clinical characteristics were missing, the number of patients with available data is presented 
in the first column.
In six patients MRI was not performed, because of (suspected) pregnancy (n=2), metallic 
foreign body in biceps tendon (n=1), logistical reasons (n=2) or development of clinical 
arthritis ≤2 weeks after inclusion (n=1).
Table 1 presents baseline MRI characteristics. Median continuous RAMRIS scores 
were low (online Supplementary Table S1 presents continuous RAMRIS scores for individual 
joints/bones). Univariable analyses showed that higher MRI inflammation scores were 
associated with arthritis development (Table 3).
Then the continuous MRI inflammation scores were dichotomised. Since it was 
recently observed that MRI-detected inflammation is also present in the general population 
and depends on age, anatomical location and type of inflammation 10, these were considered 
when defining an ‘abnormal MRI’. A joint (or bone in case of BME) was categorised as 
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positive for inflammation when <5% of the general population of the same age category 
had  inflammation  at  this  location (online Supplementary Table S2 presents frequencies of 
positive joints/bones for MRI-detected inflammation). Sixty-six patients with CSA (45.8%) 
had a positive MRI for any subclinical inflammation, indicating that at least 1 joint/bone had 
synovitis, BME or tenosynovitis (Table 1): 20.1% of the patients had 1 positive joint/bone, 
18.8% 2-5 positive joints/bones and 6.9% ≥6 positive joints/bones (the maximum number 
of positive joints/bones was 24). When evaluating the individual MRI features, 25.7% of the 
patients had MRI-detected synovitis, 16.7% BME and 29.2% tenosynovitis (Table 1).
Univariable Cox regression analyses with arthritis development as outcome revealed 
that presence of any MRI-detected subclinical inflammation at baseline was associated with 
a six times increased hazard on arthritis (HR=6.12, 95% CI 2.32 to 16.19, p<0.001, Figure 1). 
In addition, the hazard on clinical arthritis increased when more joints/bones were scored 
positive for MRI inflammation (HR=1.23 per additional positive joint/bone, 95% CI 1.13 to 
1.33, p<0.001). Evaluating the three MRI features separately showed the strongest association 
for MRI-detected tenosynovitis (HR=7.56), though MRI-detected synovitis and BME were 
also significantly associated with arthritis development (HR=2.22 and 2.39 respectively, 
all p<0.05, Table 3). Because synovitis, BME and tenosynovitis were frequently present in 
the same patient (Table 1), multivariable Cox regression analyses were done to determine 
which type(s) of MRI-detected inflammation were independently associated with arthritis 
development (Table 3). We observed that MRI-detected tenosynovitis was independently 
associated (HR=8.39, 95% CI 3.38 to 20.81, p<0.001) with arthritis development.
Figure 1. Development of clinical arthritis over time for all patients and for the patients with and without MRI-
detected inflammation separately. Presented are the curves for development of clinical arthritis over time in all 149 
patients with CSA and for the patients with a positive and a negative MRI separately (six patients did not undergo an 
MRI). The HR of developing arthritis with a positive MRI was 6.12 (95% CI 2.32 to 16.19, p<0.001). All patients were 
followed for ≥6 months (median follow-up duration 75 weeks). The vertical lines indicate that a patient is censored.
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Combination of clinical factors, ACPA and subclinical MRI inflammation in relation to 
arthritis development
Then, we questioned if the association of subclinical MRI inflammation with arthritis 
development was independent of the associations of other factors (age, initial localisation 
of the symptoms, CRP-level, ACPA-positivity). Multivariable Cox regression analyses (Table 
4) revealed an increased hazard for younger patients (HR=0.96 per year older, 95% CI 0.93 
to 0.996, p=0.028), patients with initial localisation of symptoms in small and large joints 
(HR=4.30 compared with small joints only, 95% CI 1.70 to 10.86, p=0.002), patients with 
higher CRP-levels (HR=1.05/mg/L, 95% CI 1.01 to 1.09, p=0.021), ACPA-positive patients 
(HR=6.43, 95% CI 2.57 to 16.05, p<0.001) and patients with presence of any MRI-detected 
subclinical inflammation (HR=5.07, 95% CI 1.77 to 14.50, p=0.002). Similar results were 
obtained when including continuous total MRI inflammation scores instead of MRI positivity 
Table 3. Results of Cox regression analyses of MRI-detected subclinical inflammation at baseline in relation to 
arthritis development
HR (95% CI) p-value
Continuous RAMRIS scores
Univariable
Total inflammation score, per unit 1.14 (1.08 to 1.20) <0.001
Total synovitis score, per unit 1.29 (1.14 to 1.47) <0.001
Total BME score, per unit 1.28 (1.13 to 1.46) <0.001
Total tenosynovitis score, per unit 1.25 (1.11 to 1.39) <0.001
Multivariable
Total synovitis score, per unit 1.09 (0.86 to 1.38) 0.47
Total BME score, per unit 1.20 (1.03 to 1.38) 0.016
Total tenosynovitis score, per unit 1.15 (0.94 to 1.41) 0.17
MRI dichotomised for the presence of any subclinical inflammation and for specific inflammatory features
Univariable
Presence of any MRI-detected 
inflammation
6.12 (2.32 to 16.19) <0.001
Presence of MRI-detected synovitis 2.22 (1.03 to 4.78) 0.042
Presence of MRI-detected BME 2.39 (1.04 to 5.46) 0.039
Presence of MRI-detected 
tenosynovitis
7.56 (3.30 to 17.32) <0.001
Multivariable
Presence of MRI-detected synovitis 0.72 (0.31 to 1.69) 0.45
Presence of MRI-detected BME 2.09 (0.91 to 4.81) 0.084
Presence of MRI-detected 
tenosynovitis
8.39 (3.38 to 20.81) <0.001
Presented are the HRs of analyses including 143 patients with CSA that underwent MRI of which 27 developed 
clinical arthritis. The HR of 1.14 for the total inflammation score indicates that when the total MRI inflammation 
score increased with 1 unit the hazard on arthritis development increased with a factor 1.14.
83Progression from CSA to arthritis       |
5
Table 4. Results of multivariable Cox regression analysis of clinical and serological factors and MRI-detected 
subclinical inflammation at baseline in relation to arthritis development
HR (95% CI) p-value
Age, per year 0.96 (0.93 to 0.996) 0.028
Localisation of initial symptoms
  Small joints only Ref Ref
  Large joints only 2.35 (0.41 to 13.61) 0.34
  Small and large joints 4.30 (1.70 to 10.86) 0.002
CRP-level, per mg/L 1.05 (1.01 to 1.09) 0.021
ACPA-positive 6.43 (2.57 to 16.05) <0.001
Presence of any MRI-detected inflammation 5.07 (1.77 to 14.50) 0.002
Presented are the HRs of multivariable analyses including 142 patients with CSA that underwent MRI of which 27 
developed the outcome clinical arthritis. One patient that underwent MRI had missing data on localisation of initial 
symptoms and was not included in present analysis.
(see online Supplementary Table S3). Hence, MRI-detected inflammation was associated 
with progression to clinical arthritis, independent of other clinical and serological factors.
Sensitivity analyses on initiation of DMARD treatment
Sensitivity analyses were performed with initiation of DMARD therapy as outcome. Twenty-
five out of the 30 patients that developed clinical arthritis were started with DMARD 
treatment. Repeating the latter multivariable Cox regression analysis (including clinical and 
serological factors and presence of any MRI-detected inflammation) with DMARD initiation 
as outcome revealed similar results (data not shown).
Diagnostic value of ACPA and subclinical MRI inflammation
The previous analyses showed that the presence of subclinical MRI inflammation and ACPA 
were the two strongest and independent factors associated with arthritis development. We 
continued with determining test characteristics of both factors with arthritis development 
within the first year as outcome (Table 5). To this end, analyses were restricted to the patients 
with CSA with 1 year follow-up who had data on ACPA and MRI (n=122). Of these, 21 
(17.2%) had developed clinical arthritis within this year. Two patients developed arthritis 
after the first year had passed; these patients are now categorised in the non-arthritis group.
Test characteristics of ACPA
The sensitivity of ACPA for arthritis development was 57%, indicating that 57% of the 
patients with CSA that developed arthritis were ACPA-positive and 43% ACPA-negative. Of 
the patients that developed arthritis 24% were negative for ACPA and RF. The specificity of 
ACPA was 93%. The positive predictive value (PPV) of ACPA was 63%, indicating that 63% 
of ACPA-positive patients with CSA have developed clinical arthritis within 1 year (Table 5).
Test characteristics of subclinical MRI inflammation
Subclinical MRI inflammation was present in 81% of the patients that have developed arthritis 
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within 1 year (sensitivity=81%). The specificity was 63%. In case of a positive MRI, 31% of the 
patients progressed to arthritis (PPV) within 1 year and of all persons with a negative MRI 
at baseline only 6% developed arthritis (100% minus negative predictive value (NPV)) (Table 
5). These 6% concerned four patients; three of them developed initial clinical arthritis in a 
joint that was not depicted on MRI and one developed arthritis 17 weeks after inclusion in 
joints that were depicted on MRI.
Test characteristics of subclinical MRI inflammation within ACPA-negative and ACPA-
positive patients with CSA
Test characteristics for subclinical MRI inflammation were determined within the ACPA-
negative and ACPA-positive patients separately to evaluate the diagnostic value in the 
different sub-groups (Table 5). Although patient numbers became small, especially in the 
ACPA-positive subgroup, these stratified analyses indicate the value of subclinical MRI 
inflammation if ACPA results are known. Within the ACPA-positive patients 71% with a 
positive MRI progressed towards arthritis within 1 year (PPV=71%). Hence, whereas the 
chance on arthritis in case of ACPA-positivity in the total CSA population was 63%, within 
the ACPA-positive patients with a positive MRI it was 71%. Of the ACPA-positive patients 
with a negative MRI 60% did not develop arthritis within 1 year (NPV). Within the ACPA-
negative patients with CSA, a negative MRI made the chance on arthritis development very 
low (3%, 100% minus NPV). Furthermore, the sensitivity of a positive MRI in ACPA-negative 
patients was 78%. Thus, whereas 43% of the patients that developed arthritis had a negative 
ACPA test, 78% of these patients were identified by a positive MRI at baseline. Similar results 
were obtained in ACPA-negative and RF-negative patients (data not shown).
DISCUSSION
This longitudinal study of patients with CSA, with a median follow-up duration of 75 weeks 
observed that part of the patients with CSA progressed to arthritis. The majority already 
had subclinical MRI inflammation when presenting with CSA and progressed to arthritis 
within 4-5 months. These data indicate that the period of CSA and subclinical inflammation 
is relatively short and encompasses several months.
MRI-detected inflammation is one of the risk factors for arthritis development 
explored in this study. Thirty-one per cent of patients with CSA with a positive MRI 
progressed to arthritis within 1 year. Arthritis development within the 1st year was rare (6%) 
if the baseline MRI was negative.
The association of subclinical MRI inflammation with arthritis development was 
independent of other factors such as ACPA. Interestingly, the effect sizes in the multivariable 
analyses of both variables were in the same range. In clinical practice serological results are 
generally available before imaging tests are ordered. To get a better impression of the additional 
value of MRI, the analyses on the diagnostic value of MRI were performed in the ACPA-
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positive and ACPA-negative subgroups. This revealed that the risk of arthritis development 
within 1 year was 71% if ACPA-positive patients had a positive MRI. Additionally, 60% of the 
ACPA-positive patients with a negative MRI did not develop arthritis within 1 year. MRI was 
valuable in ACPA-negative patients with CSA as the majority (78%) of the ACPA-negative 
patients that developed arthritis had a positive MRI at baseline.
A strength of this study is that a positive MRI was defined using the prevalence 
of MRI features in the general population as reference, lowering the risk of false-positive 
MRI findings. Of the different types of MRI-detected inflammation (synovitis, BME, 
tenosynovitis), tenosynovitis was most predictive for arthritis development. Previous studies 
showed that MRI-detected tenosynovitis is frequently present in RA 11 and rarely present in 
the general population 10.
A limitation is that in the first 77 patients MRI of the feet was made without 
contrast-enhancement. This may have affected the RAMRIS scores for synovitis on the feet. 
In this study, we scored MRIs without contrast conservatively, which may have resulted in 
an underestimation of inflammation on MRIs without contrast enhancement 12. Another 
limitation is the median follow-up duration of 75 weeks. It is unsure whether longer follow-
up will change our results; nonetheless, we observed that the majority of patients had already 
progressed in the first months after inclusion.
Further replication studies are needed in other CSA populations before it can be 
decided if MRI is a useful tool in CSA in daily practice. In this study, MRI was used because an 
accepted validated scanning and scoring protocol exists 8, it is a minimal operator-dependent 
procedure and the prevalence of MRI-detected inflammation in the general population is 
known 10. These issues are not yet solved for ultrasound and further studies are needed to 
determine whether ultrasound might also be useful in CSA.
Previous studies on patients with symptoms without clinical arthritis evaluated 
patients with unspecified arthralgia 4,5,13,14. These studies identified morning stiffness and 
joint tenderness as predictors for progression to arthritis 4,5. These clinical factors were not 
associated with arthritis development in patients with CSA. This is presumably caused by the 
fact that patients with CSA were selected on the basis of their symptoms and signs. Indeed, 
the frequency of morning stiffness in CSA was higher than that in unspecified arthralgia 4,5.
The reported risk of developing arthritis within 1 year in autoantibody-positive 
patients with unspecified arthralgia was 20-34% and up to 41-43% if other risk factors were 
present 4,5. Of patients with CSA that were ACPA-positive 63% progressed to arthritis within 
1 year, suggesting that the predictive value of ACPA is higher in CSA than in unspecified 
arthralgia.
The present study is the first exploring the outcome of patients with CSA. We did 
not aim to derive a prediction rule because the current data set is too small to use part of 
the data for identification and the other part for validation. In addition, we anticipated that 
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for accurate prediction more predictors are needed than those entered in our multivariable 
analysis. Further work is needed to this end.
In conclusion, the phase of CSA without clinically apparent arthritis but with 
subclinical inflammation encompasses several months. Present data suggest that MRI is 
diagnostically relevant in this disease phase. With regards to the role of MRI in identifying 
patients with an increased risk of arthritis, the absolute value of MRI may be higher in ACPA-
negative then in ACPA-positive patients with CSA, as ACPA-positive patients with CSA 
already have a higher prior risk of arthritis development. Importantly, MRI is also useful to 
rule out imminent arthritis; patients with a clinical suspicion to progress to RA but a negative 
MRI had a low risk of developing arthritis. Further studies are needed to identify the set of 
variables that optimally identifies patients with RA in the phase of arthralgia without clinical 
arthritis and to examine if treatment in this phase is more effective than initiating treatment 
when clinical arthritis has developed.
SUPPLEMENTARY DATA
Supplementary data are published on the website of the Annals of the Rheumatic Diseases.
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Additional File. RAMRIS-based frequencies of synovitis, BME and tenosynovitis per joint/bone, age category and 
grade of severity; presented are percentages present in symptom-free persons (derived from reference 10)
MCPs
Grade 1 Grade 2 Grade 3
<40 40-59 ≥60 <40 40-59 ≥60 <40 40-59 ≥60
years years years years years years years years years
Synovitis
MCP-2 0 8 19 0 0 0 0 0 0
MCP-3 0 14 17 0 0 0 0 0 0
MCP-4 0 2 4 0 0 0 0 0 0
MCP-5 0 1 6 0 0 0 0 0 0
BME*
MCP-2 2 2 4 0 0 0 0 0 0
MCP-3 2 3 6 0 0 0 0 0 0
MCP-4 0 0 0 0 0 0 0 0 0
MCP-5 0 2 0 0 0 0 0 0 0
Tenosynovitis
Extensor MCP-2 0 0 0 0 0 0 0 0 0
Extensor MCP-3 0 1 0 0 0 0 0 0 0
Extensor MCP-4 0 0 0 0 0 0 0 0 0
Extensor MCP-5 0 0 0 0 0 0 0 0 0
Flexor MCP-2 0 1 6 0 0 0 0 0 0
Flexor MCP-3 0 3 12 0 0 0 0 0 0
Flexor MCP-4 0 3 6 0 0 0 0 0 0
Flexor MCP-5 0 1 2 0 0 0 0 0 0
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Wrist
Grade 1 Grade 2 Grade 3
<40 40-59 ≥60 <40 40-59 ≥60 <40 40-59 ≥60
years years years years years years years years years
Synovitis
Intercarpal-CMC joint 4 16 27 0 0 0 0 0 0
Radio-carpal joint 0 17 35 0 0 0 0 0 0
Distal radio-ulnar joint 0 8 17 0 0 0 0 0 0
BME
Metacarpal-1 basis 0 3 8 0 0 2 0 0 4
Metacarpal-2 basis 4 1 2 0 0 0 0 0 0
Metacarpal-3 basis 0 0 2 0 0 0 0 0 0
Metacarpal-4 basis 0 0 2 0 0 0 0 0 0
Metacarpal-5 basis 0 0 0 0 0 0 0 0 0
Trapezium 0 0 4 0 0 4 0 0 4
Trapezoid 2 1 6 0 0 0 0 0 0
Capitate 6 3 4 2 0 0 0 0 0
Hamate 0 3 8 0 0 0 0 0 0
Scaphoid 2 7 19 0 0 0 0 0 0
Lunate 6 19 27 0 1 4 0 0 0
Triquetrum 2 6 2 0 0 0 0 0 0
Pisiform 0 0 0 0 0 0 0 0 0
Distal radius 0 0 0 0 0 0 0 0 0
Distal ulna 0 7 8 0 0 0 0 0 0
Tenosynovitis
I extensor 0 0 0 0 0 2 0 0 0
II extensor 0 0 0 0 0 0 0 0 0
III extensor 0 0 0 0 0 0 0 0 0
IV extensor 0 0 2 0 0 0 0 0 0
V extensor 0 0 0 0 0 0 0 0 0
VI extensor 0 9 12 0 0 0 0 0 0
1 flexor 0 0 0 0 0 0 0 0 0
2 flexor 0 0 0 0 0 0 0 0 0
3 flexor 0 0 0 0 0 0 0 0 0
4 flexor 2 0 2 0 0 0 0 0 0
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MTPs
Grade 1 Grade 2 Grade 3
<40 40-59 ≥60 <40 40-59 ≥60 <40 40-59 ≥60
years years years years years years years years years
Synovitis
MTP-1 4 11 13 0 0 2 0 0 0
MTP-2 0 1 0 0 0 0 0 0 0
MTP-3 0 1 0 0 0 0 0 0 0
MTP-4 0 0 0 0 0 0 0 0 0
MTP-5 0 0 4 0 0 0 0 0 0
BME*
MTP-1 10 12 23 0 1 8 0 0 0
MTP-2 2 0 0 0 1 0 0 0 0
MTP-3 0 1 0 0 0 0 0 1 0
MTP-4 0 1 0 0 0 0 0 0 0
MTP-5 0 1 4 0 0 0 0 0 0
Presented are the percentages out of the total number of persons in each age category: 51 symptom-free persons were 
included in the category <40 years, 90 persons in the category from 40-59 years and 52 persons in the category ≥60 
years. These tables are used for present study of patients with CSA to derive age, MRI-feature and location specific 
reference values for a ‘positive MRI’. The locations that were inflamed in ≥5% of individuals are highlighted in dark. 
Joints/bones in the CSA-patients with scores as presented in in the light areas are categorized as positive for MRI-
detected inflammation and the joints/bones with scores as presented the dark areas as negative. 
* BME is scored in the proximal and distal MCP and MTP bones separately. The scores of the 2 bones are summed 
into a 1 score, therefore the range is 0-6 in the MCP and MTP joints. Five bones scored a grade 2 in MTP-1 this 
consists of 4 persons with a grade 1 in both the proximal and the distal bone and 1 person had a score of 2 in the 
proximal bone of MTP-1
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Sir, Within RA, early initiation of treatment is associated with a higher chance of achieving 
DMARD-free sustained remission 1–3. The absolute number of RA patients achieving this 
beneficial condition is still low. It is hypothesised that treatment initiation in the early 
phase of symptoms, without clinically detectable arthritis, will be more effective in disease 
modulation and will reduce the persistent nature of the disease 4. Trials are needed to study 
this hypothesis. For this purpose, we need to identify patients in a symptomatic phase before 
synovitis is clinically apparent.
The clinical presentation characterizing RA in the early symptomatic phase of this 
disease is unknown. A method for differentiating patients with arthralgia at risk of RA 
from other patients with joint symptoms is to use clinical expertise as a starting point. 
Rheumatologists see many patients presenting with arthralgia, but without clinically apparent 
arthritis. These patients fall into three categories: patients with a clear diagnosis for their 
arthralgia; patients without a clear diagnosis but not considered at risk for RA according to 
their rheumatologists (unexplained arthralgia); and patients with clinically suspect arthralgia 
(CSA) - based on their clinical presentation, rheumatologists suspect these patients will 
progress to RA 5. This study explored the diagnostic accuracy of the clinical expertise of 
rheumatologists.
Between April 2012 and December 2013, 145 newly referred patients to the 
rheumatologic outpatient clinic in Leiden (the Netherlands) were identified as having CSA. 
In the same period, 1791 newly referred patients had unexplained arthralgia according 
to the local registry that records the diagnosis at first visit for financial purposes. Patients 
with arthralgia were considered to have reached the outcome when they had developed 
clinical arthritis within 1 year after first presentation with arthralgia and fulfilled the 1987 
classification criteria for RA. For CSA patients, this was determined within the CSA cohort 
5. For the unexplained arthralgia patients, the outcome was determined by investigating 
which of the 1,791 patients were included in the Leiden Early Arthritis Clinic (EAC) cohort 
within 1 year after first presentation and also fulfilled the 1987 criteria 6. To ensure that no 
converters were missed in the unexplained arthralgia group, all final diagnoses according 
to the mentioned registry were checked, and all files were checked for patients in whom 
the diagnoses remained unexplained but who had more than four visits at the outpatient 
clinic. These additional ways to search did not yield any additional patient with 1987 RA. All 
patients included in the CSA and EAC cohorts gave informed consent, and approval for these 
cohorts was obtained from the Medical Ethics Committee of the Leiden University Medical 
Center. The approval included collection of clinical and serological data and the use of these 
data for analyses, including this analysis.
At the 1-year follow-up, 16 of the patients identified as CSA patients had progressed 
to arthritis and fulfilled the 1987 criteria for RA within 1 year (11%). Likewise, 4 of the 1,791 
unexplained arthralgia patients were included in the EAC and fulfilled the 1987 criteria 
(0.2%). The odds ratio was 55 (95% CI=18-168, p<0.001), the sensitivity of the clinical 
95Clinical expertise and CSA       |
6
expertise was 80%, the specificity was 93% and the accuracy was 93%. The four RA patients 
who had initially presented with arthralgia and who were not identified as having CSA 
had the following presentations: one patient had arthralgia with inflammatory symptoms 
(morning stiffness, most severe symptoms in early morning), but the rheumatologist did not 
label the patient as having CSA; one patient had inflammatory symptoms and psoriasis and 
was suspected of progressing towards psoriatic arthritis instead of RA, and therefore was not 
labelled as having CSA; in one person the symptoms were attributed to a recent Hepatitis B 
vaccination; and one person had no inflammatory symptoms or signs at all.
The performance of autoantibody testing in the diagnostic process of arthritis and 
RA in first-line care is not promoted by the Dutch guideline for general practitioners 7. 
More locally in the Leiden area, general practitioners are even discouraged from performing 
autoantibody tests before referral, and they are encouraged to refer promptly. In line with 
this, the large majority of patients were referred without results for ACPA or RF. Hence, the 
diagnosis of having CSA was essentially based on symptoms and signs. We realise that this 
health care system is differently organised than that in other parts in Europe. Therefore, our 
setting provides a unique opportunity for exploring the accuracy of clinical expertise based 
on symptoms and signs only. After the first visit to the outpatient clinic, autoantibody testing 
was carried out. Three of the four patients who were not identified as having CSA based on 
their clinical presentation and who did develop RA were ACPA-positive. This illustrates that 
the evaluation of the presence or absence of CSA was not driven by results of autoantibody 
status. We do not have data on ACPA-status for the patients with unexplained arthralgia who 
did not progress to RA. Therefore, this study does not allow us to identify the predictive value 
of ACPA testing in patients who are clinically not suspected of progressing towards RA.
In conclusion, the present data revealed the value of the rheumatologists’ expertise in 
differentiating arthralgia patients based on clinical presentation (history, symptoms, signs) 
only. A potential disadvantage is its subjectivity. Therefore, a current EULAR taskforce is 
deriving criteria for CSA, using a consensus-based approach 8.
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During the transition to rheumatoid arthritis (RA) many patients pass through a phase 
characterised by the presence of symptoms without clinically apparent synovitis. These 
symptoms are not well-characterised. This taskforce aimed to define the clinical characteristics 
of patients with arthralgia who are considered at risk for RA by experts based on their clinical 
experience. 
Methods 
The taskforce consisted of 18 rheumatologists, 2 patients, 3 health professionals and 1 fellow. 
The process had three phases. In phase-1, a list of parameters considered characteristic 
for clinically suspect arthralgia (CSA) was derived; the most important parameters were 
selected by a three-phased Delphi-approach. In phase-2, the experts evaluated 50 existing 
patients on paper, classified them as CSA/no-CSA and indicated their level of confidence. A 
provisional set of parameters was derived. This was studied for validation in phase-3, where 
all rheumatologists collected patients with and without CSA from their outpatient clinics.
Results 
The comprehensive list consisted of 55 parameters, of which 16 were considered most 
important. A multivariable model based on the data from phase-2 identified 7 relevant 
parameters: symptom duration <1-year, symptoms of MCP-joints, morning stiffness duration 
≥60 minutes, most severe symptoms in early morning, first-degree relative with RA, difficulty 
with making a fist, positive squeeze-test MCP-joints. In phase-3, the combination of these 
parameters was accurate in identifying arthralgia patients who were considered at risk of 
developing RA (AUC=0.92, 95%CI=0.87-0.96). Test characteristics for different cut-off 
points were determined.
Conclusion 
A set of clinical characteristics for patients with arthralgia who are at risk of progression to 
RA was established. 
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INTRODUCTION
The development of rheumatoid arthritis (RA) is a multistep process. A European League 
Against Rheumatism (EULAR) study group differentiated the following phases: (1) presence 
of genetic and environmental risk factors for RA, (2) systemic autoimmunity associated with 
RA, (3) symptoms without clinical arthritis, (4) unclassified arthritis and finally (5) RA 1. The 
symptomatic phase preceding clinical arthritis is the first opportunity to clinically recognise 
patients who are at risk for progression to RA. In contrast to the other phases that have 
been studied extensively, this phase is less well studied.  Whilst a few studies reported on 
symptoms experienced by patients in this phase and on their impact on daily life 2–4, clinical 
characteristics that are specific for this phase have not yet been identified by a consensus-based 
approach 1,5,6. This situation hampers the conduct of studies and clinical trials in this phase 
of the disease. It has been shown that early initiation of disease modifying anti-rheumatic 
drug (DMARD) treatment in RA is more effective in modulating the erosive and persisting 
nature of RA compared to delayed initiation of DMARD treatment 7–9. Hence interventions 
in the initial clinical phase of the disease, which precedes the onset of clinical arthritis, may 
be more effective in reducing the risk of disease persistence and the development of damage 
10. However, studies to address this require the inclusion of homogeneous sets of patients. 
Clinical expertise, which includes pattern recognition, guides decisions in daily 
practice and has also been used as reference for the development of several tools or criteria 
in the field of rheumatology 11–14. Patients with Clinically Suspect Arthralgia (CSA) have 
articular symptoms without signs of arthritis and are considered to be at increased risk for 
progression to RA 15. Hence, the identification of the presence of CSA is based on clinical 
expertise. Recent data revealed that patients with CSA constitute only a small percentage 
of all patients with arthralgia who visit the rheumatology outpatient clinic for the first time 
(~7%), and that a proportion of patients with CSA did indeed progress to RA during follow-
up (~20%) 16. It was also suggested that clinical experience was accurate to distinguish 
patients with arthralgia at risk of RA from other arthralgia patients (OR 55). In particular, 
only a minority of patients who presented with arthralgia and subsequently developed RA 
were not recognised by the rheumatologist 17.
Although the concept of CSA is appropriate for use in clinical practice, a drawback 
is its subjectivity, which may result from differences in practice and experience. Therefore 
the phenotype of CSA needs to be defined. This taskforce aimed to identify a combination of 
clinical features that best characterise patients with arthralgia who are at risk of RA according 
to an expert multidisciplinary group of European rheumatologists, other health professionals 
and patients. This approach was similar to that which led to the definition of inflammatory 
back pain, a definition which was subsequently integrated in the ASAS classification criteria 
18,19. The taskforce intended to derive a set of clinical parameters to enable the inclusion of 
homogeneous sets of patients in subsequent studies. It was considered inappropriate to use the 
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phrase ‘classification criteria’ for the product as, basically, classification concerns testing the 
presence or absence of a disease. CSA is not in itself a disease, but a combination of symptoms 
and signs. It was anticipated that clinical characteristics alone are insufficient predictive for 
RA, that a combination of clinical and other factors (e.g. autoantibodies, imaging results) are 
necessary to identify patients with imminent RA, and that the derived clinical definition can 
later become part of criteria for imminent RA. Thus in sum, the present taskforce aimed to 
define arthralgia at risk for RA. 
METHODS
Expert committee
The expert committee comprised 18 rheumatologists, one methodologist (RL, who was also 
one of the rheumatologists), two nurse specialists, one physiotherapist, two patients and 
one research fellow, originating from 15 European countries. The target populations are 
rheumatologists and health professionals working in secondary care.
Three-phased process
The process consisted of three phases and two meetings. Expert opinion was the reference. 
Per phase consensus was obtained before proceeding to the next phase. 
Phase-1
Phase-1 aimed to develop a comprehensive list of clinical parameters (both symptoms at 
history taking and signs at physical examination) that were considered by the experts to be 
relevant to distinguish arthralgia that precedes RA from other types of arthralgia. A modified 
Delphi approach was used. First, all taskforce members were asked to indicate all symptoms 
and signs that they considered potentially relevant. All parameters mentioned to be relevant 
by at least two experts or by the patients (based on personal experience) were added to 
create a comprehensive list. In the next three quantitative rounds the participants selected 
the parameters they considered most relevant by weighing. After each round, the list of 
parameters was modified based on the results; parameters on which consensus was reached 
(either relevant or irrelevant) were not evaluated in the next round. The group response of 
the previous round and the modified list were presented to the group before they voted in the 
next round. 
Phase-2
Phase-2 aimed to develop a provisional set of clinical parameters describing CSA. The 
experts reviewed clinical data from 50 patients who had previously presented with arthralgia 
but without clinically detectable arthritis to the rheumatology outpatient clinic of the Leiden 
University Medical Centre (the Netherlands). Of these, 26 were considered to have CSA by 
the treating rheumatologist 15; the prevalence of CSA in this patient set was thus artificial and 
much higher than in a general rheumatology outpatient clinic. The experts were blinded for 
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grouping by the treating rheumatologists. Clinical data relating to the parameters selected in 
Phase-1 were presented to the experts as being present or absent in these ‘paper patients’. The 
experts were asked to classify each patient as having CSA or no-CSA and to provide the level 
of confidence with their classification on a numerical rating scale from 0 (not confident) to 
10 (very confident). 
Two approaches were used to analyse the data from Phase-2. First, to gain insight into 
the degree of equivalence of the expert classifications, the frequencies of the classifications 
were plotted against the level of confidence of each classification per patient, as described 
previously 19. Individual histograms represented all experts’ judgments on individual patient 
and were evaluated independently by three reviewers (AvdHvM, RL, HvS); each reviewer 
decided whether the experts agreed on the classification as ‘CSA’, ‘no-CSA’ or ‘unclassifiable’. 
If all reviewers had the same judgment the patient was categorised accordingly. Otherwise, 
agreement between the reviewers was reached on how to categorise a patient. The parameters 
selected in phase-1 were compared for the patients in the three groups (CSA, no-CSA and 
unclassifiable). Then, to statistically identify the parameters that best discriminated between 
CSA and no-CSA, a multilevel model was used with one level being the expert and the other 
level being the patient; this analysis which was done on 900 judgments about CSA included 
the data of all 50 patients, each classified by 18 rheumatologists. This mixed effects model 
with crossed random effects was applied with the weighted CSA classification as outcome and 
the clinical parameters as independent variables. This model was used to take into account 
that each expert assessed the same 50 patients. Crossed random effects were included as the 
symptoms are nested in the combination of expert and patient and thus the residuals of the 
two levels are still correlated, even after taking the two levels of the analysis into account 
20,21. Clinical parameters with a p-value ≤0.05 in univariable analyses were included in 
multivariable analysis. The parameters with a positive coefficient in the multivariable analysis 
were combined to a provisional set of parameters describing CSA. These data were presented 
at the first meeting. 
Phase-3
Phase-3 aimed to validate the provisional set of parameters in the outpatient clinics of the 
participating rheumatologists. They were asked to select newly referred patients without a 
defined time limit of symptoms and without arthritis but with arthralgia who they considered 
to have an increased risk of RA based on history taking and physical examination (patients 
with CSA) and patients who had no evident diagnosis or explanation for the arthralgia at 
first visit but were not considered at risk for RA (no-CSA). Patients who at presentation had 
evident diagnoses, such as fibromyalgia or osteoarthritis, were not included in the no-CSA 
group. In addition, the participants were encouraged to base the decision of CSA on the 
clinical presentation only and not on results of additional investigations. Due to differences in 
health care settings, some rheumatologists had access to the result(s) of laboratory or imaging 
investigation(s) at first presentation for the majority of their patients. The presence or absence 
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of additional test results at the time of identification of CSA or no-CSA was recorded. The 
provisional set of parameters derived from phase-2 was tested using multivariable logistic 
regression analyses in the identified CSA and no-CSA patients. Thus again clinical expertise 
was the reference. The performance of the combination of parameters was assessed using the 
area under the receiver operating characteristic curve (AUC). Sensitivity and specificity were 
determined for different cut-off points. The data from this phase were discussed during the 
second meeting. The final set of parameters was established by voting. 
RESULTS
Phase-1 – Identifying relevant parameters for CSA
First, all experts identified as many parameters as possible that they considered relevant when 
evaluating whether arthralgia patients did or did not have CSA. The total list consisted of 55 
parameters (Supplementary Table S1) and included both parameters that were considered 
to increase and decrease the likelihood of CSA. By selecting and weighing in three rounds, 
the number of parameters on the list was reduced to 16 (Table 1). Consensus was reached to 
proceed with these 16 parameters to phase-2. 
Phase-2 – Development of provisional set of parameters describing CSA
First, in order to get an overview of the data, each of the 50 patients were classified as having 
CSA, no-CSA or being unclassifiable based on their individual histograms which represented 
the classifications of all experts. Seventeen patients were unequivocally classified as no-
CSA, 14 as CSA and 19 patients were considered unclassifiable (examples of the histograms 
are presented in Supplementary Figure S1). Table 1 presents the frequencies of the clinical 
parameters for the groups of patients identified as no-CSA, unclassifiable and CSA. 
Then, using data from all 50 patients, a multilevel model with weighted CSA 
classification as outcome was used to select the parameters that best discriminated between 
CSA and no-CSA. Results of univariable and multivariable analyses are presented in 
Supplementary Table S2. The following 7 variables were presented during the first meeting 
as a provisional set of parameters describing CSA: joint symptoms of recent-onset (duration 
<1 year), symptoms located in MCP-joints, symmetric symptoms or signs (bilateral in same 
joint region), duration of morning stiffness ≥60 minutes, most severe symptoms present in 
the early morning, difficulty with making a fist and positive squeeze-test of MCP-joints. At 
the meeting, it was suggested to remove the item symmetry from the multivariable analysis 
(because of p>0.05 in univariable analysis) and to force MTP-involvement and a positive 
family history in the analysis (as these items were judged as very relevant by many experts). 
The results are presented in Supplementary Table S3. Thereafter, consensus was reached on 
the following 7 parameters to characterise arthralgia that is clinically suspect for progression 
to RA: joint symptoms of recent-onset (duration <1 year), symptoms located in MCP-joints, 
duration of morning stiffness ≥60 minutes, most severe symptoms present in the early 
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morning, presence of a first-degree relative with RA, difficulty with making a fist and positive 
squeeze-test of MCP-joints (Box 1).
Phase-3 – Validation 
In total 322 patients with arthralgia were identified in the different centres (Supplementary 
Table S4), 142 patients with CSA and 180 arthralgia patients without CSA. Of them, 78 and 
61 respectively were identified based on clinical information only (i.e. without data relating to 
additional investigations); these 139 patients were used in the main analysis. When weighing 
the parameters based on the B coefficient of the logistic regression analysis after rounding 
the coefficients to whole points, the combination of 7 parameters performed well to explain 
the clinical expertise (AUC 0.93, 95%CI 0.89-0.97). When using all variables unweighted, 
the combination of 7 parameters performed equally well in identifying arthralgia patients 
who were considered to be at risk of RA by the experts (AUC 0.92, 95%CI 0.87-0.96) 
(Supplementary Table S5). The experts agreed that unweighted parameters were more 
convenient. When analysing all 322 patients, similar AUCs were obtained (Supplementary 
Table 1. Parameters that were selected in phase-1, and frequencies of these parameters in the patients that in phase-2 








  Joint symptoms of recent-onset (duration <1 year) 41% 74% 92%
  4-10 joints with symptoms 47% 57% 21%
  Symptoms in MCP-joints 35% 63% 93%
  Symptoms in MTP-joints 35% 53% 57%
  Symptoms in several small joint regions (MCP, wrists, PIP, MTP-joints) 35% 68% 93%
  Symmetric symptoms or signs (bilateral in same joint region) 77% 58% 100%
  Duration of morning stiffness ≥60 minutes 6% 37% 71%
  Most severe symptoms in the early morning 27% 69% 90%
  Improvement of symptoms during the day 15% 36% 90%
  Increasing number of joints with symptoms over time 70% 71% 90%
  Patient-experience of swelling of small hand joints 31% 47% 77%
  Presence of a first-degree relative with RA 7% 33% 36%
Physical examination
  Difficulty with making a fist 8% 31% 43%
  Local tenderness involved joints at physical examination 63% 84% 86%
  Positive squeeze-test of  MCP-joints 14% 26% 69%
  Positive squeeze-test of  MTP-joints 22% 21% 39%
Data on symptoms of recent-onset was missing in 1 patient, on most severe symptoms in early morning in 6 patients, 
on improvement of symptoms during the day in 8 patients, on increasing number of joints with symptoms over time 
in 11 patients, on patient-experience of swelling in 2 patients, on difficulty with making a fist, presence of a first-
degree relative with RA, local tenderness of joints, squeeze-test of MCP- and MTP-joints in 4 patients.
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Table S6). 
The sensitivities and specificities belonging to the number of positive parameters are 
presented in Table 2. A sensitivity >90% was obtained in the presence of ≥3 parameters and a 
specificity >90% in the presence of ≥4 parameters. All taskforce members unanimously agreed 
that arthralgia that is suspected for progression to RA is defined by the seven parameters 
presented in Box 1 and that these parameters are to be used in patients with arthralgia but not 
clinical arthritis in whom there is not a better explanation for the arthralgia.
DISCUSSION
The development of RA is a multi-step process. In this project we defined the combination of 
symptoms and signs that characterise patients at risk of developing RA. In clinical practice, 
rheumatologists identify patients with CSA based on their expertise. The presence of CSA may 
trigger rheumatologists to monitor patients closely and/or to undertake specific laboratory 
testing or imaging. For daily rheumatologic practice the concept of CSA has been shown to 
be adequate to differentiate patients with arthralgia 16,17, but it is subjective and this results 





≥ 1 100.0% 14.1%
≥ 2 98.4% 53.8%
≥ 3 90.2% 74.4%
≥ 4 70.5% 93.6%
≥ 5 32.8% 100.0%
≥ 6 16.4% 100.0%
≥ 7 1.6% 100.0%
Box 1. EULAR defined characteristics describing arthralgia at risk for RA 
These parameters are to be used in patients with arthralgia without clinical 
arthritis and 
without other diagnosis or other explanation for the arthralgia.
History taking:
• Joint symptoms of recent-onset (duration <1 year)
• Symptoms located in MCP-joints
• Duration of morning stiffness ≥60 minutes
• Most severe symptoms present in the early morning
• Presence of a first-degree relative with RA
Physical examination:
• Difficulty with making a fist
• Positive squeeze-test of  MCP-joints
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in heterogeneity. For scientific studies homogeneous sets of patients are required. Therefore, 
we aimed to capture clinical expertise and represent it in a set of defined clinical parameters. 
The process incorporated three phases and two meetings, and the product was obtained by a 
data-driven and consensus-driven approach. Unanimous agreement was obtained on seven 
parameters reflecting the aggregated expertise of rheumatologists, health care professionals 
and patients from fifteen European countries.
This taskforce was able to successfully identify and collate a homogenous and 
measurable set of clinical parameters of CSA based on clinical expertise of rheumatologic 
experts for use in future studies. Further longitudinal studies are required to assess if this 
definition reduces the number of arthralgia patients that need additional testing, and to 
determine the predictive accuracy of these clinical parameters for the development of RA, 
both when used alone and in combination with the results of additional investigations. Thus, 
the result of this taskforce should serve as the basis for the next step, which is the initiation 
of longitudinal data-driven projects, which ultimately results in the development of criteria 
for imminent RA. Most likely such criteria will include both clinical and investigation based 
parameters (such as laboratory and imaging results). 
Because a clinical definition alone is unlikely to be sufficiently accurate to identify 
RA patients in a symptomatic pre-arthritis phase, and because CSA is not a disease but the 
description of a phenotype, it was decided that the product of this taskforce should not be 
referred to as ‘classification criteria’ but as a ‘definition’. Furthermore, while the physicians 
in the taskforce argued that the word ‘patient’ may have an unwarranted connotation, the 
patient representatives in the task force justified the use of the term ‘patient’ by pointing to 
the fact that these individuals had presented with pain and other symptoms and had been 
referred to secondary care. 
The parameters characterising arthralgia at risk of RA may serve as the basis for 
observational studies and intervention trials performed in the symptomatic pre-arthritis 
phase. Depending on the study a more sensitive or more specific definition may be preferred. 
A high sensitivity may be preferred if the clinical criteria are used as first inclusion criterion, 
as in this situation the number of CSA patients that are missed by the criteria should be low. 
Subsequently, additional tests can be applied to ensure sufficient specificity. If in contrast, 
patients are mainly selected based on clinical characteristics, a higher specificity may be 
preferred to prevent false-positives. Given this, the taskforce deliberately avoided a single cut-
off point to define arthralgia at risk of RA, but provided the test characteristics of a spectrum 
of cut-off points. A high sensitivity (>90%) is obtained if ≥3 out of the 7 parameters are 
present; a high specificity (>90%) requires the presence of ≥4 of the 7 parameters. 
The clinical variables were considered to distinguish arthralgia patients who are at 
risk of RA from patients with other types of (not specified) arthralgia. Patients that at first 
presentation clearly had other diagnoses, such as fibromyalgia or osteoarthritis, were not 
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included in the control groups of phases 2 and 3. This is in line with clinical practice, as 
there is no diagnostic dilemma in the patients with evident diagnoses. Similar to the 2010 
ACR/EULAR classification criteria for RA that should not be applied to arthritis patients 
with diagnoses other than RA 14, the present set of parameters is reserved for patients with 
arthralgia with no definitive diagnosis but a clinical suspicion of RA.
The definition was derived for use in secondary care. Because of this target 
population, the taskforce was composed largely of rheumatologists and their expertise was 
used as a reference. General practitioners were not involved. The taskforce discussed whether 
our present product may be useful as a referral tool for general practitioners, as has been 
done by others 22. Whilst the taskforce was of the opinion that the present set of parameters 
might also be valuable to identify patients with arthralgia at risk of RA in primary care, it was 
agreed that the applicability of the present definition in the primary care setting would need 
to be assessed through future research in primary care. 
It was acknowledged that there may be some redundancy in the seven parameters 
expressing risk for RA. Further prospective studies will be required to elucidate if one of the 
parameters can be omitted without losing discriminative ability. 
A limitation of our approach is that the experts who developed the list of relevant 
parameters in Phase-1 and scored the patients in Phase-2 also identified patients for the 
validation phase. It is possible that the discussions that were held and the data from the first 
two phases influenced their clinical expertise while selecting patients with CSA and arthralgia 
patients without CSA. However many experts also involved other colleagues to select patients 
with CSA from their clinics and these colleagues were not involved in the first two phases of 
the project. 
Differences in health care settings affect the ability to identify patients in a 
symptomatic phase prior to presenting with clinically apparent arthritis. E.g., between centres 
and countries there are differences in the possibilities for early access. Some of the differences 
between health care settings were incorporated by inviting experts from different centres and 
different countries and by using a consensus-based approach. There were also differences 
in the extent to which additional investigations were performed prior to the first clinical 
evaluation in speciality care. As the aim of the taskforce was to provide a clinical definition, 
and as knowledge of the results of additional investigations may influence the selection of 
patients in phase 3, patients in whom knowledge of additional investigations were known 
at first presentation were initially excluded from analyses. This ensured that patients were 
exclusively identified on the clinical presentation. However, a sub-analysis including also the 
other patients did not give different results, revealing robustness of the data. 
The taskforce had discussed if the individual parameters needed to be defined. 
Consensus was derived that this project was not aiming at what definition of a specific 
domain was best, but rather what domains contribute most to the ‘phenotype’ of CSA, given 
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all the restrictions. 
In conclusion, a set of clinical characteristics describing arthralgia at risk of RA 
was established. The combination of these parameters accurately reflected expert opinion 
about CSA. Test characteristics were determined for different cut-off points. For a sensitive 
definition, arthralgia at risk of RA can be defined by the presence of ≥3 parameters and the 
presence of ≥4 parameters yielded a high specificity. Longitudinal studies are required to 
determine the predictive accuracy of these clinical parameters alone and when combined 
with the results of additional investigations, such as laboratory testing or imaging.
SUPPLEMENTARY DATA
Supplementary data are available from the author upon request.
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The severity of radiologic progression is variable between rheumatoid arthritis (RA) patients. 
Recently, several genetic severity variants have been identified and were replicated, these 
belong to 12 loci. This study determined the contribution of the identified genetic factors 
to the explained variance in radiologic progression and whether genetic factors, in addition 
to traditional risk factors, improve the accuracy of predicting the severity of radiologic 
progression.
Methods
426 early RA patients with yearly radiologic follow-up were studied. The main outcome 
measure was the progression in Sharp-van der Heijde score (SHS) over 6 years, assessed as 
continuous outcome or categorised in no/little, moderate or severe progression. Assessed 
were improved fit of a linear mixed model analysis on serial radiographs, R2 using linear 
regression analyses, C-statistic and the net proportion of patients that was additionally 
correctly classified when adding genetic risk factors to a model consisting of traditional risk 
factors. 
Results
The genetic factors together explained 12–18%. When added to a model including traditional 
factors and treatment effects, the genetic factors additionally explained 3–7% of the variance 
(p-value R
2
change=0.056). The percentage of patients that was correctly classified increased 
from 56% to 62%; the net proportion of correct reclassifications 6% (95% CI 3 to 10%). The 
C-statistic increased from 0.78 to 0.82. Sensitivity analyses using imputation of missing 
radiographs yielded comparable results.
Conclusion 
Genetic risk factors together explained 12–18% of the variance in radiologic progression. 
Adding genetic factors improved the predictive accuracy, but 38% of the patients were still 
incorrectly classified, limiting the value for use in clinical practice.
115Predicting the severity of joint damage       |
8
INTRODUCTION
The severity of rheumatoid arthritis (RA) is commonly expressed by the extent of damage 
of hand and feet joints. Joint damage can be measured objectively with validated scoring 
methods and is associated with long-term functional disability 1. The severity is highly 
variable between patients; many patients show mild progression and few severe progression. 
The processes underlying these differences are partly understood. The observation that 
the heritability of radiologic progression is 45-58% 2 underlined the notion that genetic 
factors play a role. Presently, several genetic risk factors for radiologic progression have 
been identified and replicated. Some of these variants were also associated with differences 
in mRNA or protein expression 3–6. Here, we aimed to explore the relevance of currently 
known genetic risk factors with regards to (1) explaining the interindividual variance in 
radiologic progression and (2) improving the accuracy of predicting radiologic progression 
for individual patients.
Known traditional risk factors explain about one-third of the variance in joint damage 
after 5 years of disease; the majority of these risk factors were related to patient characteristics 
(age, gender), inflammation (acute phase reactants, swollen joint counts) and the presence of 
auto-antibodies 7. The contribution of the genetic risk factors to the explained variance has 
not been explored.
Prediction of RA severity on the level of individual patients is not yet accurate. Several 
matrices to predict rapid radiologic progression have been derived, consisting of three or four 
risk factors. Most of these matrices are not validated in the general RA population, and failed 
to correctly classify ~50% of patients. In particular, the patients who developed progressive 
disease were not recognized 8–13. Consequently, the value of these matrices for clinical practice 
is still limited. Whether the addition of genetic factors improves prediction is unknown.
This study examined the variance in joint damage progression explained by recently 
identified genetic risk factors and their value in improving the prediction of the severity 
of joint damage progression. We assessed traditional performance measures of prediction 
models and the net proportion of RA patients that is additionally correctly classified when 
adding risk factors to a prediction model consisting of known risk factors.
PATIENTS AND METHODS
Patients
Between 1993 and 2006, 600 RA patients (1987-ACR-criteria) were included in the Leiden 
Early Arthritis Clinic (EAC) 7. Inclusion in the EAC took place when arthritis was confirmed 
at physical examination and symptom duration was less than 2 years. At first visit, patients and 
rheumatologists filled questionnaires, 66-swollen and 68-tender joint counts were performed 
(66-SJC and 68-TJC 14), and blood samples were taken. Patients were followed yearly. The 
initial treatment strategy differed for different inclusion periods: patients included in 1993–
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1995 were initially treated with NSAIDs, patients included in 1996–1998 were initially 
treated with hydroxychloroquine or sulphasalazine, and patients included since 1999 were 
promptly treated with methotrexate. The severity of radiologic progression differed for these 
three treatment groups; therefore, treatment effects were incorporated in the analyses. The 
traditional risk factors studied were age, gender, symptom duration at first visit, localisation 
initial joint symptoms, 66-SJC, presence of anti-citrullinated peptide antibodies (ACPA), 
presence of rheumatoid factor (RF) and erythrocyte sedimentation rate (ESR).
Selection of genetic risk factors and genotyping
We selected single nucleotide polymorphisms (SNPs) using the following criteria: the SNP 
was studied in relation to the severity of radiologic progression in several cohorts and the 
association was independently replicated or found significant in a meta-analysis including 
all published data. Based on these criteria, we came to a selection of genetic variants that is 
presented in table 1. Notably, rs4810485 in CD40 and rs7607479 in SPAG16 were identified 
as risk factors for radiologic progression only in ACPA-positive RA. Genotypings in the EAC 






Chr. MAF* Tested 
Model*
R2 ΔSHS0-6years 
(%) in RA 
(n=239)
R2 ΔSHS0-6years (%) 
in ACPA-pos RA 
(n=144)
SE 29 HLA-DRB1 6 0.39 add 4.0 <0.01
rs4810485 (T) 15 CD40 20 0.24 rec 0.1 <0.01
rs7667746 (G) 16 IL-15 4 0.33 rec 2.6 3.9
rs7665842 (G) 16 IL-15 4 0.40 rec 2.7 3.7
rs4371699 (A) 16 IL-15 4 0.19 rec 0.3 1.0
rs6821171 (C) 16 IL-15 4 0.29 rec 0.1 1.4
rs1896368 (G) 4 DKK-1 10 0.47 add 0.3 1.1
rs1896367 (A) 4 DKK-1 10 0.41 add 0.4 0.7
rs1528873 (A) 4 DKK-1 10 0.47 add 2.1 3.0
rs2104286 (C) 18 IL2RA 10 0.24 add 0.3 <0.1
rs8192916 (A) 3 GRZB 14 0.42 rec 0.8 1.4
rs1119132 (A) 17 IL-4R 16 0.13 rec 0.5 1.1
rs7607479 (C) 6 SPAG16 2 0.33 add 0.6 2.5
rs26232 (T) 19 C5orf30 5 0.29 add 0.3 <0.1
rs11908352 (A) 5 MMP-9 20 0.21 add 4.7 1.3
rs451066 (A) 5 rs1465788 14 0.20 add 1.1 0.2
rs1485305 (T) 30 OPG 8 0.44 add 1.4 0.6
The presented R2s were based on univariable analyses for each individual risk factor. *The MAFs and tested models 
are presented as reported in the previous studies. MAF=minor allele frequency; R2= proportion of explained 
variance; ΔSHS0-6years= progression in Sharp-van der Heijde score over six years; add=additive; rec=recessive; 
SE=shared epitope.
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Figure 1. Flow chart of patient selection. 
Baseline characteristics of the included (n=426) and excluded patients (n=174) were not different (data not shown). 
The patients with follow-up until six years (n=239) were younger compared to the patients without complete follow-
up until six years (n=187) (mean (SD) 53.9 (14.5) versus 60.0 (15.7) years, p<0.001), had a higher 66-SJC (median 
(IQR) 9 (5–16) versus 8 (3–13), p=0.009) at baseline and were more frequent ACPA-positive (60.3% vs 44.4%, 
p=0.001). RMA=repeated measurement analysis; R2=proportion of explained variance. 
were done with allele-specific kinetic PCR analysis 15, Illumina Golden Gate platform 3,4,16,17, 
Illumina Immunochip 5,18, Sequenom iPLEX 6 and LightSnp (Roche) 19. Quality control of 
genotyping was performed as described previously 3–6,15–19. 426 patients had complete data on 
all evaluated traditional and genetic risk factors (figure 1).
Radiologic outcome
X-rays were taken at baseline and with yearly intervals. Totally, over 7 years, 2680 X-ray sets of 
hands and feet of 426 patients were made and scored by one experienced reader using Sharp-
van der Heijde scores (SHSs) blinded to any clinical or genetic data (intraclass correlation 
coefficient 0.91). The numbers of patients with radiologic data at baseline and over 4, 5, 6 
and 7 years were, respectively, 321, 286, 239 and 206. The main outcome measure in this 
study was radiologic progression in the first 6 years after inclusion (ΔSHS0– 6 years=SHS6 years–
SHS0 years). Although radiologic data was known up till 7 years, the progression over 6 years 
was chosen as main outcome as fewer patients completed 7 years of follow-up. For some 
accuracy measures the continuous outcome was categorised in three groups of progression 
over 6 years: ΔSHS0–6 years ≤6, 7–30 and >30 units, indicating no/little, moderate and severe 
radiologic progression (figure 3A). The first cut-off was chosen as progression of ≤1 SHS-
unit per year is minimal; the latter cut-off was chosen because rapid radiologic progression is 
generally defined as an increase of 5 SHS-units per year 8–10. In all analyses, the difference in 
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Table 2. Different measures to evaluate the performance of prediction models; inherent to the statistical method 
used, progression over six years was assessed as a continuous or categorical outcome variable.
Aspect and measure Characteristics Used model and radiologic outcome 
Overall performance: ‘goodness-of-fit’ of model, quantification of how close predictions are to the observed 
outcome; captures both aspects of calibration and discrimination
   Improved fit Improved fit of model after adding 
additional variables to the model 
(%). Measured as relative increase 
in Nagelkerke R2 (modified version 
of Cox and Snell’s pseudo R2) 23.
Linear mixed model analysis with yearly 
SHS scored X-rays over six years as outcome. 
Patients with missing radiographs at a 
certain time point were included.
   R2 Variance in outcome explained 
by the included variables. The 
explained variance can be corrected 
for the number of variables in the 
model (adjusted R2) (%).
Linear regression analysis with radiologic 
progression between baseline and six years 
(ΔSHS0-6years) on a continuous scale as 
outcome.
Analyses are done on patients with complete 
data (n=239) and on all patients (n=426) 
when imputing missing radiological data.
Discrimination: ability to discriminate between those with and without the outcome
   C-statistic Assessing pairs of patients where 
one has more severe outcome than 
the other, it reflects the fraction 
of patients where those with the 
more severe outcome have higher 
predictions than those with the less 
severe outcome 24.
Linear regression analyses where the 
predicted ΔSHS0-6years is compared with the 
observed ΔSHS0-6years categorized in no/little, 
moderate and severe progression (ΔSHS0-6years 
≥6, 7-30 and >30).
Calibration: agreement between observed and predicted outcomes
   Calibration Scatterplot with predicted outcome 
on the x-axis and observed 
outcome on the y-axis.
Scatter plot of observed versus predicted 
progression over six years (ΔSHS0-6years), both 
as continuous outcomes.
Reclassification: ability to reclassify patients by adding predictors to the model
   Net correct 
   reclassification
Comparing the predicted 
classification with the observed 
classification when using two 
models; assessed is the net change 
in the correct direction (correct 
minus incorrect reclassifications).
Linear regression analyses in which the 
predicted ΔSHS0-6years is calculated. Then both 
the observed and predicted ΔSHS0-6years are 
categorized in no/little, moderate and severe 
progression (ΔSHS0-6years ≥6, 7-30 and >30).
Analyses were done on patients with 
complete data (n=239) and on all patients 
(n=426) when imputing missing radiological 
data.
R2=proportion of explained variance; ΔSHS0-6years=progression in Sharp-van der Heijde score over six years
SHS was log10-transformed to approximate a normal distribution.
Analyses
The performance of prediction models can be evaluated using different aspects, see table 2 
20,21. Inherent to the method of determining these aspects, the radiologic progression rate over 
6 years was studied as a continuous or categorised outcome.
Improved fit - First, a linear mixed model analysis was used with serial log10-
transformed SHS over 6 years as response variable and time and risk factors as variables. 
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The ARH1 covariance matrix was used as suggested previously by Knevel et al 22. Valuable 
of this repeated measurement analysis (RMA) is that it takes advantage of within-patient 
correlations of serial X-rays and allows the inclusion of patients with missing X-rays at 
certain time-points (figure 1). The improved fit of the model when adding treatment effects, 
traditional risk factors, genetic risk factors or combinations of these to a model consisting 
of only time effect was measured as the relative increase in the Nagelkerke R2 between the 
models with the risk factors of interest and with only the time effect 23. Importantly, this is 
not a direct measure of the explained variance, which cannot be determined in RMA such 
as linear mixed model analysis. Therefore, the R2 was subsequently determined in linear 
regression analyses.
R2 - This reflects the absolute proportion of the variance that is explained by the 
factors in the model and was determined using linear regression analyses with ΔSHS0–6 years as 
outcome. A limitation of this outcome is that only patients with complete follow-up could be 
studied (figure 1). Regression models were fitted that included treatment effects, traditional 
risk factors, genetic risk factors or combinations of these. Because adding more variables to a 
model will increase the fit of a model and thus the R2, the adjusted R2 was also calculated. This 
includes a correction for the number of variables in the regression model.
C-statistic - Harrel’s C-statistic was assessed as described in the online supplementary 
methods 24. It reflects the accuracy of discriminating patients with and without the outcome 
and does not reflect the absolute risk on an outcome. For clinical risk prediction it is more 
relevant that a new model can more accurately stratify individuals into risk categories. Hence, 
calibration (agreement between observed and predicted outcomes) and reclassification have 
gained popularity 25,26.
Calibration and Reclassification - First, the observed ΔSHS0–6 years was plotted 
against the ΔSHS0–6 years that was predicted by linear regression models including treatment 
effects and traditional factors or including treatment effects, traditional and genetic factors 
(calibration plot). Then the actual observed ΔSHS0–6 years and the predicted ΔSHS0–6 years 
were categorised in three severity groups (ΔSHS0–6 years ≤6, 7–30 and >30 units). To assess 
the improvement in predictive performance gained by adding genetic information to 
the prediction model, the proportion of patients that was correctly reclassified (correct 
reclassifications minus incorrect reclassifications) was determined. This was done for the 
total population and for each severity group separately.
Sensitivity analyses
The R2 depends on the variance of the outcome. Therefore, the R2 may change in case 
other follow-up durations are studied. To assess the influence of this effect, the R2 was also 
determined for radiologic progression over 4, 5 and 7 years (ΔSHS0–4 years, ΔSHS0–5 years and 
ΔSHS0–7 years). 
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Only 239 of the 426 patients had complete radiologic data till year 6. As missing was 
not completely at random, we repeated the linear regression analyses with missing radiologic 
data imputed. We performed single conditional mean imputation by replacing missing 
values with the values predicted by the RMA with SHSs over 7 years of disease as outcome, 
and time and all traditional and genetic risk factors as variables. Subsequently, the R2 and 
reclassifications were again determined.
Some of the genetic variants were identified as risk factors for radiologic progression 
in ACPA-positive RA, the more severe subset of RA. Therefore, the analyses of R2 and 
reclassifications with ΔSHS0–6 years as outcome were repeated in the ACPA-positive subgroup 
(n=144).
Analyses were performed using SPSS V.20.0 and Stata V.12.
RESULTS
Patients and traditional risk factors
Patient characteristics are presented in table 3. The median SHS at baseline was 5.0 (IQR 
2.0–10.0) and at year 6 it was 22.3(IQR 9.0–47.0); the median SHS0–6 years was 14.0 (IQR 4.5– 
39.0). Treatment effects explained 7.1% of the variance of radiologic progression over 6 years 
(ΔSHS0–6 years). The R2 of the individual traditional risk factors, determined in univariable 
regression analyses showed the highest values for ACPA and RF (R2 22.8% and 19.4%, 
respectively, table 3). All traditional risk factors together explained 31.2% of the variation and 
treatment effects and traditional risk factors combined explained 36.5% (figure 2A, see online 
supplementary table S2A). The adjusted R2s were respectively 28.5% and 33.7% (figure 2D).
Genetic risk factors
Improved fit
First, all radiologic data of 426 patients were assessed using RMA. Models without and with 
genetic risk factors were compared, revealing that the model including the genetic risk factors 
had a 3.2% better fit in predicting radiologic progression com-pared to a model including 
only treatment effects and traditional risk factors (see online supplementary table S1). Since 
this measure is difficult to interpret, we continued with determining the R2.
R2
The R2 of individual genetic risk factors was determined in univariable analyses (table 1). 
Rs11908352 in MMP-9 and the human leucocyte antigens-shared epitope (HLA-SE) alleles 
had the largest R2 (4.7% and 4.0%, respectively). All genetic risk factors together explained 
18.1% of the variance in ΔSHS0–6 years (figure 2B). The adjusted R
2 was 11.8% (figure 2E). 
Next, it was studied to what extent the genetic risk factors increased the R2 compared to a 
model including treatment effects and traditional risk factors. A model including all factors 
(treatment effects, traditional and genetic risk factors) resulted in an R2 of 43.9% and adjusted 
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Table 3. Characteristics of patients and the R2 of each individual characteristic for radiologic progression over six 
years.
All patients (n=426) R2 ΔSHS0-6years (%) in RA 
(n=239)
R2 ΔSHS0-6years (%) ACPA-
pos RA (n=144)
Age, mean (sd), years 56.6 (15.3) <0.1 <0.1
Female gender, n (%) 290 (68.1%) 1.7 0.9
Symptom duration at 
first visit, median (IQR), 
months
4.4 (2.4-8.6) 2.3 0.7
Localization initial joint 
symptoms
<0.1 0.1
Upper extremities, n (%) 204 (47.9%)
Lower extremities, n (%) 57 (13.4%)
Upper and lower 
extremities, n (%)
165 (38.7%)
66-SJC, median (IQR), n 8 (4-14) 2.0 <0.1
BMI, median (IQR), n 25.4 (23.0-27.6) 3.1 1.8
ACPA-positive, n (%) 227 (53.3%) 22.8 -
IgM-RF positive, n (%) 248 (58.2%) 19.4 0.3
ESR, median (IQR), 
mm/h
33.0 (18.0-55.0) 2.7 2.0
The presented R2 s were based on univariable analyses of each individual risk factor. 239 patients of the total included 
426 patients completed follow-up until six years, 144 of these patients were ACPA-positive. R2=proportion of 
explained variance; ΔSHS0-6years=progression in Sharp-van der Heijde score over six years.
R2 of 36.7%. As the R2 of the model, including treatment and traditional risk factors was 
36.5%, the increase in the R2 by genetic risk factors was 7.4% (p-value R
2
change=0.056, figure 
2C, see online supplementary table S2A). When comparing adjusted R2s, genetic factors 
increased the R2 with 3.0% (figure 2F).
C-statistic
The C-statistic increased from 0.78 (95% CI 0.73 to 0.82) for a model with treatment and 
traditional factors to 0.82 (95% CI 0.77 to 0.86) for a model including treatment, traditional 
and genetic factors. 
Calibration and reclassification
Observed progression rates were plotted against predicted progression rates by a linear 
regression model with treatment effects and traditional risk factors as variables. When 
categorising patients in three groups (ΔSHS0–6 years ≤6, 7–30 and >30 units) 134 of 239 patients 
(56.1%) were correctly classified. When genetic factors were added, 148 out of 239 patients 
(61.9%) were correctly classified by the model (figure 3B,C). Hence in total this concerned a 
net increase in correctly classified patients (proportion of correct reclassifications) of 5.9% 
(95% CI 3.2 to 9.6%). Evaluating the reclassifications per severity group, showed no net 
change for the group with no/little progression, a 5.1% net increase in correctly classified 
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8 Figure 2. (A-C) Proportions of explained variance (R
2) (D–F) and adjusted explained variance (adjusted R2) in 
progression in Sharp-van der Heijde score over six years (ΔSHS0–6 years) by treatment effects and traditional risk 
factors (A and D), genetic risk factors (B and E), and treatment effects, traditional and genetic risk factors (C and 
F). The treatment strategy differed for different inclusion period. Therefore, the effects of treatment were determined 
before adding traditional and genetic factors (A, C, D and F). The studied traditional risk factors are presented in 
table 3 and included age, gender, symptom duration at first visit, localisation initial joint symptoms, 66-SJC, BMI, 
ACPA-positivity, RF-positivity and ESR. The studied genetic risk factors are presented in table 1 and included genetic 
variants in HLA-DRB1, CD40, IL-15, DKK-1, IL2RA, GRZB, IL-4R, SPAG16, C5orf30, MMP-9 and OPG. The 
data presented are based on the patients with complete data over six years (n=239). Analyses on all patients after 
imputation of missing data (n=427) revealed similar results, see online supplementary table S2B. The p-value for 
change in R2 after adding genetic factors was 0.056 for patients with complete data.
patients for the group with moderate progression, and a 13.2% net increase in correctly 
classified patients for the group with severe progression (figure 3C, see online supplementary 
table S3). Thus, the proportion of patients that was correctly reclassified when adding genetic 
factors increased in particular in the most severe patient group.
Sensitivity analyses
To check for consistency, ΔSHS0–4 years, ΔSHS0–5 years, and ΔSHS0–7 years  were also assessed as 
outcomes. Adding genetic risk factors to a model with treatment effects and traditional 
risk factors yielded an increase in R2 of 5.5% for ΔSHS0–4 years (p-value R
2
change=0.085), 7.1% 
for ΔSHS0–5 years (p-value R
2
change =0.035) and 9.8% for ΔSHS0–7 years (p-value R
2
change=0.026) (see 
online supplementary table S4).
When missing SHSs were imputed and all 426 patients were studied, the increase in 
R2 when adding genetic factors to a model with treatment and traditional risk factors and 
ΔSHS0–6 years as outcome was 5.3% (p-value R
2
change=0.001) (see online supplementary table 
S2B). The net proportion of patients that was correctly reclassified was 5.4% (95% CI 3.5 to 
8.0%); for the groups with no/little, moderate and severe progression these were respectively 
1.3%, 6.6% and 9.5%. The proportion of correctly classified patients was 286/426 (67.1%) (see 
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online supplementary table S4).
In the subset of ACPA-positive patients, the median SHS at year 6 was 32.5 (IQR 
17.3–65.8), and the median ΔSHS0–6 years 24.0 (IQR 10.6–57.5). The genetic factors together 
explained 17.1% of the variance in ΔSHS0–6 years. Adding genetic factors to a model already 
including treatment effects and traditional risk factors increased the R2 with 15.1% (p-value 
Figure 3. (A) Distribution of observed progression in Sharp-van der Heijde score over six years (ΔSHS0–6 years), (B) 
observed versus predicted ΔSHS0–6 years by a model consisting of treatment effects, traditional and genetic risk factors 
and (C) numbers of patients per categorized observed and predicted ΔSHS0–6 years by models without and with genetic 
risk factors, resulting in the net proportion of correct reclassifications. (B) The dots in the boxes represent the 148 of 
the 239 patients in whom the severity of radiologic progression over six years was correctly predicted by the model, 
including treatment effects, traditional and genetic risk factors. (C) The model without genetic risk factors correctly 
classified 134 of 239 patients (56.1%) and the model with genetic risk factors correctly classified 148 of 239 patients 
(61.9%), resulting in a total net proportion of correct reclassifications of 5.8% (95% CI 3.2 to 9.6%). Evaluating 
reclassifications per severity group showed, respectively, no net change (5 correct and 5 incorrect reclassifications, 
0/72), a 5.1% net increase (10 correct and 5 incorrect reclassifications, 5/99) and a 13.2% net increase (14 correct 
and 5 incorrect reclassification, 9/68) in correct classifications for the groups with no/little, moderate and severe 
progression (see also online Supplementary table S3).




change=0.11, see online supplementary table S5). The net proportion of correctly reclassified 
patients was 4.9% (95% CI 2.0 to 9.8%); for three severity groups, these were 0%, 3.1% and 
8.6%. The model including all factors classified 91/144 (63.2%) of the ACPA-positive patients 
correctly (see online supplementary table S6).
DISCUSSION
New genetic risk factors for radiologic progression in RA have been identified recently. This 
study evaluated how much of the variance in radiologic progression is explained by these 
genetic factors together and whether these genetic factors improve predicting the severity 
of the disease course. We observed that genetic risk factors together explained 12–18% of 
the variance in joint destruction, and that adding the genetic factors to a prediction model 
already consisting of treatment effects and traditional risk factors resulted in a net increase 
of correctly classified patients of 6%. This increase was largely due to improved identification 
of patients with severe progression. Based on the Icelandic RA population, the heritability of 
radiologic progression was estimated at 45–58% 2. Our observation that studied genetic factors 
explained around 18% suggest that part of the heritability is still missing. Several explanations 
may account for this. Part of the relevant genetic variants may still be unidentified or gene-
gene interactions may play a role. The heritability in the Icelandic and Dutch RA population 
may also be dissimilar, prohibiting a direct comparison of percentages.
Adding genetic factors to a model with known risk factors had a small but 
independent contribution (3–7%) to the explained variance in radiologic progression. An 
explanation that this increase is less than the 12–18% of variation found for genetics alone is 
that part of the genetic factors are associated with traditional risk factors that were already 
included in the model. Probably these genetic factors relate to the outcome by mediating 
through these traditional risk factors and, therefore, they do not contribute to the model 
when the intermediate risk factors are also included. This observation differs from previous 
observations done for RA susceptibility where identified genetic susceptibility factors did not 
contribute independently to predicting the development of RA using a model with traditional 
factors, among which is ACPA 27. The variants that had the largest independent contribution 
to the increase in R2 were rs1528873 (DKK-1), rs7607479 (SPAG16) and rs11908352 (MMP-9) 
(data not shown). Intriguingly, all these proteins are involved in bone metabolism or cartilage 
destruction, processes that were not represented by the assessed traditional factors. Notably, 
due to the strong correlation between ACPA and HLA-SE, adding only HLA-SE to a model 
already containing ACPA was not helpful (R2 change 0.1%, p-value R
2
change=0.63). Conversely, 
the R2 change when adding the non-HLA variants to the model including traditional factors 
was 7.3% (p-value R
2
change=0.045).
The existing prediction matrices for rapid radiologic progression consist of a few 
traditional risk factors, were developed in a selected set of severe RA patients, could not 
adequately classify ~50% of the patients and had difficulties with identifying the patients 
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with severe progression in particular 8–13. We evaluated nine traditional factors in a general 
population of RA patients, and observed that also here, 46% of RA patients were incorrectly 
classified. When evaluating traditional and genetic factors 62% of RA patients were correctly 
classified and 38% misclassified. Assuming that clinicians prefer to have at least 80% of 
the patients correctly predicted, the derived models including genetic variants were still 
insufficient for use in clinical practice. Importantly, with the help of genetic factors, the correct 
identification of especially those RA patients with severe radiologic progression increased.
We have chosen to study genetic variants that were replicated in independent 
studies or found significant in meta-analysis including all published data. Variants that 
were associated with radiologic progression in only one or two cohorts but not replicated or 
significant in meta-analyses were not included 28. Potentially, future research will reveal more 
severity factors for RA and might increase the predictive accuracy.
Because of the negative implication of our conclusion, we did not seek for external 
validation or internal validation using cross-validation. The observed R2 values may have 
been overestimated as many variables were included. Controlling for overfitting was done 
by determining the adjusted R2 (correcting for the number of variables). However, some 
variables were correlated (for SNPs the correlation coefficients were <0.8) and, consequently, 
the correction may have been too stringent and the adjusted R2 values underestimated. 
Presumably, the actual explained variance lies between the presented R2 and adjusted R2 
values.
Several sensitivity analyses were done to check for the consistency of the results on 
the R2. Because missing radiologic data may be due to selection bias, analyses were also 
repeated after imputation of missing radiographs. Nonetheless, the consistent results in all 
sensitivity analyses indicate the reliability of our results.
Because some of the genetic risk factors were identified in ACPA-positive RA, we also 
performed subanalyses on ACPA-positive patients. Compared to the total RA population, the 
R2 of the traditional risk factors was smaller (this may be explained by absence of the effect 
of ACPA) and the increase in R2 when adding genetic factors was larger. Importantly, the R2 
values between the total and ACPA-positive population cannot be directly compared, as the 
total variance in ΔSHS0–6 years differed. The number of ACPA-positive patients was relatively 
small, providing another limitation.
In conclusion, all genetic severity factors together explained 12–18% of the variance 
in radiologic progression. Additional use of genetic factors resulted in increased correct 
classification of patients in severity risk groups. Nonetheless, 38% of the patients were still 
not correctly classified. Therefore, we considered the predictive performance of the derived 
prediction model insufficient for use in clinical practice.
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SUPPLEMENTARY DATA
Supplementary data are published on the website of the Annals of the Rheumatic Diseases.
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The severity of rheumatoid arthritis (RA) is variable between patients, and the processes 
underlying these interindividual differences are scarcely understood. Although it has been 
observed that the severity of joint destruction is heritable 1, and several identified genetic 
risk factors have been replicated in independent cohorts 2,3, a large part of the total genetic 
effect is still unexplained. Unraveling the biologic processes that determine the course of 
RA increases our comprehension of disease progression and may convey novel targets for 
focused therapies.
Lee et al reported a milder disease course in patients carrying the FOXO3A minor 
allele (G) of rs12212067 4. That candidate gene study addressed genetic variants in the immune 
pathways of interleukin-2 (IL-2) and IL-7 and was initially performed in patients with 
Crohn’s disease. It was observed that the rs12212067 minor allele was associated with higher 
transcription of FoxO3 in blood monocytes after lipopolysaccharide stimulation and with 
down-regulation of tumor necrosis factor α (TNFα) and other proinflammatory cytokines 
and up-regulation of IL-10. The relevance of FoxO3 in disease outcome was supported by 
associations with more severe malaria and less severe joint damage in patients with early RA4.
FoxO3 is a transcription factor that is involved in the regulation of immune cell 
homeostasis 5. Increased expression of FoxO3 in polymorphonuclear cells has been described 
in RA 6. The results described by Lee et al are promising, because identification of predictors 
of interindividual differences in disease outcome is the Holy Grail of personalised medicine. 
This finding therefore requires replication in independent cohorts. The challenges within 
the field of RA severity are that large longitudinal cohorts with well-characterised data are 
scarce, and that cohorts of patients who were treated in an era when disease-modifying 
antirheumatic drugs (DMARDs) were less potent and strategies were not guided by the 
Disease Activity Score (DAS) are rare 7. We examined rs12212067 in FOXO3A in relation to 
the severity of RA in multiple cohorts; the majority of patients studied were treated in the era 
before the introduction of biologic agents and DAS-guided therapy.
The main outcome of our study was radiographic progression. Five independent data 
sets were studied, comprising a total of 2,300 patients with RA and 5,512 radiographs. RA 
was defined according to the American College of Rheumatology 1987 revised criteria 8. All 
patients gave informed consent, and approval was obtained from the local medical ethics 
committees.
The Leiden Early Arthritis Clinic (EAC) cohort comprised 597 patients with early 
RA, all of whom were included between 1993 and 2006 9. At baseline and at yearly follow-up 
visits over 7 years, a total of 3,143 sets of radiographs of the hands and feet were obtained. 
These radiographs were scored according to the Sharp-van der Heijde (SHS) method 10 by one 
reader in chronologic order (within-reader intraclass correlation coefficient [ICC] 0.91). The 
initial treatment strategy differed for different inclusion periods: patients included in 1993–
1995 were initially treated with nonsteroidal anti-inflammatory drugs, patients included 
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in 1996–1998 were initially treated with hydroxychloroquine or sulfasalazine, and patients 
included in 1999–2006 were promptly treated with methotrexate 9.
The Umeå cohort consisted of 459 patients with early RA from Sweden, in whom 
RA was diagnosed between 1996 and 2010 11. A total of 868 sets of radiographs of the hands 
and feet obtained at baseline and year 2 were scored using the Larsen method 12, as described 
previously 11. All patients were initially treated with methotrexate or sulfasalazine. Treatment 
with biologic agents during the 2-year follow-up period was uncommon (5.7%).
The North American Rheumatoid Arthritis Consortium (NARAC) study group 
comprised 384 unrelated patients in whom RA was diagnosed between 1953 and 2002 13. One 
set of radiographs of the hands was available for each patient. The radiographs were scored 
according to the SHS method (ICC 0.99).
The Wichita cohort consisted of 101 patients from a single practice in Wichita, 
Kansas, in whom RA was diagnosed between 1963 and 1999 14. Radiographic evaluations 
were not performed at protocolised time points; 358 sets of hand radiographs were obtained 
during the first 15 years after disease onset. These were scored in a known time order, using 
the SHS method (ICC 0.98).
The National Data Bank for Rheumatic Diseases (NDB) cohort comprised 759 
patients from the US and Canada, in whom RA was diagnosed between 1944 and 1999 15. 
One set of radiographs of the hands was available for each patient. The radiographs were 
scored using the SHS method (ICC 0.98). The patients in the 3 North American cohorts were 
treated in an era when biologic agents were uncommon.
Genotyping in the Leiden EAC, Umeå, Wichita, and NDB cohorts was performed 
using the Illumina ImmunoChip according to the manufacturer’s protocols, as previously 
described 16, and data for rs12212067 located on chromosome 6 were extracted. In the 
NARAC cohort, genotyping was performed using Illumina HapMap 500 BeadChips 13,17. 
Data for rs12212067 were not available in the NARAC group, but data for a perfect proxy for 
this variant (rs11153120) were retrieved (r2 1.00).
In all data sets, the radiographic scores were log-transformed before analyses to 
approximate a normal distribution. In each data set, the relative progression rate in patients 
with the rs12212067 minor allele was estimated, using patients with the common genotype 
as reference. An additive model was used. For the analyses in the cohorts with multiple 
measurements per patient (Leiden EAC, Umeå, and Wichita), a multivariate normal 
regression analysis was performed, with radiographic damage as the response variable 18. 
For the data sets with one radiographic measurement per patient (NARAC and NDB), the 
estimated yearly progression rate (the total SHS divided by the number of disease-years at 
the time of radiography) was studied. Details on the statistical methodology and adjustment 
factors are available in the online Supplementary Methods (available on the Arthritis & 
Rheumatology website). Because all of the obtained effect sizes represented the relative 
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increase in the progression in joint destruction per year per minor allele, the effect sizes and 
standard errors of the individual analyses could be compared and combined in an inverse-
variance weighted meta-analysis.
Because of the observation that the rs12212067 minor allele was associated with 
lower TNFα expression and higher production of anti-inflammatory interleukins 4, which 
presumably affect not only joint damage but also arthritis persistency, a second outcome 
measure, achieving sustained DMARD-free remission, was studied. Sustained DMARD-
free remission is defined as the sustained absence of clinically detectable arthritis after 
discontinuation of DMARD therapy. This is described elsewhere and in the online 
Supplementary Methods. This stringent definition of remission is a proxy for cure 19. Data on 
achieving DMARD-free remission were available only in the Leiden EAC cohort during 15 
years of follow-up. Kaplan-Meier survival analyses were performed.
The characteristics of the patients are shown in the online Supplementary Table 1. 
In the largest cohort, consisting of 3,143 radiographs and 597 patients, rs12212067 was not 
statistically significantly associated with the severity of radiographic progression (p=0.14). 
No tendency toward less severe joint damage in the presence of the minor G allele was 
observed (Figure 1A). Significance was not obtained in any of the other cohorts. The meta-
analysis did not reveal a significant association with radiographic progression (p=0.10), 
and the directionality of the effect sizes was not uniform (Figure 1B). When the secondary 
outcome of achieving sustained DMARD-free disease remission was evaluated, no significant 
association was observed (p=0.54) (Figure 1C).
Although the analyses described by Lee et al were performed in a mixed autoantibody-
positive and antibody-negative population 4,20,21, we also performed analyses adjusted and 
stratified for the presence of anti–citrullinated protein antibodies (ACPA). In the analyses 
that were additionally adjusted for ACPA, rs12212067 was not significantly associated with 
the severity of radiographic progression (see online Supplementary Figure 1A). In the meta-
analysis of the ACPA-positive subgroup, a significant result was obtained using the fixed-
effects model but not the random-effects model; the directionality of the effect sizes was 
diverse (see online Supplementary Figure 1B). In the meta-analysis of the ACPA-negative 
subgroup, no association between rs12212067 and radiographic progression was observed. 
For the outcome of achieving sustained DMARD-free disease remission, no significance was 
observed in the ACPA-positive and ACPA-negative strata (p=0.77 and p=0.62, respectively).
In conclusion, from a clinical perspective, it is highly relevant to unravel the biology 
determining disease outcome. A recent study demonstrated a protective association between 
a genetic variant in FOXO3A and the severity of radiographic joint destruction in 2 early 
RA cohorts consisting of both ACPA-positive and ACPA-negative patients 4,20,21. Using 5 
independent RA cohorts, we could not replicate an association of FOXO3A with the severity 
of RA, implying that the initial observation in UK cohorts cannot be extrapolated to other 
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Figure 1. Relationship of FOXO3A rs12212067 genotypes with radiographic progression and DMARD-free 
sustained remission. (A) Median raw Sharp-van der Heijde (SHS) scores during 7 years of follow-up in patients in 
the Leiden EAC cohort. (B) Inverse-variance weighted meta-analysis of the annual radiographic progression rate in 
5 cohorts, consisting of 2,300 patients and 5,512 radiographs (I2 0.0%, p=0.59; for both the fixed-effects and random-
effects models, p=0.10). (C) Frequency of achieving sustained DMARD-free remission in the Leiden EAC cohort 
(p=0.54 by log rank test). Only 6 patients had the GG genotype, and none of them achieved disease remission. The 
frequencies of the minor allele (G) were 9.3% in the Leiden EAC cohort, 12.0% in the Umeå cohort, 8.6% in the 
NARAC cohort, 9.3% in the Wichita cohort, and 10.5% in the NDB cohort. ES=effect size; 95% CI=95% confidence 
interval.
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populations. This may reflect some differences in regulating progression in very early disease, 
which was the focus of the UK studies. Some data sets studied here were smaller than the UK 
cohorts; consequently, these individual cohorts were underpowered to replicate the signal 
individually. However, when the 5 data sets were combined, the number of radiographs was 
larger than that in the original study, and the meta-analysis was adequately powered to identify 
statistically significant differences and prevent false-negative results. The prevalence of ACPA 
in our cohorts was similar or higher than that in the original cohorts 20,21. After stratification 
for ACPA, the p-value for a meta-analysis with a fixed-effects model was less than 0.05 within 
ACPA-positive patients; however, the directionality of the effect sizes was variable. The 
question of whether SNP rs12212067 in FOXO3A is associated with joint destruction in the 
ACPA-positive subgroup of patients with RA requires further investigation. The absence of 
an association of rs12212067 with sustained DMARD-free remission (the reverse of disease 
persistency) further supported the notion that FOXO3A is not a major factor regulating the 
severity of the course of RA.
SUPPLEMENTARY DATA
Supplementary data are published on the website of Arthritis & Rheumatology.
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We recently reported an association of the SPP1 rs9138 and rs11439060 functional variants 
with the risk of rheumatoid arthritis (RA), the association being greater in anti-citrullinated 
peptide autoantibody (ACPA)-negative patients. We hypothesised that SPP1 may contribute 
to the severity of joint destruction in RA, specifically in the ACPA-negative population.
Methods 
Patients with RA in the ESPOIR cohort underwent genotyping for SPP1 rs9138 and 
rs11439060. Radiographs of the hands and feet were obtained at the first visit and at 1- and 2 
year follow-up. Association analyses were performed by ACPA-status. A replication study of 
the relevant subset of the Leiden Early Arthritis Clinic (EAC) cohort was performed. 
Results 
In the ESPOIR cohort (652 patients), rs9138 was significantly associated with radiological 
progression of joint destruction at 2 years, the association being restricted to 358 ACPA-
negative patients (p=0.034). In the replication study within the Leiden EAC cohort (273 
ACPA-negative patients), rs4754, which is in complete linkage disequilibrium with rs9138, 
was significantly associated with joint damage progression in ACPA-negative patients at 2 
and 7 year follow-up (p=0.019 and p=0.005, respectively). Combined analysis of the two 
cohorts revealed a 0.95 fold rate of joint destruction per year per minor allele (p=0.022).
Conclusions 
The SPP1 rs9138 variant contributes to joint damage progression in ACPA-negative RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic, inflammatory, autoimmune disease characterised by 
peripheral synovial joint inflammation which can lead to joint destruction. Approximately 
two-thirds of RA cases are seropositive for rheumatoid factor or anti-citrullinated peptide 
autoantibodies (ACPA) 1. The heritability of ACPA-positive and ACPA-negative disease is 
comparable 2, and recent association studies have provided further support for distinct genetic 
aetiologies of ACPA-positive and ACPA-negative RA subsets 3,4. ACPA-positive RA patients 
are particularly characterised by progressive joint destruction 5. However, little information 
is available on joint destruction processes in the ACPA-negative subset. Currently, we cannot 
offer personalised medicine for patients with RA because we cannot identify those who will 
have the most severe disease course, nor do we understand the pathogenesis underlying these 
interindividual variances. To improve this situation, identification of risk factors for joint 
destruction is required.
Genetic variants are estimated to contribute to 58% of the total variance in RA joint 
destruction, with clinical and serological risk factors explaining only about one-third of the 
total phenotypic variation 6. Most risk alleles for RA joint destruction have been identified in 
ACPA-positive patients or in pooled ACPA-negative and ACPA-positive patients, but we lack 
information about the genetic contribution to ACPA-negative RA severity 7–9. Identifying 
individual genetic risk factors would increase our understanding of the mechanisms 
underlying variation in severity of joint destruction, particularly in ACPA-negative disease.
Recently, through a large case-control association study, our group reported a 
significant contribution of the combination of the SPP1 rs11439060 and rs9138 frequent 
alleles to risk of RA, the magnitude of the association being greater in ACPA-negative patients 
3. These patients fulfilled the 1987 American College of Rheumatology (ACR) revised criteria 
for RA, which include radiographic changes typical of RA 10; so ACPA-negative individuals 
may have had joint destruction to be classified as having RA. SPP1 encodes osteopontin 
(OPN), an extracellular-matrix glycosylated phosphoprotein with multiple functions 
including bone formation and remodelling 11. Consequently, we hypothesised that SPP1 




The exploratory study included 652 patients with RA from the ESPOIR cohort who were 
positive or negative for ACPA and were included in the large case-control association study 
previously reported 3,12. The replication study included 273 ACPA-negative RA cases from the 
Leiden Early Arthritis Clinic (EAC) cohort (table 1) 13. All patients fulfilled the 1987 ACR 
revised criteria for RA 10. They all provided informed written consent as approved by the 
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recruiting site review board at each of the affiliated institutions.
Genotyping
In the exploratory study with the ESPOIR cohort, SPP1 rs11439060 and rs9138 variants 
were genotyped by use of a competitive allele-specific PCR system (Kaspar genotyping; 
Kbioscience, Hoddeston, UK) 3. In the Leiden EAC cohort, SPP1 rs4754, which is in complete 
linkage disequilibrium with rs9138 3, was genotyped using Illumina Human CytoSNP-12V2.
Radiographic joint destruction
In both the ESPOIR and Leiden EAC cohorts, all radiographs of hands and feet were scored 
by the Sharp-van der Heijde score (SHS) by one experienced reader per cohort who was 
blinded to clinical, biological and genetic data 14. The intraclass correlation coefficient was 
0.97 and 0.91, respectively.
Statistical analysis
A multivariate regression analysis (MRA) was used, with radiographic damage as the 
response variable (see online supplementary text for a detailed description of the MRA). The 
analyses were performed with the genetic variable and its interaction with time in the model, 
reflecting a constant and a time-dependent effect of progression of joint damage, respectively 
15.
To validate our a priori hypothesis (ie, the contribution of SPP1 rs11439060, rs9138 
and the rs11439060-rs9138 risk allele combination in the ACPA-negative population), we 
selected the best-fit model at the exploratory stage, as previously described, which was then 
replicated in the Leiden EAC cohort 3. MRA of both ACPA-negative populations was used 
to assess the magnitude of the SPP1 effect on radiographic joint destruction in early RA. 
Analyses used SPSS V.20.0.
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We analysed data for 652 patients with RA and 1768 radiographs. For a complete overview of 
the MRA of SPP1 rs11439060, rs9138 and risk allele combination, see online supplementary 
table S1. Briefly, the best-fit model involved rs9138 (see online supplementary table S2). In 
agreement with our a priori hypothesis, rs9138 was significantly associated with radiographic 
progression over a 2 year follow-up in ACPA-negative patients, as seen by an additive model 
with a 0.93 fold rate of joint destruction per year per minor allele as compared with the wild-
type (p=0.034) (figure 1A-C).
Replication study
We analysed data for 273 ACPA-negative patients in the Leiden EAC cohort and 704 
radiographs over a 2 year follow-up. We replicate the contribution of rs9138, as MRA revealed 
that rs4754 was associated with radiographic progression over the 2 year follow-up with a 
0.81 fold rate of joint destruction for each minor allele at any time compared with the wild-
type (p=0.019). Analysis of 1,316 radiographs over 7 years of follow-up revealed a persistent 
effect of rs4754, with a 0.78 fold rate of joint destruction for each minor allele at any time 
compared with the wild-type (p=0.005; figure 2A).
Combined analysis of early RA during the 2 year follow-up
Data for 631 ACPA-negative patients and 1,664 radiographs were available for the combined 
analysis of the ESPOIR and Leiden EAC cohorts. MRA over the 2 year follow-up revealed 
a 0.95 fold rate of joint destruction per year per minor allele compared with the wild-type 
(p=0.022; figure 2B).
DISCUSSION
The rate of progression of joint damage in RA is highly variable and is associated with the 
Figure 1. Association of SPP1 rs9138 and joint damage progression in RA patients in the exploratory study. 
Multivariate regression analysis modelled median Sharp-van der Heijde scores (SHS) in patients with RA in the 
ESPOIR cohort (exploratory study) at 1 and 2 year follow-up. (A) Overall RA patients. (B) ACPA-positive RA 
patients. (C) ACPA-negative RA patients. Maj=major allele; min=minor allele.
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severity of the disease. Genetic variants are estimated to contribute to most of the local 
variance in RA joint destruction. Several data have suggested that OPN, encoded by SPP1, 
may be involved in bone erosion. In addition, we recently identified SPP1 as a new RA 
susceptibility gene, the magnitude of the association being greater in ACPA-negative disease 
3. Because ACPA-negative patients fulfilled the ACR modified criteria, SPP1 may contribute 
to the variation in joint destruction in this particular subset of the disease.
For the two SPP1 rs11439060 and rs9138/rs4754 RA risk variants investigated, the 
rs9138/rs4754 common allele contributed to joint destruction of RA - that is, the minor allele 
had a protective effect. This finding is in agreement with our a priori hypothesis because 
the rs9138 common A allele has been identified as an ACPA-negative RA risk allele 3. The 
replication study, including analyses at the same time of follow-up (2 years) and also after 
a longer period (7 years), provided evidence that the SPP1 rs9138 variant contributes to the 
severity of radiographic damage in ACPA-negative RA in both the early and intermediate 
course of the disease. Analyses of the combined sets revealed an interaction between SPP1 
rs9138/rs4754 and time at the 2 year follow-up, which suggests a strong effect of SPP1 on 
radiographic damage at the early stage of the disease. A recent study of the ESPOIR cohort 
found that the first-year radiographic progression was a predictor of further progression in 
early RA, which suggests that, after the early period of the disease, time has a constant effect 
16.
Complex diseases, such as RA, invariably involve multiple genes and often exhibit 
variable symptom profiles. The extent to which disease symptoms, course and severity differ 
between affected patients may result from underlying genetic heterogeneity. Genes with 
modifier effects may or may not also influence disease susceptibility. Indeed, SPP1 seems 
to act as a susceptibility and a modifier gene. The effect of the rs11439060 variant differed 
Figure 2. Association of SPP1 rs4754 and joint damage progression in RA patients in the replication study and 
combined analysis at 2 year follow-up. (A) Multivariate regression analysis modelled median Sharp-van der Heijde 
scores (SHS) in patients with RA in the Leiden EAC ACPA-negative cohort during a 7 year follow-up (B) and 
combined analysis of the ESPOIR and Leiden EAC ACPA-negative cohorts at a 2 year follow-up. Maj=major allele; 
min=minor allele.
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in this study compared with our previous case-control study 3, the rs11439060-rs9138 risk 
allele combination not being identified as the best-fit model. Nonetheless, a contribution 
of rs11439060 could not be definitely excluded; the sample size required to detect such 
association with a power of 80% would be 1,000 ACPA-negative patients with early RA.
To our knowledge, this is the first report of the identification of a genetic variant 
associated with joint damage progression in ACPA-negative RA. We took advantage of two 
cohorts including sequential radiographs of hands and feet, which strengthened the evidence 
of the contribution of SPP1 rs9138. Several studies have reported an association of the rs9138 
A risk allele with low serum levels of soluble OPN 3,17. However, to date, the exact role of OPN 
in RA joint damage is controversial: distinct murine models of RA have shown conflicting 
results on the relevance of OPN in bone erosion pathogenesis 18,19, and, more importantly, 
OPN blockade was found to be unlikely to induce robust clinical improvement in patients 
with RA 20.
In conclusion, we have identified and replicated a genetic SPP1 variant predisposing 
to joint damage progression in ACPA-negative RA. Further studies of OPN at the protein 
level are required to better understand the role of this variant in the pathogenesis of the 
progression of radiographic damage in ACPA-negative RA.
SUPPLEMENTARY DATA
Supplementary data are published on the website of the Annals of the Rheumatic Diseases.
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The severity of joint damage progression in rheumatoid arthritis (RA) is heritable. Several 
genetic variants have been identified, but together explain only part of the total genetic effect. 
Variants in Interleukin-6 (IL-6), Interleukin-10 (IL-10), C5-TRAF1, and Fc-receptor-like-3 
(FCRL3) have been described to associate with radiographic progression, but results of 
different studies were incongruent. We aimed to clarify associations of these variants with 
radiographic progression by evaluating six independent cohorts.
Methods 
In total 5,895 sets of radiographs of 2,493 RA patients included in six different independent 
datasets from the Netherlands, Sweden, Spain and North America were studied in relation 
to rs1800795 (IL-6), rs1800896 (IL-10), rs2900180 (C5-TRAF1) and rs7528684 (FCRL3). 
Associations were tested in the total RA populations and in anti-citrullinated peptide 
antibodies (ACPA)-positive and ACPA-negative subgroups per cohort, followed by meta-
analyses. Furthermore, the associated region C5-TRAF1 was fine-mapped in the ACPA-
negative Dutch RA patients.
Results
No associations were found for rs1800795 (IL-6), rs1800896 (IL-10) and rs7528684 (FCRL3) 
in the total RA population and after stratification for ACPA. Rs2900180 in C5-TRAF1 was 
associated with radiographic progression in the ACPA-negative population (p-value meta-
analysis = 5.85×10−7); the minor allele was associated with more radiographic progression. 
Fine-mapping revealed a region of 66Kb that was associated; the lowest p-value was for 
rs7021880 in TRAF1. The p-value for rs7021880 in meta-analysis was 6.35×10−8. Previous 
studies indicate that the region of rs7021880 was associated with RNA expression of TRAF1 
and C5.
Conclusion 
Variants in IL-6, IL-10 and FCRL3 were not associated with radiographic progression. 
Rs2900180 in C5-TRAF1 and linked variants in a 66Kb region were associated with 
radiographic progression in ACPA-negative RA.
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INTRODUCTION
Thanks to the introduction of novel treatments and up-to-date treatment strategies, the 
severity of joint destruction in rheumatoid arthritis (RA) has decreased considerably 
1. Nonetheless, in daily clinical practice radiographic progression is still prevalent and 
understanding the mechanisms underlying the inter-individual differences in radiographic 
progression is relevant. The heritability of joint destruction has been estimated to be 45% to 
58% 2. Thus far, several genetic risk factors for radiographic progression have been replicated 
in independent studies or found significant in meta-analyses of different cohorts, but together 
explain only 18% of variance in radiographic progression 3.
Part of the ‘missing heritability’ might be explained by not yet identified common 
genetic variants that associate with radiographic progression in RA. The literature on genetic 
variants for radiographic progression was reviewed recently 4. Published and yet unpublished 
data were combined, and it was concluded that for 12 genetic variants their associations 
with radiographic progression were either replicated in independent cohort studies or 
found significant in meta-analysis of multiple cohorts. However, the associations between 
rs1800795 in Interleukin (IL)-6, rs1800896 in IL-10, rs2900180 in C5-TRAF1 and rs7528684 
in Fc-receptor-like-3 (FCRL3) and joint damage were not clear 4. Rs1800795 in IL-6 was 
associated with radiographic joint damage at baseline in 964 United Kingdom (UK) RA 
patients, but the association was mainly observed in autoantibody-positive patients 5. IL-10 
was observed as a severity factor evaluating 138 RA patients 6, but not in a study of 108 RA 
patients 7. Rs2900180 in C5-TRAF1 was identified in a cross-sectional study 8; it was also 
found significant in another UK cohort 9, but not in other datasets 4. Rs7528684 in FCRL3 was 
observed as a severity factor in two studies 10,11, although the association was once restricted 
to the subgroup with a disease duration of at least 10 years 11 and not found in other datasets 
4,12.
Presumably, the scarcity of large well-defined longitudinal cohorts of RA patients 
who were treated in eras when early, tailored treatment and use of biologics were uncommon 
may have contributed to the incongruent findings.
In order to increase the comprehension on the associations of these variants with 
radiographic progression in RA and in the anti-citrullinated peptide antibodies (ACPA)-
positive and ACPA-negative subgroups, we performed the present study and evaluated these 
genetic variants in six independent European and North American RA cohorts in one of the 
largest studies to date on RA severity.
METHODS
Study population
The six cohorts consisted in total of 5,895 sets of radiographs of 2,493 RA patients who 
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fulfilled the 1987 American College of Rheumatology (ACR) criteria (Table 1). All patients 
gave their informed consent and approval was obtained from the local Ethical Committee of 
each hospital.
Leiden Early Arthritis Clinic (EAC) - This cohort contained 597 Dutch early RA 
patients included between 1993 and 2006 13. At baseline and during yearly follow-up visits 
over seven years, 3,143 sets of hand and feet radiographs were made and chronologically 
scored by one experienced reader according to the Sharp-van der Heijde method (SHS) 
(within reader intraclass correlation coefficients (ICC) 0.91). The initial treatment strategy 
differed for different inclusion periods: patients included in 1993 to 1995 were initially 
treated with nonsteroidal anti-inflammatory drugs (NSAIDs), patients included in 1996 to 





Wichita NDB NARAC Total
Total number of patients 597 459 383 101 568 385 2,493
Total number of sets of 
radiographs
3,143 868 573 358 568 385 5,895
Radiographic follow-up 
in years*
7 2 10 15 NA NA
Disease duration in years 
at radiograph, mean 
(SD)**




Method of scoring SHS Larsen SHS SHS SHS SHS



















































MAF rs1800795 (G) 
(IL-6), %
42.0 46.5 33.8 46.5 40.8 42.1§
MAF rs1800896 (T) (IL-
10), %
48.1 44.3 52.7 49.0 48.5 45.6
MAF rs2900180 (A) (C5-
TRAF1), %
36.0 36.4 27.8 36.6 35.6 39.0
MAF rs3761959 (A) 
(FCRL3), %§§
45.5 44.2 42.2 50.0 49.7 47.4
*For the studies with longitudinal radiographic data (more than one radiograph in time), the maximum radiographic 
follow-up duration was reported. ** For the studies with one radiograph per patient, the mean disease duration at 
time of the radiograph was reported. +ACPA status was missing in 12 patients from the Leiden EAC cohort, in 
48 patients from the HCSC-RAC cohort and in 1 patient from the Wichita cohort. §Data on rs1800795 were not 
available in the NARAC; data on a proxy rs1554606 (R2=0.868) were available. §§In all cohorts data on rs7528684 
were not available; data on a perfect proxy rs3761959 (R2=1.000) were available. MAF=minor allele frequency; 
NA=not applicable.
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1998 were initially treated with hydroxychloroquine or sulfasalazine and patients included in 
1999 to 2006 were promptly treated with methotrexate 13.
Umeå - This cohort involved 459 Swedish early RA patients included between 1995 
and 2010. At baseline and after two years in total, 868 radiographs of hands and feet were 
made and scored using the Larsen score by two trained readers as described previously 14. 
Treatment strategies differed between 1995 and 2000, 2000 and 2005 and 2006 and 2010, 
resulting in less severe radiographic progression in the subsequent treatment periods.
Hospital Clinico San Carlos - rheumatoid arthritis cohort (HCSC-RAC) - This 
Spanish cohort comprised 383 early RA patients, diagnosed between 1976 and 2011 15. 
During the first 10 years after disease-onset 573 radiographs of hands were made and scored 
chronologically according to the SHS (ICC 0.99). Initial treatment strategies differed for 
different inclusion periods: <1990 (initial treatment with NSAIDs), 1990 to 1999 (initial 
monotherapy conventional disease-modifying antirheumatic drugs (DMARDs), 2000 to 
2004 (initial mono-therapy regularly and combination therapy rarely), 2005 to 2009 (initial 
combination therapy regularly used as well as biologics) and 2010 to 2011 (tailored treatment).
Wichita - This cohort comprised 101 patients from one practice in Wichita (KS, US) 
diagnosed between 1963 and 1999 16. In total, 358 sets of hand radiographs were made during 
the first 15 years after disease onset and scored with known time-order using the SHS (ICC 
0.98).
National data bank for rheumatic diseases (NDB) - This dataset included 568 patients 
from the US and Canada, who were diagnosed between 1980 and 1999 17. One radiograph set 
of the hands was available per patient and SHS-scored (ICC 0.98).
North American Rheumatoid Arthritis Consortium (NARAC) - This dataset 
comprised 385 unrelated RA patients, who were diagnosed between 1953 and 2002 18. One 
radiograph set of the hands was available per patient. The radiographs were SHS-scored (ICC 
0.99). The patients in the three North American cohorts developed RA in eras when early, 
tailored treatment and use of biologics were uncommon; no treatment effects were observed 
for different era of diagnoses.
Genotyping
In the EAC, Umeå, HCSC-RAC, Wichita and NDB cohorts genotyping was done using the 
Immunochip according to Illumina’s protocols as described previously 19,20. In the NARAC 
genotyping was performed using the Illumina Hapmap 500 BeadChip as described elsewhere 
18. Genotyping data were extracted of rs1800795 in IL-6, rs1800896 in IL-10, rs2900180 in 
C5-TRAF1 and rs7528684 in FCRL3. Data on rs1800795 were not avail-able in the NARAC 
but genotyping data of a proxy rs1554606 (R2=0.868 and D’=0.932) were retrieved. In all 
cohorts, data on rs7528684 (FCRL3) were not available; data on a perfect proxy rs3761959 (R2 
and D’ both 1.000) were studied.
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Fine-mapping
The C5-TRAF1 region was fine-mapped in ACPA-negative patients of the EAC. Data of 
genetic variants in the region of rs2900180 were retrieved using the Immunochip, starting 
at the upstream haplotype block of PHF19 until the downstream haplotype block of C5 
(chromosome 9: 122,680 Kb to 122,927 Kb). Genotypic data were accepted after quality 
control as described elsewhere 20, requiring minor allele frequency (MAF) >0.0001, Hardy-
Weinberg equilibrium (HWE) p>0.001 and genotyping success rate >0.99. Genetic outliers 
and relatives (both defined by principal component analysis) and patients with a gender 
mismatch between the data file and DNA were excluded. In this way, 424 SNPs were 
obtained and analysed for their association with radiographic progression. The variant with 
the strongest association was subsequently associated with radiographic progression in the 
ACPA-negative patients of the Umeå, HCSC-RAC and NDB cohorts.
Downstream effect
To identify functional downstream effects of C5-TRAF1, a search was performed in publically 
available databases and datasets 21–26. Explored were the RegulomeDB 21, datasets that have 
evaluated constitutive RNA expression by mapping expression quantitative trait locus 
(eQTL) in peripheral blood samples from 8,086 individuals 22 and purified CD4+ T-cells and 
monocytes from 461 individuals 23, and datasets that have evaluated response eQTLs (QTLs 
associated with change in expression after stimulation) on lymphoblastoid cell lines from 40 
individuals 24, monocytes from 432 individuals 25 and monocytes derived dendritic cells from 
534 individuals 26.
Statistical analysis
Associations between genotypes and radiographic joint damage were analysed per 
cohort using an additive model. In all datasets, radiographic scores were log-transformed 
(log10(radiographic score +1)) to approximate a normal distribution. The residuals of the 
used models were normally distributed around the zero-line in all cohorts, indicating a good 
fit of the models (Additional file 1).
In the cohorts with multiple sets of radiographs over time (EAC, Umeå, HCSC-RAC 
and Wichita) a multivariate normal regression model for longitudinal data was used with 
radiographic scores as response variable. This method takes advantage of the within-person 
correlation between repeated measurements; as such, the radiographic progression rates were 
estimated more precisely in the cohorts with serial radiographs compared to datasets with 
one radiograph per patient (for a detailed description see reference 27. The obtained effect 
size (beta) was back-transformed to the normal score and indicated the fold rate of joint 
destruction per year per minor allele compared to the reference genotype.
In the cohorts with a set of radiographs at one time-point (NDB and NARAC) the 
estimated yearly progression rate was calculated (total SHS divided by number of disease 
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year at the time of the radiograph) in order to make the estimates of the progression rates 
comparable to those in the other datasets. A linear regression analysis was used with 
estimated yearly progression as outcome variable. Here, also, the obtained effect size was 
back-transformed and indicated the fold rate of joint destruction per year per minor allele 
compared to the reference common genotype.
In all datasets, adjustments were made for age and gender. In the cohorts that included 
patients in periods with different treatment strategies (EAC, Umeå and HCSC-RAC) analyses 
were also adjusted for the inclusion period as proxies for differences in treatment strategies.
The majority of datasets studied were estimated to be insufficiently powered to find 
statistically significant associations in the individual cohorts. Therefore, the effect sizes and 
standard errors of the individual analyses were combined in an inverse-weighted variance 
meta-analysis to test the overall association. This was allowed because the obtained effect sizes 
of the individual datasets, although different methods were used to score joint destruction 
(SHS and Larsen), all represented the relative increase (without units) of progression in joint 
destruction per year. The meta-analysis weights the results with a low standard error stronger 
than the results with a high standard error, preventing an overrepresentation of less precise 
data on the outcome. Subsequently, datasets with smaller 95% confidence intervals (CI) had a 
larger weight in the meta-analysis.
The cut-off for statistical significance was set at p<4.17×10−3 using the Bonferroni 
correction (four variants tested in the total RA population and ACPA-positive and ACPA-
negative subgroups: 0.05/12 tests=4.17×10−3). For the fine-mapping analyses the cut-off for 
statistical significance was set at p<1.18×10−4, also using the Bonferroni correction (0.05/424 
tests=1.18×10−4). Analyses were performed using IBM SPSS version 20 and Stata version 12.0.
RESULTS
Patient characteristics and analyses on total RA population
The minor allele frequencies for rs1800795 (G) in IL-6, rs1800896 (T) in IL-10, rs2900180 (A) 
in C5-TRAF1 and rs3761959 (A) (=perfect proxy rs7528684 (G)) in FCRL3 in the different 
cohorts are presented in Table 1. First, analyses were done on the total RA population. 
Statistical significance was obtained in none of the individual cohorts. The directionality 
of the effects was variable across the cohorts (Figure 1). Also in the meta-analyses on the 
six cohorts (2,493 patients and 5,895 sets of radiographs in total) no significant associations 
were obtained for rs1800795 in IL-6 (fixed effects model p=0.72), rs1800896 in IL-10 (fixed 
effects model p=0.93), rs2900180 in C5-TRAF1 (fixed effects model p=0.22) and rs7528684 
in FCRL3 (fixed effects model p=0.83).
Analyses of ACPA-positive and ACPA-negative RA
As some of the initial reports on these four genetic variants stratified or adjusted the analyses 
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Figure 1. Genetic variants in IL-6 (A), IL-10 (B), C5-TRAF1 (C) and FCRL3 (D) in relation to radiographic joint 
damage progression. Presented are the yearly radiographic progression rates per individual cohort and the meta-
analyses evaluating the six cohorts combined, consisting in total of 2,493 patients and 5,895 sets of radiographs. None 
of the studied genetic variants were significantly associated with radiographic progression, neither in the individual 
cohorts nor in meta-analysis. Rs1800795 (IL-6) I2 0.0%, p=0.67; fixed effect p=0.72, random effect p=0.72; rs1800896 
(IL-10) I2 20.8%, p=0.28; fixed effect p=0.93, random effect p=0.89; rs2900180 (C5-TRAF1) I2 28.7%, p=0.22; fixed 
effect p=0.22, random effect p=0.63; rs7528684 (FCRL3) I2 26.0%, p=0.24; fixed effect p=0.83, random effect p=0.73.
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for the presence of ACPA and as ACPA-positive and ACPA-negative RA are considered as 
separate disease entities, analyses were performed on radiographic progression in ACPA-
positive and ACPA-negative RA separately. The ACPA-positive subgroup comprised 1,748 
patients (with 3,820 sets of radiographs) who were included in six cohorts. The ACPA-
negative subgroup included 681 patients (with 1,933 sets of radiographs) who were included 
in the EAC, Umeå, HCSC-RAC and NDB cohorts (Table 1).
Rs1800795 (IL-6), rs1800896 (IL-10), and rs7528684 (FCRL3) were not associated 
with radiographic progression, neither in the ACPA-positive nor in the ACPA-negative 
group of RA patients (Additional file 2). Rs2900180 in C5-TRAF1 was not associated with 
radiographic progression in ACPA-positive RA (Additional file 2). In contrast, in ACPA-
negative RA a significant association with radiographic progression was observed in the EAC 
(p=2.88×10−5) (Figure 2A). The directionality of the effect was similar in the Umeå, HCSC-
RAC and NDB cohorts. Also, the meta-analysis revealed a significant association (fixed 
effects model p=5.85×10−7) (Figure 2B). In all cohorts, patients with the minor allele had 
a higher rate of joint destruction. For instance, RA patients included in the EAC with one 
minor allele had a 1.045 fold rate of joint destruction per year compared to patients with the 
common genotype; this equals a 36% (1.045^7) higher rate of joint destruction over seven 
years (Figure 2A).
Figure 2. Rs2900180 in C5-TRAF1 in relation to radiographic progression in ACPA-negative RA patients. (A) 
Depicted are the median SHSs during seven years of follow-up of ACPA-negative RA patients with different 
genotypes in the Leiden EAC. Patients had per minor allele a 1.045 fold rate of joint destruction per year compared 
to patients with the common genotype (p=2.88×10−5). (B) Yearly radiographic progression rates per individual 
cohort and the meta-analysis evaluating the cohorts with ACPA-negative patients. Analysis of the ACPA-negative 
subgroup of the Wichita cohort was not performed as it included only three ACPA-negative patients. I2 33.0%, p= 
0.22; fixed effect p=5.85×10−7, random effect p=0.0024.
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Fine-mapping
To examine if other genetic variants within the C5-TRAF1 region had statistically stronger 
associations with the rate of joint destruction than rs2900180, this region was fine-
mapped in the ACPA-negative EAC patients. In total, 43 variants had a p-value below the 
threshold for multiple correction (p<1.18×10−4) of which 34 were statistically more strongly 
associated with radiographic progression than rs2900180 (Figure 3, Additional file 3). The 43 
associating variants, including rs2900180, were all located within a 66 Kb region spanning 
TRAF1 and extending downstream to the C5-TRAF1 intergenic region and upstream to 
the TRAF1-PHF19 intergenic region. The variant with the lowest p-value was rs7021880 
located in TRAF1 (beta=1.052 per year per minor allele, p=1.39×10−6). In a conditional 
analysis on rs2900180 and rs7021880 (R2=0.864), both variants lost statistical significance 
(rs2900180 beta=0.99 p=0.77; rs7021880 beta=1.06 p=0.057). This suggests that these two 
variants reflected one signal, although it is noteworthy that the effect size of rs2900180 was 
reduced to 0.99 and the effect size of rs7021880 increased slightly. Additionally, the fine-
mapping analyses were performed when conditioning on the strongest associating variant 
rs7021880. No variants were statistically significant associated with radiographic progression 
independent of rs7021880 (Additional file 4). In meta-analysis of the ACPA-negative patients 
of the EAC, Umeå, HCSC-RAC and NDB cohorts rs7021880 was significantly associated 
with radiographic progression (fixed effects model p=6.35×10−8) (Additional file 5).
Downstream effect
To identify functional downstream effects of the region of rs7021880, a database and literature 
search of transcription studies was performed. The RegulomeDB indicated that this locus has 
multiple signs of transcriptional activity 21. Based on RNA expression evaluated by eQTL 
mapping of peripheral blood samples of 8,086 individuals 22, the minor allele of rs7021880 
was negatively correlated with RNA expression of different genes in this region (cis-eQTL), 
with the lowest p-value for the expression of TRAF1 (p=4.93×10−35) (Additional file 6). 
However, the strongest correlation between variants in this region with TRAF1 expression 
was observed for rs2416804 in TRAF1 (D’=1.000, R2=0.668 with rs7021880). A study 
evaluating CD4+ T-cells and monocytes of 461 individuals observed that several variants in 
the region of rs7021880 had cis-eQTL effects on TRAF1 (in T-cells) and on C5 (in monocytes) 
23. Both studies explored constitutive expression 22,23. The effect of a regulatory variant on gene 
expression, however, may depend on the presence of certain stimuli. Response eQTLs have 
been studied in different cell types using different stimuli 24–26. In lymphoblast cell lines of 40 
Asian individuals variants in the C5-TRAF1 region were associated with TRAF1 expression 
after phorbol myristate actetate (PMA) stimulation, but not with C5 expression 24. Monocytes 
are cardinal innate immune cells that upon stimulation, exhibit large scale gene transcription 
and cytokine production. A recent study in 432 individuals showed that the expression of 
TRAF1 and C5 significantly changed in monocytes after stimulation with lipopolysaccharide 
(LPS) 25. Furthermore, rs7021880, associated with radiographic progression in our study, as 
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Figure 3. LD plots of the C5-TRAF1 region. (A) Total region in hapmap CEU patients and (B) fine-mapped in Leiden 
EAC. The colors reflect de D’ between the SNPs. Coordinates relate to NCBI36 hg18 release 2006. (C) Results of the 
multivariate normal regression analysis for 424 variants in the C5-TRAF1 region in the ACPA-negative patients of 
the EAC. Rs2900180 is the initially studied variant, rs7021880 is the variant with the lowest p-value and rs10818488 
is the variant we previously studied in relation to radiographic progression and did not associate with radiographic 
progression in the total population 29. Also in the current study, rs10818488 did not pass the cut-off for multiple 
testing correction in the ACPA-negative patients. Using the Bonferroni correction (considering 424 variants studied) 
the cut-off for statistical significance was set at 1.18×10−4 as represented by the horizontal line.
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well as several other variants in this region, affected gene expression after two hours of LPS 
stimulation; a strong cis-effect was seen for expression of TRAF1 (p for rs7021880 = 1.20×10−6, 
t-stat=−5.00) (Additional file 7) 25. Similarly, in a comparable study of stimulation-specific 
eQTLs in dendritic cells derived from peripheral blood monocytes of 534 individuals, the 
RA susceptible variant rs881375 in the intergenic TRAF1-PHF19 region (R2=0.902, D’=1.000 
with rs7021880) showed response eQTL after LPS and influenza stimulation (respectively 
p=6.33×10−8 and 1.04×10−10) 26. Together these data indicate a response eQTL effect on 
monocytes and dendritic cells derived from monocytes for rs7021880 and its proxy SNPs.
DISCUSSION
This study aimed to increase the understanding of the relevance of four previously identified 
risk factors for the severity of joint destruction in RA. To this end, 2,493 RA patients (and 
5,895 sets of radiographs) included in six independent cohorts from different parts of Europe 
and North America were studied. In contrast to previous observations in smaller studies, 
the variants in IL-6, IL-10 and FCRL3 were not associated with radiographic progression. 
This indicates that these variants do not mediate the severity of structural damage in RA. 
A statistically significant association, confined to the ACPA-negative subgroup of RA was 
found for rs2900180 in C5-TRAF1. Fine-mapping of this region revealed the lowest p-value 
for rs7021880 in TRAF1, although this signal was not independent of other variants in this 
region. The putative relevance of rs7021880 and its surrounding region was supported by 
differences in RNA expression of TRAF1 in peripheral blood and monocytes in relation to 
these genotypes.
We have strongly considered whether the findings on the C5-TRAF1 region may 
be false positive. However, despite the fact that all replication cohorts individually had less 
power than our first cohort and it was unlikely to find statistically significant results in the 
individual replication cohorts, the obtained effect sizes and directionalities were similar 
in the Umeå, HCSC-RAC and NDB cohorts. Also, the meta-analysis on these cohorts was 
highly significant (p=6.35×10−8 for rs7021880). Therefore, in our view, it is more likely that 
the finding on C5-TRAF1 in ACPA-negative RA is a true positive finding than a false positive 
finding.
The association of rs2900180 in C5-TRAF1 with radiographic progression was 
previously observed in two studies on the total RA population 8,9. The first study concerned 
761 RA patients of the Norfolk Arthritis Register (NOAR) with a radiograph after one or five 
years; 61% of these patients were ACPA-negative. In ACPA-stratified analyses after one year 
follow-up the effect was significant in ACPA-negative RA patients but not in ACPA-positive 
RA patients 8. The second study reevaluated the NOAR with longitudinal radiographs and 
also included patients of the Early Rheumatoid Arthritis Study (ERAS); ACPA status was not 
reported here 9. The difference in findings in the UK cohorts and our cohorts with regard to 
ACPA might be the consequence of different frequencies of ACPA-negativity between the 
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cohorts. In the NOAR, the proportion of ACPA-negative patients was higher than in our 
cohorts (61% versus 28% of the total study population of the six cohorts) 8. Therefore, the 
ACPA-negative patients may have contributed more to the results obtained for the NOAR 
total RA population than in the total RA populations studied here. The consistency of the 
directionality of the effect (the minor allele associated with more severe damage) in the 
cohorts studied in the present study and the previously studied cohorts of NOAR and ERAS 
supported the validity of our findings.
Fine-mapping was performed to explore the C5-TRAF1 region comprising 
rs2900180 which is located on chromosome 9 and intergenic between C5 and TRAF1. The 
threshold for significance of the fine-mapping analyses was corrected for 424 tests which 
is quite restrictive as the markers included in the analyses are not independent. However, 
this threshold decreased the chance of false positive findings and, in total, 43 variants had 
a p-value below this threshold. These variants were all highly correlated and located in a 66 
Kb region covering TRAF1 and downstream extending to the C5-TRAF1 intergenic region 
and upstream to the TRAF1-PHF19 intergenic region. Also, these 66 Kb are located within a 
larger region with a high LD spanning from C5 to PHF19 (based on Ceu HapMap data and 
as described previously 28). In a conditional analysis including both the initial (rs2900180) 
and the strongest associating variant (rs7021880), we could not distinguish which variant 
is the most important. Therefore, the conclusion is that the region encompassing rs7021880 
and rs2900180 is associated with radiographic progression. Larger fine-mapping studies 
are required to conclude definitely on the extent of the region that presumably contains the 
causal variant.
Previously, we reported that rs10818488, which is also located in the C5-TRAF1 
region (intergenic C5-TRAF1), was not associated with radiographic progression in 2,666 
RA patients belonging to seven cohorts. No stratification for ACPA was done for this analysis 
29. Also, when rs18018488 was analysed in the total RA population of the present study 
which included four cohorts that were studied previously and two additional cohorts, no 
significant associations were obtained (data not shown). In the present study, rs10818488 
was also included in the fine-mapping data of the ACPA-negative patients and did not 
pass the threshold for multiple testing (which was p<1.18×10−4; the p-value for rs10818488 
was 6.21×10−4) (Figure 3C). To explore the relation between rs10818488 and rs2900180 
genotypes, the genotypes were compared (Table 2), showing incomplete correlations which 
is in line with the R2 of 0.668 between these two variants. For instance, all patients with 
genotype AA for rs2900180 had genotype AA for rs10818488, but also other patients had 
genotype AA for rs18018488. In total, 41 of the 276 ACPA-negative patients (14.9%) had 
different genotypes which explains the difference in the obtained p-values for rs10818488 and 
rs2900180. The minor allele of rs2900180 that associated in the present study with a higher 
rate of joint destruction in ACPA-negative RA is also associated with a higher risk of RA 18,28. 
Rs2900180 was observed to associate with susceptibility to RA in both Caucasian and Korean 
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patients, in contrast to rs10818488, which was observed to be a risk factor for RA only in 
Caucasian patients 30. Hence, apparently not only the association with RA severity but also 
the associations with RA susceptibility are slightly different for rs2900180 and rs10818488.
A correlation of rs7021880 located in TRAF1 with TRAF1 expression was observed 
in whole blood, although rs7021880 was not the strongest associating genetic variant 
with TRAF1 expression 22. These data are valuable but reflect on a mixture of cells and 
constitutive expression. Interestingly, very recently two studies evaluated eQTL effects 
on RNA expression of monocytes or dendritic cells derived from monocytes after several 
stimuli (response eQTL). These data are attractive since monocytes play a relevant role in 
the development and progression of RA and because it is conceivable to suggest that variants 
that associate with progression of the disease are expressed in response to inflammatory 
stimuli. Hence, differences in such expression may affect the disease course. The expression 
of TRAF1 in monocytes was significantly altered after LPS stimulation compared to naïve 
monocytes and rs7021880 genotypes were associated with this change in expression after 
stimulation 25. Genetic variants might thus affect the level of TRAF1 expression in response 
to stimulation. Similar findings were observed in dendritic cells derived from monocytes for 
rs881375, a good proxy of rs7021880 (R2=0.902) 26. TRAF1 is involved in the NF-ĸB pathway, 
providing a potential pathway for how these genetic variants may influence progression of 
joint destruction. The analyses on the large bioinformatics databases supported the notion 
that the region surrounding rs7021880 has a regulatory function in monocytes, but these 
databases did not allow us to perform conditional analyses on the genetic variants in this 
region in relation to RNA expression to identify independent effects. In addition, in several of 
the studies explored the directionality of the effects on expression was not clearly presented, 
hampering the interpretation of the potential effects of rs7021880. Although most studies 
reported on the expression of TRAF1, eQTL effects on C5 in certain cell types have also been 
reported. The data available do not allow us to conclude whether effects on expression are 
consistent across cell types. More studies are needed to explain how the C5-TRAF1 region is 
relevant for radiographic progression in ACPA-negative RA.
The variants in IL-6, IL-10 and FCRL3 were not associated with radiographic 
Table 2. Genotypes of rs10818488 and rs2900180 in the ACPA-negative Leiden EAC patients
rs2900180 (A) Total
GG AG AA
rs10818488 (A) GG 88 0 0 88
AG 22 113 0 135
AA 2 17 34 53
Total 112 130 34 276
Presented are the frequencies of the genotypes for rs2900180 (A) and rs10818488 (A) in the 276 ACPA-negative RA-
patients of the Leiden EAC. The R2 between these variants was 0.668. Minor allele frequencies within this group were 
35.9% and 43.7% for rs2900180 and rs10818488, respectively.
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Table 3. Overview of genetic variants for radiographic progression that are replicated in independent cohorts or 
found significant in meta-analysis
Severity variant (risk 
allele)
Located in/nearby gene(s) 
(chromosome)
Risk population Functional associations
SE 31 HLA-DRB1 (chr 6) All RA Associated with ACPA-
presence
rs4810485 (T) 32 CD40 (chr 20) ACPA-pos NA




rs1896368 (G) 34 DKK-1 (chr 10) All RA Serum level DKK-1
rs1896367 (G) 34
rs1528873 (A) 34
rs2104286 (T) 35 IL2RA (chr 10) All RA Serum level IL2Rα
rs8192916 (A) 36 GRZB (chr 14) All RA+ RNA expression in whole 
blood (eQTL)
rs1119132 (A) 37 IL4R (chr 16) All RA§ NA
rs7607479 (T) 38 SPAG16 (chr 2) ACPA-pos Serum level MMP-3
rs26232 (C) 39 C5orf30 (chr 5) All RA** NA
rs11908352 (A) 20 MMP-9 (chr 20) All RA++ Serum level MMP-9
rs451066 (A) 20 rs1465788 (chr 14) All RA§§ NA
rs1485305 (G) 40 OPG (chr 8) All RA*** NA
rs2900180 (A) C5-TRAF1 (chr 9) ACPA-neg RNA expression whole 
blood and monocytes
*After adjustment for ACPA, comparable effect sizes were observed (data not shown). +After stratification for ACPA, 
significant associations were observed in both subgroups (ACPA-negative beta=1.05 and p=1.98x10-3; ACPA-positive 
beta=1.03 and p=5.40x10-2). §After stratification for ACPA, comparable effect sizes were observed in both subgroups 
(data not shown). **After adjustment for ACPA and RF a significant association was observed (beta=0.90, p=0.03). 
++ After stratification for ACPA, the effect size was larger in the ACPA-positive than in the ACPA-negative subgroup. 
However, considering the small number of patients per subgroup, none of the analyses resulted in significant 
p-values. §§After stratification for ACPA, almost similar effect sizes were observed in both subgroups. However, 
considering the small number of patients per subgroup, none of the analyses resulted in significant p-values. ***After 
stratification, a significant association was observed in ACPA-negative patients (beta=1.29, p=0.001) but not in 
ACPA-positive patients, although a similar trend was observed (beta=1.14, p=0.11). After adjustment for ACPA 
and RF the association remained significant (beta=1.20, p=0.02). eQTL=expression quantitative trait locus; NA=not 
applicable
progression. Also, the directions of the effects between the different cohorts were diverse 
and no tendency for association was observed. The initial findings on these variants were 
obtained in studies with a lower number of patients and radiographs than in present study.
This study was started in response to findings of a recent review of the literature 
on genetic variants that are associated with radiographic progression in RA 4. Although 
genotyping data of five of the cohorts were retrieved from the Immunochip, we did 
not intend to analyse the whole Immunochip, as this was done recently in a study that 
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included three of the six studies that are examined in the present study 20. This study was 
focused on the variants for which existing data were contradictory and we went into detail 
by also performing analyses stratified for ACPA. The total number of genetic variants for 
radiographic progression that are identified and either replicated in independent cohort 
studies or found significant in meta-analysis is now thirteen (including C5-TRAF1) of which 
nine were identified in the total RA population (summarised in Table 3). The ACPA-negative 
subgroup was studied separately in only five studies (excluding the present study). Of these, 
rs8192916 in GRZB and rs1485305 in OPG were reported to have a statistically significant 
association with radiographic progression within the ACPA-negative subgroup; for the other 
three variants (rs1119132 in IL4R, rs11908352 in MMP-9 and rs451066 on chromosome 14) 
similarity in effect sizes were reported but statistical significance was not obtained which may 
be due to smaller sample sizes. The data in Table 3 and the present data show that genetic risk 
factors for radiographic progression in ACPA-positive and ACPA-negative RA are not similar 
and further support the notion of two separate disease subsets of RA.
CONCLUSION
In conclusion, in contrast to initial reports, variants in IL-6, IL-10 and FCRL3 are not 
associated with radiographic progression. The association between rs2900180 in C5-TRAF1 
and radiographic progression is confined to ACPA-negative RA. A region surrounding 
rs2900180 affects TRAF1 expression in whole blood and monocytes. Further functional 
studies are needed to elucidate the underlying biological mechanisms in more detail.
SUPPLEMENTARY DATA
Supplementary data are published on the website of Arthritis, Research & Therapy.
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For decades it has been known that the HLA-DRB1 shared epitope (SE) alleles are associated 
with an increased risk of development and progression of rheumatoid arthritis (RA). 
Recently, the following variations in the peptide-binding grooves of HLA molecules that 
predispose to RA development have been identified: Val and Leu at HLA-DRB1 position 11, 
Asp at HLA-B position 9, and Phe at HLA-DPB1 position 9. This study was undertaken to 
investigate whether these variants are also associated with radiographic progression in RA, 
independent of SE and anti-citrullinated peptide antibody (ACPA) status.
Methods 
A total of 4,911 radiograph sets from 1,878 RA patients included in the Leiden Early Arthritis 
Clinic (the Netherlands), Umeå (Sweden), Hospital Clinico San Carlos-Rheumatoid Arthritis 
(Spain), and National Data Bank for Rheumatic Diseases (US) cohorts were studied. HLA 
was imputed using single-nucleotide polymorphism data from an Immunochip, and the 
amino acids listed above were tested in relation to radiographic progression per cohort using 
an additive model. Results from the 4 cohorts were combined in inverse-variance weighted 
meta-analyses using a fixed-effects model. Analyses were conditioned on SE and ACPA status.
Results 
Val and Leu at HLA-DRB1 position 11 were associated with more radiographic progression 
(meta-analysis p=5.11x10-7); this effect was independent of SE status (meta-analysis p=0.022) 
but not independent of ACPA status. Phe at HLA-DPB1 position 9 was associated with more 
severe radiographic progression (meta-analysis p=0.024), though not independent of SE 
status. Asp at HLA-B position 9 was not associated with radiographic progression.
Conclusion
Val and Leu at HLA-DRB1 position 11 conferred a risk of a higher rate of radiographic 
progression independent of SE status but not independent of ACPA status. These findings 
support the relevance of these amino acids at position 11.
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INTRODUCTION
The development and course of rheumatoid arthritis (RA) are in part determined by genetic 
factors. Although the genetic risk factors underlying RA development and progression of 
joint destruction are largely non-overlapping 1, the genetic variants encoding the so-called 
HLA-DRB1 shared epitope (SE) alleles are associated with both the risk of RA development 
and the severity of the disease course 2–4.
The association of HLA class II with RA has been known for decades. The association 
between HLA-DR and RA was first reported in 1976 5. Subsequent identification of risk HLA-
DRB1 alleles that all shared a similar amino acid sequence at positions 70–74 in the peptide-
binding groove of the HLA-DRB1 molecule led to the formulation of the SE hypothesis 6. This 
hypothesis postulates that the SE motif itself may be directly involved in the pathogenesis of 
RA by allowing the presentation of an arthritogenic peptide to T cells. Thus far, these peptides 
have not been identified. With the identification of anti-citrullinated peptide antibodies 
(ACPA) in the late 1990s, it became clear that SE alleles mainly predispose to ACPA-positive 
RA 3,7. The relevance of HLA-DRB1 for ACPA-negative RA was set by the identification of 
HLA-DRB1*03 (part of the conserved ancestral A1-B8-DRB1*03 haplotype) as a risk factor 
for ACPA-negative RA 8,9.
Recently, a further refinement of the association between HLA and RA was 
proposed by Raychaudhuri et al 10. Using a case-control design with 5,018 ACPA-positive 
RA patients and 14,974 controls, the class I and class II HLA regions were explored. The 
strongest association was reported for HLA-DRB1 positions 11 and 13 (which are in high 
linkage disequilibrium). The amino acids Val and Leu at position 11 conferred a high risk, 
and Ser was protective. These associations were independent of the SE status. Furthermore, 
performing further conditional analyses, independent associations were observed for variants 
in HLA-B position 9 (Asp predisposed to RA) and HLA-DPB1 position 9 (Phe predisposed 
to RA). In a subsequent study using a similar approach, the authors also investigated 2,406 
ACPA-negative RA patients and 13,930 controls 11 and observed that Leu and Ser at HLA-
DRB1 position 11 and Asp in HLA-B position 9 were associated with an increased risk of 
ACPA-negative RA.
These risk positions are located in the peptide-binding grooves of the HLA molecules. 
Studies of MHC class I and class II in mice have shown that a difference of only one or a few 
amino acids at such a crucial place may result in the presentation of totally different peptides 
12,13. Therefore, the finding that additional amino acids located in the antigen-presenting 
binding grooves associate with RA development is relevant and hypothetically may fuel 
further studies to detect arthritogenic peptides involved in RA susceptibility 10. Because the 
HLA-DRB1 SE alleles are among the strongest genetic factors for a progressive disease course, 
the recent findings of Raychaudhuri et al prompted us to determine the relevance of the 
newly identified risk factors for the severity of the course of RA, measured using radiographic 
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joint damage progression. More specifically, first, we aimed to investigate whether Val, Leu, 
and Ser at HLA-DRB1 position 11, Asp at HLA-B position 9, and Phe at HLA-DPB1 position 
9 are associated with radiographic progression in the total RA population and, if so, whether 
these effects are independent of the well-known SE effect (HLA-DRB1 positions 70–74). 
Second, since the SE alleles predispose to ACPA and the SE alleles are not associated with 
radiographic progression independent of ACPA 7,14, we aimed to analyse whether the newly 
identified associations are independent of ACPA. Third, we aimed to evaluate whether Leu 
and Ser at HLA-DRB1 position 11 and Asp at HLA-B position 9, identified as risk factors for 
ACPA-negative RA, are associated with joint damage progression in ACPA-negative RA. To 




Patients were included from the following 4 cohorts: the Leiden Early Arthritis Clinic 
(EAC), the Umeå cohort, the Hospital Clinico San Carlos-Rheumatoid Arthritis Cohort 
(HCSC-RAC), and the National Data Bank for Rheumatic Diseases (NDB). In all cohorts, 
RA was defined according to the American College of Rheumatology 1987 criteria 15. 
The characteristics of the patients in each cohort are presented in Supplementary Table 1. 
Informed consent was obtained from all patients, and approval was obtained from the local 
ethics committee of each study.
Leiden EAC - This cohort consisted of 594 Dutch patients with early RA who were enrolled 
between 1993 and 2006 16. The mean±SD age at diagnosis was 57.0±15.6 years, 67.0% of 
the patients were women, and 52.8% were ACPA-positive (as determined by anti-cyclic 
citrullinated peptide 2 [anti-CCP2] antibody test). Radiographs of the hands and feet were 
obtained at baseline and during yearly follow-up visits. In total 3,121 sets of radiographs 
obtained over 7 years of follow-up were chronologically scored by 1 experienced reader, who 
was blinded with regard to any clinical or genetic data, using the Sharp-van der Heijde score 
(SHS) (within reader intraclass correlation coefficient [ICC] 0.91). Initial treatment strategies 
changed over time. Patients enrolled in 1993-1995 were initially treated with nonsteroidal 
anti-inflammatory drugs (NSAIDs), patients enrolled in 1996-1998 were initially treated 
with hydroxychloroquine or sulfasalazine, and patients enrolled in 1999-2006 were initially 
treated with methotrexate.
Umeå cohort - This Swedish cohort comprised 365 patients with early RA enrolled between 
1995 and 2010. The mean±SD age at diagnosis was 54.3±14.5 years, 69.6% of the patients 
were women, and 71.8% were ACPA-positive (as determined by anti-CCP2 antibody test). 
At baseline and after 2 years, a total of 687 radiographs of the hands and feet were obtained 
and scored using the Larsen score by 2 trained readers as previously described 17. Treatment 
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strategies differed between 1995-2000, 2000-2005, and 2006-2010, resulting in less severe 
radiographic progression in the subsequent treatment periods.
HCSC-RAC - This Spanish dataset involved 380 patients with early RA, diagnosed 
between 1976 and 2011 18. The mean±SD age at diagnosis was 53.8±14.2 years, 76.3% of 
the patients were women, and 48.6% were ACPA-positive (as determined by anti-CCP2 
antibody test). During the first 10 years after disease onset, 564 radiographs of the hands 
were obtained and scored with known time-order using the SHS (ICC 0.99). Initial treatment 
strategies differed for different inclusion periods. Prior to 1990, patients were initially treated 
with NSAIDs, from 1990 to 1999 patients received initial monotherapy with conventional 
disease-modifying antirheumatic drugs, from 2000 to 2004 patients received initial mono-
therapy regularly and combination therapy rarely, from 2005 to 2009 patients received initial 
combination therapy regularly as well as biologic agents, and from 2010 to 2011 patients 
received tailored treatment.
NDB - This dataset included 539 patients from the US and Canada who were diagnosed 
between 1980 and 1999 19. The mean±SD age at diagnosis was 48.6±12.6 years, 78.5% of the 
patients were women, and 79.6% were ACPA-positive (as determined by anti-CCP2 antibody 
test). One set of hand radiographs was available per patient after a mean disease duration 
of 10.1 years (range 1–20 years) and scored according to the SHS (ICC 0.98). No treatment 
effects were observed for different periods of diagnosis since all patients developed RA in eras 
when early, tailored treatment and the use of biologic agents were uncommon.
Genotyping 
For all cohorts, we used SNP2HLA to impute classic alleles and corresponding amino 
acid polymorphisms for HLA class I loci (HLA-A, -B, and -C) and class II loci (HLA-
DPA1, -DPB1, -DQA1, -DQB1, and -DRB1) 20. We obtained patient genotypes using an 
Illumina Immunochip platform 1,21 and used data collected by the Type 1 Diabetes Genetics 
Consortium as a reference 22. The HLA imputation has been described in detail previously 
10,11,20. For the present study, the classic HLA-DRB1 alleles and the amino acids at HLA-DRB1 
position 11, HLA-B position 9, and HLA-DPB1 position 9 were extracted.
Analyses of the associations between variants and radiographic progression
First, the SE alleles, defined based on HLA-DRB1 positions 70-74 according to the SE 
hypothesis 6 (DRB1*0101, *0102, *0104, *0401, *0404, *0405, *0408, *0413, *0416, *1001, and 
*1402), were tested in relation to radiographic progression. Subsequently, the amino acids 
that were shown to confer risk to develop RA in the study by Raychaudhuri et al 10 (Val and 
Leu at HLA-DRB1 position 11, Asp at HLA-B position 9, and Phe at HLA-DPB1 position 9) 
were studied in relation to radiographic progression. Analyses were done per cohort using an 
additive model (0, 1, or 2 risk amino acids). Since Val and Leu at position 11 both conferred 
increased risk, these were combined (i.e., radiographic progression in the presence of 0, 1, or 
2 Val and/or Leu was studied). Because the SE alleles and Val or Leu on position 11 are often 
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present together, conditional analyses were performed allowing us to investigate whether Val 
and Leu were associated with radiographic progression independent of the known association 
between HLA-DRB1 SE status and radiographic progression. Furthermore, for the SE alleles 
it is known that the alleles are not associated with radiographic progression independent of 
ACPA; in other words, the SE alleles are not associated with radiographic progression as such 
but this effect is mediated by ACPA 7,14. To determine whether the same is valid for the newly 
identified risk factors, analyses were subsequently adjusted for ACPA status.
Previously, the amino acid Ser at HLA-DRB1 position 11 was found to protect 
against RA development 10. In this study, the association of Ser (0, 1, or 2 amino acids) with 
radiographic progression was analysed.
The above-mentioned analyses of Val and Leu and of Ser at HLA-DRB1 position 11 
do not take into account the polymorphic nature of HLA-DRB1 in which different amino 
acids encoded by the same position may have a predisposing or protective effect. It is crucial 
to ascertain that the predisposing effect identified is not actually due to the absence of a 
protective effect and vice versa. Stratification is the most thorough method to differentiate 
between these effects and has been used before to distinguish true effects from the effect of 
the absence of other alleles 2,23,24. Therefore, patients were stratified into one of the following 6 
groups: susceptible/ susceptible (S/S), susceptible/neutral (S/N), susceptible/ protective (S/P), 
neutral/neutral (N/N), neutral/protective (N/P), and protective/protective (P/P). Val and Leu 
at HLA-DRB1 position 11 were the susceptibility amino acids, Ser at this position was the 
protective amino acid, and Asp, Pro, and Gly were the neutral amino acids. Then the groups 
of S/S, S/N, and N/N were compared to determine whether the effect of Val and Leu was truly 
predisposing and not the result of the concomitant absence of Ser. Similarly, the groups of 
P/P, P/N, and N/N were compared to determine whether the effect of Ser was truly protective 
and not the result of the concomitant absence of the susceptibility amino acids Val and Leu.
Finally, we evaluated whether the variants that were reported to predispose to ACPA-
negative RA 11 (Leu and Ser at HLA-DRB1 position 11 and Asp at HLA-B position 9) were 
associated with radiographic progression in ACPA-negative RA.
Statistical analysis
In all datasets, radiographic scores were log-transformed (log(score+1)) to approximate a 
normal distribution. The residuals of the used models were normally distributed around the 
0-line in all cohorts, indicating a good fit of the models. In the cohorts in which multiple 
sets of radiographs were obtained over time (EAC, Umeå, and HCSC-RAC), a multivariate 
normal regression model for longitudinal data was used with radiographic scores as outcome 
1,25,26. This method takes advantage of the within-person correlation between repeated 
measurements; as such the radiographic progression rates were estimated more precisely in 
the cohorts with serial radiographs compared to datasets with one radiograph per patient (for 
a detailed description, see ref. 26). In the cohort in which a radiograph set was obtained at 
169HLA-DRB1 and joint damage       |
12
a single time point (NDB), the estimated yearly progression rate was calculated (total SHS/
disease duration in years at time of radiograph) to make the estimates of the progression rates 
comparable to those in the other datasets. Linear regression analysis was used with estimated 
yearly progression as outcome variable. In both models used, the effect sizes obtained were 
back-transformed and indicated the fold rate of joint destruction per year per risk amino acid 
compared to the reference.
In all datasets, adjustments were made for age and sex. In the cohorts that included 
patients in periods with different treatment strategies (EAC, Umeå, and HCSC-RAC), 
analyses were also adjusted for the inclusion period as proxies for differences in treatment 
strategies.
The individual datasets studied were estimated to be insufficiently powered to find 
statistically significant associations when performing conditional analyses. Therefore, the 
effect sizes and standard errors of the results from the individual cohorts were combined in 
inverse-weighted variance meta-analyses with fixed effects to test the overall association. This 
was allowed because the effect sizes obtained for the individual datasets, though different 
methods were used to score joint destruction (SHS and Larsen), all represented the relative 
increase (without units) of progression in joint destruction per year. The meta-analysis 
weights the results with a low standard error stronger than the results with a high standard 
error, preventing an overrepresentation of less precise data in the outcome. Subsequently, 
datasets with smaller 95% confidence intervals had a larger weight in the meta-analysis. 
Figure 1. Frequencies of HLA-DRB1 shared epitope (SE) alleles and the amino acids at HLA-DRB1 position 11, 
HLA-B position 9, and HLA-DPB1 position 9. Frequencies are expressed as the percentage of a total of 3,756 alleles/
amino acids. Of the 1,878 patients, 69.0% were positive for the HLA-DRB1 SE (at least 1 SE allele), 71.2% were 
positive for Val/Leu at HLA-DRB1 position 11 (at least 1 Val or Leu amino acid), 23.8% were positive for Asp at 
HLA-B position 9 (at least 1 Asp), and 93.0% were positive for Phe at HLA-DPB1 position 9 (at least 1 Phe).
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P-values less than 0.05 were considered significant. Statistical analysis was performed using 
SPSS version 20 and Stata 12.0.
RESULTS
Frequencies of variants
The allele frequencies of HLA-DRB1 SE and the amino acids at HLA-DRB1 position 11, 
HLA-B position 9, and HLA-DPB1 position 9 in the total population studied are presented in 
Figure 1. Of the 6 amino acids possible at HLA-DRB1 position 11, Val, Ser, and Leu were most 
prevalent in the total RA population (prevalence of 33.2%, 31.7%, and 14.0%, respectively). 
Within the ACPA-positive group of RA patients, Val was the most prevalent amino acid 
(41.6%), and within the ACPA-negative group, Ser was the most prevalent (43.7%). At HLA-B 
position 9, Tyr was the most prevalent and Asp the least prevalent amino acid (prevalence of 
62.4% and 12.6%, respectively). At HLA-DPB1 position 9, Phe was the most common amino 
acid with a prevalence of 74.4%. For HLA-B and HLA-DPB1, the frequencies of amino acids 
were similar for ACPA-positive and ACPA-negative RA.
HLA-DRB1 SE alleles
First, the association between the HLA-DRB1 SE alleles and radiographic progression was 
studied. As expected, the SE alleles were associated with more severe radiographic progression 
(p=6.41x10-7 in the fixed-effects meta-analysis of the 4 cohorts) (Figure 2). When SE and 
ACPA were analysed concomitantly, the significance of the SE alleles was lost (meta-analysis 
p=0.20) and ACPA was still significant (meta-analysis p=2.22x10-16). The association between 
the SE alleles and radiographic progression was thus not independent of ACPA, suggesting 
that ACPA play a role in the causal path of the SE alleles and radiographic progression.
HLA-DRB1 position 11
Patients with the risk amino acids Val and Leu had a higher rate of joint damage progression; 
this reached statistical significance in 3 individual cohorts (EAC p=4.94x10-5, Umeå p=0.032, 
and NDB p=0.013) and in the meta-analysis (p=5.11x10-7) (Figure 2). To illustrate, the raw 
radiographic data for RA patients included in the Leiden EAC are presented in Figure 3. 
In these patients, the presence of one Val or Leu amino acid was associated with a 1.033-
fold rate of joint destruction per year compared to patients without these amino acids; this 
equals a 26% (1.033 to the power 7) higher rate of joint destruction over 7 years. To further 
illustrate the effects, RA patients with 1 and 2 Val or Leu amino acids, respectively, had SHS 
scores that were 10 and 16.5 points higher than patients without any Val or Leu amino acids 
(Figure 3). Conditioning on SE status revealed an independent association of position 11 
with radiographic progression (meta-analysis p=0.022) (Figure 2). This indicates that Val or 
Leu on HLA-DRB1 position 11 was associated with radiographic progression independent of 
the HLA-DRB1 SE status.
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In order to determine whether the effect of Val and Leu at position 11 on radiographic 
progression was independent of the effect of ACPA on radiographic progression, analyses 
were also adjusted for ACPA status. Similar to the SE alleles, the effect of Val and Leu on 
radiographic progression was not independent of ACPA status (meta-analysis p=0.12).
We next studied amino acid Ser at HLA-DRB1 position 11 in more detail, since this 
variant was reported to protect against RA 10. Analysis showed that Ser was associated with 
Figure 2. Associations of amino acids at HLA-DRB1, HLA-B, and HLA-DPB1 that are known to predispose to RA 
development with radiographic progression in RA. The yearly radiographic progression rates per risk amino acid in 
each individual cohort are shown. P-values are from the fixed-effects meta-analyses evaluating the 4 cohorts, which 
consisted of a total of 1,878 patients and 4,911 sets of radiographs. Risk amino acids were defined according to the 
findings of Raychaudhuri et al 10. For the DRB1 shared epitope (SE), I2 22.9%, p=0.27, fixed-effects p=6.41x10-7, 
and random-effects p=2.01x10-4. For Val/Leu at DRB1 position 11, I2 23.0%, p=0.27, fixed-effects p=5.11x10-7, and 
random-effects p=2.19x10-4. For Val/Leu at DRB1 position 11 adjusted for SE status, I2 37.3%, p=0.19, fixed-effects 
p=0.022, and random-effects p=0.066. For Asp at B position 9, I2 0.0%, p=0.59, fixed-effects p=0.43, and random-
effects p=0.43. For Phe at DPB1 position 9, I2 0.0%, p=0.85, fixed-effects p=0.024, and random-effects p=0.024. For 
Phe at DPB1 position 9 adjusted for SE status, I2 0.0%, p=0.90, fixed-effects p=0.093, and random-effects p=0.093. 
ES=effect size.
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a lower rate of joint destruction (meta-analysis p=5.99x10-3) (Figure 4A). Because of the 
polymorphic nature of HLA-DRB1 and because predisposing as well as protective associations 
of variants encoded by the same position with radiographic progression were observed, we 
subsequently performed stratified analyses to distinguish between true-positive signals (i.e., 
a truly predisposing variant) and false-positive signals (i.e., seemingly predisposing but 
actually caused by the absence of protective variants). First, the association of Val and Leu 
was studied when comparing patient groups with S/S, S/N and N/N, thus excluding patients 
with the protective amino acid Ser. Carrying Val and Leu was still associated with more 
radiographic progression (meta-analysis p=0.010) (Figure 5A), and this association remained 
after additionally conditioning on SE status (meta-analysis p=0.012) (Figure 5B), indicating a 
truly predisposing association for Val and Leu with radiographic progression. Furthermore, 
when performing stratified analysis to evaluate the effect of Ser in patients not carrying the 
predisposing variants Val and Leu (thus comparing 3 groups of patients: P/P, P/N, and N/N) 
the protective effect of Ser was lost (meta-analysis p=0.48) (Figure 4B). This might suggest 
Figure 3. Radiographic progression in RA patients in the Leiden EAC cohort per number of risk alleles or amino 
acids at HLA-DRB1, HLA-B, and HLA-DPB1. The median raw and unmodeled Sharp-van der Heijde scores (SHS) 
during 7 years of follow-up of 594 RA patients are shown. The p-values obtained by multivariate normal regression 
analyses comparing the genotypes in relation to radiographic progression were p=5.33x10-5 for the DRB1 shared 
epitope (SE) alleles, p=4.94x10-5 for Val/Leu at DRB1 position 11, p=0.044 for Ser at DRB1 position 11, p=0.62 for 
Asp at B position 9, and p=0.036 for Phe at DPB1 position 9.
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that the protective effect of Ser observed in the total RA population was the consequence of 
the absence of the predisposing amino acids Val and Leu rather than a truly protective effect.
HLA-B position 9
Because risk factors for RA located outside the HLA-DRB1 region were also identified, we 
subsequently studied the association of 2 amino acids that are located elsewhere in the HLA 
region. First, the association between amino acid Asp at HLA-B position 9 and radiographic 
progression was assessed. No association was observed, neither in the individual cohorts nor 
in a meta-analysis (meta-analysis p=0.43). Also, no tendency for association was observed 
(Figure 2) (Figure 3 illustrates the raw radiographic data for HLA-B position 9 in the Dutch 
RA patients). 
HLA-DPB1 position 9
The other variant that is not located within the HLA-DRB1 region was HLA-DPB1. Amino 
acid Phe at position 9 in HLA-DPB1 was significantly associated with more severe radiographic 
progression (meta-analysis p=0.024) (Figure 2) (Figure 3 illustrates raw radiographic data 
for RA patients in the EAC). However, after conditioning on SE status, no significance was 
obtained (meta-analysis p=0.093) (Figure 2). Furthermore, when conditioning the effect of 
Figure 4. Association of Ser at HLA-DRB1 position 11 with radiographic progression of RA in the total population 
(A) and in the subgroup of patients who did not carry any predisposing Val or Leu amino acids (B). (A) Yearly 
radiographic progression rates per Ser amino acid at HLA-DRB1 in the total population. Data are shown for each 
individual cohort and for the fixed-effects meta-analyses evaluating the 4 cohorts, consisting of a total of 1,878 
patients and 4,911 sets of radiographs. I2 0.0%, p=0.40, fixed-effects p=5.99x10-3, and random-effects p=5.99x10-3. 
(B) Yearly radiographic progression rates per Ser amino acid at HLA-DRB1 in the patients who did not carry any 
predisposing Val or Leu amino acids. To determine whether the observed association of Ser with radiographic 
progression was truly protective and not due to the concomitant absence of the predisposing amino acids Val and 
Leu, analyses were performed within the subgroup of patients not carrying Val and Leu (thus, patients with 2 copies 
of Ser, patients with 1 Ser and 1 neutral amino acid, and patients with 2 neutral amino acids were compared). Data 
are shown for each individual cohort and for the fixed-effects meta-analyses evaluating the 4 cohorts, consisting of a 
total of 541 patients and 1,477 sets of radiographs. I2 9.5%, p=0.35, fixed-effects p=0.48, and random-effects p= 0.56.
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Predisposing variants within ACPA-negative RA
Recently, the amino acids Leu and Ser on HLA-DRB1 position 11 and Asp on B position 9 
were identified as risk factors for ACPA-negative RA 11. Associations between these amino 
acids and radiographic progression were also studied within the ACPA-negative subgroup, 
consisting of 657 patients with 1,877 radiograph sets. No significant results were obtained 
for Leu/Ser at HLA-DRB1 position 11 or Asp at HLA-B position 9 (meta-analysis p=0.18 
and p=0.28, respectively). Also, the directionality of the effects was diverse (Figure 6) (see 
Supplementary Figure 2).
DISCUSSION
This study was undertaken to investigate whether genetic variants at HLA-DRB1 position 
11, HLA-B position 9, and HLA-DPB1 position 9, which were recently identified as risk 
factors for RA, were also associated with radiographic progression in RA, and whether the 
associations were independent of HLA-DRB1 SE status and ACPA status. We observed 
Figure 5. Association of Val and Leu at HLA-DRB1 position 11 with radiographic progression in the subgroup of RA 
patients who did not carry any Ser at position 11 (A) and with additional adjustment for shared epitope (SE) status 
(B). (A) Yearly radiographic progression rates per Val or Leu amino acid at HLA-DRB1 position 11 in patients who 
did not carry any Ser at position 11. These analyses were performed to determine whether the observed association 
of Val and Leu with radiographic progression was truly predisposing and not due to the concomitant absence of Ser 
(thus, patients carrying 2 copies of Val or Leu, patients with 1 Val or Leu and 1 neutral amino acid, and patients with 
2 neutral amino acids were compared). Data are shown for each individual cohort and for the fixed-effects meta-
analyses evaluating a total of 781 patients and 1,747 sets of radiographs. I2 0.0%, p=0.92, fixed-effects p=0.010, and 
random-effects p=0.010. (B) Yearly radiographic progression rates per Val or Leu amino acid at HLA-DRB1 position 
11 in patients who did not carry any Ser at position 11, adjusted for SE status. I2 0.0%, p=0.90, fixed-effects p=0.012, 
and random-effects p=0.012.
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that RA patients carrying the amino acids Val or Leu at HLA-DRB1 position 11 had more 
severe radiographic progression. Despite linkage between the variants at position 11 and the 
HLA-DRB1 SE alleles, the effect of Val and Leu was independent of the known SE effect. In 
addition, similar to the SE alleles, the effect of Val and Leu at HLA-DRB1 position 11 was not 
independent of ACPA. Therefore, the findings of the present study validate the relevance of 
these amino acids at position 11 in HLA-DRB1.
Identifying which variants in the HLA region are associated with the development 
or course of RA provides the opportunity to increase the understanding of the mechanisms 
underlying the progression of RA. The recent observation that the genetic variants that are 
associated with risk of RA development and those that are associated with risk of a progressive 
course of RA are largely different suggests that the processes driving disease development and 
disease severity are to a large extent dissimilar 1. However, a few genetic variants are risk 
factors for both RA development and RA severity, highlighting the importance of the pathway 
indicated by these risk factors throughout the disease. One such risk factor is the presence 
of the SE alleles encoded by HLA-DRB1 positions 70-74, which act via ACPA on disease 
development and outcome. The findings of the present study demonstrate that Val and Leu at 
HLA-DRB1 position 11 are also associated with both the development and severity of RA as 
measured by radiographic progression.
The hope of the formulation of the SE hypothesis was that it would allow the 
Figure 6. Association of Leu and Ser at HLA-DRB1 position 11 and Asp (A) at HLA-B position 9 (B) with 
radiographic progression in ACPA-negative RA. Data are shown for each individual cohort and for the fixed-effects 
meta-analyses evaluating the 4 cohorts, consisting of a total of 657 patients and 1,877 sets of radiographs. Risk amino 
acids were defined according to the findings of Han et al 11. (A) Yearly radiographic progression rates per risk amino 
acid Leu or Ser at HLA–DRB1 position 11 in ACPA-negative patients. I2 60.8%, p=0.054, fixed-effects p=0.18, and 
random-effects p=0.59. (B) Yearly radiographic progression rates per risk amino acid Asp at HLA-B position 9 in 
ACPA-negative patients. I2 0.0%, p=0.56, fixed-effects p=0.28, random-effects p=0.28.
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identification of the autoantigens of RA 6. However, thus far, arthritogenic peptides have not 
been found. Mouse studies have revealed that small changes in amino acids located within the 
antigen-presenting binding site may have large influences on the antigens that are presented 
12,13. The amino acids at position 11 and position 13 are observed to be in very tight linkage 
disequilibrium 10; therefore, only the amino acids of position 11 were analysed. Future studies 
will reveal whether taking the amino acids at position 11 and 13 into account will be helpful 
in identifying the pathogenic antigens that result in immune activation and autoantibody 
production, thereby stimulating disease development or progression.
Investigation of the HLA region is challenging due to high linkage disequilibrium. 
This is illustrated by the fact that 91.8% of all patients evaluated in the present study that 
had 0, 1, or 2 SE alleles also had, respectively, 0, 1, or 2 Val/Leu amino acids at HLA-DRB1 
position 11, implying that the observation of an additive value of position 11 was actually 
based on a relatively small proportion of patients. In addition, the association between SE and 
radiographic progression is strong, providing another reason why large datasets are required 
to determine whether other HLA variants have additional effects that are independent of the 
SE effect. Thus far, to the best of our knowledge, no studies have been published providing 
replication of the results regarding RA susceptibility published by Raychaudhuri et al in 
completely independent datasets 10. Also in this respect, the findings of the present study, 
though evaluating a different outcome, support the relevance of position 11 on HLA-DRB1.
In addition to linkage and power issues, the polymorphic nature of the HLA-DRB1 
region in which the same position can encode for both predisposing and protective variants 
adds another level of complexity. To unravel these effects, adjusted multivariable analyses 
and stratified analyses can be done. The advantage of adjusting in multivariable analyses 
is that it is more powerful than subgroup analyses; however, this is at the cost of possible 
disturbing effects due to the assumptions underlying the model and eventual disturbances 
due to multicollinearity. In our view, in the present setting, stratified analyses yield the 
most conclusive results. We observed that Val and Leu at HLA-DRB1 position 11 were truly 
predisposing to more severe disease. In contrast, our data suggested that carrying the amino 
acid Ser at the same position was not protective. Although a protective effect was observed 
initially, in stratified analyses (excluding the effect of the absence of predisposing effects of Val 
and Leu), Ser was not significantly associated with less severe radiographic progression. These 
data might suggest that Ser does not have a protective effect on the severity of radiographic 
progression in RA. However, it is also possible that the present study was insufficiently 
powered to detect a protective effect of Ser in the subgroup of patients studied. We cannot 
discriminate between these two possible explanations, and further studies are needed to 
determine the association of Ser with the severity of radiographic progression.
Raychaudhuri et al also defined 16 haplotypes, based on positions 11, 71, and 74 
in HLA-DRB1 10. We did not perform haplotype analyses, since in our view stratification is 
needed to distinguish predisposing or protective haplotypes from the absence of protective 
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and predisposing haplotypes, respectively, and then subgroups became too small.
Within the field of RA susceptibility, it has been notable that Ser has been reported to 
be protective against ACPA-positive RA but predisposing to ACPA-negative RA 10,11. Because 
of this finding, we also evaluated the association of Ser with progression in the ACPA-
negative subgroup. The presence of Ser in these patients was not associated with the severity 
of radiographic progression.
We could not identify an association between Asp at HLA-B9 and radiographic 
progression. This position, which is highly correlated with HLA-B*08, is part of the conserved 
ancestral A1-B8-DRB1*03 (8.1) haplotype and has been associated with susceptibility to 
ACPA-negative disease 8,9. In contrast to the undisputed association of DRB1*03 or this 
haplotype with susceptibility to ACPA-negative RA, we did not detect an association with the 
severity of the disease in RA or in ACPA-negative RA.
The presence of Phe at HLA-DPB1 position 9 was associated with the severity of 
radiographic progression, but significance was lost (p=0.093) when conditioning for the 
HLA-DRB1 SE status. This might suggest that Phe at HLA-DPB1 is not associated with 
radiographic progression independent of the association between SE status and radiographic 
progression. Notably, the directionality of the effect of Phe at HLA-DPB1 was similar in all 
cohorts, with more severe progression in the patients carrying Phe. Although the linkage 
between this position with the HLA-DRB1 SE alleles is less than for HLA-DRB1 position 
11 with SE (in our study 32.7% of the patients who had 0, 1, or 2 SE alleles also had, 
respectively, 0, 1, or 2 Phe amino acids at HLA-DPB1 position 9), it is possible that our data 
were insufficiently powered to find an independent association of Phe with radiographic 
progression. The present data do not allow making definite conclusions regarding HLA-
DPB1 and radiographic progression; though if an effect is present, this effect seems to act in 
the path of ACPA, similar to HLA-DRB1.
In order to get some indication of the variance in joint destruction explained by 
the genetic factors studied, the interindividual variance in joint destruction in the Leiden 
RA patients at year 7 was evaluated. The SE alleles explained 4.2% of the variance in joint 
destruction and the combination of SE alleles, HLA-DRB1 position 11, HLA-DPB1 position 
9, and HLA-B position 9 explained 4.5%. This is lower than the variance in the risk of ACPA-
positive RA explained by a combination of HLA-DRB1 positions 71, 74, and 11, HLA-DPB1 
position 9, and HLA-B position 9, which was reported to be 12.7%10.
To conclude, Val and Leu at position 11 in the HLA-DRB1 locus were recently 
identified as additional susceptibility factors for ACPA-positive RA. We observed that these 
amino acids were also associated with a more severe disease course, an effect that was not 
independent of ACPA status. Further 3-dimensional modeling studies or binding assays, such 
as described previously by Scally et al 27 are needed to determine whether the present findings 
result in novel insights in the consequences of the HLA-DRB1 motif on antigen presentation 
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and its function as an immune response gene.
SUPPLEMENTARY DATA
Supplementary data are published on the web site of Arthritis & Rheumatology.
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Although rheumatoid arthritis (RA) is generally a chronic disease, a proportion of RA 
patients achieve disease-modifying antirheumatic drug (DMARD)-free sustained remission, 
reflecting loss of disease-persistence. To explore mechanisms underlying RA persistence, we 
performed a candidate gene study. We hypothesised that variants associating with lack of 
radiographic progression also associate with DMARD-free sustained remission.
Methods 
645 Dutch RA patients were studied on DMARD-free sustained remission during a maximal 
follow-up duration of 10 years. Variants associated with radiographic progression under an 
additive model in the total RA population (Human Leukocyte Antigens (HLA)-DRB1-shared 
epitope (SE), Dickkopf-1 (DKK1)-rs1896368, DKK1-rs1896367, DKK1-rs1528873, C5Orf30-
rs26232, Interleukin-2 receptor-α (IL2RA)-rs2104286, Matrix metalloproteinase-9 (MMP-9)-
rs11908352, rs451066 and Osteoprotegerin (OPG)-rs1485305) were studied. Cox-regression 
analyses were performed and Bonferroni correction applied. Soluble IL2Rα (sIL2Rα)levels 
were studied. For replication, 622 RA patients included in the French Evaluation et Suivi 
de POlyarthrites Indifférenciées Récentes cohort (ESPOIR) cohort were investigated. Results 
were combined in inverse-variance weighted meta-analysis.
Results
Similar as previously reported, the SE-alleles associated with less remission (hazard ratio 
(HR)=0.57, 95% confidence interval (95% CI)= 0.42-0.77, p=2.72x10−4). Variants in DKK-
1, C5Orf30, MMP-9 and OPG were not associated with remission. The IL2RA rs2104286 
minor allele associated with a higher chance on remission (HR=1.52, 95% CI=1.16-1.99, 
p=2.44x10−3). The rs2104286 minor allele associated with lower sIL2Rα levels (p=1.44x10−3); 
lower sIL2Rα levels associated with a higher chance on remission (HR per 100 pg/L=0.81, 
95% CI=0.68-0.95, p=0.012). When including rs2104286 and sIL2Rα levels in one analysis, 
the HR for rs2104286 was 2.27 (95% CI=1.06-4.84, p=0.034) and for sIL2Rα 0.83 (95% 
CI=0.70-0.98, p=0.026). Within ESPOIR, the HR of rs2104286 was 1.31 (95% CI=0.90-1.90). 
The meta-analysis revealed a p-value of 1.01×10−3. 
Conclusion
 IL2RA rs2104286 and sIL2Rα level associated with RA persistence. IL2RA variants are known 
to protect against multiple sclerosis, diabetes mellitus and RA. Besides HLA-SE, IL2RA 
rs2104286 is thus far the only known genetic variant associated with both joint destruction 
and RA persistence. This underlines the relevance of IL2RA for RA.
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Introduction
Persistent inflammation and progression of joint damage are the two hallmarks of rheumatoid 
arthritis (RA). At present, clinically relevant joint destruction has become infrequent owing 
to modern treatment strategies. Despite this improvement, RA is still a chronic disease in 
the majority of patients. Some patients, however, are able to stop taking disease-modifying 
antirheumatic drugs (DMARDs) without restart of DMARD treatment and without 
recurrence of arthritis; this is called DMARD-free sustained remission. This disease remission 
reflects the opposite of RA persistence and frequencies of DMARD-free sustained remission 
are reported to vary between 5 and 22 % 1–5. A thorough comprehension of the mechanisms 
promoting disease persistence is required to derive targeted interventions aiming to reduce 
the chronic nature of RA. At present, however, the biologic mechanisms underlying disease 
persistence are largely unknown.
Only a few risk factors for RA persistence (absence of achieving DMARD-free 
sustained remission) have been reported and replicated. One of these factors is prolonged 
symptom duration at treatment start 1,4,6,7. This risk factor points to a so-called “window of 
opportunity” in RA but the processes underlying this association are unidentified. Another 
risk factor is the presence of RA-related autoantibodies 1,2. Although it is not exactly known 
how these autoantibodies exert their effect, several possibilities have been proposed 8. 
However, the presence of rheumatoid factor (RF) or anti-citrullinated peptide antibodies 
(ACPA) explain only a proportion of the variance in achieving DMARD-free remission as 
the large majority of autoantibody negative RA patients have persistent disease and some 
patients with autoantibodies can achieve remission 9. One genetic risk factor has been 
found associated with arthritis persistence in two European cohorts: the presence of human 
leukocyte antigen (HLA)-DRB1 shared epitope (SE) alleles. This risk factor presumably acts 
in the same pathway as ACPA 1,2.
To increase the understanding of processes underlying disease persistence, it is 
valuable to study patients who have achieved DMARD-free sustained remission over time, 
because this reflects loss of disease persistence. This study aimed to identify further risk 
factors for achieving DMARD-free sustained remission. To this end, a candidate gene study 
was performed. To select genetic candidates, we hypothesised that genetic variants which 
are associated with a lack of radiographic joint damage also associate with DMARD-free 
sustained remission. Nine variants reported to associate with radiographic progression 
using an additive model in the total RA population were studied in relation to DMARD-
free sustained remission in an observational cohort of 645 Dutch RA patients with a 
maximal follow-up of 10 years. Significant associations were evaluated for replication in a 
second cohort, comprising 622 French RA patients. One of the nine studied variants was the 
already known risk factor HLA-DRB1 SE 1; this variant was included in the present study 
for a complete overview. Another interesting gene is interleukin-2 receptor alpha (IL2RA); 
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variants in IL2RA have shown to be associated with a decreased risk for development of RA 
10,11 and for the development of other autoimmune diseases such as multiple sclerosis (MS) 
12 and diabetes mellitus (DM) 13,14. Furthermore, rs2104286 in IL2RA is, apart from the HLA 
SE, the only genetic factor that associates with the risk of RA development 10 and with the 
severity of radiographic progression within RA 15.
METHODS
Patients
RA patients fulfilling the 1987 American College of Rheumatology (ACR) criteria for RA and 
included in two European cohorts were studied. All patients gave their informed consent, 
and approval was obtained from the local medical ethics committees.
Leiden Early Arthritis Clinic cohort - A total of 645 RA patients who were included 
between 1993 and 2008 were studied. The Leiden Early Arthritis Clinic (EAC) is a Dutch 
population-based inception cohort that started in 1993 and has been described previously 
2. Consecutively referred patients were included when arthritis was present at physical 
examination and symptom duration was <2 years. The initial treatment strategy was different 
for patients included and diagnosed during different inclusion periods: patients included 
in 1993-1995 were initially treated with nonsteroidal anti-inflammatory drugs (NSAIDs) 
and then DMARDs were initiated with delay; patients included in 1996-1998 were treated 
early with rather mild DMARDs such as hydroxychloroquine or sulfasalazine; and patients 
included in 1999-2008 were treated promptly with methotrexate 2.
Evaluation et Suivi de POlyarthrites Indifférenciées Récentes cohort - Evaluation et 
Suivi de POlyarthrites Indifférenciées Récentes (ESPOIR) is a prospective cohort study that 
started in 2002, including patients with RA or a suspicion to develop RA from 14 French 
rheumatology centers. Patient can be included if aged 18-70 years and at least two swollen 
joints are present for >6 weeks and <6 months 16. In total, 622 RA patients consecutively 
included between 2002 and 2005 were studied.
In both cohorts at baseline and at the yearly follow-up visits, questionnaires were 
completed, physical examination was performed, and serum samples and radio-graphs were 
taken 2,16.
Outcome
DMARD-free sustained remission was defined as the sustained absence of arthritis (by 
physical examination) after discontinuation of DMARD therapy, including biologics and 
glucocorticoids (systemic and intra-articular). In the Leiden EAC cohort, arthritis had to be 
absent for the entire follow-up period and at least during 1 year. For patients with a follow-
up longer than 10 years, the follow-up duration studied was restricted to 10 years. Medical 
files of all patients were studied on remission, and this was determined until 5 April 2012. 
185IL2RA and persistence of RA       |
13
Patients who achieved DMARD-free sustained remission initially but relapsed later over time 
(n=2) did not fulfill the criterion that arthritis should remain absent during the total follow-
up period and were included in the non-remission group. In the ESPOIR cohort, the follow-
up was shorter and restricted to 5 years. To be classified as having DMARD-free sustained 
remission, arthritis had to be absent during at least 1 year after cessation of DMARDs but 
not necessarily during the rest of the follow-up. Here the outcome was assessed reviewing the 
structured visits in the database; medical files were not explored.
Single nucleotide polymorphism selection and genotyping
Single Nucleotide Polymorphisms (SNPs) selection for the present study was based on a 
recently performed literature review on genetic variants in relation to radiographic progression 
17 and the following criteria were used: (1) the SNP has been reported and replicated or found 
significant in meta-analysis of several cohorts to associate with radiographic joint damage 
progression. Furthermore, the observed association with radiographic progression was done 
(2) using an additive model and (3) in the total RA population and not confined to either the 
ACPA-positive or ACPA-negative subgroup. The latter two criteria were included because it 
was expected that performing analyses on DMARD-free sustained remission using a recessive 
model (in which the group of patients with two minor alleles is in general small) or in only a 
subgroup of patients with or without autoantibodies would have insufficient power to reach 
statistical significance. This expectation was substantiated by power analyses (calculated 
using PASS 11; NCSS, Kaysville, UT, USA) based on our cohort (645 RA patients and 332 
ACPA-positive patients). These analyses revealed that for an 80 % power study for an additive 
association in the total RA population, a hazard ratio (HR) of 1.5 would be required, but for 
an 80 % power study for a recessive association in the total RA population or for an additive 
association in only the ACPA-positive subgroup, HRs would be required of respectively 2.5 
and 3.1 which are too high to be expected of SNP effects because SNPs generally have low 
effect sizes 11.
Based on the criteria, nine genetic variants were selected for evaluation in the Leiden 
EAC cohort: SE in HLA-DRB1 18, rs1896368, rs1896367, and rs1528873 in Dickkopf-1 (DKK-
1) 19, rs2104286 in IL2RA 15, rs26232 in C5Orf30 20, rs11908352 in matrix metalloproteinase-9 
(MMP-9) 21, rs451066 at chromosome 14 21, and rs1485305 in osteoprotegerin (OPG) 22. Newly 
identified SNPs that were significantly associated with DMARD-free sustained remission in 
the Leiden EAC cohort were selected for evaluation in the ESPOIR cohort.
Within the Leiden EAC cohort, the HLA-DRB1 alleles were genotyped using two-
digit typing which was complemented by four-digit typing of the DRB1*04 alleles and by 
specific probes to detect the presence of the SE sequences in individuals carrying DRB1*01 or 
DRB1*10 alleles 1. The following alleles were classified as SE alleles: DRB1*0101, DRB1*0102, 
DRB1*0104, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0408, DRB1*0413, DRB1*0416, 
DRB1*1001, and DRB1*1402 23. Genotyping data on rs1896368, rs1896367, and rs1528873 in 
186 |       Chapter 13
13
DKK-1 and on rs1485305 in OPG were retrieved using Illumina’s Golden Gate platform with 
an overall error rate <2.5 % and success rates >95% 19,22. rs26232 in C5Orf30 was genotyped 
using LightSnp (Roche) with an overall error rate <1% and success rates >99% 20. Genotyping 
data on rs2104286 in IL2RA, rs11908352 in MMP-9, and rs451066 at chromosome 14 were 
retrieved using Illumina’s Immunochip with an overall error rate <1 % and success rates 
>98%. Hardy-Weinberg equilibrium for all SNPs was p >0.001 15,21.
Within the ESPOIR cohort, rs2104286 was genotyped used allele-specific kinetic 
polymerase chain reaction ana-lysis by KBiosciences (UK) using the KASPar method. The 
success rate was 97.9 % as described previously 24.
Soluble IL2Rα
In 159 Dutch RA patients, soluble interleukin-2 receptor alpha (sIL2Rα) levels were evaluated 
using the standard sandwich enzyme-linked immunosorbent assay (ELISA) for sIL2Rα. The 
ELISA was performed according to the manufacturer’s recommendations (BD Biosciences). 
The serum levels were determined for a previous study on IL2RA 15. Samples were collected at 
a median disease duration of 4 years (range 1-9 years). For patients who achieved remission, 
the sIL2Rα level was determined in samples taken before remission was achieved.
Statistical analysis
Cox proportional hazard regression analyses were carried out with DMARD-free sustained 
remission as the outcome. The date of remission was defined as 1 year after the date at which 
DMARDs were withdrawn owing to remission of disease. Time to remission was the time 
from date of inclusion to the date of remission. Patients who did not achieve remission were 
censored at the date when all medical files were studied on the achievement of DMARD-free 
sustained remission (5 April 2012). Analyses were adjusted for age, gender, and inclusion 
period (a proxy for the differences over time in applied treatment strategies), similar to 
previous reports 2,3,19. Genotypes were tested additively. The association of sIL2Rα levels 
(continuous variable) was tested similarly with an additional adjustment for disease duration 
at the time of sample collection. For the genetic variants, the cut-off for statistical significance 
was set at p<5.56x10−3 (0.05/9 tests) using the Bonferroni correction for multiple testing. For 
the test on the serum level, p<0.05 was considered significant. In the ESPOIR cohort, a similar 
Cox proportional hazard regression analysis adjusted for age and gender was performed. 
ESPOIR RA patients were diagnosed in a relatively short interval and no adjustments were 
made for initial treatment strategies. Results of the two cohorts were combined in an inverse-
variance weighted meta-analysis. Analyses were performed using IBM SPSS version 20 
(Armonk, NY, USA) and STATA version 12 (College Station, TX, USA).
RESULTS
Patients
The baseline characteristics of the 645 studied RA patients in the Leiden EAC cohort are 
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presented in Table 1. During the median follow-up duration of 8.6 years (interquartile 
range (IQR) 5.5-10.0 years), 119 patients achieved DMARD-free sustained remission. The 
incidence rate for achieving remission was 2.4 per 100 person-years (119 events during the 
total follow-up of all patients of 4,885 years). The patients who achieved remission did so after 
a median disease duration of 4.3 years (IQR 2.9-6.1 years). Patients who achieved DMARD-
free sustained remission had shorter symptom duration at disease onset (median 12.9 versus 
20.3 weeks, p<0.001) and had less frequent autoantibodies (ACPA-positivity, 13.0 % versus 
61.3 %, p<0.001; RF-positivity, 27.1 % versus 64.7 %, p<0.001) compared with patients who 
did not achieve remission (Table 1).
Genetic variants and achieving DMARD-free sustained remission
Presence of the SE alleles was significantly associated with DMARD-free sustained remission 
(p=2.72×10−4). The HR per SE allele on achieving DMARD-free sustained remission was 0.57 
(95% confidence interval (95% CI)=0.42-0.77) compared with patients without SE alleles 
(Table 2; Additional file 1); this finding is in line with previous reports. 
Rs1896368, rs1896367, and rs1528873 (all DKK-1), rs26232 (C5Orf30), rs11908352 
(MMP-9), rs451066 (chromosome 14), and rs1485305 (OPG) were not associated with 
Table 1. Patient characteristics of the Leiden EAC






not achieved during 
follow-up (n=526)
Baseline
  Age (years), mean (SD) 56.9 (15.6) 58.8 (16.9) 56.5 (15.3)
  Female, n (%) 430 (66.7) 74 (62.2) 356 (67.7)
  Symptom duration (weeks), median (IQR) 18.8 (10.3-37.3) 12.9 (7.3-28.6) 20.3 (11.4-40.0)
  66 Swollen joint count, median (IQR) 8 (4-13) 9 (4-15) 8 (4-13)
  CRP level in mg/L, median (IQR) 18 (8-42) 18 (8-43) 18 (7-37)
  ACPA-positive, n (%) 332 (52.5) 15 (13.0) 317 (61.3)
  RF-positive, n (%) 371 (57.8) 32 (27.1) 339 (64.7)
Follow-up
  Duration until DMARD-free sustained 4.3 (2.9-6.1) N/A
  remission in years, median (IQR)
Data was missing on swollen joint count in 7 patients, on CRP level in 29 patients, on ACPA in 13 patients, on RF in 
3 patients and on symptom duration in 47 patients.
The median symptom duration and the frequencies of ACPA-positivity and RF-positivity were significantly different 
between patients that achieved and not achieved DMARD-free sustained remission during follow-up (all p<0.001). 
The other baseline characteristics did not differ between the groups.
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Genetic variants and achieving DMARD-free sustained remission in relation to ACPA 
status
Because genetic risk factors for ACPA-positive and ACPA-negative RA are different and 
ACPA-positive and ACPA-negative RA are considered separate disease entities, we studied 
whether the observed associations were independent of ACPA or were restricted to a subset of 
RA patients. The analyses of HLA-DRB1 SE and rs2104286 (IL2RA) were therefore repeated 
with additional adjustment for ACPA and when stratifying for ACPA status.
When including both SE and ACPA in one analysis, SE was not significantly 
associated (HR=0.92, 95% CI=0.67-1.26, p=0.61) whilst ACPA remained significant 
(HR=0.13, 95% CI=0.072-0.22, p=7.68x10-13), suggesting that ACPA act in the path of the 
SE alleles and DMARD-free sustained remission. Similarly, the SE alleles were not associated 
with remission in the ACPA-positive and ACPA-negative subgroups separately (p=0.84 and 
p=0.51 respectively; Figure S2A in Additional file 2).
Adding ACPA as additional adjustment factor in the analysis of rs2104286 (IL2RA) 
in relation to DMARD-free sustained remission revealed an HR for rs2104286 of 1.47 (95% 
CI=1.12-1.93, p=5.78x10−3), suggesting that the association of rs2104286 with remission is 
independent of ACPA. Stratified analysis on rs2104286 in ACPA-positive and ACPA-negative 
subgroups showed an HR of 1.82 (95% CI=0.88-3.77, p=0.11) within ACPA-positive RA 
and an HR of 1.41 (95% CI=1.05-1.89, p=0.024) within ACPA-negative RA (Figure S2B in 
Table 2. Genetic risk factors for severity of joint damage in relation to achieving DMARD-free sustained remission 





MAF HR per minor allele 
(95% CI)
p-value
Shared Epitope 18 HLA-DRB1 (6) 39.6% 0.57 (0.42-0.77) 2.72x10-4
rs1896368 (G) 19 DKK-1 (10) 45.8% 0.98 (0.75-1.28) 0.88
rs1896367 (A) 19 41.5% 0.96 (0.73-1.25) 0.75
rs1528873 (C) 19 46.7% 1.21 (0.93-1.58) 0.15
rs2104286 (C) 15 IL2RA (10) 24.3% 1.52 (1.16-1.99) 2.44x10-3
rs26232 (T) 20 C5orf30 (5) 28.9% 1.08 (0.81-1.44) 0.61
rs11908352 (A) 21 MMP-9 (20) 20.9% 0.78 (0.56-1.09) 0.15
rs451066 (A) 21 rs1465788 (14) 19.6% 0.87 (0.63-1.21) 0.41
rs1485305 (T) 22 OPG (8) 44.2% 1.00 (0.76-1.32) 0.98
Analyses were adjusted for age, gender and inclusion period (as proxy for treatment strategy).
DMARD-free sustained remission (Table 2). Rs2104286 in IL2RA significantly associated 
with achieving DMARD-free sustained remission (p=2.44x10−3). The HR per minor C allele 
for achieving DMARD-free sustained remission was 1.52 (95% CI=1.16-1.99) compared with 
the reference genotype of patients who were homozygous for the major T allele (Table 2 and 
Fig. 1); hence patients with the minor allele had an increased chance of achieving remission 
and, as reported earlier 15, less radiographic progression.
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Additional file 2).
sIL2Rα levels and achieving DMARD-free sustained remission
Previous studies have shown correlations between rs2104286 in IL2RA and IL2Rα serum 
levels 25,26. Similarly, we have previously studied rs2104286 in IL2RA and sIL2Rα levels in 
Figure 1. Rs2104286 in IL2RA in relation to achieving DMARD-free sustained remission in RA patients of the 
Leiden EAC cohort. Rs2104286 in IL2RA was significantly associated with achieving DMARD-free sustained 
remission in 645 RA patients (p=2.44x10−3). The HR per minor C allele for achieving remission was 1.52 (95% 
CI=1.16-1.99). The analysis was adjusted for age, gender, and inclusion period (as a proxy for treatment strategy).
Figure 2. Rs2104286 in IL2RA in relation to achieving DMARD-free sustained remission in RA patients of the 
ESPOIR cohort and in meta-analysis of the Leiden EAC and ESPOIR cohorts. (A) In 622 RA patients of the ESPOIR 
cohort, the HR per minor C allele for achieving remission was 1.31 (95% CI=0.90-1.90, p=0.16). The analysis was 
adjusted for age and gender. The minor allele frequency in the ESPOIR cohort was 23.2%. (B) Results of the Leiden 
EAC and ESPOIR cohorts were combined in an inverse-variance weighted meta-analysis: I2=0.0%, p=0.53, fixed-
effect p=1.01x10−3, random-effects p=1.01x10−3.
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159 RA patients from the Leiden EAC cohort and observed a significant association; the 
rs2104286 minor allele associated with lower sIL2Rα levels (p=1.44x10−3) 15. We then explored 
whether sIL2Rα levels were also associated with DMARD-free sustained remission and 
observed that lower serum levels were indeed associated with more remission (p=0.012); per 
100 pg/ml increase in level, the HR of achieving remission was 0.81 (95% CI=0.68-0.95). In 
the 159 patients with information on sIL2Rα, rs2104286 was also associated with DMARD-
free sustained remission (HR=2.57, 95% CI=1.20-5.50, p=0.015). An analysis including both 
rs2104286 and sIL2Rα revealed an HR of 2.27 for rs2104286 (95% CI=1.06-4.84, p=0.034) 
and a HR (per 100 pg/ml) of 0.83 for sIL2Rα (95% CI=0.70-0.98, p=0.026).
Replication of rs2104286 in relation to DMARD-free sustained remission in the ESPOIR 
cohort
Subsequently, rs2104286 in IL2RA was studied for replication in 622 French RA patients. 
The mean (standard deviation) age was 48.8 (12.3) years, 76% were female, the median 
(IQR) symptom duration was 22 (13-33) weeks, and 46% were ACPA-positive. After a 
median (IQR) follow-up duration of 5.0 (3.0-5.0) years, 67 patients achieved DMARD-free 
sustained remission after a median follow-up duration of 1.5 (0.7-3.0) years. The incidence 
rate for remission was 2.7 per 100 person-years (67 events/2451 years of total follow-up in 
all patients). The number of events (n=67) was lower than that of the first cohort, so the 
power to find significance was expected to be less than that of the first phase. Evidence of a 
tendency in the same direction was still considered relevant and Cox regression analyses on 
rs2104286 and remission were performed. The HR per minor C allele for achieving DMARD-
free sustained remission was 1.31 (95% CI=0.90-1.90, p=0.16) compared with the common 
genotype. Although not reaching statistical significance, this indicates that, similar to the 
Leiden EAC cohort, patients with the minor allele had an increased chance of achieving 
remission (Fig. 2A). When additionally adjusting the analysis for ACPA, the HR was 1.37 
(95% CI=0.95-1.97, p=0.097). Meta-analysis of the results of the Leiden EAC and ESPOIR 
cohorts revealed a fixed-effect p value of 1.01x10−3 (Fig. 2b).
DISCUSSION
The biological mechanisms driving disease chronicity in RA are largely unidentified. We 
therefore aimed to determine genetic risk factors for disease persistence in RA. Because of 
the low frequency of DMARD-free sustained remission (reflecting loss of disease persistence) 
and because of the lack of multiple large cohorts with data on this disease outcome, we were 
not able to perform a hypothesis-free genome-wide association study or to analyze the whole 
Immunochip. We used a candidate gene approach instead and hypothesised that genetic 
variants which associated with the severity of joint damage also associated with disease 
persistence. In addition to the previously reported association between the HLA-DRB1 SE 
alleles and DMARD-free sustained remission (reflecting loss of disease persistence), we 
demonstrated that rs2104286 in IL2RA associated with DMARD-free sustained remission; 
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this minor allele that was previously associated with less severe radiographic progression 15 
was associated with a higher chance of DMARD-free sustained remission. Also, the lower 
level of sIL2Rα observed in the presence of the rs2104286 minor allele associated with a 
higher chance of DMARD-fee sustained remission. Altogether the present data from two 
observational cohorts indicate that the IL2RA minor allele is not only protective for the 
severity of radiographic progression but also predisposes to a less persistent course of RA.
IL2RA encodes the α-chain of the high-affinity IL-2 receptor (CD25) which is 
expressed on and upregulated after stimulation in many immune cells, including regulatory 
T-cells (Tregs) 27,28. Variants in IL2RA are also associated with the risk of development of RA 
10,11 and other autoimmune diseases such as MS 12 and type 1 DM 13,14. sIL2Rα is produced 
by proteolytic cleavage of cell-bound IL2Rα and is considered reflective of the extent of 
activation and expansion of T-cells 26,29,30. Other studies reported that the minor allele of 
rs2104286 correlated with lower sIL2Rα levels in patients and healthy individuals 15,25,26. In 
our previous study, rs2104286 was no longer associated with joint destruction after including 
sIL2Rα in the analysis, suggesting that the SNP might act in the same path that influenced the 
serum levels 15. In present study, the genetic and serological marker remained significantly 
associated with DMARD-free sustained remission. This might suggest that IL2RA exerts part 
of its effect by a path which does not influence sIL2Rα levels. However, association studies 
cannot answer causality questions.
RA is considered to consist of ACPA-positive and ACPA-negative subentities, each 
with different genetic risk variants 31,32. To determine whether the observed association was 
present in one or both subsets, stratified analyses were performed. Although these analyses 
were assumed to have insufficient power (owing to lower number of patients, and in ACPA-
positive RA also a low frequency of remission), they were performed to gain insight into the 
data. Adjusting for ACPA is more powerful. The association of rs2104286 with DMARD-free 
sustained remission was independent of ACPA.
In the present study we did not fine-map the IL2RA region in relation to DMARD-
free sustained remission because we expected to have insufficient power to find statistical 
significance after correcting for >400 tests. Previously the IL2RA region was fine-mapped 
in relation to joint damage progression, which is a more powerful analysis than the present 
survival analysis because it makes use of repeated measurements over time. rrs12722508 was 
identified as the SNP with the strongest association 15. Evaluating rs12722508 in relation to 
DMARD-free sustained remission revealed a lower p-value and larger HR for rs12722508 
(HR=1.93, p=7.90x10−4) compared with rs2104286 (HR=1.52, p=2.44x10−3). Although fine-
mapping was not performed in this study, these data strengthen the finding on IL2RA and 
DMARD-free sustained remission.
At present, there is not much literature on the description of RA persistence or 
chronicity. In the present study, patients who were unable to reach DMARD-free sustained 
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remission were considered to have persistent disease. Although other definitions for RA 
persistence can be used, we have chosen the absence of DMARD-free sustained remission 
as the outcome because it is a strict definition and the closest available proxy for cure of the 
disease.
The majority of the studied patients had persistent disease and did not achieve 
remission. Recently, we reported that the chance of achieving DMARD-free sustained 
remission in clinical practice has become a more feasible outcome with up-to-date treatment 
strategies 5. The Leiden EAC patients who were evaluated in the present study were included 
during the period 1993-2006. Treatment strategies have changed over time in these patients 
and indeed patients included in later periods had a higher chance of achieving DMARD-free 
sustained remission (data not shown). All analyses in the present study were adjusted for 
the inclusion period as a proxy for the initially applied treatment strategy, and the results 
obtained for IL2RA were thus independent of the effect of changes in treatment strategies.
Another potential limitation is that we evaluated data from longitudinal observational 
cohort studies. These data reflect the daily care of patients and not only decisions to start 
DMARDs but also decisions to stop DMARDs were left to the patients’ and rheumatologists’ 
decisions and not protocolised. In the ESPOIR cohort, mainly in the first years of its 
existence, quitting DMARD-therapy was uncommon. Consequently, the observed frequency 
of DMARD-free sustained remission may be underestimated. This may be one of the 
explanations contributing to a lower incidence of DMARD-free sustained remission in the 
ESPOIR cohort. In addition, whether DMARD-free sustained remission was achieved was 
determined slightly differently in the cohorts. In the Leiden EAC cohort, all medical files 
were checked to en-sure that DMARD-free sustained remission was present. In the ESPOIR 
cohort, data from the structured visits with yearly intervals were studied. It is possible that 
more patients included in the ESPOIR cohort would have achieved DMARD-free sustained 
remission when all information present in medical files was evaluated. Thirdly, the follow-up 
duration was shorter in the ESPOIR cohort. Differences in common practice for discontinuing 
DMARD-therapy, however, might be the most important cause for the higher frequency of 
DMARD-free sustained remission in the Leiden EAC cohort than in the ESPOIR cohort. 
Nonetheless, there was a strong tendency in the data from the ESPOIR cohort validating the 
importance of IL2RA for the disease course in RA.
The SE alleles were strongly associated with sustained DMARD-free remission. 
A similar result was previously reported (although using a dominant model instead of an 
additive model). We here observed that this association was not independent of ACPA, 
suggesting that the SE alleles act in the same path as ACPA. This finding is similar to that 
observed for SE, ACPA, and radiographic progression 33.
The studied variants in DKK-1, C5Orf30, MMP-9, and OPG were not associated 
with DMARD-free sustained remission. Although power issues might have contributed to 
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some negative findings, the absence of an association of these risk factors for radiographic 
progression with DMARD-free sustained remission suggests that the mechanisms driving 
joint damage progression and disease persistence are partially different.
At present >100 genetic susceptibility factors are known and several genetic risk 
factors for radiographic progression have been identified 11,34. These factors were largely 
dissimilar; only the HLA-DRB1 SE alleles and IL2RA were present in both lists of risk 
factors. Interestingly, the current study determined that both factors are also associated with 
persistence of RA. This suggests that both variants are of crucial importance for the processes 
mediating RA development and progression.
IL-2/IL-2 receptor signaling is important during immune responses of both effector 
T-cells and Tregs. Quantitatively, Tregs require less IL-2/IL-2 receptor signaling than 
effector T-cells to support their development and function 35,36. Recently, the first results on 
immunomodulation with low-dose IL-2 in other autoimmune diseases have been published, 
showing efficacy on upregulation of Tregs 35,36 and improved clinical outcome 37. Monoclonal 
anti-CD25 antibodies (daclizumab) have also been shown effective in reducing disease 
activity in autoimmune diseases 38; this effect is not only ascribed to direct effects on T-cells 
but also on natural killer (NK) cells and dendritic cells 38. To the best of our knowledge there 
are no data on IL-2 treatment for RA. However, if low-dose IL-2 treatment is effective, the 
results of IL-2 therapy in RA might also be dependent on the IL-2 receptor status of the 
patient, which is genetically determined. Hence, the IL2RA genotype presumably affects the 
response of IL-2 therapy and might be relevant for personalised medicine.
Conclusion
Genetic studies are useful because they can point to mechanisms that are pivotal for disease 
development or disease progression. This study observed that rs2104286 in IL2RA and the 
sIL2Rα level are associated with RA persistence. Besides the HLA-DRB1 SE, IL2RA is the 
only genetic risk factor for development of RA and for both radiographic progression and 
persistence. This underlines the relevance of IL2RA for RA. Further research is needed to 
gain more insight into the underlying mechanisms of arthritis persistence.
SUPPLEMENTARY DATA
Supplementary data are published on the website of Arthritis, Research & Therapy.
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Sir, currently the treatment of Rheumatoid arthritis (RA) is aimed at achieving low disease 
activity score (DAS) remission. The ultimate aim, however, is to achieve disease-modifying 
antirheumatic drug (DMARD)-free sustained remission, which reflects the persistent absence 
of arthritis after cessation of treatment and is the closest proxy available for cure of RA. 
Although at present DMARD-free sustained remission can only be achieved in a minority of 
RA patients, recent data revealed that this outcome has become increasingly achievable due 
to improved treatment strategies 1. The processes underlying resolution of disease persistence 
are unknown. An understanding of these processes might give clues for intervention targeted 
at disease resolutions. Furthermore, except for ACPA or RF, biomarkers for disease persistence 
are unknown. A recent study by Audo et al 2 prompted us to investigate the association 
between serum osteoprotegerin (OPG) levels and DAS remission as well as DMARD-free 
sustained remission. This study showed, using data of one cohort, that a low ratio of OPG to 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was associated with DAS28 
remission (DAS <2.6) after 1 year and that this association was completely explained by the 
OPG level. OPG is a member of the tumor necrosis factor (TNF) superfamily molecules. 
Besides its well-known role in bone metabolism, OPG has pro-inflammatory effects that likely 
act via the nuclear factor (NF)-kB pathway. As such, OPG has been implicated as a disease 
activity marker for inflammatory bowel disease 3. The present study has two aims: first, we 
sought for replication of the association of OPG levels with DAS remission, as replication of 
findings in independent cohorts is pivotal; and second, because OPG may associate with the 
severity of inflammation in the short-term, we explored the association of OPG levels with 
achieving DMARD-free sustained remission as long-term treatment outcome. 
We studied 158 RA patients (1987 ACR criteria) included in the Leiden Early 
Arthritis Clinic cohort 4 between 1993 and 2005 (67% female, mean (SD) age 56.2 (13.5) 
years, 64% ACPA-positive). OPG levels were determined using ELISA 5,6 in sera collected at a 
median disease duration of 4 (range 1-9) years, while patients were treated with conventional 
DMARDs. At the moment of serum collection, the mean (SD) DAS44 was 2.3 (1.1), 53% 
of patients had a DAS44 <2.4 and none of the patients were in DMARD-free sustained 
remission. For analyses, OPG levels were stratified in quartiles with similar patient numbers. 
The outcomes were achieving DAS44 remission (DAS44 <2.4 and <1.6) 1 year after serum 
collection and; achieving DMARD-free sustained remission during follow-up (median 
follow-up 10 year, IQR 9-10 years). DMARD-free sustained remission was defined as the 
sustained absence of arthritis (by physical examination) after discontinuation of DMARD 
therapy, including biologics and glucocorticosteroids, for the entire follow-up and the follow-
up should be at least one year after cessation of DMARD-treatment. Patients that relapsed 
during follow-up were not in the DMARD-free sustained remission group. All medical files 
were explored on this outcome until 5 April 2012 1. Logistic and Cox regression analyses were 
performed with adjustments for age, gender and treatment strategy 4. The analyses of DAS44 
remission were additionally adjusted for DAS44 at sample collection and the analysis of 
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DMARD-free sustained remission were additionally adjusted for disease duration at sample 
collection. All patients gave informed consent and approval was obtained from the medical 
ethics committee of the Leiden University Medical Center.
One hundred and sixteen patients (73.4%) and 67 patients (42.4%) had achieved 
DAS44 remission when, defined, respectively, as DAS <2.4 and DAS <1.6 1 year after serum 
collection. Per quartile decrease in OPG the odds ratio (OR) for achieving DAS44 remission 
during the next year was 1.65 (95% CI 1.11 to 2.47, p=0.014) when defining DAS44 remission 
as a DAS <2.4. Similar results were obtained when defining DAS44 remission as a DAS <1.6 
during the next year (OR=1.55, 95% CI 1.084 to 2.22, p=0.016). Sixteen patients (10.1%) 
achieved DMARD-free sustained remission after a median of 6 years of disease (IQR 4-8) 
and 3 years (IQR 1-4) after serum collection. Lower OPG level associated significantly with 
a higher chance of DMARD-free sustained remission (hazard ratio on remission per quartile 
decrease in OPG level 1.92 (95% CI 1.043 to 3.52, p=0.036) (Figure 1).
In conclusion, we here replicated the finding that low OPG levels were predictive for 
an increased chance of DAS remission during the next year. The findings were similar when 
using DAS remission defined as DAS44 <2.4 or <1.6. These validated results suggest that 
OPG is a biomarker that might be useful to assess during treatment in order to predict the 
chance of a low disease activity during the next year. Interestingly, serum OPG levels were also 
associated with the chance of DMARD-free sustained remission. Together these data suggest 
that OPG levels are reflective of a process influencing the severity of inflammation both on 
the short and long-term. Intriguingly, OPG levels did not correlate with DAS remission at 
the same point in time. This may suggest that the change in OPG level precede the change 
in inflammation that is measured by the DAS. Longitudinal studies are needed to explore 
this. In addition further studies are needed to confirm the association between OPG levels 
and DMARD-free sustained remission and to investigate the mechanisms underlying this 
association. Because it is likely that achieving DMARD-free sustained remission will become 
a preferred treatment goal in the future, further studies are also required to examine whether 
serum OPG levels are useful to guide treatment decisions and to predict if this favourable 
disease outcome is achievable.
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Figure 1. Osteoprotegerin levels in relation to achieving DMARD-free sustained remission in 158 rheumatoid 
arthritis patients. Depicted are the modeled (by the Cox regression analysis) percentages of 158 rheumatoid arthritis 
patients of the Leiden Early Arthritis Clinic cohort that achieved DMARD-free sustained remission during 10 years 
follow-up. Quartile 1 presents the lowest OPG levels and quartile 4 the highest level. The hazard ratio on achieving 
DMARD-free sustained remission was 1.92 (95% CI 1.043 to 3.52) per quartile decrease in OPG level (p=0.036). 
Quartile 1, 2, 3 and 4 concerned respectively 39, 40, 40 and 39 patients.
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Disease-modifying antirheumatic drug (DMARD)-free sustained remission, the sustained 
absence of synovitis after cessation of DMARD therapy, is a relevant long-term outcome of 
rheumatoid arthritis (RA) if (1) its occurrence is promoted by treatment and (2) this status 
reflects resolution of symptoms and disability. This study investigated both items. 
Methods
1,007 patients with RA diagnosed between 1993 and 2011, included in the Leiden Early 
Arthritis Clinic, were studied on achieving DMARD-free sustained remission. Patients 
included in 1993–1995 were initially treated with nonsteroidal anti-inflammatory drugs, in 
1996–1998 mild DMARDs were started early, from 1999 onwards methotrexate was initiated 
promptly and from 2005 onwards disease activity score (DAS)-steered treatment was 
common. Remission rates were compared using Kaplan-Meier curves and Cox proportional 
regression.
Results
In total, 155 patients achieved DMARD-free sustained remission. Specific treatment 
strategies were significantly associated with achieving remission (p<0.001). Cox regression 
adjusted for anti-citrullinated peptode antibodies/rheumatoid factor, swollen joint count, 
erythrocyte sedimentation rate and C-reactive protein revealed HRs for DMARD-free 
sustained remission of 1.13 (95% CI 0.48 to 2.64) in patients diagnosed in 1996-1998, 2.39 
(1.07 to 5.32) in patients treated with early methotrexate (inclusion 1999-2004) and 3.72 (1.60 
to 8.62) in those treated early with methotrexate and DAS-steered therapy (inclusion 2005-
2011). At the time of remission, the Health Assessment Questionnaire was at the level of 
the general population (median 0.13, IQR 0–0.63). Also, patient-rated visual analogue scale 
(VAS) morning stiffness, fatigue, pain and disease activity were low (median (IQR) mm, 14 
(2–27), 10 (0–47), 6 (0–20), 7 (0–20), respectively).
Conclusions 
More intensive treatment strategies increased the chance for DMARD-free sustained 
remission, indicating that RA chronicity can be influenced. Patients with RA achieving 
DMARD-free sustained remission have a normalised functional status.
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INTRODUCTION
The disease prospects of patients newly diagnosed with rheumatoid arthritis (RA) today are 
much better than they were decades ago 1. The severity of joint destruction has decreased 
during the last years, and nowadays, clinically relevant joint destruction has become 
infrequent in Western countries. These advances are the result of several changes in treatment 
strategies. Whereas in the early 1990s disease-modifying antirheumatic drugs (DMARDs) 
were commenced within two years after symptom onset, DMARDs are according to current 
guidelines started directly after the diagnosis RA is made. Second, more potent DMARDs 
have been introduced as first-line therapy and biologics have become available. Finally, during 
the last 10 years disease activity-guided treatment adjustments have become common.
Since joint destruction has become a less relevant long-term disease outcome, other 
long-term out-comes will become more important. DMARD-free sustained remission 
is defined as the absence of sustained synovitis after cessation of DMARD therapy and is 
an interesting long-term outcome as it reflects loss of arthritis persistence. Because this 
definition intends to reflect a final disease outcome, it is different from remission outcomes 
that are assessed to measure treatment efficacy (for instance, clinical remission or low-disease 
activity). Observational studies and clinical trials have reported that DMARD-free sustained 
remission can be achieved in approximately 10-15% of the patients with RA 2–6.
Several questions regarding the outcome DMARD-free sustained remission remain 
to be answered. First, it is yet unknown whether this disease outcome is modifiable with 
antirheumatic treatment. We hypothesised that disease persistence (measured by its 
counterpart DMARD-free sustained remission) is influenced by treatment. To study this, we 
evaluated if patients that were treated with current treatment regimens achieve DMARD-free 
sustained remission more often than patients that were treated one or two decennia ago. If 
no difference could be observed, DMARD-free sustained remission is not a relevant long-
term treatment goal; however, if up-to-date treatment strategies increase the occurrence 
of DMARD-free sustained remission, it is an important outcome to pursue. Second, the 
definition of DMARD-free sustained remission is based on joint swelling exclusively (that 
requires being persistently absent). In order to explore the quality of this disease outcome for 
patients, we studied the functional status and patient-reported symptoms such as pain and 
morning stiffness at the time when DMARD-free sustained remission was achieved. Finally, 
we answered the question whether variation in time after diagnosis until achieving DMARD-
free sustained remission might reflect different patient subsets. We hence evaluated if patients 
that achieved DMARD-free sustained remission early, intermediate or late in disease course 
differed in clinical, functional or patient-reported symptoms.




Patients studied were included consecutively in the Leiden Early arthritis Clinic (EAC) 
between February 1993 and April 2011. The EAC is described elsewhere in detail 7. In short, 
inclusion required the presence of confirmed synovitis and a symptom duration <2 years. At 
baseline and yearly follow-up visits, questionnaires were filled, joint counts performed and 
laboratory investigations made.
From the total cohort (n=2,731), patients that fulfilled the 1987 American College 
of Rheumatology criteria for RA 8 during the first year were selected (n=1,007). Patients 
with RA were treated according to routine care and the rheumatologists’ judgements. The 
treatment strategies that were usually applied changed over time. Generally, patients included 
in 1993-1995 were initially treated with nonsteroidal anti-inflammatory drugs (NSAIDs) 
and DMARDs were started with delay, patients included in 1996-1998 were treated with 
mild DMARDs (mainly hydroxychloroquine or sulphasalazine) promptly after diagnosis 
and patients included from 1999 onwards were treated initially with methotrexate. Disease 
activity score (DAS)-steered treatment adjustments became common from 2005 onwards. 
These inclusion periods were used as a proxy for the changes in treatment strategies.
DMARD-free sustained remission
The outcome DMARD-free sustained remission was defined as the sustained absence of 
synovitis (by physical examination) after discontinuation of DMARD therapy (including 
biologics and systemic or intra-articular corticosteroids) for the entire follow-up and at 
least for one year after DMARD withdrawal 4,9. This stringent definition of remission is the 
opposite of disease persistence. All medical files were explored on this outcome until 5 April 
2012. Patients that had achieved DMARD-free sustained remission but relapsed later on 
(n=3) were excluded (figure 1).
The time till achieving DMARD-free sustained remission was rather arbitrarily 
divided into three groups: the ‘early remission’ group, when remission was achieved within 
3 years after baseline, the ‘intermediate remission’ group, when remission was achieved 
between 3 and 5 years after baseline, and the ‘late remission’ group, when remission was 
obtained after 5–13 years.
Statistical analysis
The χ2, t test, one-way analysis of variance and Kruskal-Wallis tests for group comparisons 
were used. Rates of achieving DMARD-free sustained remission were evaluated using Kaplan- 
Meier analysis with period of inclusion entered as grouping factor. The date of remission was 
defined as one year after the date at which DMARDs were withdrawn due to remission of 
disease. Time to remission was measured as the time from date of inclusion in the cohort to 
the date of remission. Cases that did not achieve remission were right-censored by their last 
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known date of assessment. Equality of time-to-event function between the groups was tested 
with log-rank test. Cox proportional hazards regression models were used incorporating 
adjustments for the anti-citrullinated peptide antibody (ACPA)/rheumatoid factor (RF) 
status and measures of inflammation (swollen joint count (SJC), C-reactive protein (CRP) 
and erythrocyte sedimentation rate (ESR)).
A multivariate normal regression was used to depict the course of several features 
over time; it was not intended to test for statistical significances. Because Health Assessment 
Questionnaire (HAQ) and patient-assessed outcomes are known to vary with age and to be 
different for men and women 10,11, adjustments were made for age and gender. The multivariate 
normal regression takes advantage of within-patient correlation in repeated measurements 
and can handle missing data. The remission group, effect of time and interaction term between 
these variables were entered as categorical variables into the model. The best-fit covariance 
matrix (unstructured) was chosen according to the smaller value of the Akaike information 
criterion. Analyses were performed with the IBM SPSS, V.22 (SPSS, Chicago Illinois, USA).
RESULTS
Frequency of DMARD-free sustained remission over time
Table 1 presents the baseline characteristics of the 155 patients with RA who achieved 
DMARD-free sustained remission and the 731 patients who did not achieve it. In line 
with what has previously been described 4, patients who achieved DMARD-free sustained 
Figure 1. Flow diagram of the selection of the study participants.
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15 remission, compared with those who did not, were less often ACPA or RF-positive (18% vs 
62%, and 31% vs 65%, both p<0.001) and had shorter symptom duration at inclusion (median 
(IQR) of 3 months (2–7) vs 5 months (2–9), p<0.001). Patients who achieved remission, 
compared with those who still had persistent RA through the study period, did not have 
milder disease characteristics at baseline in terms of SJC, tender joint count (TJC), ESR, CRP, 
HAQ, morning stiffness, fatigue and frequency of high titre of ACPA.
Subsequently, the patients with RA were split into the four inclusion periods. Patients 
included in the more recent inclusion periods were less often ACPA-positive, had lower SJC 
and lower levels of acute phase reactants but they had more pain and morning stiffness at the 
first visit (table 2). Of these statistical differences, the difference in SJC was mostly clinically 
Table 1. Baseline characteristics of the patients with RA in the study in total and according to achieved DMARD-free 
sustained remission or not during the follow-up






Age (years), mean (SD) 56.5 (15.6) 57.4 (16.4) 56.3 (15.5)
Females, n (%) 591 (67) 97 (63) 494 (68)
Symptom duration (months), med (IQR) 4.4 (2.3-8.4) 2.9 (1.8-6.5)** 4.7 (2.4-8.6)**
Smoking ever, n (%) 437 (56) 78 (54) 359 (56)
Period of inclusion, n (%)
  1993-1995 63 (7) 7 (5) 56 (8)
  1996-1998 158 (18) 24 (15) 134 (18)
  1999-2004 289 (33) 66 (43) 223 (31)
  2005-2011 376 (42) 58 (37) 318 (43)
ACPA-positive, n (%) 464 (54) 26 (18)** 438 (62)**
  ACPA low-positive†, n (%) 37 (8) 2 (8) 35 (8)
  ACPA high-positive†, n (%) 427 (92) 24 (92) 403 (92)
RF-positive, n (%) 517 (59) 48 (31)** 469 (65)**
Disease markers
  ESR (mm/h), med (IQR) 32 (17-51) 29 (16-48) 32 (18-53)
  CRP (mg/L), med (IQR) 15 (6-37) 16 (16-33) 15 (6-38)
  SJC (0-66), med (IQR) 8 (4-13) 8 (4-15) 8 (4-13)
  TJC (0-68) , med (IQR) 7 (5-11) 8 (5-11) 7 (5-11)
  HAQ (0-3) , med (IQR) 1.0 (0.63-1.50) 1.0 (0.62-1.50) 1.0 (0.63-1.50)
  Patient-assessed disease activity (VAS 0-100 mm), med (IQR) 54 (34-75) 51 (33-67)* 55 (34-76)*
  Pain (VAS 0-100 mm), med (IQR) 51 (34-69) 48 (29-65) 52 (34-70)
  Fatigue (VAS 0-100 mm), med (IQR) 48 (16-69) 40 (12-60)* 50 (17-70)*
  Morning stiffness (VAS 0-100 mm), med (IQR) 63 (36-80) 57 (36-76) 64 (36-81)
*p<0.05, **p<0.001 for between-group
†ACPA low-positive refers to values that are higher than the ULN but ≤3 times the ULN for the assay, high-positive 
that are >3 times the ULN
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relevant (the median SJC of 12 in 1996-1998 and of 6 in 2005-2011). Distribution of high and 
low titres of ACPA was equal in the inclusion periods. Figure 2 presents the Kaplan-Meier 
estimates of the percentages of patients achieving DMARD-free sustained remission stratified 
by periods of inclusion. Patients that were treated according to more recent treatment 
strategies achieved remission more often (p<0.001). The mean time to remission (SD) was 7.8 
(3.4), 6.9 (4.0), 4.8 (2.7) and 3.1 (1.4) years for patients treated with the subsequent treatment 
strategies.
To determine whether shorter follow-up for part of the patients in the last inclusion 
period and difference in follow-up time in different inclusion periods had influenced the 
results, the Kaplan-Meier analyses were repeated (1) limiting the latest inclusion period till 
January 2009, thus allowing for duration of follow-up of at least 3 years, and (2) limiting 
the maximal follow-up to 5 years. The difference between the treatment groups remained 
statistically significant (both analyses p<0.001, see online supplementary figure S1). The 
Kaplan-Meier analyses were also repeated in the ACPA-positive and ACPA-negative 
subgroups, both showing significant results (p=0.001 and 0.014, respectively), but DMARD-
Table 2. Baseline characteristics of the patients with RA according to period of inclusion










Age (years), mean (SD) 54.8 (14.7) 55.5 (16.9) 57.2 (15.0) 56.7 (15.8) 0.55
Females, n (%) 46 (73) 103 (65) 194 (67) 248 (66) 0.70
Symptom duration (months), med 
(IQR)
5.8 (3.1-11.4) 4.2 (2.0-6.9) 4.5 (2.4-9.0) 4.2 (2.1-7.5) 0.042
Smoking ever, n (%) 32 (56) 67 (47) 125 (49) 213 (65) <0.001
ACPA-positive, n (%): 49 (78) 89 (56) 145 (52) 181 (51) 0.001
  ACPA low-positive, n (%) 5 (10) 8 (9) 12 (8) 12 (7) 0.82
  ACPA high-positive, n (%) 44 (90) 81 (91) 133 (92) 169 (93) -
RF-positive, n (%) 42 (67) 89 (56) 174 (60) 212 (57) 0.45
ESR (mm/h), med (IQR) 44 (25-74) 37 (20-57) 32 (20-52) 29 (11-44) 0.13
CRP (mg/L), med (IQR) 21 (11-43) 20(9–48) 15 (7-39) 12 (4-28) 0.92
SJC (0–66), med (IQR) 8 (5-15) 12 (6.5–20) 8 (4-14) 6 (3-11) <0.001
HAQ (0–3), med (IQR) 1.0 (0.53-1.34) 1.0 (0.62-1.47) 1.0 (0.53-1.50) 1.0 (0.63-
1.50)
0.52
Patient-assessed disease activity 
(VAS 0-100 mm), med (IQR)
51 (28-73) 47 (25-63) 53 (39-74) 60 (36-76) 0.001
Pain (VAS 0-100 mm), med (IQR) 47 (23-60) 45 (24-59) 52 (35-67) 56 (38-71) <0.001
Fatigue (VAS 0-100 mm), med 
(IQR)
38 (12-54) 32 (12-64) 49 (20-69) 50 (15-70) 0.12
Morning stiffness (VAS 0-100 
mm), med (IQR)
63 (28-77) 50 (23-76) 64(39-82) 66 (40-80) <0.009
P-values are for overall comparison of the characteristics between the four groups by period of inclusion
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free remission was more frequent in the ACPA-negative groups (online supplementary figure 
S2).
In Cox proportional hazards regression, the association between achieving remission 
and treatment strategy was confirmed; with the inclusion period 1993-1995 (initial treatment 
with NSAIDs) as reference, the HRs (95% CI) for the patients initially treated with mild 
DMARDs (inclusion 1996-1998), initially treated with methotrexate (1999-2004) and then 
with methotrexate and DAS-steered treatment (2005-2011), were 1.5 (0.6 to 3.4), 2.9 (1.3 to 
6.4) and 5.3 (2.3 to 12.1), respectively. After adjustment for autoantibody status, baseline SJC, 
ESR and CRP the HRs were 1.13 (0.48 to 2.64), 2.39 (1.07 to 5.32) and 3.72 (1.60 to 8.62), 
respectively, showing an increased chance for DMARD-free sustained remission in patients 
treated according to more recent strategies.
Disease symptoms and functional status at the time of achieving DMARD-free sustained 
remission
The definition of DMARD-free sustained remission is based on the absence of swollen joints; 
other clinical measures and functional and patient-reported symptoms are not included 
in the definition. We therefore explored other disease-associated outcomes at the time of 
achieving remission. Of all 155 patients with remission, information on follow-up visits was 
missing in 48%. The missing data were completely not at random as patients with DMARD-
free sustained remission declined their visit to the research nurse more often than patients 
with RA with persistent disease. Patients with complete data and with missing data at the time 
when DMARD-free sustained remission was achieved did not differ statistically significant 
Figure 2. Kaplan-Meier estimates of the percentages of patients with RA achieving DMARD-free sustained remission, 
stratified for the different treatment strategies. The periods of inclusion were used as proxy for the differences in 
treatment strategy. Patients included in 1993-1995 were initially treated with NSAIDs and DMARDs were initiated 
with delay, patients included in 1996-1998 were treated early with mild DMARDs (mainly hydroxychloroquine 
or sulphasalazine) and patients included from 1999 onwards were promptly treated with methotrexate and DAS-
steered treatment adjustments became common from 2005 onwards. Pooled over strata p<0.001 by log-rank test, 
test for trend p<0.001. Remission was achieved in 7 patients out of 63 patients included in 1993-1995, in 24 out of 
158 patients included in 1996- 1998, in 66 out of 289 patients included in 1999-2004 and in 58 out of 376 patients 
included in 2005-2011.
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by age, sex, symptom duration, year of inclusion and baseline disease characteristics, except 
for patients’ rated disease activity (median visual analogue scale (VAS) (mm) in patients with 
and without missing data 53 (36–72) and 47 (31–61), p=0.032). Obtained data were studied 
and missing data were not imputed. 
The median TJC at the time of remission was 0 (IQR 0–1) and at a group level acute 
phase reactants were within normal limits (median (IQR) ESR 8 (5–11) mm/h and CRP 3 (3–
5) mg/L). Regarding functional ability, we observed that the patients that achieved DMARD-
free sustained remission had a median HAQ at diagnosis of 1.0 (IQR 0.62–1.50) (table 1) 
and at the time of remission of 0.13 (IQR 0–0.63) (table 3). The VAS fatigue median was 40 
(12–60) mm at baseline but 10 (IQR 0–47) at the time DMARD-free sustained remission 
was obtained. Also, the VAS pain was low at the time of DMARD-free sustained remission, 
median 6 (IQR 0–20), while it was 48 (29–65) at baseline. The VAS morning stiffness 
decreased also to low levels in the patients that achieved remission; its median was 57 (36–76) 
mm at baseline and 14 (2–27) at the time of remission (table 3).
Analyses in patients with RA that achieved DMARD-free sustained remission early, 
intermediate or late in disease course
It was observed that the time till DMARD-free sustained remission varied between the 
patients. Theoretically, the rapidity with which DMARD-free remission is achieved may 
reflect differences in patient subsets. To explore this, characteristics of the patients that 
achieved DMARD-free sustained remission early (within 3 years), intermediate (3-5 years of 
disease) or late (5-13 years) in disease course were compared. No differences were observed 
either at baseline (online supplementary table S1) or at the time of achieved DMARD-free 
sustained remission (table 3). In order to illustrate the time course of HAQ and patient-
reported symptoms in patients that achieved DMARD-free sustained remission early, 
intermediate and late in disease course, the median values as predicted by normal regression 
with adjustments for age and gender were plotted (figure 3). As a reference, the course of 
these variables for patients with persistent RA was plotted. The course of the CRP, ESR and 
TJC over time was depicted likewise (online supplementary figure S3). In all patients, the 
largest improvement was shown in the first year. Better outcomes across all measures were 
observed in the patients who achieved remission compared with those who did not.
DISCUSSION
This study explored the relevance of achieving DMARD-free sustained remission in two 
domains. Because DMARD-free sustained remission is generally considered to be an 
outcome that is obtained in only a minority of patients with RA and that the persistent nature 
of RA cannot be modified, the first aim was to evaluate whether the incidence of DMARD-
free sustained remission changed with the use of up-to-date treatment strategies. The present 
data revealed indeed an increase in chance for DMARD-free sustained remission when 
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patients were treated according to early and more intensive strategies in standard clinical 
practice. These findings are relevant as these data imply that also persistence of inflammation 
(which is the second hallmark of RA next to joint destruction) can be influenced. Significant 
differences were seen for the two most recent inclusion periods 1999-2011. Whether DAS-
steered treatment is of additional value compared with initial methotrexate alone cannot be 
definitely concluded based on the present data as the follow-up duration of the inclusion 
period 2005-2011 was shorter than that of the other inclusion periods. But prompt treatment 
with methotrexate is clearly beneficial.
As DMARD-free sustained remission is defined by the findings of rheumatologists 
at physical examination, second, we evaluated whether this disease outcome is also relevant 
from the patient perspective. It was observed that when DMARD-free sustained remission 
was achieved the median HAQ score was 0.13. The mean HAQ for the normal population 
is reported to be 0.25 12; this suggests that the functional ability at the time DMARD-free 
sustained remission is achieved is normalised. Several patient-reported symptoms were 
studied. The VAS pain on a 100 mm scale in the general population is reported to be 11.5 
and the VAS fatigue 20.5. Also, here the VAS scores at the time of DMARD-free remission 
(6 and 10, respectively) were lower than the reference values 13–16, suggesting that important 
RA-related symptoms as pain and fatigue have resolved. Together, these observations indicate 
that DMARD-free sustained remission is a disease outcome reflecting health state close 
to expected in the general population with regard to functioning and several RA-related 
Table 3. Disease characteristics of the patients with RA at the time of achieved DMARD-free sustained remission in 
total and by groups according to time to remission after inclusion.
Remission achieved in disease course






Age (years) 62.1 (16.5) 58.8 (17.7) 63.7 (17.3) 63.1 (14.0)
ESR (mm/h), med (IQR) 8 (5-11) 8 (4-12) 9 (5-17) 6 (4-9)
CRP (mg/L), med (IQR) 3 (3-5) 3 (3-5) 3 (3-4) 4 (3-7)
TJC (0-68), med (IQR) 0 (0-1) 1 (0-2) 0 (0-1) 1 (0-3)
HAQ (0-3), med (IQR) 0.13 (0-0.63) 0 (0-0.38) 0.25 (0-0.63) 0.25 (0.10-
1.50)
Patient-assessed disease activity (VAS 
0-100 mm)
7(0-20) 9 (0-21) 6 (1-14) 7 (0-26)
Pain (VAS 0-100 mm), med (IQR) 6 (0-20) 4 (0-20) 8 (0-19) 4 (0-33)
Fatigue (VAS 0-100 mm), med (IQR) 10 (0-47) 3 (0-35) 21 (2-50) 13 (1-49)
Morning stiffness (VAS 0-100 mm), 
med (IQR)
14 (2-27) 2 (0-32) 15 (3-20) 16 (2-53)
The data presented for the total remission group, early (remission achieved <3 years after baseline), intermediate 
(3–5 years after baseline) and late remission (>5–13 years) groups are based on the following number of patients: 
for ESR 61, 26, 24 and 11, respectively; for CRP 39, 17, 12, 10; for TJC 56, 20, 24, 12; for HAQ 60, 23, 27, 10; VAS 
patient-assessed disease activity and pain 71, 28, 30, 13; VAS fatigue 61, 27, 22, 13; and VAS morning stiffness 49, 
19, 20 and 10.
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symptoms.
DMARD-free sustained remission was defined as the absence of synovitis after 
DMARD cessation during the total follow-up that should be at least one year. The follow-up 
duration after DMARD cessation may potentially influence the outcome. Patients that have 1 
or 2 years’ follow-up after DMARD cessation might flare later on while they are now classified 
as being in DMARD-free sustained remission, whereas patients with a longer follow-up after 
DMARD cessation and who flared after several years of remission are not in the DMARD-
free remission group. This might be an issue for the fourth inclusion group; all other inclusion 
groups were followed for many years. In a subanalysis, patients included after 2009 were 
excluded and only patients included in 2004-2009 were studied, thus allowing three follow-
up years for all patients. The results were unchanged, suggesting a minor influence of the 
shorter follow-up of the fourth inclusion group.
Patients included in the more recent inclusion groups were less often ACPA-positive, 
Figure 3. The course of patient-reported disease features by time to achieved remission early, intermediate and late 
in disease course. Presented are predicted median values obtained by the multivariate normal regression model 
adjusted for age at inclusion and gender. Patients that achieved DMARD-free sustained remission within 3 years after 
inclusion, after 3-5 years or between 5 and 13 years were referred to as early, intermediate and late remission. The 
lines representing the remission subgroups terminate at follow-ups with available data. As reference, the predicted 
values for the group of patients that did not achieve remission (dotted lines) are also shown.
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the number of swollen joints fewer and acute phase reactants lower. Although all patients 
studied fulfilled the 1987 criteria for RA, this may suggest that these patients had somewhat 
milder disease at the time of diagnosis. Also when adjustments were made for these baseline 
differences, patients treated according to recent protocols achieved DMARD-free sustained 
remission significantly more often. The finding of changed RA over time with better clinical 
status in contrast to worse reported subjective disease measures has been reported before 17. 
This presumably reflects a change towards diagnosing (and treating) RA in a milder disease 
phase in recent years and higher patients’ expectation of ‘well-being’ status 18.
An optimal study design to determine the effect of treatment strategies on DMARD-
free sustained remission is a randomised clinical trial. However, at present, it will not be 
considered ethical to perform a trial with study arms using outdated treatment strategies. 
We used the longitudinal data of our observational cohort in which patients were treated 
according to the rheumatologists’ expertise. We used the different time periods as proxies for 
different treatment strategies and the oldest inclusion group as reference.
It is known that the symptom duration at treatment initiation importantly affects the 
chance for DMARD-free sustained remission 19. There were no large differences in symptoms 
duration between the inclusion periods (table 2), and when symptom duration was added 
as adjustment factor, the HRs were mostly unchanged (data not shown). Hence, symptom 
duration did not confound the results.
The biological mechanisms underlying RA persistence are unknown. We questioned 
whether patients that achieved DMARD-free sustained remission early in the disease 
constitute a different subset of patients than those that achieve it later on. We compared 
patient characteristics and ACPA titres between these groups at baseline and at the time 
of DMARD-free sustained remission and observed no relevant differences. DMARD-free 
sustained remission was also achieved in patients that carry autoantibodies. In total, 31% of 
the patients with DMARD-free sustained remission were RF-positive and 18% were ACPA-
positive. Thus, the presence of autoantibodies does not absolutely impede achievement of 
this outcome. Exploratory analyses within ACPA-positive and ACPA-negative subgroups 
showed significant differences for the treatment strategies (online supplementary figure S2). 
Although RA persistence is more frequent in ACPA-positive RA, the present data suggest 
that treatment affects RA persistence in both ACPA-negative and ACPA-positive RA. More 
detailed studies on these subgroups are needed.
Presumably the mechanisms that promote the development of DMARD-free 
sustained remission, and thus the loss of RA persistence, are different from the mechanisms 
mediating treatment response. In this light it is interesting to note that the predictors of 
DMARD-free sustained remission (ACPA, symptom duration) are different from previously 
reported predictors for DAS response (male gender, older age, lower body mass index, lower 
baseline disease activity) 20–22.
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The major limitation of our study is that a proportion of patients with DMARD-
free sustained remission declined their research visits during remission (they were seen by 
rheumatologists only). ‘Feeling well’ might be causative for this. If this would have introduced 
bias, the results obtained are likely derived from the worst selection of patients with 
DMARD-free sustained remission because the patients who had the best physical function 
or the least symptoms in particular refused further study participation. We did not observe 
large differences in baseline characteristics between DMARD-free remission patients with 
and without data at the time of remission.
In conclusion, RA can no longer be considered as an inevitably chronic disease. The 
results of the present study indicate that DMARD-free sustained remission is increasingly 
achievable in the recent years of early and intensified antirheumatic therapy. Therefore, 
DMARD-free sustained remission is an advantageous long-term disease outcome that is 
relevant to pursue.
SUPPLEMENTARY DATA
Supplementary data are published on the website of the Annals of the Rheumatic Diseases.
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Fatigue is prevalent and disabling in rheumatoid arthritis (RA). Surprisingly, the long-
term course of fatigue is studied seldom and it is unclear to what extent it is influenced by 
inflammation. This study aimed to determine the course of fatigue during 8 years follow-
up, its association with the severity of inflammation and the effect of improved treatment 
strategies.
Methods 
626 patients with RA included in the Leiden Early Arthritis Clinic cohort were studied during 
8 years. Fatigue severity, measured on a 0–100 mm scale, and other clinical variables were 
assessed yearly. Patients included in 1993–1995, 1996–1998 and 1999–2007 were treated with 
delayed treatment with disease-modifying antirheumatic drugs (DMARDs), early treatment 
with mild DMARDs and early treatment with methotrexate respectively. After multiple 
imputation, the serial measurements were analysed using linear quantile mixed models.
Results 
Median fatigue severity at baseline was 45 mm and remained, despite treatment, rather 
stable thereafter. Female gender (effect size=4.4 mm), younger age (0.2 mm less fatigue 
per year), higher swollen and tender joint counts (0.3 mm and 1.0 mm more fatigue per 
swollen or tender joint) and C reactive protein-levels (0.1 mm more fatigue per mg/L) 
were independently and significantly (p<0.05) associated with fatigue severity over 8 years. 
Although improved treatment strategies associated with less severe radiographic progression, 
there was no effect on fatigue severity (p=0.96).
Conclusions
This largest longitudinal study on fatigue so far demonstrated that the association between 
inflammation and fatigue is statistically significant but effect sizes are small, suggesting that 
non-inflammatory pathways mediate fatigue as well. Improved treatment strategies did not 
result in less severe fatigue. Therefore, fatigue in RA remains an ‘unmet need’.
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INTRODUCTION
Fatigue is common in rheumatoid arthritis (RA) and considered as one of the most important 
disease outcomes by patients 1. Although fatigue is not clearly defined and the cut-off for 
clinically relevant fatigue of most fatigue measures is unknown, the prevalence of fatigue in 
RA has been reported to be 40–80% 2,3. The majority of studies evaluating fatigue in RA had 
cross-sectional designs or studied patients with RA with different disease durations; therefore 
little is known on the long-term course of fatigue 4.
The importance of fatigue in RA is underlined by the finding that more severe fatigue 
is predictive for decreased physical and mental health-related quality of life, depression 
and loss of work ability 5–7. Both a Patient Perspective Workshop at OMERACT (Outcome 
Measures in Rheumatology) in 2007 and a EULAR/ACR task force in 2008 recommended 
that ‘each trial should report on fatigue’ 8,9. Furthermore, since severe radiographic joint 
destruction (the traditional outcome measure in trials) is no longer prevalent, other outcomes 
will become more important. In the light of these developments, it is surprising that so little 
is known about the fatigue severity during the disease course.
The causation of fatigue in RA is thought to be multidimensional. A recently 
proposed conceptual model suggests that fatigue is the result of interactions between three 
factors: disease-process related factors, cognitive and behavioural factors (thoughts, feelings, 
behaviours) and personal factors (personal life issues) 10. Scientific data supporting this model 
are mostly derived from cross-sectional studies and are conflicting 4. A recent systematic 
literature review concluded that none of the studied associations were consistent across all 
published data 4. Most consistent were the associations of fatigue severity with the degree of 
pain and physical impairments. To a lesser extent, there was some consistency in the results 
showing that depressive mood/depression and female sex associated with more severe fatigue 
2,4,11–15. In contrast, the relation between markers of inflammation and fatigue remained 
disputable as contradictory results were obtained on the associations between fatigue and 
erythrocyte sedimentation rate, C reactive protein (CRP), joint counts and disease activity 
scores 2,4,11–15. Thus, although intuitively it is generally felt that fatigue in RA is in part the 
consequence of inflammation (either clinically apparent or subclinical inflammation), the 
question whether and to what extent fatigue in RA is mediated by inflammation remains 
unanswered.
This study aimed to assess (1) whether fatigue severity differed at disease onset 
between patients presenting with RA and other forms of early arthritis. Within RA, a large 
longitudinal 8 years study on fatigue was performed aiming to determine (2) the course of 
fatigue, (3) the association between the course of inflammation and the course of fatigue and 
(4) the effect of improved treatment strategies, which have resulted in better suppression of 
disease activity, on the course of fatigue.
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PATIENTS AND METHODS 
Longitudinal cohort
All patients were included in the Leiden Early Arthritis Clinic cohort, a population-based 
inception cohort in the Netherlands that started in 1993 and has been described in detail 
previously 16. In short, inclusion took place when arthritis was confirmed at physical 
examination and symptom duration was <2 years. At baseline, rheumatologists completed 
questionnaires, 66-swollen and 68-tender joint counts (SJC and TJC) were performed, patients 
filled out questionnaires among which the Health Assessment Questionnaire (HAQ), hand 
and feet radiographs were taken, as well as blood samples for routine laboratory screening 
(including CRP, haemoglobin (Hb), immunoglobulin (Ig)M-rheumatoid factor (RF) and 
anti-citrullinated peptide antibodies (ACPA) (anti-CCP2, Eurodiagnostica, the Netherlands). 
Written informed consent was obtained from all patients. The study was approved by the 
local Medical Ethics Committee.
To measure fatigue severity, patients were asked by the research nurses to note the point that 
best reflected the fatigue they had experienced during the last day 17. This was expressed on 
a visual analog scale (VAS) ranging from 0 (no fatigue) to 100 mm (extreme fatigue) for the 
patients assessed between 1993 and 2010 and on a numerical rating scale (NRS) ranging from 
0 (no fatigue) to 10 (extreme fatigue) from 2010 onwards, when digital recording forms were 
introduced. Since the VAS and NRS are known to correlate strongly 18,19, results of the NRS 
were multiplied by 10.
Follow-up visits were performed yearly and included standard clinical assessment including 
joint counts, rating the fatigue severity, HAQ and radiographs of hands and feet. Serial 
radiographs were scored with known time-order by one experienced reader using Sharp-van 
der Heijde scores (SHS) blinded to any clinical data (intraclass correlation coefficient 0.91), 
as described previously 16. The initial treatment strategy of patients with RA has changed over 
time. Generally, patients included in 1993–1995 were initially treated with nonsteroidal anti-
inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) were 
initiated with delay, patients included in 1996–1998 were early treated with mild DMARDs 
(mainly hydroxychloroquine or sulphasalazine) and patients included in 1999–2007 were 
early treated with methotrexate. In addition, since 1999 DMARD-therapy was more rapidly 
adjusted in case of insufficiently suppressed disease activity score (DAS-steered treatment).
Patient selection
Between 1993 and March 2013 in total 3,112 early patients with arthritis with different 
diagnoses were included in the EAC. Of these patients, 2,442 (78.5%) had baseline fatigue 
data. Patients with and without baseline fatigue data did not differ in age, gender, SJC, TJC, or 
frequency of ACPA-positivity or having RA; patients with missing baseline fatigue data had 
slightly higher CRP-levels (median (IQR) 12 mg/L (4–37) versus 10 mg/L (3–27), p=0.002). 
All 2,442 early patients with arthritis were studied to compare fatigue at disease onset across 
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different diagnoses.
Of the 2,442 early patients with arthritis included between 1993 and 2013, 902 
patients fulfilled the 1987-ACR criteria for RA. Associations of baseline characteristics with 
fatigue at disease onset in RA were studied in these 902 patients.
Longitudinal studies on yearly measured fatigue were done on the 626 patients with 
RA included before 2007, providing the possibility to have completed 8 years follow-up. 
Similar as for fatigue, SJC, TJC, CRP, Hb, HAQ and SHS were measured yearly, providing 
the opportunity to test associations between fatigue and the concomitantly measured clinical 
variables during follow-up. In other words, this allowed studying the course of other variables 
in relation to the course of fatigue. Furthermore, in these patients the effects of improved 
treatment strategies in RA on three different long-term outcomes were studied, namely 
radiographic progression, SJC and fatigue over time.
A large majority of patients without RA (e.g. patients with reactive arthritis, 
inflammatory osteoarthritis or paramalignant arthritis) were not followed for many years. 
Patients diagnosed with undifferentiated arthritis (UA), psoriatic arthritis/spondylarthropathy 
with peripheral arthritis (PsA/SpA), (pseudo)gout and systemic connective tissue disease 
(SCTD) often did not complete 8 years follow-up but considerable proportions completed 3 
years follow-up. In these patients, available fatigue data were evaluated to determine whether 
the 3 years course of fatigue was different in RA compared to other forms of chronic arthritis.
Statistical analyses
As fatigue severity was non-normally distributed, median levels were presented and 
modelled. Cross-sectional quantile regression analyses were used for the comparisons 
on baseline fatigue data (comparisons across different diagnoses and within RA). For the 
longitudinal 8-year analyses of fatigue within RA linear quantile mixed models were used 20,21 
modelling the course of medians over time instead of means as in linear models 22. SJC, TJC, 
CRP, Hb, SHS and HAQ were measured yearly and not constant over time and analysed for 
its association with fatigue over time as time-dependent variables. Age, gender, ACPA and 
RF reported or measured at baseline were analysed. Before performing the analyses within 
RA, multiple imputation was used to deal with missing data for fatigue severity, symptom 
duration, duration of morning stiffness, SJC, TJC, CRP, Hb, RF, ACPA, SHS and HAQ. Five 
datasets were created for both the analyses of associations with fatigue at disease onset within 
RA and for the repeated measurements over 8 years by using multivariate imputation by 
chained equations that generates multiple imputations for incomplete multivariate data by 
Gibbs sampling 23.
The association between the different treatment strategies (reflected by the proxy 
different inclusion period) and radiographic progression was analysed over 8 years using a 
multivariate normal regression analysis adjusted for age and gender, as described in detail 
previously 24,25. A linear quantile mixed regression analysis was used to analyse whether 
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different treatment strategies associated with the number of swollen joints over 8 years.
Analyses were performed using R statistical software package 26,27 and SPSS V.20.0. 
P-values <0.05 were considered significant.
RESULTS
Baseline fatigue severity across different forms of early arthritis
Table 1 presents the characteristics of the studied patients. First, we studied whether the 
fatigue severity differed between patients presenting with RA and other forms of early 
arthritis. Of the 2,442 patients with fatigue data at disease onset, 902 patients had RA and 
1,540 patients other diagnoses. Figure 1A presents medians of fatigue severity for different 
diagnoses. Patients with SCTD and RS3PE recorded significantly more severe fatigue than 
patients with RA (medians respectively 59 mm and 58 mm compared to 49 mm in RA; 
p<0.05 adjusted for age and gender). Patient groups that experienced significantly less fatigue 
than patients with RA were patients with UA (median 37 mm), PsA/SpA (median 30 mm) 
and septic arthritis (25 mm) (all p<0.05 adjusted for age and gender). Four included patients 
were finally diagnosed with post-traumatic joint swelling; these patients had a median fatigue 
severity of zero (figure 1). Evaluating available data on the fatigue course over the first 3 years 
of disease revealed a similar trend as for the baseline data: patients with SCTD remained 
more severe fatigued than patients with RA and patients with PsA/SpA and (pseudo)gout had 
less severe fatigue also during follow-up (figure 1B).
Baseline fatigue severity in relation to baseline characteristics in RA
Within the 902 patients with RA it was studied whether fatigue at disease onset associated 
with other baseline characteristics (table 2). Independent associations with more severe 
fatigue were observed for female (p=0.001), patients with more morning stiffness (p=0.002), 
more tender joints (p<0.001) and patients without ACPA (p=0.003). Also longer symptom 
duration at disease presentation associated with more severe fatigue at the first visit (p<0.001). 
Additionally, patients that reported a higher level of disability (HAQ) reported also more 
severe fatigue (20.5 mm increase in fatigue severity with 1 point increase in HAQ, p<0.001).
Course of fatigue in RA
626 patients with RA were studied during 8 years follow-up. At baseline, the median (IQR) 
fatigue severity was 45 mm (18–65) and, despite initiation of treatment, the fatigue severity 
slightly decreased during the first year but then remained rather stable (figure 2).
Course of fatigue in relation to course of inflammation in RA - univariable analyses
Measures of inflammation (SJC, TJC and CRP) changed during the disease course as result 
of either the disease itself or the applied intervention. Similar to fatigue, these markers were 
measured yearly, allowing determining associations between the course of inflammation and 
the course of fatigue during 8 years. Patients that over time remained to have higher number 
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of swollen joints, tender joints and CRP-levels also remained more fatigued (all p<0.001). 
The observed effect sizes of the inflammatory markers were all small. For example, presence 
of one additional swollen joint over time associated with 0.7 mm more fatigue over time and 
patients with 1 mg/L higher CRP over time reported 0.1 mm more fatigue (table 3).
Although we aimed to evaluate whether the course of inflammation associated 
with the course of fatigue, some other clinical variables that might be of importance when 
evaluating fatigue severity were studied. Female and younger patients remained more 
fatigued over time (females 6.1 mm more severe fatigue than males, p<0.001; 0.2 mm less 
severe fatigue per year older, p=0.043, table 3). The course of fatigue was similar for patients 
with and without RA-related autoantibodies. Patients with lower Hb-levels during the disease 
course remained more fatigued (p=0.003).
Table 1. Baseline characteristics
Patients with RA with 
fatigue data at disease 
onset (n=902)*
Non-RA early patients 
with arthritis with 
fatigue data at disease 
onset (n=1540)†
Patients with RA with 
repeated fatigue data over 8 
years (n=626)‡
Age at disease onset, 56.6 (15.3) 49.9 (17.4) 56.5 (15.5)
mean (SD), years
Female, n (%) 607 (67.3) 868 (56.4) 429 (68.5)
Inclusion period 1993–2013 1993–2013 1993–2007
Symptom duration, 18.3 (9.3–34.7) 13.1 (5.1–29.1) 19.3 (10.7–39.3)
median (IQR), weeks
Morning stiffness, 60 (30–120) 30 (0–60) 60 (30–120)
median (IQR), minutes
SJC, median (IQR) 7 (4–12) 2 (1–6) 8 (4–14)
TJC, median (IQR) 4 (7–10) 4 (2–7) 8 (5–12)
CRP, median (IQR), mg/L 14 (6–33) 8 (3–23) 17 (8–39)
Hb, mean (SD), mmol/L 8.2 (0.8) 8.4 (0.9) 8.1 (0.8)
ACPA-positive, n (%) 456 (52.1) 105 (9.1) 326 (54.1)
RF-positive, n (%) 516 (57.9) 228 (15.1) 364 (59.2)
SHS, median (IQR) 5 (2–11) N/A 5 (2–11)
HAQ, median (IQR) 1 (0.6–1.5) 0.6 (0.3–1.0) 1 (0.6–1.5)
*Symptom duration was missing in 54 patients, morning stiffness in 78 patients, SJC in 14 patients, TJC in 236 
patients, CRP in 30 patients, Hb in 18 patients, ACPA-status in 27 patients, RF-status in 11 patients, SHS in 372 
patients and HAQ in 108 patients.
†Symptom duration was missing in 113 patients, morning stiffness in 188 patients, SJC is 37 patients, TJC in 467 
patients, CRP in 78 patients, Hb in 43 patients, ACPA-status in 392 patients, RF-status in 31 patients and HAQ in 221 
patients. The radiographs of the patients without RA were not SHS scored.
‡Symptom duration was missing in 37 patients, morning stiffness in 19 patients, SJC in 4 patients, TJC in 334 
patients, CRP in 36 patients, Hb in 16 patients, ACPA-status in 23 patients, RF-status in 11 patients, SHS in 19 
patients and HAQ in 104 patients. The missing values were imputed for the analyses of associations between fatigue 
and other variables within RA. SJC=66-swollen joint count; TJC=68-tender joint count; SHS=Sharp-van der Heijde 
score; HAQ=health assessment questionnaire; N/A=not applicable
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Furthermore, patients with more functional impairment during the disease course 
(higher HAQ-scores), were also more severe fatigued; per point increase in HAQ the fatigue 
severity increased with 14.6 mm (p<0.001). (Figures that present fatigue scores over time in 
relation to some characteristics are available from the corresponding author on request).
Course of fatigue in relation to course of inflammation in RA - multivariable analysis
Characteristics with p<0.05 in univariable analyses and clinically relevant variables were 
included in multivariable analysis. This revealed that higher SJC (p=0.022, 0.3 mm more 
fatigue per swollen joint), higher TJC (p<0.001, 1.0 mm more fatigue per tender joint) and 
higher CRP (p=0.049, 0.1 mm more fatigue per mg/L CRP) (table 3) associated with more 
severe fatigue over time, indicating a significantly independent association of the severity 
of inflammation over time with persistence of more severe fatigue. Also female (p=0.022, 
Figure 1. Fatigue severity across early patients with arthritis with different diagnoses at disease onset (A) and over 
3 years of disease (B). (A) Presented are medians and IQRs of fatigue severity at disease onset. An asterisk indicates 
a significant different fatigue level compared to RA when adjusted for age and gender. The numbers of patients 
at baseline are 902 for RA, 73 for SCTD, 48 for RS3PE, 96 for reactive arthritis, 19 for paramalignant arthritis, 65 
for sarcoidosis, 25 for others, 126 for inflammatory OA, 13 for lyme arthritis, 706 for UA, 271 for PsA/SpA, 90 
for (pseudo) gout, four for septic arthritis and four for post-traumatic joint swelling. (B) Presented are medians of 
fatigue severity over 3 years of disease. Available, unmodelled data without imputation of missing data is depicted. 
The numbers of available fatigue data per diagnosis at baseline, one, 2 and 3 years follow-up were respectively: 73, 32, 
25 and 21 for SCTD; 902, 537, 411 and 432 for RA; 706, 270, 155 and 139 for UA; 271, 151, 110, 101 for PsA/SpA; 90, 
13, 4 and 2 for (pseudo)gout. SCTD=systemic connective tissue disease;
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difference with males 4.4 mm) and younger patients (p=0.016, 0.2 mm lower scores per year 
older) reported more severe fatigue.
Improved treatment strategies and the course of fatigue in RA
In general, improved treatment strategies in RA have resulted in improved disease outcomes. 
To validate this notion in present dataset, we explored the association of the described 
treatment strategies with the severity of radiographic progression. A significant difference 
in radiographic progression was observed between the three groups: with delayed DMARD-
treatment as reference (inclusion 1993–1995), patients early treated with mild DMARDs 
(inclusion 1996–1998) had 0.97-fold less severe radiographic progression per year (p=0.026) 
and patients early treated with methotrexate followed by DAS-steered treatment (inclusion 
1999–2007) had 0.92-fold less severe radiographic progression per year (p<0.001, figure 3A). 
We also evaluated whether the median number of swollen joints over time was different for 
the patients with RA treated with different treatment strategies. Indeed, improved treatment 
strategies associated with a reduction in SJC during disease course: with the delayed treatment 
group (1993–1995) as reference, patients early treated with mild DMARDs (1996–1998) had 
1.4 less swollen joints (p=0.005) over 8 years and patients early treated with methotrexate 
(1999–2007) had 3.6 less swollen joints over 8 years (p<0.001) (figure 3B). In line with these 
observations, we hypothesised that improved treatment strategies also associated with a less 
severe fatigue course. However, no univariable association was observed. Patients with RA 
Table 2. Fatigue severity at disease onset in relation to clinical variables at disease onset in rheumatoid arthritis
Effect size in 
mm (SE)
p-value Effect size 
in mm (SE)
p-value
Univariable analyses Multivariable analysis
Female 7.1 (3.4) 0.040* 7.6 (2.3) 0.001*
Age at onset, per year -0.004 (0.1) 0.95 -0.01 (0.1) 0.20
Symptom duration, per week 0.1 (0.02) <0.001* 0.1 (0.02) <0.001*
Morning stiffness duration, per minute 0.04 (0.01) <0.001* 0.03 (0.01) 0.002*
SJC, per joint 0.4 (0.2) 0.010* -0.3 (0.2) 0.071
TJC, per joint 1.4 (0.2) <0.001* 1.1 (0.2) <0.001*
CRP, per mg/L 0.1 (0.05) 0.072 0.1 (0.03) 0.096
Hb, per mmol/L -3.6 (1.2) 0.002* -0.9 (1.5) 0.54
ACPA-positivity -4.3 (3.0) 0.15 -7.9 (2.6) 0.003*
RF-positivity -0.3 (2.4) 0.90 3.8 (2.7) 0.15
SHS, per point 0.02 (0.2) 0.93
*p<0.05.
Presented are the results of the analyses on 902 patients with RA with fatigue severity at disease onset as outcome and 
the other variable at disease onset as independent variable. Variables with p-values <0.05 in univariable analyses and 
clinically relevant variables were included in multivariable analysis. The effect sizes indicate how much the fatigue 
severity at disease onset on a 0–100 mm scale changed with 1 unit increase in the other variable at disease onset. 
For example, women have a 7.1 mm higher fatigue severity at baseline compared to men and the fatigue severity 
measured at disease onset increased 1.4 mm per tender joint.
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Figure 2. The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. Presented are the 
median values with IQR of fatigue severity in 626 early patients with RA with missing data imputed. The numbers of 
patients with available data per year were: 510 for baseline, 350 for year 1, 298 for year 2, 280 for year 3, 266 for year 
4, 251 for year 5, 208 for year 6, 192 for year 7 and 166 for year 8.
Table 3. Fatigue severity over 8 years in relation to the course of inflammation and other variables in rheumatoid 
arthritis
Effect size in mm 
(SE)
p-value Effect size in mm 
(SE)
p-value
Univariable analyses Multivariable analysis
Female 6.1 (1.7) <0.001* 4.4 (1.9) 0.022*
Age at disease onset, per year -0.2 (0.1) 0.043* -0.2 (0.1) 0.016*
SJC, per joint 0.7 (0.1) <0.001* 0.3 (0.1) 0.022*
TJC, per joint 1.1 (0.1) <0.001* 1.0 (0.1) <0.001*
CRP, per mg/L 0.1 (0.03) <0.001* 0.1 (0.04) 0.049*
Hb, per mmol/L -3.6 (1.2) 0.003* -0.9 (1.1) 0.38
ACPA-positivity -0.5 (2.0) 0.79 0.4 (2.1) 0.84
RF-positivity -3.3 (1.7) 0.053 -1.9 (2.1) 0.36
SHS, per point -0.1 (0.1) 0.14
Presented are the results of the longitudinal analyses in 626 patients with RA. Variables with p-values <0.05 in 
univariable analysis and clinically relevant variables were included in multivariable analysis. The outcome (fatigue) 
and the clinical variables SJC, TJC, CRP, Hb and SHS were measured yearly. Gender, age, RF and ACPA were 
determined at disease onset. The effect sizes indicate how much the fatigue on a 0–100 mm scale change with 1 unit 
increase in the other variable. For example, 1 mg/L increase in CRP is associated with a 0.1 mm increase in fatigue 
severity measured at the same time point during 8 years follow-up and women have a 6.1 mm higher fatigue score at 
every time point over 8 years than men. 
early treated with mild DMARDs or methotrexate did not experience less severe fatigue over 
time compared to patients treated with initial treatment with NSAIDs and delayed DMARD-
therapy (p=0.80 and p=0.79, respectively, figure 3C). This indicates that despite improved 
treatment strategies and subsequent decreased inflammation-levels during the disease course, 
the fatigue severity in RA remained unchanged.
DISCUSSION
Although fatigue in RA is convincingly known to be associated with functional loss and is 
considered an important outcome measure for clinical trials 8,9, little is known on its long-
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term course. Furthermore, the results of existing studies on the causation of fatigue were 
conflicting with regards to whether fatigue is associated with inflammatory markers. This 
large longitudinal study evaluated the course of fatigue in RA and observed that patients with 
higher inflammatory markers (more tender/swollen joints, higher CRP-level) over time also 
experienced more severe fatigue over time. Hence, persistence of inflammation is statistically 
significant associated with more severe fatigue, but the observed effect sizes were small. 
Furthermore, improved treatment strategies did not result in a less severe fatigue course.
Previous studies evaluating fatigue in RA observed inconsistent results on whether 
inflammation associated with fatigue. The majority of these studies had cross-sectional study 
designs or short follow-up 4 and were presumably underpowered to observe significance for 
small effects. Present study was powerful because of the repeated measurements during 8 
years follow-up and by the use of a statistical method that takes advantage of the correlation 
between the serial measurements. Although we clarified that a relation between persistent 
inflammation and persistent fatigue is present, the question is whether the observed effect 
sizes are clinically relevant. The minimal clinically important difference (MCID) for the VAS 
fatigue, which is the smallest improvement in score that is perceived as beneficial by patients, 
has been reported to be around 10 mm 28 and the unadjusted effect size per swollen joint was 
0.7 mm, indicating that per five additional swollen joints, fatigue severity increased with 3.5 
mm on a 0–100 mm scale. Although the observed effect sizes were small, when a combination 
of characteristics is present, for instance several tender/swollen joints and increased CRP, the 
limit of a clinically meaningful difference of fatigue is reached.
Based on the observed association between inflammation and fatigue and on 
the efficacy of improved treatment strategies on both inflammation and radiographic 
progression, we hypothesised that these treatment strategies had resulted also in less severe 
fatigue. The inclusion periods were used as proxies for treatment strategy. A limitation is 
that other (unmeasured) factors changed over time as well. Nonetheless, patients with RA 
treated according to nowadays regimens experienced equally severe fatigue as patients 
initially treated with NSAIDs and initiation of DMARDs with delay. This finding might be 
unexpected as the latter patient group had less severe inflammation over time (for instance 
lower SJCs) and we had observed that less inflammation associated with less severe fatigue. 
Apparently other factors with contrary effects on fatigue were present as well.
We then hypothesised that patients treated with nowadays regimens and consequently 
with less inflammation during the disease, rated their fatigue higher and therefore the 
decrease in levels of inflammation was not accompanied by a decrease in fatigue severity. To 
gain support for this hypothesis, an additional multivariable analysis including inflammatory 
markers and the applied treatment strategy (inclusion period) was performed. This revealed 
that when adjusted for inflammatory measures, patients treated in most recent treatment 
group (inclusion 1999–2007) had indicated significantly more severe fatigue compared to 
patients included in 1993–1995 (p=0.013). Furthermore, SJC and CRP were not significantly 
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associated anymore (data are available from the corresponding author on request). This result 
is in line with that of Putrik et al 29 who observed that patients with RA in countries with 
higher welfare scored worse on patients-reported outcomes like fatigue despite lower levels 
of inflammation. Also in line is a study that compared patients with RA in 1985 and 2000, 
showing that improvement in objectively measured disease outcomes was not accompanied 
by improvement in patient-reported pain 30. Although causality can never be proved using 
association analyses, a similar effect might explain the persistence of fatigue despite decreased 
levels of inflammation. Present results, at least illustrate the multidimensional origin of 
fatigue and imply that non-inflammatory pathways are relevant as well. Consequently, other 
types of intervention should be initiated to reduce the disease burden caused by fatigue 31.
Notably, biologics were rarely used in the patients with RA studied here (<5%) 24; 
Figure 3. Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of 
swollen joints (B) and fatigue severity over time (C). Presented are three long-term outcomes in relation to treatment 
strategies. Treatment strategies are reflected by different inclusion periods as the initial treatment strategy differed 
for different inclusion periods. The inclusion period 1993–1995 comprised 100 patients, 1996–1998 166 patients and 
1999–2007 360 patients. Radiographic progression: 1993–1995=reference, 1996–1998 β=0.97 p=0.026; 1999– 2007 
β=0.92 p<0.001. The β indicates the fold rate of joint destruction per year compared to the reference. Swollen joint 
count: 1993–1995=reference, 1996–1998 effect size=−1.4 p=0.005; 1999–2007 effect size=−3.6 p<0.001, omnibus 
test for overall significance of model p<0.001. The effect size indicates the difference in number of swollen joints 
compared to the reference. Fatigue severity: 1993–1995=reference, 1996–1998 p=0.80; 1999–2007 p=0.79; omnibus 
test for overall significance of model p=0.96.
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other studies are needed to determine whether treatment with biologics differently affect 
fatigue severity in RA.
We observed more severe fatigue in female patients with RA. This is in line with 
results obtained in other studies 4. Sex differences in RA have been reported not only for 
fatigue but also for other patient-reported out-comes like pain, function and global status 
with female having worse scores 32,33.
The fatigue data were non-normally distributed. To prevent that a small proportion 
of patients disproportionally affected the study results, quantile regression analyses were 
performed. This method models medians instead of means and is more robust to outliers. 
Over time patients had missing data, both on fatigue and other variables. Since these missing 
values were not completely at random, analyses of available data may introduce bias 34 and 
therefore, multiple imputation was performed. However, no large differences are seen in the 
8-year course of fatigue when using available data only and after imputation of missing values 
(data are available from the corresponding author on request).
We performed analyses on group level. We realise that this inflicts simplicity of reality 
because changes of individuals are averaged. However, presumably, there are individual 
patients with a remarkable decrease in fatigue severity during disease course (in response 
to treatment or otherwise), while others may have stable or increasing levels of fatigue. To 
get some insight in this assumption, we evaluated fatigue severity on patient level during 
the first 2 years of disease. It was observed that during the first and second year of disease, 
respectively 49% and 62% of the patients had rather stable fatigue levels while the others had 
an increase or decrease in fatigue severity. Furthermore, it was observed that the patients with 
most severe fatigue were partly different at different time-points (data are available from the 
corresponding author on request). This indicates that on patient level fatigue severity can 
differ during the disease course and that on group level fatigue remains a persistent problem 
in RA.
We measured fatigue severity using a VAS. Several other fatigue measures are available; 
these are multi-item or multidimensional measures that explore broader fatigue issues or 
various domains of fatigue. Such multidimensional measures are useful for exploring fatigue 
causality and evaluation of fatigue interventions. Compared to such tools, a VAS provides a 
one-dimensional assessment of fatigue that is focused on its severity. Advantageous of the 
VAS is that it is simple to administer. Also the test-retest, construct validity and sensitivity to 
change in RA are reported to be good 17.
Present study mainly focused on the longitudinal course of fatigue in patients with 
RA, though we also evaluated whether fatigue severity of patients with RA differed to fatigue 
experienced by patients with other forms of early arthritis. Patients with SCTD and RS3PE 
had significantly more severe fatigue and patients with UA, PsA/SpA or septic arthritis had 
significantly less fatigue compared to patients with RA. However, some of the observed 
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differences were small and it can be questioned whether these differences are clinically 
relevant. The differences observed at baseline remained present over time. To the best of our 
best knowledge, this has not been reported on this scale previously.
To conclude, in this large longitudinal study on fatigue in RA, fatigue was a persistent 
problem, despite treatment. The median level of fatigue experienced by a population-based 
cohort of patients with RA remained even after many years of disease around 40 mm and the 
applied treatment strategies did not reduce fatigue levels. Therefore, as persistent fatigue is 
associated with functional loss, fatigue in RA remains an ‘unmet need’.
SUPPLEMENTARY DATA
Supplementary data are available from the author on request.
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In this thesis, studies were performed on the very early and early phases of rheumatoid 
arthritis (RA). In Part I, the phase of Clinically Suspect Arthralgia (CSA) was investigated. 
Since it became clear that early aggressive treatment of RA has much more effect in 
terms of preventing joint damage progression and achieving remission, a challenge in the 
rheumatologic field is now to identify and treat RA as soon as possible. The earliest moment 
to clinically recognise patients who may develop RA is the phase of CSA. In Part II and III, 
studies were performed within early RA. In Part II, genetic risk factors for a more severe 
disease course, mainly joint damage progression, were studied. These studies contributed to 
our understanding of processes that are fundamental to disease progression. Part III focussed 
on other outcomes in RA, among which patient-reported outcomes. 
PART I: THE PHASE OF CLINICALLY SUSPECT ARTHRALGIA
This thesis started (Chapter 2) with a review on literature on the preclinical phases of 
RA 1. This revealed that there is convincing evidence that autoantibody development and 
maturation occurs before clinically detectable arthritis develops and suggestive evidence 
that systemic and local inflammation are already present in this phase. RA development can 
thus be considered a multiple hit process in which RA-related processes can be active already 
years before RA is diagnosed. The studies reviewed were mainly performed in autoantibody-
positive populations and we observed that studies on the preclinical and very early phases of 
autoantibody-negative RA were scarce. This review ended with a research agenda for studies 
on the very early phases of RA.
The phase of symptoms without clinically apparent arthritis is the first moment that 
imminent RA can be clinically recognised. Since the symptoms that are characteristic for 
this phase are not yet known 1, we studied this phase by investigating patients with Clinically 
Suspect Arthralgia (CSA). CSA was defined as arthralgia without clinically detectable 
arthritis that was considered by the rheumatologist clinically suspect to progress to RA 
and thus, the decision on whether a patient had CSA depended on the clinical expertise of 
the rheumatologist. In addition, the decision on the presence of CSA was made at the first 
visit before additional tests were performed and thus did not depend on the autoantibody-
status of the patient. This concept differed from that used in other studies focusing on this 
symptomatic phase that studied autoantibody-positive patients with unspecified arthralgia or 
non-specific musculoskeletal symptoms 2–4. The advantage of the CSA approach is that it is in 
line with the clinical practice where patients present with certain symptoms and the decision 
to perform additional investigations is based on the clinical presentation. Furthermore, it 
allows identification of both autoantibody-negative and autoantibody-positive RA in the 
early symptomatic phase. 
The set-up of the rheumatology outpatient clinic of the Leiden University Medical 
Centre is uniquely suited to identify patients in very early disease phases. General practitioners 
have been encouraged for several years to refer any patient with a suspicion of arthritis. The 
237Summary and discussion       |
17
start of an Early Arthritis Recognition Clinic (EARC) in 2010, initially aimed to improve 
early detection of clinical arthritis, also provided an excellent opportunity to identify patients 
with CSA 5. Since 2012 these patients have been included in an observational cohort and 
these patients were studied in this thesis.
In Chapter 3, we investigated the characteristics of patients with CSA at inclusion 
in the cohort. Subclinical inflammation of hand and foot as measured by MRI was present 
in 44% of the CSA patients. Subclinical MRI-inflammation was here defined as a RAMRIS 
MRI-inflammation score of ≥3. This cut-off was quite arbitrarily but based on MRI-findings 
of 19 symptom-free persons in which a score of ≥3 was rare. Furthermore, 28% of the CSA 
patients were positive for RA-related autoantibodies. We observed that CSA patients with 
MRI-inflammation were older and more frequently ACPA-positive than patients without 
MRI-inflammation. However, a combination of clinical and serological characteristics 
incompletely differentiated patients with and without MRI-inflammation. These data 
suggested that the information provided by MRI cannot be easily replaced by commonly 
used clinical and serological markers and that MRI-detected inflammation may have some 
diagnostic value. This was later on, in Chapter 5, further explored. 
Studies on the preclinical and very early phases of RA that were performed by other 
groups thus far were mainly done in patients carrying autoantibodies and the very early 
phase of autoantibody negative RA was relatively unexplored. Therefore, in Chapter 4, we 
studied subclinical MRI-inflammation in ACPA-negative CSA patients and observed that 
RAMRIS MRI-inflammation scores of ACPA-negative CSA patients were significantly higher 
than those of 19 age-matched symptom-free controls. This suggested that ACPA-negative RA 
has, similar as ACPA-positive RA 6 an early phase of symptoms without clinical arthritis in 
which subclinical MRI-inflammation is present. 
In Chapter 5, we studied patients with CSA and the presence of subclinical MRI-
inflammation in these patients for the first time longitudinally. However, a relevant issue of 
the use of MRI in the early phases of RA is that MRI is a very sensitive imaging technique 
and it is unknown which scores should be considered as normal and which reflect pathology. 
Data of several MRI-studies on small numbers of symptom-free persons (including the 
MRI-data in symptom-free persons used in Chapter 3 and 4) showed ‘MRI-abnormalities’ 
to some extent, but were difficult to compare because different MRIs, scanning protocols 
and scoring methods were used 7. Therefore, we recently performed a large-scale MRI-
study in 193 symptom-free persons recruited from the general population 8. MRI-detected 
inflammation was prevalent in these persons without joint symptoms as 72% had a RAMRIS 
MRI-inflammation score ≥1; synovitis and BME were more prevalent than tenosynovitis. 
MRI-inflammation was especially prevalent at higher age and at preferential locations 
(MCP2, MCP3, wrist and MTP1 joints). These findings suggested an influence of aging, 
which was observed both in these symptom-free persons as in the CSA patients studied in 
Chapter 3, and potentially of mechanical strains because some of the preferential locations 
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for MRI-inflammation in the symptom-free persons are also known as preferential location 
for arthritis and destruction in RA. Based on these data of MRI-findings in symptom-free 
persons reference values for a normal MRI were suggested. These values were specified for 
age, MRI-feature and anatomic location. To prevent false-positive MRIs in our CSA patients, 
we applied these reference values to define the presence of subclinical MRI-inflammation for 
our study within CSA patients. 
Within our longitudinal study in patients with CSA (Chapter 5) we observed that 17% 
of all patients progressed from CSA to clinical arthritis within the first year after inclusion. 
Patients with subclinical MRI-inflammation had an increased risk to develop clinical arthritis 
as 31% of the patients with a positive MRI developed arthritis within one year. The majority 
did so within the first 4-5 months after inclusion, indicating that the period of CSA and 
subclinical inflammation is relatively short. When subclinical MRI-inflammation was absent, 
progression to clinical arthritis was rare (6%). In addition, we observed that tenosynovitis 
was more predictive than synovitis and BME as it associated independent of the other MRI-
features with arthritis development. Tenosynovitis is uncommon in the general population 
8, has been reported to be frequently present in early RA 9 and has been demonstrated to be 
present in mice in the preclinical phase before synovitis developed 10. Together, these data 
may suggest that tenosynovitis may be a very early and potentially the initiating feature in 
arthritis development. Repeated MRI with short-time intervals during the process of arthritis 
development would give more insight in the timing of pathologic events occurring inside the 
joints. Within CSA, also ACPA-positivity associated with progression from CSA to arthritis. 
Both the presence of subclinical MRI-inflammation and ACPA-positivity were independently 
predictive for arthritis development. We used the presence and absence of MRI-inflammation 
and ACPA to stratify CSA patients in groups with different risks on arthritis development. 
Although the absolute value of MRI might be higher in ACPA-negative than in ACPA-
positive CSA patients because ACPA-positive patients had already a higher prior risk of 
arthritis development, present data suggested that MRI is diagnostically relevant in the phase 
of CSA. This role is probably located in both identifying patients with an increased risk of 
arthritis development and ruling out imminent arthritis. The latter because the prior chance 
of arthritis decreased from 9% to 3% in the ACPA-negative CSA patients when the MRI was 
negative and from 63% to 40% in the ACPA-positive patients.
The decision on whether a patient had CSA was based on the clinical expertise of 
the rheumatologist as the symptoms that are characteristic for the early symptomatic phase 
of RA are not well-characterised. In Chapter 6, we studied the value of clinical expertise 
as selection criterion for CSA. Clinical expertise is a valuable tool in the medical and also 
specifically for the rheumatologic diagnostic process. For example, the clinical expertise was 
used in the process to develop the 2010 ACR/EULAR criteria for RA 11 and for the set-up of 
the French ESPOIR cohort 12. We observed that clinical expertise is also useful for selecting 
arthralgia patients at risk of RA because arthralgia patients that were considered by their 
239Summary and discussion       |
17
rheumatologist to have CSA had an odds ratio of 55 to develop RA compared to arthralgia 
patients not considered to have CSA. 
In Chapter 7, we aimed to define the clinical characteristics of patients with 
arthralgia who are considered at risk of RA. It can be assumed that interventions in the 
symptomatic phase preceding the onset of clinical arthritis may be more effective in terms 
of reducing the risk of disease persisting and preventing joint damage. However, studies to 
address this require the inclusion of homogeneous sets of patients. Therefore, with a EULAR 
taskforce comprising 18 rheumatologists, a methodologist, 3 health professionals, 2 patients 
and a research fellow we defined a set of clinical features that best characterise patients with 
arthralgia that are according to the clinical expert-opinion at risk of RA development. A three-
phase process was used consisting of 1) identifying relevant items using a Delphi approach, 
2) deriving candidate criteria by evaluating patients that were presented on paper and 3) by 
validating the criteria with newly referred arthralgia patients. The following set of parameters 
that describe arthralgia at risk of RA was defined: joint symptoms of recent-onset (duration 
<1 year), symptoms located in MCP joints, duration of morning stiffness 60 minutes, most 
severe symptoms present in the early morning, presence of a first-degree relative with RA, 
difficulty with making a fist and positive squeeze-test of MCP joints. In the validation phase, 
this combination of parameters was accurate in identifying arthralgia patients that were 
considered at risk of RA development as the AUC was 0.92. Test characteristics belonging 
to the number of positive parameters were presented and depending on the study a more 
sensitive or specific definition can be used.
Further perspectives on studies within CSA
In short, based on this thesis we learned that:
• The clinical expertise is useful to identify arthralgia patients who may develop RA, 
because patients with CSA are at increased risk of developing arthritis.
• Both ACPA-positive and ACPA-negative RA have a phase with CSA and MRI-detected 
subclinical inflammation. 
• MRI-detected subclinical inflammation might have a diagnostic value in patients with 
CSA. This is true for both ACPA-positive and ACPA-negative patients but the absolute 
value might be higher in ACPA-negative patients.
• The developed definition of arthralgia at risk for RA which represents the consensus-
based expert opinion of rheumatologist can serve as basis for future studies and trials in 
the CSA phase.
Our approach to study the symptomatic phase of RA without clinical arthritis is in line with the 
care at Dutch rheumatologic outpatient clinics. Therefore this might allow implementations 
of the results obtained in this thesis in Dutch rheumatologic care. However, first, replication 
of our findings in independent CSA populations, which do not yet exist, is needed. 
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To address the question whether intervention in the symptomatic phase preceding 
arthritis development is beneficial it is needed that patients with arthralgia with an increased 
risk on RA are identified. To this end, the risk factors for progression from CSA to clinical 
arthritis that we identified in our CSA cohort are helpful as they will contribute to accurate 
risk stratification within CSA. Subclinical MRI inflammation and ACPA were the most 
important risk factors and we performed risk stratification based on these two factors. 
However, our CSA population was too small to develop a full prediction model which may 
provide most accurate risk stratification. Such a prediction model, including all potential 
predictors (such as patient characteristics, symptoms, findings at physical examination, 
serological inflammation markers, different autoantibodies and MRI-inflammation), will 
reveal which factors are independently predictive for the development of arthritis and may 
allow to stratify the risk of arthritis/RA development more accurately. To this end, a large 
CSA population is needed of which part can be used for identification and the other part for 
validation. In addition, to perform trials in the symptomatic phase it is important to include 
a homogeneous group of patients. For this, the consensus expert-opinion based definition of 
CSA consisting of 7 clinical items is helpful. However, it is unknown how good this definition 
is in identifying patients who will later on progress to RA (thus the predictive accuracy of the 
definition). Therefore, a subsequent prospective study is needed in which patients with CSA 
according to the definition will be longitudinally followed on the development of RA. The 
diagnostic accuracy of the clinical definition alone is most likely not highly accurate because it 
is only based on clinical features. Presumably, combining the clinical definition with findings 
of additional investigations, such as results of serological tests (f.e. ACPA, RF and/or CRP) 
or imaging (f.e. MRI or US) will improve the diagnostic accuracy and will results in criteria 
for ‘imminent RA’. This process is similar as the process that first led to the definition of 
inflammatory back pain which was subsequently integrated in the ASAS classification criteria 
13,14. Future research in which our own CSA cohort might be part of a large international 
prospective study with multiple cohorts will hopefully result in accurate risk stratification 
and can be the basis of dedicated trials. 
We observed that MRI-detected subclinical inflammation might have a diagnostic 
value in patients with CSA and that MRI-detected tenosynovitis was most predictive for 
progression from CSA to clinical arthritis. This thesis comprised the first MRI-studies 
in patients with CSA. Further studies are needed to determine if the diagnostic value of 
MRI can be improved by assessing for example MRI-inflammation at specific locations or 
combinations of MRI-features. In addition, the value of other imaging techniques such as 
ultrasonography (US) in the CSA phase is not yet determined. Although MRI and US can 
both depict tenosynovitis, MRI has several advantages compared to US, such as that MRI is a 
minimal operator-dependent procedure and the presence of a validated scanning and scoring 
protocol for MRI 15. If validated scanning and scoring protocol for US will become available, 
further studies are needed to assess the value of US in CSA.
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Next to studies on predicting which CSA patients will progress to clinical arthritis, 
longitudinal studies within CSA patients may also provide more insight in mechanisms 
underlying RA development at both systemic and local levels. Biomarkers, such as gene 
expression profiles and autoantibody profiles can be assessed and related to MRI-detected 
inflammation and arthritis development. Longitudinal MRIs in individual patients will shed 
light on what happens inside the joints. Comparing MRIs performed in CSA and in the early 
clinical arthritis phase will reveal whether the extent and localisation of MRI-inflammation 
change during conversion from CSA to clinical arthritis. 
Furthermore, additional work is needed for early identification of RA (at risk) within 
the primary care. General practitioners (GPs) have, as gatekeeper for access to rheumatologic 
care, an important role in early identification of patients with (an increased risk of) RA. GPs 
work in populations with different background risks and the symptoms that are characteristic 
for RA at risk in the GP population are unknown. Their guideline recommends that patients 
suspected for RA should be referred on short-term, but no specific recommendations on 
the symptoms and signs that should be assessed before referral are included 16. The set-up 
of an EARC has improved the identification of early arthritis substantially 5, but whether 
knowledge on symptoms that are predictive for RA (at risk) in the GP population and the 
development of a referral tool would improve early identification further should be subject of 
subsequent studies.
Summary of research agenda:
• Replication of the findings done in our CSA cohort in independent CSA cohorts.
• To identify with high accuracy a homogenous group of CSA patients who will 
progress to RA. Additional risk factors for progression to RA should be identified 
that can contribute to dedicated risk stratification and might finally result in criteria 
for ‘imminent RA’. The EULAR definition for CSA and European collaboration of the 
taskforce may be helpful to this end. 
• If we can identify arthralgia patients at risk accurately, trials will reveal whether 
intervention can prevent onset of clinical arthritis, disease chronicity, functional 
disability or quality of life or whether it will reverse subclinical MRI-inflammation.
• Evaluating whether the diagnostic accuracy of MRI-detected inflammation in the CSA 
phase can be improved by evaluating f.e. specific locations and/or combinations of 
MRI-features.
• Evaluating of the value of imaging modalities such as ultrasonography and PET-CT in 
the CSA phase.
• Examining the sequence of pathologic events that occur in the period between onset of 
CSA and arthritis development both on systemic and local level in longitudinal studies. 
 ◆ Systemic level:  gene expression profiles, serological inflammatory markers and 
epitope spreading of (different) autoantibodies. 
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 ◆ Local/joint level: repeated MRIs and determining the timing of the inflammatory 
features that are visualised (synovitis, tenosynovitis, BME, erosions).
• Development of referral tool for first line care in order to further decrease the time of 
referral to second line care of patients at risk of or with RA.
PART II: GENETIC FACTORS AND DISEASE OUTCOME IN RHEUMATOID 
ARTHRITIS
In this part, genetic risk factors for a more severe course of RA were investigated. Studying 
genetic variations in relation to disease outcome can increase our comprehension of disease 
progression, may convey novel targets for focused therapy and may improve personalised 
medicine. The main studied outcome was joint damage progression, one of the hallmarks of 
RA which can be measured objectively by scoring radiographs of hands and feet using the 
Sharp-van der Heijde scoring method 17. The other studied outcome was arthritis persistence 
which is the other hallmark of RA and can be investigated by studying its opposite, the 
achievement of DMARD-free sustained remission 18. 
For present studies, we selected patients fulfilling the 1987 ACR criteria for RA. In 
our view, these criteria for patient selection were most appropriate to perform basic research 
as the use of the 2010 ACR/EULAR criteria would have resulted in a more heterogeneous 
study population 11. 
Prediction of joint damage severity on the level of the individual patients is not 
yet accurate, hampering individualised treatment. Matrices developed to predict rapid 
radiographic progression correctly classified only approximately half of all patients 19–21 and 
are not used in clinical practice. At the start of this thesis, several genetic risk factors had 
been found to be associated with joint destruction in previous studies 22–32. When adding 
these genetic factors to a prediction model for radiographic progression that already included 
traditional factors, we observed that the predictive accuracy improved from 56% correct 
classifications to 62% (Chapter 8). In addition, genetic risk factors together explained 12-18% 
of the variance in radiographic progression. However, still 38% of patients were incorrectly 
classified by the full model and we considered the predictive performance of the derived 
model including genetic factors insufficient for use in clinical practice.
Replication of findings is crucial in the field of genetics. Therefore, in addition to 
the Leiden Early Arthritis Clinic (EAC) cohort 33, several other cohorts were used in the 
studies on genetic risk factors, including the Swedish Umeå 34, Spanish HCSC-RA 35, North-
American Wichita 36, NDB 37 and NARAC 38, and French ESPOIR 12 cohorts. These cohorts 
were all smaller than the EAC cohort and comprised less radiographs over time, though 
could be used to replicate and substantiate observed associations. In Chapter 9, the initially 
published finding that a variant in FOXO3A was associated with joint damage progression in 
two cohorts of the UK 39 was not replicated in five other cohorts suggesting that FOXO3A is 
not a major factor regulating the severity of the course of RA. 
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Using candidate-gene approaches, we identified two genetic variants that were 
associated with joint damage progression within the ACPA-negative RA population. This 
is relevant because the large majority of risk variants for progression have been identified 
in ACPA-positive or pooled populations. First, rs9138 in SPP1, initially identified as 
susceptibility variant for RA 40 and encoding osteopontin which has a function in bone 
formation and remodeling was observed to associate with radiographic progression within 
ACPA-negative RA (Chapter 10). Second, in Chapter 11, variants that have been described 
to associate with radiographic progression but for which the results of different studies were 
incongruent were studied in six cohorts. Rs2900180 in C5-TRAF1 significantly associated 
with radiographic progression; the association was confined to the ACPA-negative subgroup. 
The region of rs2900180 in C5-TRAF1 was fine-mapped and another variant had a stronger 
association, but we could not statistically distinguish which variant was most important. 
The studied variants in IL-6, IL-10, and FRCL3 were not associated and the initial findings 
on these variants done in studies with lower patient numbers and radiographs could be 
considered false-positive, underlining the relevance of replication of findings. For both 
rs9138 in SPP1 and for rs2900180 in C5-TRAF1 there was data available that the (region of 
the) variant is related to expression on RNA or protein level 40–42. These studies, done on the 
level of genetics and expression suggested that the identified regions are relevant in pathways 
mediating disease progression.
The HLA-DRB1 region is the most important genetic risk factor for both RA 
development and progression that is identified thus far. In particular the SE alleles, sharing 
a similar amino sequence at position 70-74 in the peptide-binding groove, and acting via 
ACPAs on disease development and outcome, are relevant 22,43,44. However, the underlying 
biological pathway is not yet unravelled. Recently, a further refinement of the association of 
HLA and RA was proposed. Using advanced statistical methods, the strongest association 
with RA development was reported for HLA-DRB1 position 11 (or 13 which are in high 
linkage disequilibrium); this association was independent of the SE alleles 45,46. Studying four 
cohorts, we observed that the amino acids Valine or Leucine at position 11 were associated 
with joint damage progression (Chapter 12). This association was independent of the 
presence of the SE alleles but not independent of ACPA. Future studies will reveal whether 
taking position 11 and 13 into account will be helpful in identifying the pathogenic antigens 
that result in immune activation and autoantibody production, thereby stimulating disease 
development and progression.
In Chapter 13, a candidate-gene study on arthritis persistence (the absence of 
achieving DMARD-free sustained remission) was performed. Genetic risk factors for joint 
damage progression were studied in relation to persistence and it was observed that besides 
the HLA-DRB1 SE alleles, rs2104286 in IL2RA was associated with arthritis persistence in 
two cohorts. In addition, lower soluble IL2Rα (CD25) levels associated with a higher chance 
of remission. Intriguingly, IL2RA and SE are the only variants identified thus far that are 
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associated with RA development, joint damage progression and persistent inflammation. This 
underlines the relevance of these variants, but also suggested that the mechanisms driving 
joint damage progression and disease persistence are partially different. 
In Chapter 14, serum level osteoprotegerin (OPG) was studied in relation to arthritis 
persistence. Besides the well-known role of OPG in bone metabolism, OPG also has pro-
inflammatory effects and it was reported that the serum level was associated with achieving 
Disease Activity Score (DAS)-remission the next year 47. Here, we replicated this latter finding. 
In addition, OPG level also associated with DMARD-free sustained remission. Together 
these data suggested that OPG levels are reflective of a process influencing the severity of 
inflammation both on the short and long-term.
Further perspectives on studies on risk factors for disease outcome 
Including the genetic risk factors identified in this thesis, thus far, fourteen genetic variants 
have been identified and were replicated to associate with radiographic progression: HLA-
DRB1, CD40, IL15, DKK1, IL2RA, GRZB, IL4R, SPAG16, C5orf30, MMP9, intergenic 
downstream of ZFP36L1 and C14orf181, OPG, SPP1 and C5-TRAF1. We observed that these 
variants together explained approximately 20% of the variance in radiographic progression. 
This cannot be directly compared to the estimation that 45-58% of the severity of joint damage 
is heritable which was estimated in Icelandic RA patients 48, but it suggests that part of the 
heritability is still missing. In line with this, we observed that radiographic progression could 
not be accurately predicted using all known, both traditional and genetic, risk factors. This 
‘missing heritability’ might be explained by not yet identified common genetic variants that 
associate with joint damage, rare variants with large effects on joint damage or by gene-gene 
or gene-environment interactions. To this end, radiographic data of several cohorts should be 
combined to enable large studies.
The other long-term outcome that was studied was arthritis persistence (the absence 
of achieving DMARD-free sustained remission). It is likely that achieving DMARD-free 
sustained remission will become a preferred treatment goal in the future, but only few risk 
factors for arthritis persistence are known thus far. We performed a candidate-gene study and 
hypothesised that genetic risk factors for joint damage might also be risk factors for arthritis 
persistence. This approach sounds reasonable as both outcomes are a reflection of the long-
term disease course. However, in fact there is no clear evidence that underlying processes 
of joint damage and arthritis persistence are overlapping. In addition, it is unclear whether 
the patients with severe joint damage are similar to the patients with persistent arthritis. 
Ideally, we had performed a hypothesis-free genome-wide association study (GWAS) or had 
analysed the whole Immunochip 49 in relation to arthritis persistence. Unfortunately, this 
was hampered by the low frequency of DMARD-free sustained remission and the absence 
of multiple cohorts with data on this disease outcome. Collection of data on this outcome in 
multiple cohorts would allow such large genetic studies.
245Summary and discussion       |
17
Thus far, multiple genetic risk factors have been identified for RA development or 
disease progression within RA. Previously, it was observed that the genetic variants that are 
associated with susceptibility to RA and joint damage progression of RA are largely different 
30. In this thesis, we studied the genetic risk factors for joint damage, which are mainly 
located in genes involved in inflammation, immunity or bone/cartilage metabolism, in 
relation to arthritis persistence and observed that also these were largely non-overlapping. 
The HLA-DRB1 alleles and a variant in IL2RA, both located in genes involved in immunity/
inflammation, were the only variants that associated with both joint damage progression and 
arthritis persistence. Variants in genes involved in bone/cartilage metabolism associated with 
joint damage, but not with arthritis persistence. Overall, these data suggest that the processes 
driving the development of RA, progression of joint damage within RA and persistence of 
arthritis within RA are largely different. However, further studies are needed to unravel these 
pathways and to give more insight in whether the identified variants are causal and how 
these variants are involved in disease development and disease progression. For this, large 
fine-mapping studies and functional studies are needed, respectively to identify all variants 
that are linked to the variants with the strongest association and to determine the potential 
functional consequences of these variants. Recent advances in technology and bioinformatics 
may be helpful to this end 50. 
In addition, we found 2 serological biomarkers that were associated with arthritis 
persistence, i.e. high soluble IL2Rα and OPG levels. These findings might give additional 
clues for targeted intervention. Interestingly, lowering soluble IL2Rα (CD25) levels with 
anti-CD25 (daclizumab) have been shown to be effective in multiple sclerosis 51. In addition, 
upregulation of regulatory T-cells with low-dose IL2 was beneficial in type 1 diabetes 52. 
Further research on longitudinal measured biomarker levels would reveal the relevance of 
specific serological biomarkers for arthritis persistence and their potential role in guiding 
treatment decisions.
PART III: OTHER OUTCOMES IN RHEUMATOID ARTHRITIS
Due to improved treatment strategies, severe joint damage is less prevalent nowadays and 
therefore, other outcome measures will become more important. A good candidate would 
be arthritis persistence and its opposite achieving DMARD-free sustained remission, which 
is the closest proxy of cure of RA and can be assessed rather objectively 18. This outcome 
was used in Chapter 13 and 14. In Chapter 15, the occurrence and relevance for patients of 
achieving DMARD-free sustained remission was studied. We observed that with nowadays 
treatment strategies the chance to achieve this favourable outcome is increased. It was 
observed that also from patient perspective achieving DMARD-free sustained remission 
is an outcome to pursue as this status reflected resolution of symptoms and disability. This 
underlines the relevance of this outcome.
Patient-reported outcomes such as fatigue, functional ability and work ability are 
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also important 53 outcome measures in RA. Fatigue is a frequently reported symptom in RA, 
associated with functional disability and considered one of the most important outcomes 
by patients. The causation of fatigue in RA is thought to be multidimensional 54 and the 
contribution of inflammation in unclear. We studied the long-term course of fatigue (Chapter 
16) and observed that fatigue is a persistent problem in RA. In addition, the extent of 
inflammation over time significantly associated with the severity of fatigue though the effect 
sizes were small, indicating that non-inflammatory pathways should be considered important 
as well. Interestingly, improved treatment strategies that have resulted in less inflammation 
and improved objective outcomes of RA have not resulted in less severe fatigue. Therefore, 
fatigue in RA remains an ‘unmet need’.
FINAL CONCLUSIONS
The field of RA is moving into identification of patients as early as possible and the ultimate 
aim is to prevent RA becoming a chronic disease. To this end, the studies on the phase of 
Clinically Suspect Arthralgia (CSA), described in Part I of this thesis provided relevant 
insights. Patients with arthralgia that were considered by the rheumatologist to have an 
increased risk to progress to RA (CSA) had indeed an increased risk of RA. In addition, 
subclinical MRI-inflammation preceded clinical arthritis with a few months. Future research 
will shed more light on processes underlying progression from CSA to RA and effectiveness 
of treatment initiation in the CSA phase.
The severity of the course of RA is variable between patients and this cannot be yet 
accurately predicted. The studies in Part II and III contributed to the understanding of these 
differences in severity. Three genetic risk factors for more severe joint damage progression 
(two non-HLA and one HLA variation) and one for arthritis persistence were identified. 
Further research on functional implications of the identified variants and whether they might 
be useful as biomarkers to guide treatment decisions is needed. 
DMARD-free sustained remission, the opposite of arthritis persistence, will probably 
become an increasingly important outcome in RA as it approximates cure of RA, is relevant 
from patient perspective and is increasingly achievable nowadays although the majority 
of patients is not yet able to achieve this outcome. Future studies will reveal whether this 
beneficial outcome can be achieved more frequently when treatment is initiated in the phase 
of CSA.
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Reumatoïde artritis (RA) is een chronische ontstekingsziekte van met name de kleine 
gewrichten van de handen en voeten. Het is een veelvoorkomende ziekte, wereldwijd bij 0.5-1% 
van de bevolking, en treft vooral vrouwen van middelbare leeftijd. De gewrichtsontstekingen 
(artritis) die kenmerkend zijn voor RA gaan gepaard met pijn, zwelling en stijfheid en kunnen, 
als de ziekte niet goed behandeld wordt, leiden tot e destructie. RA is een systeemziekte wat 
inhoudt dat niet alleen de gewrichten, maar ook andere organen zoals de huid, ogen, hart 
en longen betrokken kunnen zijn bij de ziekte. Daarbij zijn systemische symptomen zoals 
vermoeidheid vaak aanwezig en is er bij RA een verhoogd risico op hart en vaatziekten.
 De oorzaken voor het ontstaan van RA zijn nog grotendeels onduidelijk, maar 
het wordt beschouwd als een auto-immuunziekte, omdat een groot deel van de patiënten 
autoantistoffen heeft. De autoantistoffen RF (reumafactor) en/of ACPA (anti-citrullinated 
peptide antibodies) komen bij ongeveer twee derde van de patiënten voor en vooral ACPA 
is kenmerkend voor RA. Waarom deze antistoffen aanwezig zijn en wat ze precies doen, is 
onbekend. Wel worden ACPA-positieve en ACPA-negatieve RA als twee subentiteiten van 
RA beschouwd met een verschillende genetische achtergrond en verschillend ziekteverloop, 
waarbij ACPA-positieve RA ernstiger is. Meer dan 100 genetische varianten zijn tot nu toe 
ontdekt die leiden tot een verhoogd risico op het ontwikkelen van RA. Dit geeft het belang 
van erfelijke factoren aan voor het ontstaan van RA. De meeste genetische risicofactoren zijn 
ontdekt voor ACPA-positieve RA waarvan de belangrijkste een groep HLA-genen zijn (de 
zogenaamde shared epitope allelen). Ook omgevingsfactoren spelen waarschijnlijk een rol bij 
het ontstaan van RA. Mensen die roken hebben een verhoogd risico op het krijgen van RA.
De behandeling van RA is de laatste twee decennia sterk verbeterd waardoor ernstige 
gewrichtsschade minder vaak voorkomt en het steeds vaker mogelijk wordt om remissie 
te bereiken en te behouden. Hieraan hebben zowel de ontwikkeling van nieuwe effectieve 
medicatie (disease-modifying antirheumatic drugs (DMARDs) en biologicals) als de 
verschuiving van een afwachtend beleid naar een beleid van direct ingrijpen als de ziekte 
zich presenteert bijgedragen. De bevinding dat het vroeg starten van de behandeling gunstig 
is voor het ziekteverloop heeft ertoe geleid dat de nadruk tegenwoordig ligt op het zo vroeg 
mogelijk herkennen van RA. 
DE FASE MET CLINICALLY SUSPECT ARTHRALGIA
Onderzoek heeft uitgewezen dat de ontwikkeling van RA een proces van jaren kan zijn. Zo 
kunnen de autoantistoffen al lang voordat de ziekte zich manifesteert aanwezig zijn. Ook kan 
aan het ontstaan van een klinisch detecteerbare artritis (een gezwollen gewricht bij lichamelijk 
onderzoek) een periode voorafgaan waarin gewrichtsklachten aanwezig zijn, maar er nog 
geen artritis is (het gewricht is niet gezwollen) (Figuur). Het onderzoeken van deze vroegste 
fasen, voordat er artritis is, kan leiden tot een beter begrip van het ontstaan van RA en biedt 
een mogelijkheid om patiënten met RA nog vroeger te herkennen dan we nu doen. Het eerste 
deel van dit proefschrift richtte zich op de fase met gewrichtspijn zonder artritis. 
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Figuur. De fasen van RA-ontwikkeling
Hoewel het duidelijk is dat een periode met gewrichtspijn zonder artritis voorafgaat 
aan het ontstaan van een klinische artritis is het onbekend welk type klachten kenmerkend 
zijn voor deze zeer vroege fase. In dit proefschrift onderzochten wij deze fase door patiënten 
met Clinically Suspect Arthralgia (CSA), klinisch verdachte gewrichtspijn (artralgie), te 
onderzoeken (Figuur). Dit is pijn van de kleine gewrichten die de reumatoloog vanwege 
het karakter van de symptomen verdacht vindt om zich ooit tot RA te ontwikkelen. Het 
besluit of een patiënt CSA heeft, is dus vooral gebaseerd op de klinische expertise, of het 
‘onderbuikgevoel’ van de reumatoloog dat de symptomen een uiting van beginnende RA 
kunnen zijn. Sinds 2012 worden deze patiënten in een cohortonderzoek in het LUMC 
onderzocht en worden ze in de tijd gevolgd op het ontwikkelen van een klinische artritis/
RA. Van de patiënten met CSA wordt een MRI maakt van de meest pijnlijke hand en voet 
om uit te zoeken of er ontsteking zichtbaar is op de MRI die (nog) niet met het lichamelijk 
onderzoek gedetecteerd kan worden; dit noemen we subklinische MRI-ontsteking. MRI is een 
zeer sensitieve methode om ontsteking van het gewrichtskapsel, bot en pezen weer te geven. 
Met behulp van een score worden de MRI’s beoordeeld op de aanwezigheid van ontsteking. 
De studies die zijn beschreven in dit proefschrift zijn voor een groot deel uitgevoerd in het 
Leidse CSA-cohort.
In de eerste hoofdstukken van dit proefschrift werd het CSA-cohort geïntroduceerd 
en werden de baselinebevindingen van patiënten met CSA beschreven. De belangrijkste 
redenen die de reumatologen aangaven waarom ze de gewrichtspijn klinisch verdacht 
vonden om ooit RA te worden, was gewrichtspijn die in de ochtend het ergst was en 
minder werd gedurende de dag, de aanwezigheid van ochtendstijfheid van minimaal één 
uur en het voorkomen van RA in de familie van de patiënt. Subklinische MRI-ontsteking 
was aanwezig bij 44% van de patiënten met CSA. Patiënten met en zonder MRI-ontsteking 
hadden vergelijkbare symptomen en karakteristieken en deze patiënten waren dus niet goed 
op basis van hun symptomen en karakteristieken van elkaar te onderscheiden. MRI gaf dus 
aanvullende informatie over een patiënt met CSA. 
Omdat MRI zeer sensitief is, was het belangrijk om te weten welke MRI-score als 
abnormaal beschouwd kon worden. Daarom hebben we een studie uitgevoerd waarin MRI’s 
van de hand en voet van 193 personen zonder gewrichtsklachten zijn gemaakt. Dit liet zien dat 
MRI-ontsteking vaak voorkwam bij symptoomvrije personen en dus niet alleen bij patiënten 
met RA/CSA; 72% van de personen zonder klachten had een MRI-score van minimaal 1 
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voor ontsteking. MRI-ontsteking kwam vooral voor bij oudere personen en in bepaalde 
gewrichten (zoals MCP2 en MCP3 (wijs- en middelvinger) en MTP1 (grote teen)). Met 
behulp van deze data hebben we referentiewaarden opgesteld voor een ‘normale’ MRI. Deze 
referentiewaarden waren gespecificeerd voor leeftijd en type en locatie van de ontsteking. 
In vervolgonderzoek bij CSA-patiënten hebben we deze referentiewaarden gebruikt om een 
‘positieve’ MRI voor ontsteking te definiëren. Hierdoor voorkwamen we dat de MRI’s van 
CSA-patiënten onterecht als positief werden beschouwd.
De eerste longitudinale studie van patiënten met CSA toonde aan dat 17% van de 
patiënten in het eerste jaar een klinische artritis had ontwikkeld. Deze overgang van CSA 
naar artritis gebeurde vooral in de eerste paar maanden. Het gevoel van de reumatoloog dat 
een patiënt een verhoogd risico had om RA te krijgen, was dus voor een deel van de patiënten 
terecht. Patiënten die een positieve MRI hadden, hadden een extra verhoogd risico om artritis 
te krijgen; 31% van hen ontwikkelde artritis in het eerste jaar. Ook patiënten die ACPA-
positief waren, hadden een verhoogd risico op artritis en zowel binnen de ACPA-positieve 
als de ACPA-negatieve CSA-patiënten voorspelde de aanwezigheid van een positieve MRI het 
ontstaan van artritis. Dit gaf aan dat MRI een toegevoegde waarde had in het identificeren 
van degenen die artritis gingen krijgen. Hiernaast had MRI ook een rol in het identificeren 
van de CSA-patiënten die juist een kleine kans hadden om artritis te ontwikkelen. De kans 
om artritis te ontwikkelen was namelijk slechts 6% als de MRI negatief was voor ontsteking. 
Deze studie toonde dus aan dat MRI waardevol was om binnen de totale groep CSA-
patiënten onderscheid te maken tussen patiënten met een hogere kans en met een lage kans 
op toekomstige RA.
De laatste hoofdstukken van het eerste deel gingen over de definitie van CSA. Het 
besluit of een patiënt CSA had, was gebaseerd op de klinische expertise van de reumatoloog. 
De klinische expertise wordt vaak gebruikt in de geneeskunde, bijvoorbeeld door huisartsen 
die het klinische beeld ‘pluis’ of ‘niet pluis’ vinden. Ook voor het besluit of er CSA was, 
bleek de klinische expertise een nuttig middel. Patiënten met gewrichtspijn die door de 
reumatoloog werden beschouwd als CSA hadden ongeveer 55 keer meer kans om RA te 
krijgen dan gewrichtspijn patiënten zonder CSA. 
Behalve dat gewrichtspijn klinisch verdacht moest zijn om RA te worden, 
hadden we geen verdere criteria gedefinieerd waaraan CSA moest voldoen. Echter, als we 
interventiestudies in de CSA-fase zouden willen uitvoeren om te onderzoeken of het starten 
van behandeling in de CSA-fase gunstig is, is het belangrijk dat een homogene patiëntengroep 
met CSA geselecteerd kan worden. Hiervoor waren duidelijke criteria nodig. Daarom hebben 
we met een groep van 18 reumatologen uit heel Europa een definitie voor CSA ontwikkeld. 
Deze definitie, bestaande uit 7 klinische parameters, representeert de gedeelde opvattingen 
van wat de reumatologen beschouwden als gewrichtspijn die verdacht was om RA te worden, 
dus CSA. Of deze definitie daadwerkelijk voorspellend is voor het ontwikkelen van RA moet 
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nog onderzocht worden.
HET VERLOOP VAN REUMATOIDE ARTRITIS - GENETISCHE RISICOFACTOREN
In het tweede en derde deel van dit proefschrift werden patiënten met RA onderzocht. In 
tegenstelling tot de patiënten met CSA in het eerste deel van dit proefschrift, hadden deze 
patiënten dus al de diagnose RA. 
Het ziekteverloop van RA kan veel verschillen tussen patiënten. Sommige patiënten 
hebben een invaliderend en persisterend verloop met veel gewrichtsschade terwijl bij anderen 
de ziekte milder verloopt. Waarom de ene patiënt een ernstiger ziekteverloop heeft dan de 
andere patiënt is onbekend; we kunnen dit ook niet goed voorspellen. Dus om beter inzicht te 
krijgen in mechanismen die verantwoordelijk zijn voor ziekteprogressie en om behandeling 
te individualiseren is het belangrijk om risicofactoren te identificeren voor een ernstig 
ziekteverloop. Het tweede deel van dit proefschrift richtte zich op genetische risicofactoren 
voor een ernstig verloop van RA.
De onderzoeken in dit deel van het proefschrift zijn grotendeels uitgevoerd in het 
Leidse Early Arthritis Clinic (EAC) cohort. De EAC is een cohortonderzoek dat in 1993 is 
gestart en waarin sindsdien alle patiënten die zich op de polikliniek reumatologie van het 
LUMC presenteren met een nieuwe artritis geïncludeerd worden. Echter, aangezien binnen 
de wetenschap, en speciaal binnen het veld van de genetica, replicatie van bevindingen 
essentieel is, bevatten veel studies in dit proefschrift resultaten van meerdere cohorten met 
RA-patiënten, afkomstig uit Frankrijk, Zweden, Spanje en de Verenigde Staten. 
De ernst van RA kan met verschillende maten gemeten worden. De belangrijkste 
langetermijnuitkomst is de ernst van schade aan de hand- en voetgewrichten die bepaald kan 
worden op radiologische foto’s. Deze uitkomstmaat heeft enkele voordelen: (1) gewrichtsschade 
geeft de ziektegeschiedenis weer, aangezien er wordt aangenomen dat schade zich niet of 
nauwelijks herstelt, (2) gewrichtsschade is sterk geassocieerd met andere uitkomstmaten zoals 
functionaliteit en (3) er zijn net als voor MRI gevalideerde scoringsmethoden beschikbaar 
om gewrichtsschade te scoren. De meest gebruikte scoringsmethode is de Sharp-van der 
Heijde score waarbij erosies en gewrichtsspleetvernauwing in de handen en voeten worden 
beoordeeld.
Er zijn al verscheidene risicofactoren bekend voor de ernst van gewrichtsschade. 
De belangrijkste is de aanwezigheid van autoantistoffen. Onderzoek heeft aangetoond 
dat erfelijkheid ook een belangrijke rol speelt in het ontstaan van schade: 45-58% in de 
variantie van ernst in schade is erfelijk. Hoewel er al meerdere genetische risicofactoren voor 
schade geïdentificeerd en gerepliceerd zijn, is een groot deel van het genetische effect nog 
onverklaard. 
Er zijn verscheidene voorspelmodellen voor de ernst van gewichtsschade ontwikkeld. 
Deze modellen, gebaseerd op kenmerken zoals aantal gezwollen gewrichten, antistoffen 
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en ontstekingswaarden, voorspelden echter de ernst van de schade in slechts 50% van de 
patiënten correct. Ze worden daarom niet in de klinische praktijk gebruikt. Wij onderzochten 
of de voorspelling beter zou worden als ook rekening gehouden werd met genetische 
risicofactoren voor gewrichtsschade. Ons model met alleen klinische factoren classificeerde 
56% van de patiënten correct en een model met ook genetische factoren 62%. Hoewel dit 
een verbetering in voorspellend vermogen was, werd nog steeds bij 38% van de patiënten de 
ernst van de gewrichtsschade incorrect voorspeld. Daarom beoordeelden wij het model dat 
rekening hield met genetische factoren nog steeds als onvoldoende. 
Dit proefschrift beschreef enkele kandidaat-gen studies naar genetische risicofactoren 
voor de ernst van het verloop van RA. Een kandidaat-gen studie betekent dat je hypothese 
gedreven een bepaald (deel van een) gen gaat onderzoeken. We identificeerden twee 
genetische risicofactoren voor gewrichtsschade in ACPA-negatieve RA-patiënten; dit ging 
om variaties in de genen SPP1 en C5-TRAF1. Deze bevindingen zijn relevant, aangezien de 
meeste genetische risicofactoren voor schade geïdentificeerd zijn in ACPA-positieve of een 
gepoolde ACPA-positieve en ACPA-negatieve populatie. Bovendien waren beide variaties 
geassocieerd met expressie van RNA of eiwit. Dit versterkte het bewijs dat de geïdentificeerde 
varianten (of de regio waarin ze liggen) mogelijk relevant zijn voor processen die betrokken 
zijn bij ziekteprogressie. Verder onderzoek hiernaar is nodig. 
De belangrijkste genetische risicofactoren voor gewrichtsschade zijn, net als voor 
RA ontwikkeling, de HLA-DRB1 shared epitope (SE) allelen, die coderen voor dezelfde 
aminozuurvolgorde op positie 70-74 van het HLA-DRB1 molecuul. Deze associatie wordt 
gemedieerd door ACPA wat inhoudt dat de SE-allelen leiden tot ACPA wat leidt tot de 
ontwikkeling van RA en ernstige schade als er RA is. Recent was aangetoond dat variaties in 
positie 11 van het HLA-DRB1 gen sterker dan en onafhankelijk van de SE-allelen associeerden 
met de ontwikkeling van RA. Wij toonden aan dat positie 11 op HLA-DRB1 ook associeerde 
met gewrichtsschade en dat dit tevens onafhankelijk was van de aanwezigheid van SE-allelen. 
De associatie was echter net als de associatie van SE niet onafhankelijk van ACPA. 
Een andere belangrijke langetermijnuitkomst is het bereiken van DMARD-vrije 
remissie. Dit houdt in dat na het staken van medicatie er bij het lichamelijk onderzoek geen 
artritis meer is en is dus het tegenovergestelde van persisterende ziekte. RA werd altijd gezien 
als een chronische ziekte die niet te genezen was. Echter, het bereiken van DMARD-vrije 
remissie kan beschouwd worden als een sterke benadering van genezing en wij lieten zien 
dat deze uitkomst met de huidige behandelstrategieën steeds vaker behaald kon worden. Ook 
vanuit het perspectief van de patiënt was dit een na te streven uitkomst, omdat patiënten 
in remissie geen symptomen en functiebeperking meer ervoeren. Met het afnemen van 
ernstige gewrichtsschade zal het bereiken van DMARD-vrije ziekte waarschijnlijk een steeds 
belangrijkere uitkomst worden.
Om meer inzicht te krijgen in de vraag waarom de ene patiënt een persisterende 
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chronische ziekte heeft en de andere patiënt in remissie gaat, hebben we een kandidaat-gen 
studie gedaan naar DMARD-vrije remissie. Een variant in IL2RA bleek geassocieerd met deze 
uitkomst. Ook het level IL2Rα wat meetbaar is in het bloed was geassocieerd met remissie. 
Tot nu toe is IL2RA naast HLA-DRB1 de enige genetische risicofactor voor het ontwikkelen 
van RA, de ernst van gewrichtsschade en het bereiken van remissie. Gezien de potentiële 
relevantie van IL2RA voor RA, zou het interessant zijn om te onderzoeken of medicatie die 
aangrijpt in het IL2 mechanisme en effectief is gebleken in andere auto-immuunziekten 
effectief is voor de behandeling van RA. 
CONCLUSIES
Vroege herkenning van patiënten met RA is belangrijk. De studies over de fase met Clinically 
Suspect Arthralgia (CSA) die beschreven zijn in dit proefschrift dragen bij aan inzicht in de 
vroegste fasen van RA-ontwikkeling. Patiënten met klinisch verdachte gewrichtspijn (CSA) 
hebbenn een verhoogd risico op het ontwikkelen van artritis. Subklinische MRI-ontsteking 
gaat een aantal maanden aan de ontwikkeling van artritis vooraf. Verder onderzoek zal 
meer inzicht geven in de processen die een rol spelen bij progressie van CSA naar RA, de 
toepasbaarheid van MRI in de klinische praktijk en de effectiviteit van behandeling in de 
CSA-fase.
Het ziekteverloop van patiënten met RA kan erg verschillen en we weten niet goed 
welke factoren hieraan bijdragen. In het tweede deel van dit proefschrift identificeerden 
we drie genetische risicofactoren voor gewrichtsschade en één voor persisterende ziekte. 
Aangezien gewrichtsschade tegenwoordig minder vaak voorkomt door de huidige 
behandelstrategieën en het bereiken van DMARD-vrije remissie een haalbare uitkomst is 
geworden, zal deze uitkomst steeds belangrijker worden in RA.
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